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Abstract
Autism spectrum disorder (ASD) is a common developmental disorder typified
by deficits in social communication and stereotyped behaviours. Despite evidence
of a strong genetic basis to the disorder, molecular studies have thus far had lit-
tle success in identifying risk variants or other biomarkers, and presently there is
no unified pathomechanistic explanation. Monozygotic (MZ) twins show incom-
plete concordance in autistic traits, which suggests that alternative risk pathways
involving non-shared environmental (NSE) factors could also have an important
role to play in ASD. In this thesis, we describe microarray and RNA-seq studies
characterising gene expression in a sample of 53 ASD MZ twin pairs from TEDS.
The overall aims were to: 1) establish convergent evidence for genes and path-
ways involved in the etiology of ASD comparing affected and unaffected subjects
across the sample 2) to identify those responsive to the environment by examining
differences within the discordant pairs. We found a number of genes were dif-
ferentially expressed including DEPDC1B - the most significant finding in cases
vs controls, which also showed consistent down regulation within pairs. We fur-
ther identified IGHG4, IGHG3, IGHV3-66, HSPA8P14, HSPA13, SLC15A2, and
found that these results were enriched for transcriptional control, immune, and
PI3K/AKT signalling pathways. We suggest that as these were found to be per-
turbed in the discordant twins, they could represent ASD risk pathways sensitive
to the NSE. Next, we investigated integrative genomics methods for performing
meta-dimensional analysis using the expression data along with methylation data
on the same cohort. After applying regression-based joint analysis methods, and
meta-analysis p-value combination methods to our datasets, a number of genes
obtained nominal significance across the datasets, including potential genes of in-
terest: NLGN2,UBE3A,OXTR. We suggest these represent genes with evidence for
being functionally relevant to ASD.
3
Acknowledgements
First and foremost, I’d like to express my sincerest gratitude to my supervisors
EmmaandFrank for their guidance, support and enthusiasm throughout the project,
which has been essential to its completion. I would also like to thank the following
people: Prof. Robert Plomin for kindly allowing the TEDS data to be used for this
project, and of course the TEDS families for their continuing participation in the
study, Dr. Matt J. Silver (LSHTM - MRC International Nutrition Group) for his
support and for proofreading some of the material contained within, Dr. Vincent
Plagnol (UCL - Genetics Institute), Prof. Michael A. Simpson and Dr. Nikolaos
Barkas (KCL - Division of Genetics and Molecular Medicine) for their advice on
methodological aspects of the RNA-seq study. And finally, Dr. Denise McDonald
(QUB - Centre for Experimental Medicine) and Dr. Kostas A. Papageorgiou (QUB
- School of Psychology) for their advice on academicmatters and thesis writing and
general all round encouragement. I am also grateful to the following for funding
this research: Bloomsbury Colleges (PhD studentship award), The Royal Society
(Research grant - RNA-seq experiment).
For my parents, sister, close family and friends, thank you for your love and sup-
port.
4
Contents
1 Introduction 12
1.1 Autism spectrum disorder . . . . . . . . . . . . . . . . . . . . . . . . 12
1.2 Insights from genetics . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.2.1 Quantitative studies . . . . . . . . . . . . . . . . . . . . . . . 13
1.2.2 Molecular studies . . . . . . . . . . . . . . . . . . . . . . . . 14
1.2.2.1 Chromosomal abnormalities . . . . . . . . . . . 15
1.2.2.2 Rare, single gene mutations . . . . . . . . . . . . 16
1.2.2.3 Copy number variants . . . . . . . . . . . . . . . 16
1.2.2.4 Common variants . . . . . . . . . . . . . . . . . . 17
1.2.2.5 Molecular mechanisms . . . . . . . . . . . . . . . 18
1.2.2.6 Genetic architecture . . . . . . . . . . . . . . . . . 18
1.2.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
1.3 Epigenetic regulation of gene expression . . . . . . . . . . . . . . . . 22
1.3.1 Epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.3.2 DNA methylation . . . . . . . . . . . . . . . . . . . . . . . . 23
1.3.2.1 Developmental establishment ofmethylationmarks 24
1.3.3 Methylomic assays and technology . . . . . . . . . . . . . . 24
1.3.3.1 Bisulfite sequencing . . . . . . . . . . . . . . . . . 24
1.3.3.2 Microarray . . . . . . . . . . . . . . . . . . . . . . 25
1.3.4 Epigenetic mechanisms in disease . . . . . . . . . . . . . . . 26
1.4 Profiling patterns of gene expression . . . . . . . . . . . . . . . . . . 26
1.4.1 The transcriptome . . . . . . . . . . . . . . . . . . . . . . . . 26
1.4.2 RNA varieties . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
5
Contents
1.4.3 Expression profiling assays and technology . . . . . . . . . 28
1.4.3.1 Microarray . . . . . . . . . . . . . . . . . . . . . . 28
1.4.3.2 RNA sequencing . . . . . . . . . . . . . . . . . . . 28
1.5 Non-genetic factors in ASD . . . . . . . . . . . . . . . . . . . . . . . 29
1.5.1 Epigenetic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.5.2 Environmental . . . . . . . . . . . . . . . . . . . . . . . . . . 31
1.6 Gene expression profiling in ASD . . . . . . . . . . . . . . . . . . . . 33
1.6.1 Systematic review of published findings . . . . . . . . . . . 33
1.7 Gene expression profiling of monozygotic twins with ASD . . . . . 46
1.7.1 Monozygotic twins . . . . . . . . . . . . . . . . . . . . . . . 46
1.7.2 Gene expression profiling of MZ twins with ASD . . . . . . 47
1.7.3 Potential limitations of this study . . . . . . . . . . . . . . . 47
1.7.3.1 Are gene expression measurements reliable? . . 48
1.7.3.2 Do mRNA levels correspond to protein levels? . 48
1.7.3.3 Are expression differences between MZ twins
detectable? . . . . . . . . . . . . . . . . . . . . . . 48
1.7.3.4 Whole blood as a surrogate . . . . . . . . . . . . 50
1.8 Integrating multiple genomics datasets . . . . . . . . . . . . . . . . . 51
References 53
2 Gene expression profiling of monozygotic twins with autism spectrum
disorder 75
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.2.1 Subjects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.2.2 Subject selection and study groups . . . . . . . . . . . . . . 78
2.2.3 Sample collection . . . . . . . . . . . . . . . . . . . . . . . . 79
2.2.4 HuGe microarray . . . . . . . . . . . . . . . . . . . . . . . . 80
2.2.5 Quality control I - microarray data . . . . . . . . . . . . . . 80
2.2.5.1 Inspection of array images . . . . . . . . . . . . . 80
2.2.5.2 Distribution of raw intensity measurements . . . 81
2.2.6 Data pre-processing . . . . . . . . . . . . . . . . . . . . . . . 83
6
Contents
2.2.7 Quality control II - expression data set . . . . . . . . . . . . 83
2.2.7.1 Probeset filtering / removal of background signal 83
2.2.7.2 Probeset aggregation . . . . . . . . . . . . . . . . 84
2.2.8 Exploratory analysis . . . . . . . . . . . . . . . . . . . . . . . 84
2.2.9 Differential expression analysis . . . . . . . . . . . . . . . . 85
2.2.9.1 T-test and Wilcoxon . . . . . . . . . . . . . . . . 85
2.2.9.2 Regression analysis . . . . . . . . . . . . . . . . . 86
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
2.3.1 Exploratory analysis . . . . . . . . . . . . . . . . . . . . . . . 92
2.3.2 Differential expression analysis . . . . . . . . . . . . . . . . 95
2.3.2.1 Student’s t and Wilcoxon . . . . . . . . . . . . . . 95
2.3.2.2 Regression . . . . . . . . . . . . . . . . . . . . . . 96
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
References 102
3 Characterising the transcriptome in autism spectrumdisorder usingRNA-
seq 108
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
3.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3.2.1 Subjects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
3.2.2 Pilot study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.2.3 Subject selection . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.2.4 RNA isolation . . . . . . . . . . . . . . . . . . . . . . . . . . 112
3.2.5 Library preparation . . . . . . . . . . . . . . . . . . . . . . . 112
3.2.6 Sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.2.7 Analysis pipeline . . . . . . . . . . . . . . . . . . . . . . . . . 113
3.2.8 Quality control I - pre-mapping . . . . . . . . . . . . . . . . 115
3.2.8.1 Number of reads and sequence quality . . . . . . 115
3.2.8.2 GC content . . . . . . . . . . . . . . . . . . . . . . 116
3.2.8.3 Library composition and sequence diversity . . 116
3.2.8.4 Read removal/trimming . . . . . . . . . . . . . . 117
7
Contents
3.2.8.5 Preliminary mapping and determination of in-
sert sizes . . . . . . . . . . . . . . . . . . . . . . . 117
3.2.9 Mapping . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
3.2.10 Quality control II - post mapping . . . . . . . . . . . . . . . 118
3.2.11 Quantification . . . . . . . . . . . . . . . . . . . . . . . . . . 118
3.2.12 Filtering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
3.2.13 Exploratory analysis of inter-individual expression profiles 119
3.2.14 Differential expression analysis . . . . . . . . . . . . . . . . 120
3.2.15 Quantitative trait model . . . . . . . . . . . . . . . . . . . . 123
3.2.16 Geneset testing / pathway analysis . . . . . . . . . . . . . . 124
3.2.16.1 Genesets . . . . . . . . . . . . . . . . . . . . . . . 124
3.2.16.2 Geneset testing methods . . . . . . . . . . . . . . 125
3.2.17 Comparison with microarray data . . . . . . . . . . . . . . 129
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 132
3.3.1 Exploratory analysis . . . . . . . . . . . . . . . . . . . . . . . 132
3.3.2 Differential expression analysis . . . . . . . . . . . . . . . . 132
3.3.3 Geneset testing . . . . . . . . . . . . . . . . . . . . . . . . . . 142
3.3.3.1 ASD-associated . . . . . . . . . . . . . . . . . . . 142
3.3.3.2 Geneset statistics . . . . . . . . . . . . . . . . . . 142
3.3.3.3 Pathways . . . . . . . . . . . . . . . . . . . . . . . 144
3.3.4 Comparison with microarray data . . . . . . . . . . . . . . 149
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
3.4.1 Differential expression . . . . . . . . . . . . . . . . . . . . . 150
3.4.2 Geneset testing . . . . . . . . . . . . . . . . . . . . . . . . . . 151
3.4.3 Comparison with microarray data . . . . . . . . . . . . . . 153
3.4.4 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
3.4.5 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . 155
3.4.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
References 158
4 Estimation of a significance threshold for Epigenome-Wide Association
Studies 168
8
Contents
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
4.1.1 Characteristics of 450K methylation data . . . . . . . . . . 169
4.1.2 Levels of analysis . . . . . . . . . . . . . . . . . . . . . . . . . 170
4.1.3 The multiple testing problem . . . . . . . . . . . . . . . . . . 172
4.1.4 FWER solutions to multiple testing . . . . . . . . . . . . . . 172
4.1.5 FDR solutions to multiple testing . . . . . . . . . . . . . . . 173
4.1.6 Resampling solutions to multiple testing . . . . . . . . . . . 174
4.1.7 Permutation correction . . . . . . . . . . . . . . . . . . . . . 175
4.1.8 Estimating a significance threshold for EWAS . . . . . . . . 175
4.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
4.2.1 Methylation datasets . . . . . . . . . . . . . . . . . . . . . . 176
4.2.1.1 Gambian . . . . . . . . . . . . . . . . . . . . . . . 177
4.2.1.2 CRC . . . . . . . . . . . . . . . . . . . . . . . . . . 177
4.2.1.3 Public datasets: Caucasian/Afr-Am/Cau-Am . . 178
4.2.2 Correlation structure . . . . . . . . . . . . . . . . . . . . . . 178
4.2.3 Permutation scheme . . . . . . . . . . . . . . . . . . . . . . . 179
4.2.4 Effective number of tests . . . . . . . . . . . . . . . . . . . . 180
4.2.5 Subsampling method . . . . . . . . . . . . . . . . . . . . . . 181
4.2.6 Estimation of a genome-wide threshold . . . . . . . . . . . 182
4.2.7 Sample size estimation . . . . . . . . . . . . . . . . . . . . . 183
4.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 184
4.3.1 Correlation structure . . . . . . . . . . . . . . . . . . . . . . 184
4.3.2 Permutation and effective number of tests . . . . . . . . . . 184
4.3.3 Subsampling and genome-wide threshold . . . . . . . . . . 187
4.3.4 Sample size estimation . . . . . . . . . . . . . . . . . . . . . 189
4.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
4.4.1 Correlation structure . . . . . . . . . . . . . . . . . . . . . . 189
4.4.2 450K threshold . . . . . . . . . . . . . . . . . . . . . . . . . . 192
4.4.3 Genome-wide threshold . . . . . . . . . . . . . . . . . . . . 193
4.4.4 Sample size estimation . . . . . . . . . . . . . . . . . . . . . 195
4.4.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
References 197
9
Contents
5 Integrating multi-dimensional omics datasets 204
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
5.1.1 An overview of integrative genomics . . . . . . . . . . . . . 205
5.1.2 Vertical integration . . . . . . . . . . . . . . . . . . . . . . . 207
5.1.3 Classifying vertical integrative methods . . . . . . . . . . . 208
5.1.4 Analytical challenges and considerations . . . . . . . . . . . 209
5.1.5 Integrating multi-dimensional omics datasets . . . . . . . . 210
5.2 Meta-dimensional analysis . . . . . . . . . . . . . . . . . . . . . . . . 211
5.2.1 Quality control . . . . . . . . . . . . . . . . . . . . . . . . . . 211
5.2.2 Confirmation . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
5.2.3 Feature selection . . . . . . . . . . . . . . . . . . . . . . . . . 212
5.2.4 Joint analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
5.2.4.1 Regression . . . . . . . . . . . . . . . . . . . . . . 213
5.2.5 Meta-analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 214
5.2.5.1 Combining evidence . . . . . . . . . . . . . . . . 214
5.2.5.2 Methods for combining independent p-values . 215
5.2.5.3 Combining dependent p-values . . . . . . . . . . 217
5.2.5.4 Testing the partial conjunction . . . . . . . . . . 219
5.2.5.5 Utility of p-value combination in vertical inte-
gration . . . . . . . . . . . . . . . . . . . . . . . . 220
5.3 Application of selected integrative methods to ASD . . . . . . . . . 220
5.3.1 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 220
5.3.1.1 Quality control . . . . . . . . . . . . . . . . . . . . 220
5.3.1.2 Confirmation . . . . . . . . . . . . . . . . . . . . 221
5.3.1.3 Joint analysis - p-value combination . . . . . . . 222
5.3.1.4 Joint analysis - regression modelling . . . . . . . 222
5.3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
5.3.2.1 Confirmation . . . . . . . . . . . . . . . . . . . . 223
5.3.2.2 Joint/meta analysis - p-value combination . . . . 226
5.3.2.3 Joint/meta analysis - regression . . . . . . . . . . 229
5.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
5.4.1 Application of selected integrative methods to ASD . . . . 232
5.4.2 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . 234
10
Contents
References 236
6 Discussion 243
6.1 Gene expression signatures in ASD . . . . . . . . . . . . . . . . . . . 243
6.1.1 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . 244
6.2 Significance thresholds and sample sizes required for EWAS . . . . 246
6.3 Integration of gene expression and methylation data . . . . . . . . 247
6.3.1 Future directions . . . . . . . . . . . . . . . . . . . . . . . . . 247
6.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 248
References 250
Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254
A Chapter 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 254
B Chapter 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 255
C Chapter 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 272
D Chapter 5 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
11
1 | Introduction
1.1 Autism spectrum disorder
Leo Kanner first noted “innate disturbance of affective contact” in 11 children [1],
which he termed “early infantile autism” [2]. While Kanner’s initial description
still captures some of the essential features of autism, the precise clinical definition
has been continually revised and updated to reflect advances in our understand-
ing. The latest edition of the diagnostic and statistical manual of mental disorders
V (DSM-V) classifies autism spectrum disorder (ASD) as a neurodevelopmental
condition featuring two core symptoms, 1) deficits in social communication and 2)
stereotyped behaviour [3]. This supersedes the previous DSM-IV definition which
used as its main diagnostic criteria what came to be known as the “classic triad” of
1) impaired reciprocal social interaction, 2) deficits in language and communica-
tion development, and 3) restricted repetitive behaviours and interests [4].
Perhaps one of the defining characteristics of ASD is its phenotypic heterogene-
ity, with individuals varying in the severity and extent of impairments in language
ability and cognitive development. ASD is often comorbid with other conditions
such as intellectual disability (in over 70% of ASD affected individuals) [5], macro-
cephaly (in around 20% of ASD cases) [6], epilepsy ( ∼ 25%) [7], as well as a num-
ber of rarer conditions. The DSM-IV previously used ASD as an umbrella term
bringing together a number of clinically distinct neurodevelopmental disorders
including autism, Asperger’s and pervasive developmental disorder not otherwise
defined (PDD-NOS). The DSM-V now uses ASD as a singular classification, with
12
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provisions for the inclusion of patient-specific characteristics outside of the core
symptoms, for example, the presence of a genetic syndrome with known autism
comorbidity [8]. This is believed to more accurately reflect the spectrum nature of
autism, as well as the underlying biology [9, 8].
Prevalence of ASD has rapidly risen over the past several decades, from a rate of
1 in 10,000 in the 1960’s [10], rising to 1 in 2500 in 1980’s (at time of the intro-
duction of the DSM-III) [11], with current estimates between 1 in 150 [12] to 1 in
100 [5, 13]. There is also a well-established gender imbalance, with males being 4
times as likely as females to be affected [5]. There is some debate as to whether the
increase in incidence is due to the changing and broadening of diagnostic criteria,
screening efficacy, increased awareness, or increased exposure to environmental
risks factors [14] – some of which could be linked to changes in modern lifestyles
such as increasing paternal and maternal age [15]. But before we can begin to
pick apart the etiology, we must first form a better understanding of the underly-
ing pathomechanisms. This is perhaps where research into ASD lags behind other
neurodevelopmental and psychiatric disorders, as currently there is no coherent
narrative running from etiology and disrupted cellular processes, through to de-
velopmental disruption and final manifestation of autistic behaviours.
1.2 Insights from genetics
1.2.1 Quantitative studies
ASD has been described as the “most genetic” neuropsychiatric or developmental
disorder, based on accumulated findings from several decade’s worth of quanti-
tative research. Family studies have shown sibling relative risk to be between 20
and 50 times greater than in the general population [16, 17], and subclinical autis-
tic traits such as deficits in social cognition and language are also commonly ob-
served at higher rates in first-degree relatives [18, 19](sometimes referred to as the
“broader phenotype’’).
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Twin studies estimate the proportion of liability in ASD attributable to genetic
factors (the narrow sense heritability) by comparing concordance rates between
monozygotic (MZ) and dizygotic (DZ) twins. Some early studies estimated this
at between 60 and 90% [20, 21, 22] based on concordance rates of 36% in MZs
compared to 0% in DZs [20], 91% to 0% [21], and 60% to 0% [22]. Two more
recent studies revisited twins-based heritability estimation using more up-to-date
diagnostic criteria. These have alternatively produced results in concordance with
the initial findings, as in Rosenberg et al. which reported concordance of 88% in
MZ versus 31% in DZ twins [23], while another study by Hallmayer et al. esti-
mated a much lower heritability of 38%, in addition to identifying sex differences
in concordance rates with female MZ concordance rate of 50% compared to 77%
inmales, and DZ concordance of 36% compared to 31% inmales [24]. See [25] for
a comprehensive review of these findings.
In summary, the quantitative findings, as well as indicating a strong genetic basis to
the disorder, also support the notion of ASD as a spectrum [25]. They also hint at
the underlying genetic architecture, being consistent with a multifactorial, thresh-
old model [26], where genetic and environmental factors additively combine to
increase liability to the point where it manifests as a clinically diagnosable disorder
[27]. Within such a framework however, some of these findings become difficult to
reconcile with each other. While the observed familial clustering supports the in-
volvement of genetic or shared genetic and environmental factors [26], phenotypic
variability and incomplete concordance inMZ twins are both highly suggestive of a
role for non-shared environmental factors [28]. The implications are then that the
underlying etiology of ASD cannot be completely explained by genetic factors, an
idea important in the context of this thesis, and one which we shall explore further
following a brief summary of the current molecular findings.
1.2.2 Molecular studies
Molecular genetics studies have revealed ASD to be highly genetically heteroge-
neous [29]. A number of syndromic or comorbid forms of autism are known
to arise from large-scale chromosomal abnormalities or highly penetrant, single
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gene mutations. As for non-syndromic, or idiopathic ASD cases, a number of risk
conferring de-novo copy number variants (CNVs) and single nucleotide polymor-
phisms (SNPs) have been identified, many of which overlap with the risk loci iden-
tified for syndromic forms. We will now give a brief summary of some of the ge-
netic findings andwhat they reveal about the etiology and pathomechanisms of the
disorder.
1.2.2.1 Chromosomal abnormalities
Large, microscopically visible chromosomal abnormalities are observed in approx-
imately 5-10 % of ASD cases [26], being predominantly associated with genetic
syndromes showing comorbidity with autism. Some of themost recurrent findings
are deletions and duplications in the long arm of chromosome 15, specifically the
15q11-q13 region [30]. A cluster of low-copy repeats in this region are particularly
susceptible to re-arrangements, with paternal deletions being the primary cause of
Prader-Willli syndrome, andmaternal deletions giving rise toAngelman syndrome
- both developmental conditions associated with autism [31]. Maternally inherited
duplications are also frequently observed in the form of interstitial tandem repeats
or as an extra chromosome with multiple copies, leading to the over-expression
of genes which are ordinarily silenced (by imprinting - discussed later) [32], and
causing moderate to severe autistic phenotypes [33]. Abnormalities in the 16p11.2
region represent another frequent finding, with deletion in this region resulting in
severe, highly penetrant autistic phenotypes with dysmorphic features, and dupli-
cation of the same region leading to a less severe behavioural phenotype. Some
further chromosomal abnormalities associated with autism include translocations
at 7q22, and microdeletions in 22q11, specifically in the q11.2 and q11.3 regions -
associated with rare conditions such as velocardiofacial syndrome, DiGeorge syn-
drome, and conotruncal anomaly face syndrome (see [33]).
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1.2.2.2 Rare, single gene mutations
Monogenic forms of ASD where the primary genetic lesion is known account for
5% of ASD cases [34]. Fragile X is an X-chromosome linked form of mental retar-
dation affecting males, where the underlying cause has been identified as a muta-
tion to the FMR1 gene. This leads to transcriptional silencing of the gene product
FMRP, an RNA binding protein which is involved in regulating the translation of a
number of other mRNAs at the synapse [35]. Rett syndrome is a progressive neu-
rodevelopmental disorder affecting females where the primary genetic lesion is a
loss of function mutation in the MECP2 gene, coding for a methyl-CpG-binding
protein important for regulating chromatin structure and levels of gene expres-
sion in neurons. Prader-Willli and Angelman syndromes arise from disruptions to
imprinting in the 15q11-q13 region (previously implicated by cytogenic studies).
Angelman syndrome has been linked to mutations in theUBE3A gene - which en-
codes a ubiquitin ligase that is important for protein degradation and is normally
expressed exclusively from maternal alleles in neurons [36]. Macrocephaly is fre-
quently comorbid with autism, and in a number of cases, mutations to PTEN have
been identified - a phosphatase involved in cell cycle and apoptosis that is believed
to regulate neuronal cell size through translational control [6].
A number of other rare mutations are also associated with ASD, which are typi-
cally observed in sporadic or familial cases. Identified genes include neuroligins
NLGN3/4 [37] and neurexins NRXN1 [38] and NRXN3, which are involved in
synaptic cell adhesion. Also recurrently implicated are genes coding for multi-
ple ankyrin repeat domains such as SHANK2 [39] and SHANK3 [40] - scaffolding
proteins that are important for synaptic organization, and other genes important
for synaptic function including CNTN3/4/5 [41] and CNTNAP2 [42].
1.2.2.3 Copy number variants
CNVs describe submicroscopic chromosomal deletions and duplications ranging
from around 1 Kb in size up to 1Mb, which are widespread throughout the human
genome and are believed to contribute to genetic differences between individuals
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to a similar extent as sequence variants [43]. Overall, de-novo CNVs are believed
to be present in 10% of cases [44], but it is not currently known to what extent
they contribute to overall risk. In terms of the loci identified, these often over-
lap with the chromosomal regions disrupted in the various comorbid autisms de-
tailed previously, with risk-associated CNVs frequently identified in the 15q11-13
and 16p11.2 regions, and to a lesser extent in other regions such as 1q21, 5p15.2,
7q11.23, 17p11.2, and 22q11.2 (see [8] and [45] for recent reviews of findings). A
number of CNVs have also been found either within or in the vicinity of some pre-
viously identified risk genes likeNLGN1 [46],NRXN1 [44], SHANK1 [47],CNTN4
[46], and CDH8 [48].
1.2.2.4 Common variants
Genome wide association studies (GWAS) aim to uncover common, risk confer-
ring variants for complex diseases. A small number of these studies have now been
conducted for ASD.The Gene Discovery Project of Johns Hopkins and the Autism
Consortium genotyped 3000 subjects from 780 multiplex families, and identified
an associated SNP rs10513025 on chromosome 5p15 between the SEMA5A and
TAS2R1 genes [49]. The Autism Genome Project (AGP) Consortium performed a
genome-wide scan of 4712 subjects from1558ASD families and identified rs4141463
in the MACROD2 gene as the strongest signal [50]. Wang et al. genotyped 3103
subjects from 780 samples and identified a number of associations between the
cadherinCDH9/CDH10 genes, with themost significant hit being the SNP rs4307059
[51]. More recently, and using a much larger sample, the Cross-Disorder Group of
the Psychiatric Genomics Consortium (PGC) analysed SNP data for 33,332 cases
and 27,888 controls looking at five psychiatric disorders includingASD, and identi-
fied significant associations on chromosomal regions 3p21 and 10q24 and rs2799573
within the CACNB2 gene (coding for calcium channel subunits).
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1.2.2.5 Molecular mechanisms
Taken together the identified genes converge on a number of common pathways
and cellular processes, implicating transcriptional dysregulation (as in both Fragile
X and Rett), epigenetic dysregulation (e.g. disruption of parent-of-origin based ex-
pression patterns as in Prader-Willi and Angelman, CDHs), cell growth signalling
(implicated in macrocephaly and autism), inhibition of PI3K/mTOR signalling
(e.g. PTEN), synaptic adhesion/synaptic organisation (neurexins, neuroligins, SHANKs,
CNTNAPs), synaptic function (SCN1, SCN2, CACNB2). Findings from functional
studies further support a role for some of these processes in ASD pathogenesis, as
we shall discuss further in the relevant sections to come.
1.2.2.6 Genetic architecture
The relative lack of success of GWAS in identifying common risk conferring vari-
ants for ASD has led some to question our assumptions about the likely genetic ar-
chitecture. Added to this, the odds ratios for identified genes so far have been small
and they have largely failed to replicate in other studies [52]. Broadly speaking,
variance to ASD liability arises from common variation (according to the “com-
mon variant common disease” hypothesis [53]), rare variation (“rare variant com-
mon disease” [54]), or the environment -which can be shared and non-shared (de-
scribed in further detail below). These are not mutually exclusive, and risk is likely
to reside in each component - although the overall contribution of each of these
remains a contentious issue.
Common variants: The common variant hypothesis posits that variants of small
effect (1.1 – 1.5 fold) that are present at a high frequency in the population (> 5%),
additively contribute to the variance of a trait [53, 55]. More generally in GWAS,
there has been a relative lack of success in identifying these risk conferring vari-
ants, the so called “missing heritability” issue [55]. A number of methodological
issues with GWAS can explain at least a portion of this missing heritability. Those
commonly put forward include the use of small sample sizes underpowered to de-
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tect common variants of small effect [55], causal variants not being in sufficient
linkage disequilibrium (LD) with measured SNPs to be detectable by association
[56, 57], and difficulties with disease diagnosis and ascertainment leading to sam-
ple heterogeneity or stratification (and a reduction in power) [58]. This last point
could be particularly applicable to ASD, given the known phenotypic heterogene-
ity, with the various syndromes, comorbidities, and monogenic causes displaying
different symptoms each displaying varying severities.
Several studies have attempted tomeasure the aggregate effect of common variants
on ASD liability [59, 60, 61]. These use approaches such as Genetic Relatedness Es-
timation through Maximum Likelihood (GREML), which estimates total variance
of liability by assessing the genetic relatedness of cases and controls across all the
SNPsmeasured on a genotyping array, as implemented in the Genome-wide Com-
plex Trait Analysis (GCTA) package [62]. In one of the first studies to apply the
GREML approach to ASD, Klei et al. used 965 families from the Simons Simplex
Collection (SSC) cohort and and 1141 families from the Autism Genome Project
(AGP) cohort, to derive estimates for a narrow sense heritability of > 60% for mul-
tiplex families and 40% for simplex families [59]. A study by Cross et al. using
the previously mentioned PGC sample investigated the heritability of five different
psychiatric disorders (as well as the correlation between these), and obtained a fig-
ure of 17% for the heritability by SNPs. Finally, in the most recent study, Gaugler
et al. [61] used the PAGES cohort (Population-Based Autism Genetics and Envi-
ronment Study) with over 1.6 million families to derive a heritability estimate of ∼
52% [61].
Overall, while SNP-based estimates of ASD heritability vary, they are consistently
lower than the previous estimates from twin studies. Since the GREML method
is based on a different set of assumptions it produces a lower bound estimate of
heritability, meaning that SNP-based estimates are not necessarily incompatible
with twin-based estimates. The gap between these estimates could be the result
of SNPs only tagging a proportion of the additive genetic variance. Alternatively,
it has been suggested that initial twin-based estimates were upwardly biased due
to various methodological issues including : inability to account for epistasis (G
x G interactions) [63], violation of the equal environments assumption [64], and
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failure to account for non-additive effects [61]. In support of the initial estimates
being inflated, more recent twin studies have tended to produce estimates closer
to that of the SNP-based estimates, with one of the largest and most recent studies
by Hallmayer obtaining a value of 38% for heritability [24]. As well as re-igniting
the debate about the extent to which inherited genetic risk plays a role in ASD,
these SNP-based estimates of heritability are also taken as support of the theory that
methodological issues are to blame for the lack of progress in identifying common
variants in ASD GWAS, and offer some reassurance that increases in sample sizes
should start yielding results.
Rare variants: Also contributing to disease risk are rare genetic variants present
in low frequencies in the population, which account for a large proportion of in-
dividual risk [54, 43]. Support for a substantial rare inherited component to ASD
comes from the observation that at least 10% of cases are the result of chromoso-
mal abnormalities and highly penetrant mutations. Indeed, a number of of studies
have attempted to quantify the contribution of rare inherited variants and CNVs to
ASD susceptibility. Marshall et al. performed genome-wide assessment of CNVs
and other structural abnormalities in 427 unrelated ASD cases, finding inherited
CNVs in 196 cases [65]. In a study of 411 families with sporadic ASD, Krumm
et al. found an increased burden of inherited CNVs in ASD cases compared to
their unaffected siblings, which were transmitted preferentially from the mother
[66].
In terms of the contribution from de-novo genetic point mutations and CNVs,
there have been multiple studies that have attempted to quantify these. For ex-
ample, study by Marshall et al. found that 7% of randomly selected idiopathic
cases from simplex families harboured de-novo CNVs, of which 11% had two or
more, while only 2%of cases frommultiplex families hadCNVs, compared to 1% in
controls [65]. More recent studies have made similar findings, observing de-novo
CNVs in approximately 8% of ASD cases compared to unaffected siblings [67, 68].
Another two studies examined the impact of heterozygous de-novo loss of function
mutations, finding that these occurred in around 20% of cases compared to unaf-
fected siblings [69, 70]. Gaugler et al. estimated the overall contribution of rare
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de-novo events to ASD and arrived at a slightly lower figure of 3% [61]. Here it was
also suggested that while de-novomutation is likely to make a significant contribu-
tion to individual liability, contribution to overall heritability was not likely to be
substantial.
Environment: Within the twin modelling paradigm, environmental influences
can be divided into shared/ common (C) - those affecting both twins equally and
serving to make them more phenotypically similar, and non-shared/ unique (E) -
which make twins growing up in the same family different. The non-shared envi-
ronment comprises de-novo genetic as well as non-genetic effects, the later of which
can include epigenetic, gene expression, environmental, or stochastic factors [25].
In ASD, it has been suggested that gene regulatory effects - potentially mediated
by epigenetic mechanisms, could be driving MZ discordance [24, 28]. While such
factors do not contribute to the heritable component of the disorder, they could
account for a substantial component of risk and perhaps paradoxically, they could
also explain some missing heritability. One way in which they could contribute
to missing heritability is by inflating concordance rates through “false heritabil-
ity’’ [71] and incorrectly partitioning non-additive genetic, de-novo variation, and
gene-environment interaction (G × E) into the additive genetic component [72].
Related to this, there is the possibility that gene-environment interactions could
modulate risk by altering response to certain environments (phenotypic plastic-
ity), which could further mask true genetic associations. More recent heritability
estimates leave plenty of room for the environment, for example, Gaugler et al. es-
timated the contribution of the environment to ASD liability to be approximately
40%, split between common and unique sources [61].
1.2.3 Conclusions
Overall, the findings from quantitative and molecular studies support a genetic
basis for ASD [25]. However, currently the identified common and rare variants
and de-novomutations explain no more than 20% of cases [11], and related to this,
there is still no coherent explanation of the underlying pathomechanisms of the
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disorder. The lack of progress thus far in uncovering the genetic risk architecture
of ASD is slightly perplexing, given that early estimates of the narrow sense her-
itability for ASD placed this as high 90 % [22]. More recent studies which use
SNP-based methods to estimate heritability suggest values of closer to 52% [61].
It would seem reasonable to deduce then that in the case of ASD, additive genetic
risk is likely to be a much smaller piece of the complete etiological puzzle than ini-
tially anticipated, and to better understand the biological basis of the disorder, we
must also investigate the impact of non-additive genetic and environmental fac-
tors.
In terms of where exactly this “darkmatter” of liability lies, comparisons ofMZ and
DZ twins have consistently found a moderate contribution from non-shared envi-
ronment, with estimates placing this between 20% and 38% [73, 74, 75, 76]. Epi-
demiological investigation of non-shared environmental factors is however fraught
with difficulty, especially given that these are likely to occur early in development,
and also because of the potential for confounding and reverse causation. This is
where investigation of intermediate molecular layers such as gene expression and
epigenetics may prove fruitful, as these are more tangibly linked to genetics as well
as underlying cellular processes, and can also reflect environmental influences, po-
tentially persisting long after the initial insult. In this thesis, we submit that the
characterisation ofmolecular differences between ASD discordantMZ twins could
provide a powerful means to uncover the biological mechanisms underlying the
non shared environment in ASD. Before we review the supporting evidence for
this, we will first cover some necessary background on epigenetics and regulation
of gene expression.
1.3 Epigenetic regulation of gene expression
1.3.1 Epigenetics
The term epigenetics is used to refer to mitotically heritable chemical modifica-
tions to DNA that alter the expression of a gene without changing the underlying
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sequence [77, 78]. Epigenetic regulation of gene expression is crucial for establish-
ing cell-specific patterns of expression during normal development [77, 78], and
for gene silencing - to control gene dosage in females by X-inactivation [79, 80], or
for allelic-silencing at specific loci according to parent-of-origin during imprinting
[81, 80].
A variety of different epigenetic modifications and marks act in concert to either
promote or repress a transcriptionally active chromatin state. These primarily con-
sist of chemical modifications to DNA such as cytosine methylation (discussed be-
low) and hydroxymethylation - which block transcription factor binding or recruit
chromatin structure modifying proteins, and post-translational histone tail mod-
ifications - which directly alter chromatin conformation. Examples of histone tail
modifications include: the addition/removal of methylation groups from lysine
residues (e.g. methylation of H3K4 and H3K36 for transcriptional activation, and
of H3K9 and H3K27 for repression), and also of acetyl groups (e.g. acetylation of
H3K9 and H4K14 for activation) - see [82] for an in-depth review. In addition to
these, there are a number of non-coding RNAs (ncRNAs) that interact with the
above mechanisms and also play an integral part of the epigenome (discussed fur-
ther in the next section).
1.3.2 DNA methylation
DNAmethylation is one of the best characterised epigenetic marks, describing the
addition of a methyl group to the 5 carbon of a cytosine base to form 5 methyl-
cytosine (5mC); a reaction catalysed by a group of enzymes called DNA methyl-
transferases [78]. This predominantly occurs in the context of CpG dinucleotides,
the majority of which are methylated. There are around 28 million such sites in
the human genome [83], and these tend to cluster in regions referred to as CpG
islands, characterised by high GC and CpG content [84]. These regions are typi-
cally associated with gene promoters, and are usually unmethylated, indicating a
transcriptionally active state for the gene, becoming methylated in the process of
differentiation [77]. DNA methylation of CpG islands promoters results in down-
regulation of gene expression, typically by blocking transcription factor binding,
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or by attracting methyl-binding proteins that in turn recruit chromatin modify-
ing activities [77]. CpG sites are also present downstream of promoters in gene
bodies, in both island and non-island contexts, where the relationship between
methylation and transcriptional regulation is not as generalizable and varies ac-
cording to genomic context, either following the canonical mechanism for silenc-
ing and/or downregulation, or paradoxically resulting in upregulation of expres-
sion [85].
1.3.2.1 Developmental establishment of methylation marks
During development, DNA methylation and histone marks are erased during two
distinct phases of epigenetic reprogramming (see review articles: [86, 87]). This
resetting of the epigenome occurs in primordial germ cells from day 10.5 to 13.4,
and then in the zygote after fertilization and extending into preimplantation devel-
opment [86]. The erasure of DNA methylation is widespread and comprehensive,
with overall methylation levels dropping as low as 10% (compared to 70% prior)
[88], thus allowing de-novo establishment of methylation patterns during devel-
opment to occur on a “blank slate”. These new methylation patterns are estab-
lished first in the germ cells, targeting CGIs which are required to be methylated,
for example, imprinting control regions which are important establishing parent-
of-origin specific expression in imprinted genes. A second wave of erasure then
occurs in the zygote post-fertilization in distinctive patterns on the maternal and
paternal genomes, this time not including imprinted regions. Following blastocyst
implantation, new methylation marks are then laid down which are important for
cell differentiation [87].
1.3.3 Methylomic assays and technology
1.3.3.1 Bisulfite sequencing
A number of different experimental assays have been developed to measure DNA
methylation status. The assay used largely depends on the study design and the
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aims of the study. For in-depth profiling of methylation status for a sequence of
interest in a small number of samples, the gold standard is whole-genome bisulfite
sequencing (BS-seq). BS-seq involves direct sequencing of DNA which has un-
dergone treatment with bisulfite, which converts unmethylated cytosine bases to
uracil (subsequently amplified as thymine during PCR amplification), whilst leav-
ing methylated cytosines unconverted [89]. Average, per-site methylation levels
can then be determined by effectively performing SNP calling at the sites of inter-
est, and quantifying the proportion of those which have been unconverted to those
which were converted. BS-seq can in theory be used to profile all 28 million sites,
but in reality such an approach would be prohibitive in terms of both time and cost
for studies involving a large number of samples [83].
1.3.3.2 Microarray
Epigenome-wide association studies (EWAS) attempt to characterise patterns of
methylation genome-wide, allowing for a hypothesis-agnostic investigation into
methylation for the trait or condition under consideration. For these types of
study, array based platforms are the most popular as they offer a high-throughput
quantification method, which sacrifices coverage and measurement accuracy for
reduced cost and ease of use [90]. The Illumina 450K array is one of the most
widely used, profiling just over 485,500 individual CpG sites across the genome,
covering <2% of all known CpG sites, and 99% of RefSeq genes [91]. Briefly, the
array technology works as for gene expressionmeasurement (see next section), but
in this case measuringmethylation of CpG sites by detecting base changes induced
in a sample following bisulfite conversion, by using probes with complimentary
sequence for the methylated and unmethylated variants of the alleles, yielding a
quantitative measurement of the proportion of methylated CpGs present at each
target sequence [92].
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1.3.4 Epigenetic mechanisms in disease
There has been particular interest in the role of epigenetic mechanisms in com-
plex disease, perhaps motivated by a number of important observations. Firstly,
there is the fact that marks are established early during development and undergo
two major waves of reprogramming. These periods of epigenetic plasticity repre-
sent critical periods where dysregulation could, for example in the case of neu-
rodevelopmental disorder, disrupt brain development with profound long-lasting
implications for disease susceptibility in later life (this might be considered a neu-
rological re-contextualising of the “developmental origins” hypothesis [93]). Sec-
ondly, numerous studies have shown that CpG methylation in particular, as well
as displaying inter-tissue variation within individuals, is also variable between in-
dividuals [94]. It has therefore been suggested that methylomic variation could ac-
count for some portion of phenotypic variance currently attributed to non-genetic
factors, and represent a plausible mechanism through which environment can in-
teract with genes. The “common disease genetic and epigenetic” (CDGE) hypothe-
sis [95], extends the common disease model to include this epigenetic component.
Such amodel could help to explain other complex disease phenomena, for example,
gender-based differences [96], MZ twin discordance [97], and age-related increase
in incidence [97].
The role of methylomic variation has been investigated in many conditions such
as cancers [98, 99], autoimmune disorders [100, 101] and neurodevelopmental
conditions[102, 103, 104]. A number of studies have looked for methylomic sig-
natures in ASD, and these will be summarised briefly in section 1.5.1.
1.4 Profiling patterns of gene expression
1.4.1 The transcriptome
The transcriptome is one of the most fundamental molecular levels at which phe-
notype can be influenced. As well as varying across tissues types, dynamically
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throughout the cell cycle (and over the course of development), gene expression
also displays natural variation between individuals [105]. Since gene expression
is only moderately heritable (∼30%) [106, 107, 108], these differences could then
reflect genetic as well as environmental, epigenetic, or stochastic differences. This
last point helps explain the current revival in transcriptomic studies, given the role
of the transcriptome as an intermediate, molecular phenotype, which also poten-
tially links genes and environmental effects via epigenetic mechanisms.
1.4.2 RNA varieties
Gene expression typically refers to protein codingmessengerRNAs (mRNAs), which
have important functional roles in the cell, and influence cellular phenotype in tan-
gible ways. One of the more surprising findings from contemporary genomics,
however, has been that despite the fact that the majority of the genome appears
to be transcriptionally active, only around 2% of genes are actually protein coding
[109]. In addition to important infrastructural RNAs (e.g. tRNA), are a variety
non-coding RNAs (ncRNAs), that are believed to be important for gene regula-
tion [110]. Small ncRNAs include small interfering RNAs (siRNAs), micro RNAs
(miRNAs), and PIWI-interacting RNAs (piRNAs), which regulate the activity of of
mRNA primarily through RNA interference. Long non-coding RNAs (lncRNAs),
are also involved in regulation, in some cases via interaction with epigenetic mech-
anisms such as chromatin remodelling and histone tail modification [111]. A well
characterized example of this type of regulation in action is that of the lncRNA
XIST, which silences the inactive X chromosome during X-inactivation by pre-
venting the transcriptional machinery from accessing the region and additionally
recruiting chromatin remodelling complexes to promote an inhibitory conforma-
tion [112].
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1.4.3 Expression profiling assays and technology
1.4.3.1 Microarray
For well over a decade, oligonucleotide arrays have been the technology of choice
for expression profiling [113]. Microarrays consist of millions of short fragments
of knownDNA sequence corresponding to partial sequences from annotated genes
(called probes), which are arranged and fixed onto a solid surface, typically a glass
slide. Transcripts are isolated from the sample, treated and then reverse transcribed
into cDNA, which is fluorescently labelled and hybridised to the array - these con-
stitute the target sequences. Any targets with sequence complementary to probes
will bind causing fluorescence to be emitted with intensity proportional to the the
abundance ofmRNA.The arrays are imaged in order to detect these binding events,
yielding intensity readings that can then be quantified and used to derive gene ex-
pression estimates (see [114] and [115] for detailed descriptions of the technol-
ogy).
1.4.3.2 RNA sequencing
In the past few years, microarrays have began to be replaced by RNA-sequencing
(RNA-seq) technology for gene expression profiling. In an RNA-seq experiment,
next generation sequencing is used to determine the sequence of bases making up
the various RNAs contained within in the sample (both mRNA and non-coding
varieties). In general, an RNA-seq experiment proceeds as follows: RNA from
the sample (either mRNA or total) is isolated, fragmented, and then converted to
cDNA libraries with adaptor sequences bound at both ends, which are then am-
plified by PCR and then sequenced using high-throughput genomics sequencing
technology. The resulting sequence reads are then mapped back to the genome
and quantified to produce a quantitative measure of gene expression (see [116] for
a summary). Utilising RNA-seq allows for a higher resolution investigation to be
conducted, enabling detection of a much wider range of gene expression includ-
ing low abundance transcripts that might otherwise be undetectable bymicroarray
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[117, 118], and non-coding varieties such as lncRNAs [119]. Because information
about the actual sequence is provided, other regulatory phenomena can also be in-
vestigated, including alternative splicing [118], and parent-of-origin effects (which
results in allele specific expression). Stranded approaches which preserve informa-
tion on which strand was transcribed form additionally allow antisense transcripts
to be detected [120]. Antisense transcripts are also believed to play an important
role gene regulation - a well-known example being the inhibitory role of the TSIX,
the antisense complement of the lncRNA XIST, which acts to regulate the expres-
sion of XIST during X-chromosome inactivation [112].
The main disadvantages of RNA-seq are the much greater cost associated with se-
quencing experiments, and a higher barrier for entry because of the computing re-
sources and bioinformatics required to analyse the data. Proclamations about the
“death of the microarray’’ may have therefore been premature, as for certain appli-
cations, for instance smaller scale exploratory gene expression studies, microarrays
can still often be the preferred option.
1.5 Non-genetic factors in ASD
1.5.1 Epigenetic
Current interest in the potential involvement of epigenetic mechanisms in ASD
is largely motivated by 1) demonstration of gene dosage effects for example at the
16p11.2 region [121], 2) the disruption of imprintingmechanisms observed in syn-
dromic forms of ASD such as Prader-Willi and Angelman, and 3) the involvement
of methylomic mechanisms in the pathologies of Fragile X and Rett syndromes.
In the case of Fragile X, the FMR1 gene contains a polymorphic sequence CCG in
the 5’-UTR which can undergo triplet repeat expansion, leading to hypermethyla-
tion of the promoter, histone deacetylation, and silencing of the gene [122]. FMR1
is itself encodes an RNA-binding protein, helping to regulate the expression of a
number of other mRNAs at the synapse, and its loss therefore impacts the normal
functioning of the synapse [35]. The FMR1 gene has also been implicated in idio-
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pathic ASD, with decreased gene expression in ASD affected individuals observed
[123]. As for Rett syndrome, the majority of cases are caused by a mutation in the
MECP2 gene, which encodes a methyl-CpG-binding protein important for tran-
scriptional regulation, histonemodification, and alternative splicing at the synapse.
Mutations in theMECP2 gene have been observed in a small number of ASD cases
[124], as has familial transmission ofMECP2 variants [125], and altered gene ex-
pression in ASD affected individuals as compared to controls [123]. As discussed
earlier, Prader-Willi and Angleman syndromes both arise from genetic lesions in
the 15q11-q13 region, with large paternal deletions giving rise to Prader-Willi and
largematernal deletionsUBE3A giving rise toAngelman. This region is also subject
to genomic imprinting, and it has been demonstrated that deletion of the identi-
fied imprinting control regions can give rise to both Prader-Willi and Angelman
[126]. In the case of Angelman, the causative gene has been identified as UBE3A,
where loss of function mutations cause the phenotype when inherited maternally,
but are benign when inherited paternally [126]. This is because expression of the
gene is tightly regulated via epigenetic mechanisms in a parent-of-origin specific
manner, with the paternal allele ordinarily silenced and only the maternal allele
expressed.
Motivated by these observations, there have been at least two recent investigations
into patterns of genome-wide methylation in ASD. A study by Nguyen et al. pro-
filed methylation in lymphoblastoid cell lines derived from 3 MZ discordant twin
pairs, 2 unaffected siblings, and 1 concordant control pair [127]. Autistic pairs were
diagnosed using the autism diagnostic interview-revised (ADIR) instrument, and
methylation profiling performed on CpG island arrays. The results revealed 201
genes with evidence of differential methylation when profiles from both co-twins
were compared to their unaffected siblings. Potentially relevant findings included
the identification of BCL-2 and RORA - which both displayed promoter hyper-
methylation, and pathway analysis revealed enrichment for pathways involved in
transcriptional control of expression, and nervous system development and func-
tion. Another study by our group examined methylation of 50 MZ twins pairs
including concordant, discordant, trait discordant, and age-matched controls, and
identified a number of differentiallymethylated regions associatedwith ASD [128].
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As this is highly relevant to the work described here, we reserve further discussion
of the findings until Chapter 2.
1.5.2 Environmental
It has been suggested that environmental factors could trigger the development of
ASD in individuals with an underlying genetic predisposition [129, 28]. Indeed, a
number of environmental risk factors for autism have been reliably replicated, in-
cluding: prenatal viral infection (by influenza, rubella, and cytomegalovirus [130]),
zinc deficiency [131], prenatal exposure to toxins (valproic acid [132], thalidomide
[133], psychiatric drugs [134]), and paternal age [135] (see [136] for an in-depth
review of the published findings).
Given that the timing of many of these exposures is early in fetal life, one sug-
gested mechanism by which ASD risk might be increased is through epigenomic
disruption and altered gene expression patterns during critical periods of brain de-
velopment [136, 28]. Support for this comes from the recognition that a number
of prenatal environmental risk factors are likely to directly interact with epigenetic
marks. For example, valproic acid is an anticonvulsant drug and is commonly pre-
scribed for treatment of seizures andmental health disorders such as bipolar disor-
der. Administration of valproic acid during pregnancy has been shown to increase
the risk of ASD by up to 16 times that seen in the general population [132], and
studies in rodents have shown also shown that administration in utero can impact
neurodevelopment leading to deficits in social behaviour and anxiety [137]. Given
that the agent is a known histone deacetylase inhibitor, one potential mechanism
of action is the disruption to methylation patterns and global levels of gene expres-
sion [138].
A number of studies have implicated levels of folate (vitamin B9) micronutrient
supplementation during pregnancy as a risk factor [139, 140, 141, 142].This re-
mains something of a controversial topic, especially since some of the findings
seem to be contradictory [139], with studies alternatively finding that an insuf-
ficient [141, 142] or excess [140] folate increases ASD risk. While clearly further
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research is required to establish the veracity of this link, there is at least some level
of biological plausibility. To begin with, periconceptional folate supplementation
has been shown to protect against neural tube defects [143]. One proposedmecha-
nism of action for this protective effect is through involvement of folate as a methyl
donor in the one carbon metabolic pathway [144, 145]. This pathway is essen-
tial for the establishment of DNA methylation patterns, and disruption has been
shown to decrease global methylation and affect gene expression, leading to ab-
normal brain development [145]. Linking this to ASD, are associations of muta-
tions in genes coding for constituents of the one carbon pathway, specifically S-
adenosylmethionine SAM [146] and 5-methyltetrahydrofolatereductase MTHFR
[147, 148].
Revising the multifactorial model: Based on the various genetic and epidemio-
logical findings, it seems likely that ASD susceptibility arises from both common
and rare variation, as well as epigenetic and environmental factors. An important
challenge is combining these in a unifiedmodel for population risk. While no such
model currently exists, there have been a number of attempts to combine genetic
and epigenetic effects and inherited and de-novomutation for particular subsets of
ASD cases. Jiang et al. proposed a oligogenic interaction model, where a combina-
tion of genetic and epigenetic factors both de-novo and inherited affect the expres-
sion of a small number of causative genes. This model is based on the epigenetic
and parent-of-origin effects observed in Prader-Willi and Angelman syndromes,
but the authors speculate that it might be more generally applicable in ASD [126].
Zhao et al. argued for a two-class risk model, where the majority of ASD arises
from de-novo mutation, arising in the parental germ line. Female offspring have
some protection against the behavioural manifestations of such mutations, but can
then carry the mutation, which is then passed on in a dominant mode of inheri-
tance [149].
While risk modelling is outside of the scope of this thesis, should non-genetic ef-
fects be found to have a substantial influence on ASD trait liability, then the multi-
factorial threshold model will need to be revised. A suitable model would have to
account for both genetic and epigentic risk, as well as being able to account for the
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heritability, phenotypic variance, and gender bias observed in ASD, as well as the
frequent co-occurrence with rare monogenic syndromes [150].
1.6 Gene expression profiling in ASD
1.6.1 Systematic review of published findings
It is perhaps not surprising given the importance of the transcriptome as an in-
tegrator of genetic, epigenetic and environmental influences, and the evidence for
epigenetic dysregulation inmonogenic and comorbid forms of autism, that a num-
ber of previous studies have investigated gene expression in ASD. To identify rel-
evant studies, a Pubmed search was conducted using the terms: (gene expres-
sion[Title] OR transcription[Title] OR transcriptomic[Title]) AND (autism[Title]
OR autistic[Title] OR ASD[Title]) AND ”humans”[MeSH Terms]. This yielded 47
results, which were then manually filtered to retain only those using genome-wide
approaches, giving a final list of 15 papers (shown inTable 1.1). Herewe summarise
the findings.
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Reference Sample Gender (M:F) Age range Tissue Platform Main findings
Purcell et al. (2001) 10 ASD 9:1 5-54 Brain (CB,PFC,CN) Clontech Atlas Human Neurobiology (MA) ↑ glutamate/AMPA
23 controls
Hu et al.(2006) 6 ASD/non (MZd) 6:0 6-16 LCL TIGR 40K (MA) ↑ neurological function 
4 ASD (MZc) 4:0 6-16 ↓ 5-HTT
↑↓ nervous system development
↑ inflammation
Nishimura et al.(2007) 8 ASD/FX 8:0 N/A LCL Agilent WHG G4112A (MA) ↑↓ cell communication
7 ASD/15q11-q13 7:0 ↑↓ immune related
15 controls ↑ JAKMIP1
↑↓GPR155
Garbett et al. (2008) 6 ASD 4:2 4-30 STG Affymetrix U133 Plus 2.0 (MA) ↑↓ cell communication
6 controls ↑↓ differentiation
↑↓ cell cycle
↑ immune related
↓ neuronal development
↑ transcriptome variability
Gregg et al.(2008) 35 AU 30:5 N/A Blood (whole) Affymetrix U133 Plus 2.0 (MA) ↑  NK/CD8+ cell mediated cytotoxicity
14 ASD 13:1 ↑↓ glutamate neurotransmission
12 controls
Enstrom et al.(2009) 35 ASD 30:5 2-6 Blood (whole) Affymetrix U133 Plus 2.0 (MA) ↑  NK 
12 controls ↓  cellular proliferation
Hu et al.(2009) 21 ASD 21:0 4-14 LCL Invitrogen custom (MA) ↑↓ cholesterol metabolism
21 unaff sibs ↑↓ androgen biosynthesis
↑↓ immune related
↑↓ nervous system development
↑↓ cytoskeleton
Hu et al.(2009b) 86 ASD 86:0 5-28 LCL TIGR 40K (MA) ↑↓ circadian rhythym
30 controls ↑↓ androgen sensitivity
↑↓ inflammatory response
↑↓ axon guidance
↑↓ apoptosis
↑↓ neurogenesis
↑↓ cell survival
↑↓ transcriptional regulation
Alter et al. (2011) 82 ASD 82:0 mean = 5 Blood (PBL) Affymetrix HuGe U133 Plus 2.0 (MA) ↓  variance global expression
64 controls ↓  transcriptional regulation
↑↓ zinc
Seno et al (2011) 20 ASD 13:7 N/A LCL Illumina Human-Ref8 v3 (MA) ↑↓ nervous system development
22 unaff sibs ↑↓ long term potentiation
↑↓ NOTCH signalling
↑↓ neuroligical disorders (RETT)
Kuwano et al. (2011) 21 ASD 17:4 18-35 Blood (PL) Agilent WHG oligoDNA (MA) ↓  ribosomal
21 controls ↑  MECP2
↓  FMR1
Voineagu et al. (2011) 19 ASD 14:5 2-56 Brain (STG,BA9,CV) Illumina Ref v3 (MA) ↓  synaptic
17 controls ↑  immune/inflammatory
◊ A2BP1/FOX1
Chow et al. (2012) 9 ASD (child) 9:0 2-14 Brain (DLPFC) Illumina Human-Ref8 v3 (MA) ↑↓ neurogenesis
7 control (child) ↑↓ cell cycle DNA-damage resp
6 ASD (adult) 6:0 15-56 ↑↓ apoptosis and survival
11 control (adult) ↑↓ immune response
↓  cytoskeleton and ECM
↑↓ A2A receptor
↑↓ development
↑↓ signalling
↑↓ oxidative stress
↑↓ WNT
Glatt et al. (2012) 37 ASD 29:8 1-3 Blood (PBMC) Illumina WG-6 v3 (MA) ↑↓ immune response
23 PDD ↑↓ globin
17 DD
34 LD
27 controls
Kong et al. (2013) 20 ASD 17:3 4-17 Blood (whole) Affymetrix Gene 1.0 ST (MA) ↑  ribosomal
20 unaff sibs ↑  spliceosomal 
18 controls ↑  mitochondrial
↓  neuroreceptor-ligand
↓  immune response
↓  calcium signalling
AD = autistic spectrum disorder PL = peripheral leukocytes                                MA = microarray ↑ = up regulated
PDD = pervasive developmental disorder PBMC = peripheral blood mononuclear cells ↓ = down regulated
DD = developmental delay STG = superior temporal gyrus ↑↓ = differentially regulated
LD = language delay BA9 = prefrontal cortex ◊ = differentially spliced
MZd= MZ discordant CV = cerebellar vermis
MZc = MZ concordant DLPFC = dorsolateral prefrontal cortex
FX = Fragile X PBL = peripheral blood lymphocytes
LCL = lymphoblastoid cell line
NK = natural killer cells
CB = cerebellum
PFC = prefrontal cortex
CN = caudate nucleus
Table 1.1
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In one of the first studies to investigate gene expression in the context of ASD,
Purcell et al. examined global gene expression changes in post mortem cerebellar
tissue for a sample of 10 ASD affected and 23 control subjects [151]. Two differ-
ent early array platforms were used (covering < 10,000 genes), with polymerase
chain reaction (PCR) used for validation of top differentially expressed genes, and
Western blotting used as a complementary approach to measure the protein lev-
els for these genes. Following standard data processing steps, differential expres-
sion between the groups was assessed using t tests. Overall, while the majority
of genes were found to show no differences in expression between ASD and con-
trol, 30 genes were found to be differentially expressed, including genes related
to glutamate neurotransmission: GluR1,GluR2, GluR3 and EAAT1, EAAT2, which
were found to be upregulated in ASD cases compared to controls. Protein levels
for GluR1,EAAT1, EAAT2 were also consequently found to be increased. In the
discussion, the authors suggest that the results support a glutamate hypothesis of
ASD, where given its importance for synaptogenesis and neuronal outgrowth dur-
ing development, that it could be particularly vulnerable to disruption. Several
limitations of the study are also acknowledged, including: the use of post–mortem
tissues collected long after the onset of the disorder - making it entirely possible
that the expression differences are secondary to the disorder, and the presence of
sample heterogeneity – with clinical variations such as intelligence quotient (IQ)
and presence of seizures.
Hu et al. performed genome-wide gene expression profiling of lymphoblastoid cell
lines derived from 3 pairs of MZ twin pairs discordant for ASD and 4 pairs con-
cordant for ASD [152]. For three sets of male twins, one member of each pair
had met the ADI diagnostic criteria, while the other was not and classed as ei-
ther broad spectrum or not quite autistic. Two pairs of concordant ASD twins
were also used. Expression profiling was carried out on an array platform mea-
suring ∼ 40,000 genes, and the data processed. Differential expression analysis
was performed using a modified t statistic test (SAM – significance analysis of mi-
croarrays), with significance thresholds set at FDR < 0.26 and log fold change of∼ 0.58). The results from the within-discordant pairs analysis showed 25 genes as
being significantly up-regulated in the affected twin compared to the unaffected
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twin, and 19 genes down-regulated (for the same thresholds). A number of these
genes were found to correspond to genes involved in neurological development,
and of those confirmed by qPCR included: ASS, DAPK1, IL6ST, EIFC2. Pathway
analysis across all pairs additionally highlighted nervous system development and
cytokine signalling as being enriched. Concluding, the authors suggest that their
study supports the use of peripheral tissue for identifying biomarkers, and suggest
that a blood based screen could be developed. In terms of the identified genes, it
is also observed that a number of the neurologically relevant genes are also linked
to inflammatory networks, consistent with the hypothesis of neural inflammation
being important in ASD.
Another study by Nishimura et al. also profiled lymphoblastoid cell lines [153].
Here, the cell lines were derived from individuals with twomonogenic ASD etiolo-
gies, with 8 males diagnosed as having Fragile X (FX) with associated autism and 7
males with a duplication in the 15q11-q13 region (dup (15q)), and 15 non-autistic
males used as controls. Expression profiles were generated using microarrays, the
data processed, and then compared across all three groups. A total of 293 genes
were found to be differentially expressed using ANOVA and an FDR threshold of
5%, these included FMR1 andUBE3A as expected (the single gene causes identified
for these syndromes) and CYFIP1 – a known antagonist of the FMR1 gene prod-
uct. Clusteringwas performed using theDE genes, which successfully classified the
individuals into their correct experimental groups. Further analyses identified an
overlapping set of 68 genes that were dysregulated in both FX and dup (15q) cases,
with 52 dysregulated only in FC and 12 in dup(15q). Validation of the expres-
sion of 19 selected genes was performed using qRTPCR, of which 17 were found
to be differentially expressed. Pathway analysis revealed that genes involved in cell
communication were upregulated in the 68 overlapping genes, along with enrich-
ment of immune response. In the FX dysregulated gene lists, there was enrichment
of chaperone and protein folding genes, and in the dup (15q) genes, there was en-
richment for those involved in RNAbinding andmRNAmetabolism. Next, using a
neuronal cell line and short hairpin RNA (shRNA), the expression of FMR1was re-
duced andCYFIP1 to examine the the downstream effects. Two downstream genes
were found to be significantly differentially expressed: JAKMIP1 andGPR155, and
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this was further validated in knock out mouse models. Finally, the expression of
these two genes was examined 27male sibling pairs discordant for ASD,where they
were also found to be differentially expressed. Overall, the authors claimed the re-
sults firstly demonstrated that it was possible to distinguish ASD etiologies from
each other based on gene expression signatures, secondly that there were likely to
be commonly dysregulated pathways, and thirdly that the findings were generaliz-
able to idiopathic ASD.
Expression profiling of post mortem temporal cortex in ASD was performed by
Garbett et al. [154]. The samples were taken from the superior temporal gyrus
of 6 ASD cases and 6 matched controls, gene expression quantified by microar-
ray (interrogating approximately 38,000 genes), and the data processed following
the standard analysis pipeline. Using paired t tests and significance cutoffs of log
FC > 2 and p < 0.05, 152 genes were identified as differentially expressed of which
130 showed increased expression and 22 decreased expression. For validation, 20
genes were selected for qPCR analysis, in which 80% remained significant, includ-
ing the genes HSPA6, HSPB8, MAP2K3, NOTCH2 amongst others. Higher level
analysis using gene set enrichment (GSEA) testing revealed significant overrepre-
sentation for a number of immune system related pathways including those in-
volved in antigen-specific immune response (e.g. TOLL, TNFR2, IL2R), inflam-
mation (e.g. NFKB, IL1R, GSK3) , cell death (e.g. NFKB, TNFR2, P38MAPK),
and auto-immune disease (e.g. NFKB, TOB1, FAS). In concluding, the authors
suggest that the results firstly indicate that transcript activation is more common
than repression in ASD cases, the autistic transcriptome is characterised by an over
active immune response, that transcription of genes related to cell communica-
tion, differentiation and cell cycle regulation is altered in a potentially immune
system-dependent manner, and that the transcriptome showed increased variabil-
ity in ASD.
In one of the first studies to investigate the autistic transcriptome in whole blood,
Gregg et al. [155] conducted microarray expression profiling using samples taken
from35 childrenwith autism (clinically diagnosed usingADI-R andADOS screen-
ing tests), 14 with ASD (not meeting full criteria in one or more domains), and 12
age matched and gender matched controls from the general population. Data was
37
Chapter 1. Introduction
processed as per standard procedures, and genes were tested for differential expres-
sion between the groups using unpaired t-tests, with FDR < 5% and log FC ≥ 1.5
used as thresholds. For the ASD group, no genes were found to be significantly DE
when compared to either the autism group or controls. For the autism group, 55
genes were identified as DE when compared to the control group. The differential
expression for a number of these geneswas subsequently confirmed using RT-PCR.
Pathways analysis revealed an enrichment of genes involved in natural killer (NK)
cell-mediated cytotoxicity, including the IL2RB and EAT2. Overall, these results
suggested that gene expression differences associated with autism are detectable in
whole blood, and further taken as supporting a role for abnormalities in peripheral
blood leukocytes in ASD.
Enstrom et al. also performed microarray expression profiling using whole blood
samples obtained from 52 children with ASD and 27 typically developing controls
[156]. This study focused primarily on the NK cell related genes that were previ-
ously identified in the Gregg et al. study [155]. The data was processed, and differ-
ential expression analysis was then performed using unpaired t-tests which identi-
fied 626 probes, 544 ofwhichwere downregulated and 82 upregulated inASD com-
pared to controls. From the list of upregulated probes, corresponding to 59 genes,
30 of these were associated with leukocytes and 22 were associated with cytolytic
cells, mainly NK cells. To further investigate the functional and physiological im-
plications of this altered gene expression, a number of single cell and direct protein
analyses were performed. Cell isolation showed a significantly higher proportion
of NK cells in the peripheral samples from the ASD cases, and an NK cytotoxicity
assay, showed decreased NK activity in ASD. Concluding, the authors suggest that
because NK cells are important for host defence against infections, play a role in
autoimmunity and inflammatory processes in the brain, and are the predominant
immune cells in early development, that altered NK cell response could modify
susceptibility to infections potentially impacting neural development. Thus, dif-
ferences in gene expression of NK cell related genes and the functional implica-
tions of these differences represent a neuroimmune explanation for a component
of ASD risk.
Hu et al. interrogated genome-wide gene expression in lymphoblastoid cell lines
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derived from21 sibling pairs inwhich one sibling had diagnosedASDand the other
was non-autistic [157]. To reduce phenotypic heterogeneity, only ASD presenting
with severe language impairment (as assessed by the ADIR screening test) were
selected for the study. Expression profiles were generated using a microarray mea-
suring ∼ 40,000 genes, and following standard data processing steps, differential ex-
pression analysis was performed to compare ASD affected siblings with their non-
autistic siblings, using a modified t statistic test (SAM) with significance threshold
set at a log fold change of ∼ 0.3. A number of differentially expressed genes of po-
tential relevance were identified, including SCARB1 and SRD5A1, both involved
in steroid hormone bionsynthesis, and SCN5A, a sodium channel expressed in the
limbic brain. Pathway analysis of the gene list revealed an enrichment of pathways
involved in endocrine system development, cholesterol metabolism apoptosis, dif-
ferentiation, inflammation, and epilepsy. A selection of 6 genes had their differen-
tial expression confirmed by qRT-PCR, and steroid profiling was performed on 3
randomly selected sib pairs, to test the hypothesis that the qRT-PCR confirmed dif-
ferences in SCARB1 and SRD5A1 expression could result in increased testosterone
biosynthesis, which was subsequently found to be the case. Overall, the results
were taken to suggest that disruption to normal androgen levels could have conse-
quences for neurodevelopment and function, potentially giving rise to the autistic
phenotype (and perhaps explaining the gender bias).
Another study by Hu et al. [157] used lymphoblastoid cell lines derived from 116
individuals with ASD and age-matched, unaffected controls. ASD cases were strat-
ified into 3 different groups according to severity of symptoms across the items
in the ADIR screening test, and females excluded, along with individuals with
known genetic or chromosomal abnormalities, those born prematurely, and those
with comorbid psychiatric conditions. In an accompanying study, the resulting
subgroups were analysed and found to correspond to mild ASD, severe language
impaired, and ASD with savant skills endophenotypes. Gene expression profiles
were generated using microarray technology to assess ∼ 40,000 mRNAs across the
genome, and standard array data processing steps were carried out. Differential ex-
pression analysis was then performed using SAM, with a two-class comparison of
ASD affected and controls, and a four-class comparison of the three different ASD
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subgroups and controls, with the significance threshold specified at FDR < 5%.
Selected significant results were subsequently confirmed using qRT-PCR. The re-
sults revealed a set of significantly differentially expressed genes common across all
ASD cases when compared to controls, including ITGAM, NFKB1, RHOA, SLIT2,
MBD2, with some genes further showing a quantitative relationship between level
of gene expression and severity of ASD phenotype. The analysis of the different
subgroups revealed differentially expressed genes specific to those groups. Path-
way analysis of the common DE genes in ASD revealed an enrichment of genes
involved in synaptic transmission, neurogenesis, neurulation, long term poten-
tiation, and protein ubiquitination. Separate pathway analyses were also carried
out for the ASD subgroup. For the severely-language impaired group there was
an enrichment for genes involved in apoptosis, in the mild ASD group there was
enrichment for small molecule biochemistry, free radical scavenging, and cellu-
lar function, and finally in the savant group, RNA posttranscriptional modifica-
tion was highly significant. In the severely-language impaired group, 15 genes in-
volved in regulation of circadian rhythmwere also identified. Next, to test whether
the identified differentially expressed genes had any relationship with known ASD
susceptibility loci, they were mapped to previously reported QTLs. It was found
that around a third of significant genes were associated with autism QTLs, and
that these were significantly enriched on chromosomes 7, 10, 16, 17 and 22 for the
combined group. Concluding, the results showed differences in gene expression
between the ASD subgroups and controls, with specific pathways implicated in the
different subtypes, and common genes implicated across subgroups indicating that
basic deficits may also underlie ASD, namely, apoptosis, inflammation, and axon
guidance.
Alter et al. examined global expression changes in autism related to paternal age,
using peripheral blood lymphocytes from 82 ASD affected children and 64 con-
trols [158]. Cases had a formal autism diagnosis according to DSM-IV, and were
confirmed byADOS andADI-R, individuals with known genetic disorder were ex-
cluded, along with high functioning individuals (Asperger’s). Expression profiling
was performed using microarray technology designed to measure the expression
of 38,500 genes, and standard data processing steps performed. The primary anal-
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ysis in the study was of the variance in the distribution of gene expression levels in
ASD cases compared to controls, for which the expression values were log2 trans-
formed, and the average squared deviations from the mean calculated. ASD cases
were found to have significantly decreased variance in gene expression compared
to controls. Taking paternal age into account, significantly decreased overall vari-
ance in gene expression was observed for controls in association with increasing
paternal age, and the overall variance for children from older fathers was the same
as that for children with ASD from fathers of any age. In terms of the specific dif-
ferences in expression seen, there were many more significantly down-regulated
genes in ASD children and children with older fathers. Furthermore, there was a
significant overlap between the genes found to be up or down regulated for children
with autism and children of older fathers. Pathway analysis of these overlapping
genes revealed enrichment for multiple pathways associated with transcriptional
regulation, particularly in the down regulated genes. Overall, it was concluded
that dysregulation of transcription could underlie the decreased variance in global
gene expression in children from older fathers, with increased risk for ASD.
A study by Seno et al. investigated mRNA and miRNA expression in ASD using
lymphoblastoid cell lines derived from 18 families comprising 20 severely autistic
cases along with their 20 unaffected siblings. Case status was ascertained using the
ADOS, and previously generated SNP array data was used to confirm that none of
the individuals had detectable CNVs in known susceptibility loci. Gene expres-
sion profiling was performed on platforms assaying both mRNA and miRNA, and
after following standard data processing steps, differentially expressed genes be-
tween cases and controls were identified using Generalized Estimating Equations
(GEE). In order to select a final list of genes, it was also required that the genes
showed a logFC of at least 1.5 fold in 50% of the sibling pairs. A number of po-
tentially interesting genes were identified including ARHGAP24, IFITM3, GBP4,
HEY1, and SOX9. For six of the identified genes, RT-qPCR was used to confirm
the levels of expression. Some miRNAs were also identified as being differentially
expressed, the top hit being miR-199b-5p. Pathway analysis subsequently revealed
an enrichment for nervous system development and neurological disorders - with
Rett syndrome showing the most significant association in this category. Overall,
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the authors conclude that their results show that a number of genes and miRNAs
important for nervous system development and function are disrupted in ASD,
particularly those genes involved in kinase and NOTCH signalling. Further, the
results suggest a potential overlap with Rett syndrome.
Kuwano et al. examined expression in peripheral blood samples from 21 adoles-
cents and adults with ASD, age-matched controls, and additionally healthy moth-
ers of children with ASD and control mothers with typically developing children.
The cases had a pre-existing diagnosis of ASD, which was also confirmed using the
DSM-IV. Microarrays were used to assess gene expression across approximately
20,000 genes, and data was processed using the standard protocol. Differential ex-
pression analysis was performed using unpaired t test to compare ASD cases with
their age-matched controls, with significance thresholds specified at FDR < 0.05
and logFC > 1. A number of genes were found to be up-regulated in cases com-
pared to controls, including C12ORF58, ITGA2B, LHB, MYOG, NOVA2, NUMBL,
PLCXD2, SDK2, TAOK2, UTS2, WDTC1. Pathway analysis revealed these to be
involved in cell morphology, cellular assembly and organization, nerve system de-
velopment and function. Next, mothers of autistic children were compared to con-
trols using the same analysis strategy as before. Genes coding for ribosomal protein
were identified, as well as those involved in immune functions like antigen presen-
tation and cell-mediated immune response. Finally, the results fromASD cases and
mothers of ASD cases were compared, which revealed a large degree of overlap in
the genes and identified and the direction of their differential expression. Signifi-
cant results were confirmed by qPCR, which was also used to measure the levels of
known ASD candidate genes, where it was found that FRM1 levels were reduced
in ASD cases, andMECP2 levels were elevated in both ASD and mothers of ASD
children. Concluding, the authors state that the genes identified might help reveal
the pathology of ASD, with nervous system development and ribosomal pathways
identified, along with decreased expression of known ASD candidates.
Voineagu et al. used microarrays to profile gene expression in post-mortem tissue
samples from 19 ASD cases and 17 controls, specifically examining the superior
temporal gyrus, prefrontal cortex and cerebellar vermis regions [159]. Following
data generation and processing following standard protocols, differential expres-
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sion analysis was carried out using SAM with significance set at FDR < 0.05 and
fold change > 1.3. In total, 444 genes were significantly differentially expressed
in ASD compared to controls in the cortex, and there was a significant overlap be-
tween identified genes in the frontal and temporal cortex. Only 2 genes were found
to be differentially expressed in the cerebellum, which was then excluded from fur-
ther analysis. RT-PCR was used to confirm the changes for a selection of genes, for
which 83%were subsequently confirmed. Gene enrichment analysis showed down
regulated genes were enriched for synaptic function, whereas up regulated genes
were enriched for genes involved in immune system and inflammatory response.
A number of these genes were successfully replicated in another cohort of 9 ASD
cases and controls, with many showing expression changes in the same direction
as the original discovery cohort, including the DLX1 and AHI1. Higher level, co-
expression analysis revealed that regional differences in expressionwere attenuated
in the frontal and temporal lobe in ASD cases. Further co-expression type analy-
sis revealed an overrepresentation of ASD susceptibility genes in the top module
of co-expressed genes including CADSP2, AHI1, CNTNAP2, SLC25A12. The sec-
ond module was enriched for astrocyte markers, markers of activated microglia,
immune and inflammatory genes. Next, RNA-seq was used to assess differential
splicing, where it was confirmed that a number of alternative splicing events are as-
sociated of A2BP1 are associated with ASD. Finally, to help determine the etiology
of the observed changes, the co-expression modules were tested for enrichment of
previously identifiedGWAS susceptibility loci, where it was foundwhile the synap-
tic module was enriched, the immune module was not. Overall, the results were
taken as support for the role of synaptic dysfunction and altered immune response
in ASD, and further, that synaptic changes are likely to be genetic whereas immune
changes are likely to be secondary or caused by environmental factors.
A study by Chow et al. investigated the relationship between altered gene ex-
pression in ASD and age using post-mortem dorsolateral prefrontal cortex sam-
ples from 9 ASD and 7 control children, and 6 ASD and 11 control adults. Mi-
croarrays were used to assay gene expression for 18,626 genes, and data was pre-
processed following the standard analytical procedures. To assess differential ex-
pression between young autistic, young control, adult autistic, and adult control,
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two-way ANOVA was used, and to identify genes showing an effect for interac-
tion between age and diagnosis, an overall pairwise ANOVA-based F-test was used
with significance set at FDR < 0.27. In total, 102 genes were identified that showed
differential expression in young ASD cases compared with controls and showing
an age group interaction effect. Pathway enrichment suggested enrichment for
DNA-damage response, cell cycle and apoptosis, immune signalling, neurogenesis
and neural development. A number of genes of interest were highlighted includ-
ing BRCA1, CHK2, FAS, BCL3, GREM1, FOSL2, FGF1, HOXD1, NDE1, NODAL,
PCSK6. As for the gene expression differences in adult ASD cases compared to
controls, 736 genes were identified, which were enriched for cell differentiation,
mitogenic signalling and apoptosis. Notable genes included MAPK12, CDKN1A,
NTRK3, PRKAR1A, PIK3CA, CASP9, MAPK10, ADCY6, MAGED1. Finally, com-
paring differentially expressed genes betweenASD and control independent of age,
over 2000 genes were identified. These were enriched for DNA-damage response,
apoptosis, and immune system response, and p53-PTEN signalling. Concluding,
the results showed that in young autistic brains genes and pathways important for
development are disrupted, whereas in adult brains, those important for neuro-
genesis and repair are disrupted. As for age-independent differences, the results
suggested the involvement of immune system response, DNA-damage response,
and apoptosis.
Glatt et al. performed expression profiling of peripheral blood mononuclear cells
from 60 infants and toddlers at risk for ASDs, 34 at risk for language delay, 17 at
risk for global developmental delay, and 68 typically developing controls. Chil-
dren were initially diagnosed using the ADOS and ADI-R tests. The samples were
run on microarrays and the generated data was pre-processed following standard
protocols. For the analysis, the sample was split into discovery and replication
samples, differentially expressed genes identified using analysis of covariance (AN-
COVA) with threshold for significance specified as nominal p < 0.05 and logFC ≥
1.2. The identified genes were used to build a support vector machine (SVM) clas-
sifier, which was subsequently tested for classification accuracy in the independent
replication samples. The results showed 154 genes with significant differential ex-
pression in ASD cases compared to controls, which were then used to build, opti-
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mize and test the SVM classifier. The final classifier chosen used 48 genes correctly
classified 71% of ASD subjects across 10 subsets of the discovery sample into their
correct diagnostic categories. When applied to the replication sample, the classi-
fier placed 91% of the subjects into their correct category, and the overall sensitivity
was 0.93 and specificity 0.88. Pathway analysis revealed that the 48 genes making
up the classifier were enriched for immune response and haemoglobin complex.
Concluding, the results provide robust evidence for the existence of a gene expres-
sion profile for ASD that is detectable in blood, that could serve as an accurate
diagnostic test.
Finally, Kong et al. [160] investigated gene expression in 20 ASD and unaffected
sibling pairs and 18 unrelated controls taken from the Simons Simplex Collection
(SSC). Diagnoses were made using the ADOS and ADI-R. Gene expression pro-
filing was performed using microarrays measuring a total of 28,869 genes, and the
data processed following the standard analysis strategy. In order to identify differ-
entially expressed genes between ASD cases and unaffected sibling, linear mod-
els were used, with significance threshold specified at p < 0.01. This identified
163 genes which included two previously reported ASD candidates CTNNB1 and
XPO1. The subjects were then clustered based on their gene expression profiles,
which revealed subgroups of siblings, displaying higher similarity to ASD cases -
termed proband-like, and less similar – termed control-like. Geneset enrichment
analysis revealed that ribosome and spliceosomal pathways were up regulated and
immune signalling downregulated in ASD cases compared to proband-like sib-
lings. Concluding, the gene expression profiles generated were able to distinguish
ASD affected from unaffected siblings, and further implicated upregulation of ri-
bosomal andmitochondrial genes, and down regulation of immune response path-
ways.
The overall pattern emerging from gene expression studies is of disruption of nor-
mal transcriptional control, and the potential involvement of an immune or in-
flammatory component in ASD. This perhaps in contrast to genetic studies which
have tended to implicate synaptic organization and inhibitory/excitatory pathways,
therefore the identification of these alternative pathways to ASD suggest that gene
expression profiling could be revealing another dimension to ASD pathology. A
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less generous interpretationmight be that the frequent identification of these path-
ways in fact reflects limitations with the genome-wide expression approach, par-
ticularly the use of non-primary tissues. This would seem unlikely however, as the
findings seem to be consistent across the majority of the studies, which use differ-
ent cohorts, populations, diagnostic criteria, and tissue types - including cortex and
cerebellar samples. Some limitations of these previous studies are that firstly, with
the exception of the Hu et al. study [152], they are not designed to separate gene
expression differences resulting from non-shared environmental factors, to those
arising from shared environment or genetic factors. Secondly, due to the limi-
tations of microarray profiling technology, they investigate only transcript abun-
dance, and by doing so could be missing alternative splicing and allele-specific ex-
pression events associated with ASD. Newer techniques such as RNA-seq enable
these other transcriptomic phenomena to be investigated.
1.7 Gene expression profiling of monozygotic twins
with ASD
1.7.1 Monozygotic twins
There aremany challenges associatedwith transcriptomic and epigenetic investiga-
tions, especially those comparing affected cases with unaffected controls. Because
unrelated individuals possess distinct genetic backgrounds, any observed differ-
ences at the level of gene expression or DNA methylation can be genetic or non-
genetic in origin. Using population-base case-control studies, it is often not pos-
sible to disentangle the relative contribution of these or to determine if the differ-
ences are likely to be driven by environmental factors. Primarily for these reasons,
some authors have suggested utilising twin-based study designs more generally in
the study of complex traits and conditions [161, 162, 163, 164, 165].
MZ twins are genetically identical in the absence of any identified rare, non-inherited
genetic variation, yet can often display divergent phenotypes. This has been ob-
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served for a range of neurodevelopmental conditions including schizophrenia [166],
bipolar disorder [167], and ASD [25]. Incomplete concordance in MZ twins sug-
gests a causal role for epigenetic, stochastic, and/or environmental factors. In sup-
port of this, variations in gene expression and DNA methylation are observed in
MZ twins, which may in turn underlie phenotypic variation [105, 163]. A study
design comparing discordant twins enables themolecular basis of trait discordance
to be explored, as well as providing a means to separate genetic from non-genetic
influence. This is possible becauseMZ twins, in addition to being genetically iden-
tical, are also matched for age, gender, maternal environment, population cohort
effects, and exposure to other shared environmental factors [161]. Any identified
phenotypic differences (and by extension, molecular differences) are then thought
to be predominantly attributable to non-genetic influences [168, 169].
1.7.2 Gene expression profiling of MZ twins with ASD
InChapters 2 and 3, we describe two gene expression studiesmaking up a large part
of the empirical work undertaken for this thesis. We utilise a twins-based design
with ASD concordant, ASD discordant, and matched control MZ pairs for whom
whole-blood samples and behavioural measurements are available. Gene expres-
sion profiles are generated using both microarray and RNA-seq technologies, with
the overall aim to investigate patterns of gene expression in ASD, and identify the
genes and pathways disrupted. Further, by focusing on differences within the MZ
discordant pairs, we hope to identify which perturbations are responsive to the
non-shared environment.
1.7.3 Potential limitations of this study
There are a number of potential limitations associated with the proposed methods.
As we will later rely on the data produced by our profiling experiments for integra-
tive analysis (introduced in the next section), it is worth spending some time now
considering each of these limitations in turn, as they ultimately have implications
for the types of inferences that can be made.
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1.7.3.1 Are gene expression measurements reliable?
Genome-wide approaches are predicated on the robustness of genome-wide gene
expression signatures. This is almost taken as axiomatic, given that transcriptomics
methods are so well established, but nonetheless, a large meta-analysis by Dudley
et al. showed expression profiles to be highly concordant between disease states,
across tissues, and even across separate studies [170].
1.7.3.2 Do mRNA levels correspond to protein levels?
The question of to what extent mRNA levels actually correspond to protein lev-
els, is an important one, but one that is not easily answered. Post-transcriptional
mechanisms in the cell, such as RNAi by ncRNAs, can regulate levels of mRNA,
meaning caution must be used when attempting to interpret the functional impli-
cations of increasedmRNA expression. As a general rule, increasedmRNA expres-
sion can be taken as indicative of an increased level of the protein product, how-
ever this relationship should ideally be determined on a gene-by-gene basis and in
the context of the trait being studied - to investigate potential quantitative or gene
dosage effects. Previous expression studies into ASD have for example, quantified
the abundance of protein products for genes previously identified as differentially
expressed (see earlier reviews of the Purcell et al. [151] and Hu et al. papers [157]).
We may choose a similar approach in a follow-up study, should we identify any
coding genes showing evidence of differential expression in our ASD twins.
1.7.3.3 Are expression differences between MZ twins detectable?
An important question in the context of this project, is whether expression differ-
ences between MZ twins are large enough to be detectable. A number of studies
have investigated this more generally. Firstly, Sharma et al. assessed natural varia-
tion in gene expression for 5 pairs of MZ twins and compared this to 13 unrelated
individuals using microarrays [105]. Here it was found that < 2% of genes showed
differential expression between twins, whereas for unrelated individuals this was
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much higher, at 14%. On the basis of the results it was then suggested expression
profiling of MZ twins could be valuable for identifying environmentally sensitive
expression loci. Another study by Cheung et al. examined natural variation in
gene expression in lymphoblastoid cells for a sample of 35 individuals and for 10
pairs of MZ twins with microarray[171]. For a number of genes that were iden-
tified as highly variable between unrelated individuals, the variance in expression
levels between MZ twins was found to display only 1/3 to 1/11 variation. The re-
sults were taken to indicate that a component of variation in gene expression is
likely genetically determined, but the authors did not make any statement about
the likely nature of non-genetic component.
Previous estimates for sample size requirements for gene expression profiling have
shown that around 10 cases and 10 controls would be required to detect gene ex-
pression changes of 2 SDs with 80% power at an FDR of 5% [172, 173, 174]. These
are based on case control studies, and though we were unable to find any calcu-
lation that estimated this for a twin-based study design, it seems reasonable to
postulate that an MZ twins study would have greater power due to twins being
matched for genotype and certain shared environmental influences. Indeed, sup-
port for this comes from previous work by Vischer and Posthuma, where power
to detect phenotypic variance due to environmental effects was calculated for both
studies utilising unrelated subjects and MZ-twins [175]. Here, it was found that
for traits withMZ correlation > 0.3, theMZ design is more efficient than one using
unrelated individuals. There have also been a number of studies that have looked
at power and sample sizes required for twin-based studies in the context of EWAS.
Kaminsky et al. estimated that 15-25 discordant twin pairs would be sufficient
for 80% power to detect DNA methylation differences of 1.2 fold change [176].
Bell and Tsai used simulations to quantify the sample sizes required to reach 80%
power in EWAS over a range of different effect sizes for both case-control andMZ-
differences study designs [177]. They reported a minimum required sample size
of 30 pairs of twins compared to 37 cases in order to detect nominally significant
mean methylation differences of 7% using a parametric test. Indeed, smaller sam-
ple sizes were estimated for twins as compared to unrelated individuals over a range
of different effect sizes from 7% to 15%. In sum, taking into account the previous
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power calculations for environmental variance and sample size estimations for de-
tecting DNA methylation differences between MZ twins, the expectation for this
study is that we should similarly be able to detect transcriptomic differences in our
sample of MZ twin pairs.
1.7.3.4 Whole blood as a surrogate
Ideally, we would profile disease associated transcriptomic differences in the pri-
mary affected tissue, but in neurodevelopmental disorders due to the inaccessibility
of brain tissue, often peripheral tissues are instead used. Whole blood is typically
seen as a reasonable surrogate because it is easily accessible and collection is mini-
mally invasive, and since it circulates throughout the entire body coming into con-
tact with all other tissues. The rationale for using whole blood is then that it might
be possible to detect disease-associated changes in expression in other tissues at
low levels, that more widespread global patterns of disruption might be revealed,
or finally, that blood cells could themselves respond to the same insult that lead
to the expression changes in the primary affected tissue - acting as a “sentinel” for
disease [178].
With neurodevelopmental disorders there is the added complication of the blood
brain barrier - which could prevent brain-specific transcripts from diffusing into
blood altogether, as well as the temporal aspect of the disorder - where patho-
genesis likely occured during development. In this case, the utility of blood as a
surrogate is perhaps less certain. The first step to addressing this question is to
determine the overall concordance between genes expressed in brain and those in
blood, and in fact several studies have attempted to do so. Liew et al. compared the
genes expressed in whole blood with those from nine other tissues including brain,
and found that between 66% to 82% of all coding genes were detectable in blood,
and that 81.9% of genes expressed in brain were also expressed in blood (based on
the overlap of identified genes) [178]. A more recent study by Cai et al. compared
expression profiles generated for cortex, cerebellum, and caudate nucleus, to blood
and looked at correlation between mean expression levels, as well as the preserva-
tion of brain gene co-expression modules in blood [179]. The overall level of cor-
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relation of expression between blood and brain was found to be weak, in the range
of 0.24 to 0.32, and while only a small number of brain co-expression modules
were found to be preserved in blood, those that were showed strong preservation,
suggesting their potential utility as biomarkers in neurodevelopmental investiga-
tions.
One major limitation of looking at overall concordance between mean expression
levels in brain and blood is that it does not really address the main issue which is
whether any differences in expression are detectable. While this is difficult to ad-
dress in human tissue, a study by Davies et al. investigated this in rats using a panel
of recombinant inbred strains for hippocampus and spleen [180]. Overall it was
found that a large number of genes were expressed in common between the two
different types of tissue, but even more pertinently, that the correlation between
expression depends on the variance of the transcripts across lines, with those that
vary more (i.e. showing higher heritability of expression) more highly correlated
and hence are more likely to be detectable in the surrogate. From this, we conclude
that surrogate tissues are likely to be useful for detect genetically driven expression
differences, but their utility for detecting non-genetically driven expression differ-
ences, as we are attempting to identify in ourMZASD twins, perhaps then remains
to be demonstrated.
Finally, one last important consideration in using blood as a surrogate is whether
individual differences in gene expression as assessed are stable over time. Meaburn
et al. examined the reliability of detected individual differences in gene expression
in blood samples, and found that these differences could be reliably detected 10
months after collection[108].
1.8 Integrating multiple genomics datasets
Increasingly it is appreciated that in order to make further progress in uncovering
the etiology and mechanisms underlying ASD as well as other complex traits, a
more holistic approach will be required to bring together evidence frommany dis-
parate experimental sources and attempt to understand the dynamic workings of
51
Chapter 1. Introduction
the system as a whole [129]. Within ASD genomics research, this will mean com-
bining data from the multiple molecular modalities in order to really pick apart
the relationship between genetic variation, gene regulatory mechanisms, environ-
mental perturbation of these regulatory mechanisms, typical brain development,
and autistic traits. The need for a system-level perspective on ASD is rather neatly
illustrated by the observation that while the accumulated findings from genetic as-
sociation studies suggest that ASD is primarily a disorder of the synapse, functional
approaches like expression and methylomic profiling implicate immune dysregu-
lation, inflammation, and epigenetic/transcriptomic disruption. To this end, inte-
grative genomics approaches aim to combine evidence from different layers of the
genome in order to boost power to identify molecular associations and provide a
more coherent picture of the pathomechanisms underlying complex diseases. As
we shall later discuss, quality control is an important step in data integration, and
so in Chapter 4 we address an issue related to EWAS - namely the empirical cal-
culation of an appropriate significance threshold for single CpG site differential
methylation analysis. In Chapter 5, we then delve deeper into integrative meth-
ods, applying some of these to the gene expression data generated in Chapter 3
and combining with an existing methylation dataset on the same sample.
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2 | Gene expression profiling of
monozygotic twins with autism
spectrum disorder
2.1 Introduction
Autism spectrumdisorder (ASD) is perhaps unique amongst neuropsychiatric con-
ditions in that in addition to the etiology being largely unaccounted for, there is
also no unified pathomechanistic explanation. Complicating matters somewhat
is the proposed role of non-genetic factors, as evidenced by incomplete concor-
dance in monozygotic (MZ) twins, which could be contributing to liability as well
as obfuscating any underlying genetic susceptibility. Offering a complementary
route forward to genetic studies, are functional genomics approaches which pro-
file genome-wide patterns of gene expression and methylation. Such studies must
contend with the confounding influence of genetics, along with the possibility that
molecular differences could have arisen as a secondary consequence of the disorder
[1]. To help circumvent some of these issues, it has been suggested utlizing a dis-
cordantMZ twin-based study design [2, 3, 4, 5, 1]. SinceMZ twins arematched for
age, sex, and genetic background, as well as some early environmental influences
[5], in theory any divergence in molecular profiles can be considered as the driver
of the observed phenotypic discordance [1]. It is hoped therefore that assessing
the molecular basis of twin discordance could help to separate genetic from non-
genetic factors, identifymolecular signatures in the form of altered gene expression
75
Chapter 2. Gene expression profiling...
or methylation profiles, and ultimately elucidate disorder-related pathways.
Genome-wide gene expressionprofiling ofMZ twins has previously beenperformed
for a range of psychiatric and neurological conditions including schizophrenia [6],
bipolar disorder [7], and Huntington’s disease [8]. There has however, been lim-
ited application of this methodology to ASD; we were only able to identify one
such study by Hu et al., which examined gene expression in 3 pairs of MZ ASD
discordant and two pairs of MZ ASD concordant twins, identifying differences
in gene networks involved in neurological function, nervous system development
and inflammation [9]. Interestingly, several studies have utilised MZ twins to in-
vestigate DNA methylation patterns in ASD (see Chapter 1). In what was at the
time the largest study of its kind, our group previously characterised genome-wide
methylation patterns in a cohort of 50 MZ twin pairs (100 individuals) that in-
cluded ASD concordant, ASD discordant pairs, as well as unaffected concordant
controls. The analysis strategy involved measuring differences within discordant
pairs and between groups (cases and controls) [10]. The main findings from the
within-discordant pairs comparison were that while ASD was not associated with
large-scale disruptions in methylation, a number of CpG sites were found to vary
in methylation levels between co-twins, with the top result a site in theNFYC gene
- found to be consistently hypermethylated in affected compared to unaffected co-
twins across all pairs. Between-groups analysis of cases and controls identified ad-
ditional ASD-associated differentially methylated sites. Overall, ASD-associated
differential methylation was observed in the vicinity of a number of genes pre-
viously implicated in the disorder including: AFF2, AUTS2, GABRB3, NLGN3,
NRXN1, SLC6A4.
TheMZ differences approach has thus far been under utilised in molecular studies
of ASD, and we are also unaware of any single study that has explored both gene
expression and DNA methylation differences in the same sample. Here, we ad-
dress this perceived gap in the literature by performing a follow-up to the previous
DNA methylation study by Wong et al., using the same cohort of ASD concor-
dant, ASD discordant, ASD trait discordant, and unaffected concordant control
MZ twin pairs. Genome-wide gene expression profiles for each subject are first
generated from whole blood samples using microarray technology, and two main
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analyses carried out. Firstly, a between-groups analysis of affected and unaffected
individuals, to identity disrupted genes and pathways that are common between
both concordant and discordant pairs. Secondly, we perform a within-pairs anal-
ysis of discordant pairs alongside a within-group discordant analysis, in order to
identify perturbations arising from non-genetic factors and identify those in com-
mon between discordant twin pairs. The overall aims of the study are twofold,
firstly, to uncover patterns of gene expression associated with ASD in both con-
cordant and discordant pairs, in order to provide convergent evidence for genes
and pathways disregulated in ASD. And secondly, by investigating expression dif-
ferences common inMZdiscordant pairs, identify those genes and networkswhich
are potentially sensitive to the environment. It is hoped that the results will pro-
vide further support for the findings from the previous methylation study, as well
as providing a high quality dataset for a planned integrative study aiming to estab-
lish the functional relevance of identified signals.
2.2 Methods
2.2.1 Subjects
The subjects used in this study are a subsample from the Twins Early Development
Study (TEDS), a longitudinal study investigating the cognitive and behavioural de-
velopment of twins born in the UK between January 1994 and December 1996
[11, 12, 13]. Ethical approval for the original study was provided by the Institute
of Psychiatry, Psychology and Neuroscience (IoPPN) ethics committee, reference
number 05/Q0706/228.
Participating individuals completed various web and telephone-based tests and
questionnaires at regular intervals over childhood and adolescence designed to as-
sess various aspects of cognition, language and behaviour (see [13] for further de-
tails). As part of this, twins were assessed for ASD related traits and behaviours at
ages 8 and 12 using the Childhood Aspergers Symptom Test (CAST).The CAST is
a 31 item screening test completed by parents and teachers in a non-clinical setting,
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which assesses ASD based on the DSM-IV [14] defined subscales of social symp-
toms (12 items), non-social symptoms (7 items), and communication impairments
(12 items)[15, 16]. The subscale measurements are combined additively to give a
total CAST score out of 31, with those scoring ≥ 15 categorised as “at risk”. Indi-
viduals identified as at risk were also formally assessed at home using the Autism
Diagnostic Interview-Revised (ADIR) [17] and the Autism Diagnostic Observa-
tion Schedule (ADOS) [18], both considered gold standard diagnostic tools.
2.2.2 Subject selection and study groups
Study group Classification ADI-R/ADOS Gender (M:F) Sample size
1 Concordant ASD Both 12:0 12
2 Discordant ASD Affected 6:6 12
3 Discordant social CAST Neither 6:14 20
4 Discordant communication CAST Neither 12:8 20
5 Discordant non-social CAST Neither 14:6 20
6 Concordant low CAST Neither 8:14 22
106
CAST
Total CAST ≤ x̄  
δ non-social CAST  ≥ 2 S.D.
δ communication CAST  ≥ 2 S.D.
δ social CAST  ≥ 2 S.D.
N/A
Total CAST ≥ 15
Table 2.1. Subjects were assigned to one of six study groups based on ADI-R/ADOS
diagnosis and/or CAST scores. The ADI-R/ADOS column refers to which co-twin(s) re-
ceived the diagnosis, either both, the affected twin only, or neither. In the CAST column,
 refers to the difference in scores between co-twins on each of the scales, where S.D. is
the standard deviation and x is the sample mean.
A total of 53 MZ twin pairs (106 individuals) were selected from TEDS. Selections
were based on scores on the CAST subscales and total score, and whether a clin-
ical diagnosis of ASD had been made. Study groups were defined and the twins
assigned as follows: group 1 : 6 ASD concordant pairs (both members of the pair
having had a formal ASD diagnosis), group 2 : 6 ASD discordant pairs (one mem-
ber of the pair with a formal ASD diagnosis), groups 3,4,5 : each consisting of 10
ASD trait discordant pairs for each of the CAST subscales: social, non-social, com-
munication (co-twins score greater than two standard deviations apart), and group
6 : 11 unaffected concordant control pairs (both members of twin pair scored less
than or equal to the sample mean in total CAST score). A summary of the study
groups is provided in Table 2.1 and represented visually in Figure 2.1.
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N = 20
N = 22
N = 20
group 4 group 5 group 6
Total N = 106 Key
ASD non-ASD
Male
Female
MZ twins
N = 12
N = 20
N = 12
group 1 group 2 group 3
concordant 
ASD
discordant 
ASD
discordant 
social
CAST
discordant 
communication
CAST
discordant 
non-social
CAST
concordant 
low CAST
Figure 2.1. The study sample - with group, sex, pair and ASD affected status indicated.
2.2.3 Sample collection
Participating families visited the IoPPNwhen the twins were aged 15 to have whole
blood samples taken by a trained phlebotomist. Using the Ambion PAXgene RNA
system (PreAnalytiX, QIAGEN, Germany), three 2.5 ml tubes of blood were col-
lected and stored. In addition, 3 ml of blood was collected in an EDTA tube to
assess whole blood cell subtype composition, which for all samples was found to
be within normal ranges.
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2.2.4 HuGe microarray
Microarray technology was used to produce genome-wide measurements of gene
expression for the subjects. These experiments were performed at the IoPPN, using
the Affymetrix Human Gene 1.0 ST (HuGe) platform. TheHuGe array is designed
tomeasure the expression of 32,020well-annotatedRefSeq coding transcriptsmap-
ping to a total of 21,014 Entrez genes, and does so using 25-mer probes distributed
across transcribed regions (median 26 probes per gene). Total RNA was isolated
and extracted from the PAXgene blood tube using the PAXgene blood RNA kit
(PreAnalytiX, QIAGEN, Germany), and globin related transcripts removed using
the Ambion GLOBINclear (Ambion,USA) kit. These samples were then run on
HuGe arrays (one per sample) following the manufacturer’s instructions: sense
strand cDNA was generated using the Ambion WT Expression Kit (Affymetrix,
USA), fragmented and labeled using the AffyMetrix GeneChip WT Terminal La-
belling Kit (Affymetrix, USA), and finally the prepared samples were hybridized to
the arrays and scannedusing theGeneChip Scanner 3000 7G (Affymetrix, USA).
All of data processing and analysis steps described below were performed in the
R statistical environment [19], following the analysis workflow described in the
oligo[20] package in bioconductor [21].
2.2.5 Quality control I - microarray data
2.2.5.1 Inspection of array images
The data generated by the arrays was subject to a series of quality control steps.
To begin with, following the manufacturer’s guidelines, the scanner images (.DAT
files) were manually inspected to check for spatial intensity artifacts, such as overly
bright spots, or other irregularities like scratches or air bubbles. In this instance,
no issues were detected.
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2.2.5.2 Distribution of raw intensity measurements
Plots were made of the average raw intensity andmean absolute deviation of resid-
uals for each array to help identify outlying arrays (Figure 2.2 A and B). Examining
these plots, it was observed that arrays 34 (affected male from group 4) and 37 (af-
fected female from group 5) were dissimilar to the others, displaying lower average
signal intensity and greater variance in intensity measurements. For these reasons,
these arrays were removed from the dataset, leaving expression data for 104 indi-
viduals (51 complete twin pairs) to take forward for pre-processing.
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Figure 2.2. Plots showing a. the average raw intensity, b. mean absolute deviation of
residuals for each array. Based on these plots, arrays 34 and 37 were both identified as
outliers and removed from the dataset. c. distribution of log intensity signals for each
array prior to normalization, d. distribution of intensities after RMA normalization. These
plots show the effect of normalisation in bringing the intensity distributions for each array
onto a common scale.
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2.2.6 Data pre-processing
Probeset intensity measurements (.CEL files) were processed using the oligo pack-
age, alongside the pd.hugene.1.0.st.v1 [22] annotation package. Next, RMA (ro-
bust multi-array analysis) [23], as implemented in oligo, was used to summarise
the probe level data (for core probesets targeting RefSeq annotated transcripts), ap-
ply background correction, and perform quantile to quantile normalisation, before
finally log-transforming the intensity values. The resulting expression dataset con-
tained normalised, log-transformed expression values for 33,297 probesets.
2.2.7 Quality control II - expression data set
2.2.7.1 Probeset filtering / removal of background signal
To gain an impression of data quality, the overall distribution of probeset intensity
measurements across all of the arrays was inspected. This revealed a non-normal
distribution with a large and small peak (Figure 2.2 C). The smaller peak was be-
lieved to represent low-signal probesets and potential background noise on the
arrays; a well known technical issue in array expression studies. For Affymetrix
arrays based on the Human Exon 1.0 ST design, the DABG (detection above back-
ground) method (as implemented in Affymetrix power tools command-line soft-
ware) is recommended for filtering out low-signal probesets. This works by com-
paring probesets to a set of control probes, yielding detection p-values. For the
Human Gene 1.0 ST array however, which uses only a subset of the probes on the
Exon array to perform gene-level profiling, DABG is not considered to be a robust
metric [24]. While other simple filtering strategies can be used to remove genes not
detected above background, such as removing probes that do not meet the overall
mean intensity in at least 50% of the samples, a general consensus is lacking. Based
on the previous observations about the overall distribution of intensities, a differ-
ent approach was taken, which sought to model the intensities as a mixture of two
different distributions: one representing the low-signal/background and one the
true signal, and then filtering out probes with intensity profiles matching the back-
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ground. To this end, the normalmixEM function from the mixtools package [25]
in Rwas used. Briefly, the normalmixEM function uses the expectation maximiza-
tion (EM) algorithm to iteratively fit parameters to a finite mixture model with the
goal of maximizing the expectation for a predefined number of functions, a form
ofmaximum likelihood estimation (MLE) - see [25] formore details. For each data
point, a likelihood is estimated that it has been generated by each of the functions
in the mixture. This procedure was run on the processed expression data, and any
probeset with greater than 0.8 likelihood of belonging to the smaller distribution
was filtered out, resulting in the removal of 2273 low-signal probesets (Figure 2.2
D). The code is provided in Appendix - Chapter 2 - Figure A1.
2.2.7.2 Probeset aggregation
Next, probesets were mapped to gene annotation using the biomaRt package [26],
and those mapping to the same gene were aggregated, retaining only the intensity
readings of the probeset with the greatest variance across all of the samples. This
left a total of 26,482 probesets for core analysis.
2.2.8 Exploratory analysis
The quality of the final expression dataset was assessed. Given the high heritability
of gene expression, co-twins (as genetically related individuals) would be expected
to show greater similarity in measures of transcript abundance than unrelated in-
dividuals. Similarity was assessed by two different means. Firstly, the correlation
between expression profiles for all subjects was calculated using Pearson’s r, as im-
plemented in the cor function in R:
rxy = 1
n − 1 n∑i=1(xi − xsx )(yi − ysy ) (2.1)
Secondly, the Euclideandistance for all pairwise comparisonswas calculated :
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d =¿ÁÁÀ m∑
i=1(xi − yi)2 (2.2)
across allm dimensions (probes) for samples x and y. The data was then clustered
(hierarchical, unsupervised, complete linkage method), using the dist and hclust
functions in R. Clustering was performed firstly with the entire set of probes, and
then with a subset of the top 100 sex specific transcripts published by the WEHI
bioinformatics group [27], which includes genes on the X chromosome reported
to escape X inactivation [28] and a set of Y chromosome genes [29]), to examine
clustering based on sex. The numerical data and resulting heatmaps /dendrograms
were manually inspected.
2.2.9 Differential expression analysis
2.2.9.1 T-test and Wilcoxon
Before performing the main differential expression analysis, to gain an initial im-
pression of the extent and magnitude of the differences in expression levels being
detected, traditional parametric and non-parametric inferential testing methods
were used. For the comparison of affected (ASD cases) and unaffected individuals
across groups 1,2, and 6 (concordant ASD, discordant ASD, concordant controls)
the independent two sample Student’s t-test was used:
t = X1 − X2
sp
√
1
n1
+ 1n2 (2.3)
where X is the mean, n the sample size, and sp the pooled standard deviation for
the two experimental conditions (i.e. ASD affected vs unaffected). The Wilcoxon
rank sum (or Mann-Whitney U ) test was also used as the non-parametric equiva-
lent:
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min(U1 = R1 − n1(n1 + 1)
2
; U2 = R2 − n2(n2 + 1)
2
) (2.4)
taking the minimum of the two U statistics, where R is the sum of ranks after all
observations have been ranked from smallest to largest, and n the sample size for
each of the two conditions.
For the betweenpairs comparison of affected andunaffected individuals fromgroup
2 (discordant ASD) was also performed using the paired version of the two sample
t-test:
t = XD − 0sD√
n
(2.5)
whereXD is themean differences between case and control within the pairs, 0 = 0
the mean of the population differences, sD the standard deviation of the differ-
ences, and n the number of pairs.
And for the non-parametric equivalent, the Wilcoxon matched pairs signed ranks
test was used:
W = nr∑
i=1(sgn(x2;i − x1;i) ×Ri) (2.6)
which is the sum of the signed ranks for nr the sample size of pairs with non-
zero differences, where Ri is the rank of pair (ordered by the magnitude of the
difference).
2.2.9.2 Regression analysis
It is widely acknowledged that statistics such as the t-statistic do not perform well
in genome-wide expression profiling experiments, and can lead to an increase in
the number of false positives [30, 31, 32]. One reason for this is that estimates of
variance (i.e. the denominator in the t-test) can be unstable, due to each gene on
the microarray having a different variance [32].
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Primarily for these reasons, for the main analysis the limmamethod was used [33]
(part of the bioconductor for R suite [21]).This method works by fitting a linear
model to the expression data for each gene, and testing for association with the
trait using a moderated t statistic. This approach offers several advantages over
classic tests. Firstly, it uses an empirical Bayes approach to borrow information
across genes to derive stable gene specific variance estimates [34]; particularly ad-
vantageous for experiments with small numbers of replicates, as information bor-
rowing can increase power to detect differentially expressed genes [33]. Secondly,
a regression framework allows for the inclusion of multiple covariates into the
model, which can help to separate out the systematic variation from the biological.
And thirdly, related to the previous point, experimental designs using biological
and technical replicates are supported, relevant here because of the use of paired
data.
Two major analyses were planned. To begin with, a between-groups compari-
son (case-control) would be made using ASD affected and unaffected individu-
als across groups 1,2, and 6 (concordant ASD, discordant ASD, concordant con-
trols). This was intended to capture trait-associated expression differences com-
mon to concordant and discordant cases when compared to age-matched controls,
attributable to genetic and environmental factors. Next, within-group analyses
would be carried out for the discordant groups 2,3,4,5 (discordant ASD, discordant
social CAST, discordant communication CAST, discordant non-social CAST), to
characterise ASD-associated differences attributable to non-shared environmental
factors.
Linear model selection: A linear model describes the relationship between an
outcome of interest (the dependent variable) and one or more predictor variables.
The expression values y for j genes in i subjects as explained by n variables can be
modelled as follows:
yij = 0j + 1jx1i:::njxni + ij (2.7)
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where 0 the intercept term, plus effects for n explanatory variables (1 to n), and
finally an error term . In limma, this is represented in vector form as:
Yj =Xj + j (2.8)
where Y is a vector of the expression values for gene j, X is a design matrix with
rows representing samples and columns representing the different experimental
variables/treatments, a vector of coefficients, and  the vector of error terms.
Linear regression uses the ordinary least squares method to estimate values for the
beta coefficients, with the objective to minimize the sum of the squared residuals
for the observations. In limma, each gene is regressed on the product of the design
matrix by the coefficients .
A number of different models were initially considered. In a hypothetical, fully
balanced version of the experiment, with every study group containing both males
and females and complete twin pairs, the following single combined, mixed model
could conceivably be used:
expression ∼ 0 + case + group + (1∣pair) + (case ∶ group) (2.9)
where 0 indicates that there is no intercept term, group is a reduced dimension
version of study group status where groups are classed as concordant or discor-
dant, case is the affected status, 1 | pair is the random effect of pair (effects that are
not constant across the sample, in limma, achieved through the use of the dupli-
cate correlation method [35] to model intrapair correlation). The omission of the
intercept term allows multiple different contrasts to be fit, as there is no longer a
baseline level of comparison. An experimental contrast of interest j can then be
obtained using a contrast matrix C and coefficients j from above:
j = jCT (2.10)
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Such an approachwould be advantageous as it uses the entire dataset for estimating
co-efficients, whilst allowing a variety of between-group and within-group com-
parisons to be made. For example, a case vs control analysis across all subjects
could be performed by contrasting concordant:case and discordant:case with con-
cordant:control and discordant:control, and a within-discordant group compari-
son could be made by contrasting discordant:case with discordant:control. The
within-group analyses of the remaining discordant groups, as they do not contain
any cases (only sub-clinical individuals with a high score in one of the CAST sub-
scales), would have to be performed using a separate model, but through a similar
formulation.
Unfortunately, in our dataset, because group, sex and case status are either nested
or partially correlated measures (an inherent property of the sample), and also due
to the presence of incomplete pairs, this approach could ultimately not be taken.
Instead, individual models for case-control and within-group were used.
Case-control analysis: To assess ASD associated gene-expression difference com-
mon in both concordant and discordant cases, a between pairs case-control analy-
sis was performed by fitting the following linear model:
expression ∼ pair + case (2.11)
whereby gene expression is regressed on twin pair and case status. Here, twin pair
is a categorical, fixed effect and case a binary fixed effect. Group is omitted from
the model due to potential confounding with case status, and sex has also not been
included due to nesting within the pair effect (since MZ co-twins are the same
sex).
Within-group analyses: Next, for discordant groups 2,3,4,5 (discordant ASD, dis-
cordant social CAST, discordant communicationCAST, discordant non-social CAST)
the above model was once again used to perform within-group analyses.
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Male-only case-control andmale-onlywithin-group: Both case-control andwithin-
group analyses were also performed with only male subjects to explicitly control
for sex. This was carried out because of the potential for confounding due to sex-
based differences in expression and uncertainty in the effectiveness of the linear
models in removing these effects. Given the observed sex-bias in ASD [36], there
is also a biological rationale for considering male and female cases separately, as
this represents another possible source of heterogeneity.
sex analysis: Additionally, for quality control purposes and also to serve as a
benchmark for comparative purposes, a sex-based,male-female contrastwasmade:
expression ∼ sex (2.12)
Assessing fit: The distribution of p-values from inferential tests for differential
expression would be expected to be approximately uniform, as the majority of
probes will not be associated with the trait. Should this assumption not be met,
then attempting to establish a threshold for significance becomes essentially mean-
ingless [37, 38]. Examining p-value distributions can therefore be helpful for de-
tecting experimental and analytical issues. Extreme deviation from the null can be
indicative of technical issues, such as probe cross-hybridization (non-specific bind-
ing to similar non-target sequences[39]) or sample contamination. The distribu-
tion of p-values can also be informative about the effectiveness of the overall analy-
sis strategy used: imperfect normalization and poor variance estimation have been
shown to lead to inaccurate p-value estimation [37]. To this end, quantile-quantile
(QQ) plots of observed p distribution against expected p distributions were created
and manually inspected for each of the tests.
Statistics for differential expression: The output generated by limma is a list of
genes with associated test statistics including log2 fold change (logFC), moderated
t statistic, p-value (calculated from the moderated t), and the false discovery rate
(FDR) statistic (multiple testing adjusted p-value - see Chapter 4 section 1.5). In
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this case, FDR was used to rank genes by the level of evidence for differential ex-
pression. A cut-off of 0.2 was defined as the threshold for significance, meaning
that on average,for every four true positive findings, one false positive would be
expected. This more permissive threshold was selected due to the exploratory na-
ture of the study and the small sample size.
91
Chapter 2. Gene expression profiling...
2.3 Results
2.3.1 Exploratory analysis
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Figure 2.3. Heatmap showing correlations between individuals. High levels of correlation,
r values of 0.99 and above, are indicated by the dark blue coloured squares. With high
quality expression data, the expectation would be that co-twins within pairs would be more
highly correlated, and should mainly cluster together. Furthermore, similarity to unrelated
individuals would be expected to be lower, and the highest levels of correlation found
within twin pairs, and so dark blue (high correlation) would be expected to run along the
diagonal. However, here it can be seen that there are very few twin pairs that actually
conform to this pattern, and furthermore, the sporadic patches of dark blue off the diagonal
also indicate individuals who are highly correlated with several unrelated individuals.
Exploring the measures of sample similarity, the median correlation r between co-
twins was 0.99 and for unrelated individuals slightly lower at 0.98. This is repre-
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sented visually in the heatmap (Figure 2.3). It was observed that pairs of co-twins
clustered together in nodes for only approximately half (56%) of the sample. The
dendrogram is shown in Figure 2.4. Clustering based on sex-specific genes showed
male and female subjects segregating into two distinct clusters, this is shown in
Figure 2.5).
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Figure 2.4. Dendrogram showing similarity of samples based on genome-wide expres-
sion values. Labels are coloured by group membership and co-twin number. Twins clus-
tering together in pairs are concordant for hue and discordant for shade, and cases of un-
related individuals clustering together are discordant for hue. In this instance only around
56% of co-twins are found to cluster together as expected.
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Figure 2.5. Dendrogram showing similarity of samples based on expression values for
genes known to differ in expression levels between sexes. Labels are coloured by sex.
Here it can be seen that males and females form two distinct clusters, indicating correct
labelling by sex for the samples.
2.3.2 Differential expression analysis
2.3.2.1 Student’s t and Wilcoxon
Student’s t andWilcoxon tests were first run and theQQplots showing the resulting
p-value distributions inspected (not included here). Neither method produced the
expected null distribution, instead showing uniform deflation across the range of
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p values. The same was also observed for each of the linear models - see Figure 2.6.
Once again, these were unexpected findings with important implications for the
interpretation of the results produced (see Discussion).
2.3.2.2 Regression
Figure 2.6. QQ plots showing observed vs theoretical distribution of p-values for each of
the fitted models
The top 50 differentially expressed genes from the case-control analysis of groups
1,2, and 6 are shown in Table 2.2. Overall, the fold changes appear small and the
associated p-values are not indicative of any highly significant findings. The results
also contain a number of small nuclear RNAs (snRNA or U-RNA), making up an
unexpectedly large proportion of the top 50 results.
The top 50 differentially expressed genes from the within-group 2 analysis of dis-
cordant pairs are presented in Table 2.3. As with the case-control results, the log
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fold changes are small and p-values not indicative of highly significant findings.
These issues are covered in more detail in the Discussion section.
Case-control
ENS_gene hgnc_symbol chr logFC AveExpr t P.Value adj.P.Val B
ENSG00000154188 ANGPT1 8 0.29 5.8 3.8 0.00078 1 -2.1
ENSG00000226757 4 -0.39 5.2 -3.7 0.00098 1 -2.2
ENSG00000188069 OR51F1 11 -0.42 4.8 -3.6 0.00109 1 -2.2
ENSG00000280021 11 -0.42 4.8 -3.6 0.00109 1 -2.2
ENSG00000202296 RNU6-1335P 7 -0.34 4.2 -3.6 0.00115 1 -2.2
ENSG00000222496 RN7SKP200 2 0.44 3.9 3.6 0.00131 1 -2.3
ENSG00000204613 TRIM10 6 -0.31 6.7 -3.5 0.00146 1 -2.3
ENSG00000274747 RN7SL627P 17 -0.42 5.5 -3.5 0.00175 1 -2.4
ENSG00000276088 RN7SL620P 17 -0.42 5.5 -3.5 0.00175 1 -2.4
ENSG00000276532 17 -0.42 5.5 -3.5 0.00175 1 -2.4
ENSG00000278701 17 -0.42 5.5 -3.5 0.00175 1 -2.4
ENSG00000251916 RNU1-61P 6 -0.44 4.3 -3.5 0.00175 1 -2.4
ENSG00000200248 RNA5SP214 6 -0.32 4.2 -3.4 0.00194 1 -2.5
ENSG00000222898 RN7SKP97 8 -0.33 3.5 -3.4 0.00197 1 -2.5
ENSG00000252556 RNU6-256P 11 -0.77 4.8 -3.4 0.00223 1 -2.5
ENSG00000188694 KRTAP24-1 21 -0.27 5.8 -3.4 0.00232 1 -2.5
ENSG00000189326 SPANXN4 X -0.35 4.6 -3.3 0.00262 1 -2.6
ENSG00000250799 PRODH2 19 -0.24 6 -3.3 0.0027 1 -2.6
ENSG00000238926 X -0.45 5.2 -3.3 0.00295 1 -2.7
ENSG00000200105 RNU6-251P 12 -0.33 5.4 -3.2 0.00318 1 -2.7
ENSG00000222874 RN7SKP33 20 -0.23 5.5 -3.2 0.00348 1 -2.7
ENSG00000251711 RNU6-632P 10 -0.28 4.9 -3.2 0.00389 1 -2.8
ENSG00000207087 RNU6-242P 2 0.69 5 3.2 0.00389 1 -2.8
ENSG00000223265 RNU6-592P 11 0.69 5 3.2 0.00389 1 -2.8
ENSG00000214107 MAGEB1 X -0.25 5.3 -3.1 0.00393 1 -2.8
ENSG00000276525 20 0.45 5.1 3.1 0.00408 1 -2.8
ENSG00000218472 6 -0.24 12.8 -3.1 0.00454 1 -2.8
ENSG00000202407 X -0.5 4.7 -3.1 0.00458 1 -2.8
ENSG00000177627 C12orf54 12 -0.22 4.7 -3.1 0.00494 1 -2.9
ENSG00000147874 HAUS6 9 0.3 7.4 3 0.00513 1 -2.9
ENSG00000227344 HAUS6P1 7 0.3 7.4 3 0.00513 1 -2.9
ENSG00000201988 6 -0.98 4.7 -3 0.00514 1 -2.9
ENSG00000242855 RN7SL496P 7 0.24 3.5 3 0.00575 1 -3
ENSG00000160097 FNDC5 1 -0.2 6.8 -3 0.00576 1 -3
ENSG00000196301 HLA-DRB9 6 -0.3 5.3 -3 0.0058 1 -3
ENSG00000276231 PIK3R6 17 0.37 7.8 3 0.00595 1 -3
ENSG00000199332 6 -0.3 5.6 -3 0.00601 1 -3
ENSG00000187569 DPPA3 12 0.32 5.5 3 0.00617 1 -3
ENSG00000164366 CCDC127 5 -0.5 5.6 -2.9 0.00654 1 -3
ENSG00000106689 LHX2 9 -0.2 6.6 -2.9 0.00675 1 -3
ENSG00000172199 OR8U1 11 0.24 4 2.9 0.00707 1 -3
ENSG00000160949 TONSL 8 -0.22 7.3 -2.9 0.00724 1 -3.1
ENSG00000117410 ATP6V0B 1 0.92 4.6 2.9 0.00729 1 -3.1
ENSG00000213366 GSTM2 1 0.27 8.4 2.9 0.00735 1 -3.1
ENSG00000189134 NKAPL 6 0.25 4.9 2.9 0.00741 1 -3.1
ENSG00000167658 EEF2 19 0.42 4.8 2.9 0.00752 1 -3.1
ENSG00000206775 SNORD37 19 0.42 4.8 2.9 0.00752 1 -3.1
ENSG00000200651 17 0.65 6.1 2.9 0.00761 1 -3.1
ENSG00000183130 OR2T11 1 0.26 5.9 2.9 0.00765 1 -3.1
ENSG00000279301 1 0.26 5.9 2.9 0.00765 1 -3.1
Table 2.2. Differential expression results from the case-control analysis
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Group 2
ENS_gene hgnc_symbol chr logFC AveExpr t P.Value adj.P.Val B
ENSG00000204933 CD177P1 19 -0.86 6 -5.5 0.00018 1 -2
ENSG00000204936 CD177 19 -0.86 6 -5.5 0.00018 1 -2
ENSG00000117410 ATP6V0B 1 0.92 4.7 4.3 0.00124 1 -2.6
ENSG00000252556 RNU6-256P 11 -0.77 4.8 -4.3 0.00125 1 -2.6
ENSG00000201988 6 -0.98 4.5 -4.3 0.00126 1 -2.6
ENSG00000251882 RNU6-475P 6 -0.6 5.1 -4.3 0.00127 1 -2.6
ENSG00000276525 20 0.45 5 4.2 0.00134 1 -2.6
ENSG00000164366 CCDC127 5 -0.5 5.5 -4.2 0.00141 1 -2.6
ENSG00000202296 RNU6-1335P 7 -0.34 4.3 -4.1 0.00156 1 -2.6
ENSG00000207087 RNU6-242P 2 0.69 5.2 4.1 0.00158 1 -2.7
ENSG00000223265 RNU6-592P 11 0.69 5.2 4.1 0.00158 1 -2.7
ENSG00000274747 RN7SL627P 17 -0.42 5.4 -4.1 0.00161 1 -2.7
ENSG00000276088 RN7SL620P 17 -0.42 5.4 -4.1 0.00161 1 -2.7
ENSG00000276532 17 -0.42 5.4 -4.1 0.00161 1 -2.7
ENSG00000278701 17 -0.42 5.4 -4.1 0.00161 1 -2.7
ENSG00000069764 PLA2G10 16 -0.35 4.3 -4.1 0.00181 1 -2.7
ENSG00000238379 RNA5SP103 2 -0.59 4.7 -4 0.00209 1 -2.7
ENSG00000200024 4 -0.45 5.1 -3.9 0.00248 1 -2.8
ENSG00000100811 YY1 14 0.57 6.8 3.8 0.00269 1 -2.8
ENSG00000229104 YY1P2 2 0.57 6.8 3.8 0.00269 1 -2.8
ENSG00000200248 RNA5SP214 6 -0.32 4.2 -3.8 0.00289 1 -2.8
ENSG00000224533 TMLHE-AS1 X -0.33 5.3 -3.7 0.00317 1 -2.9
ENSG00000202407 X -0.5 4.7 -3.7 0.00333 1 -2.9
ENSG00000154188 ANGPT1 8 0.29 5.6 3.7 0.00342 1 -2.9
ENSG00000276410 HIST1H2BB 6 -0.35 6 -3.7 0.00344 1 -2.9
ENSG00000201594 RNA5SP517 X -0.32 3.7 -3.7 0.00359 1 -2.9
ENSG00000252996 RNU6-1315P 12 0.36 6 3.6 0.00429 1 -3
ENSG00000187569 DPPA3 12 0.32 5.6 3.6 0.00436 1 -3
ENSG00000207808 MIR27A 19 0.3 8.7 3.5 0.00466 1 -3
ENSG00000207980 MIR23A 19 0.3 8.7 3.5 0.00466 1 -3
ENSG00000267519 19 0.3 8.7 3.5 0.00466 1 -3
ENSG00000276797 MIR24-2 19 0.3 8.7 3.5 0.00466 1 -3
ENSG00000200105 RNU6-251P 12 -0.33 5.4 -3.5 0.00498 1 -3
ENSG00000188069 OR51F1 11 -0.42 4.7 -3.5 0.005 1 -3
ENSG00000280021 11 -0.42 4.7 -3.5 0.005 1 -3
ENSG00000236965 OR52N3P 11 0.34 4.8 3.4 0.00538 1 -3.1
ENSG00000222806 RNA5SP225 6 -0.35 6.3 -3.4 0.00563 1 -3.1
ENSG00000199936 2 -0.4 5.8 -3.4 0.00571 1 -3.1
ENSG00000223271 15 -0.4 5.8 -3.4 0.00571 1 -3.1
ENSG00000222898 RN7SKP97 8 -0.33 3.6 -3.4 0.00582 1 -3.1
ENSG00000276231 PIK3R6 17 0.37 7.6 3.4 0.00597 1 -3.1
ENSG00000183130 OR2T11 1 0.26 5.8 3.4 0.00612 1 -3.1
ENSG00000279301 1 0.26 5.8 3.4 0.00612 1 -3.1
ENSG00000213366 GSTM2 1 0.27 8.2 3.4 0.00618 1 -3.1
ENSG00000199565 1 -0.37 6.7 -3.4 0.00628 1 -3.1
ENSG00000164037 SLC9B1 4 0.45 5.4 3.3 0.00663 1 -3.1
ENSG00000183704 SLC9B1P1 Y 0.45 5.4 3.3 0.00663 1 -3.1
ENSG00000214329 SLC9B1P2 2 0.45 5.4 3.3 0.00663 1 -3.1
ENSG00000227367 SLC9B1P4 22 0.45 5.4 3.3 0.00663 1 -3.1
ENSG00000233867 SLC9B1P3 10 0.45 5.4 3.3 0.00663 1 -3.1
Table 2.3. Differential expression results from the within-group analysis of discordant
ASD pairs (group 2)
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2.4 Discussion
In this study, we attempted to characterise gene expression in a cohort of ASD con-
cordant and discordant MZ twin pairs. The results from initial QC indicated that
the experimental assays had potentially generated unreliablemeasurements of gene
expression, and indeed subsequent differential expression analysis seemed to con-
firm this. Because of doubts about the quality of the data generated, we are unfor-
tunately not able to draw any conclusions about the transcriptome in ASD.
The three main observations that lead to this conclusion are worth discussing in
turn. Firstly, in relation to the raw experimental data, the observed non-normal
distribution of probeset intensities. As discussed in the Methods section, inspect-
ing the density for the overall probeset intensities for all of the arrays revealed a
second smaller intensity spike. This issue was dealt with in the course of quality
control by removing any probesets belonging to the smaller distribution, success-
fully removing the this signal. One slight concern however, is that no explicit men-
tion of this issue could be found in the literature - perhaps suggesting the data gen-
erated is somehow atypical, and that the intensity measurements from the arrays
were noisy or otherwise inaccurate.
Secondly, also in relation to the raw experimental data, was the lower than expected
similarity between co-twins in pairs, and higher than expected similarity with un-
related individuals in some instances. Global expression profiles are expected to be
more highly correlated for related individuals. In this case, just under half of the
co-twins were found to be more similar to unrelated individuals than their own
co-twins. This could be the result of sample mislabelling or swapping. However,
the expression profiles did cluster correctly by sex, making this somewhat unlikely.
One potential explanation could be contamination from genomic DNA or another
source of RNA - which would account for the overall high levels of correlation that
were observed even between unrelated samples.
Thirdly, in relation to the results of differential expression analysis, are the lack of
significant hits and unexpectedly high proportion of non-coding RNA transcripts.
Typically, a differential expression analysis might be expected to produce inflated
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p-values due to unreliable estimates of per gene variance as well as the effect of un-
modelled technical effects [34, 37]. The opposite is observed here, with QQ plots
showing overall p-value deflation. In order to reliably call a differentially expressed
gene, The Microarray Quality Control (MAQC) consortium recommend using a
log fold change cutoff of at least 1 (corresponding to a two fold change in abun-
dance) in conjunction with a stringent unadjusted p-value threshold, for example
p < 0.001 [40]. Others suggest using even higher log fold change values of between
1.5 and 2 [41]. For both case-control and within-group 2 analyses, no single gene
identified as having evidence for differential expression meets any of these criteria.
As for the constituent genes of the differentially expressed lists, a large number of
these are snRNAs, which is surprising since the HuGe array is primarily designed
to profile mRNAs, which potentially indicates sample contamination occurred, or
that there was some other unknown technical issue with the arrays.
On a related note, an issue that currently receives a great deal of attention inEpigenome-
wide association studies (EWAS) is how best to control for the numerous non-
biological sources of variation present. These can range from batch effects, for
example the date when the samples or arrays were processed and by which lab
technician, to technical effects - e.g. placement of the samples on the arrays (com-
monly the rows and columns on the individual arrays, as well as the individual chip
or plate IDs). While there is little in the way of contemporary recommendations
on such factors in gene expression studies, it seems likely that many of these same
issues could be relevant. We did not spend much time exploring these in the cur-
rent study due to the small sample size and single experimental batch, and then the
subsequent lack of observed genomic inflation (often an indication of the presence
of unmodelled technical variation), but future studies may wish to apply some of
the more recent recommendations from EWAS, such as explicitly controlling for
technical factors such as chip positional effects in the linear modelling strategy, es-
timating cell composition effects [42], or estimating and controlling for unknown
sources of variation using unsupervised methods such as ISVA (independent sur-
rogate variable analysis) [43].
Due to concerns about the reliability of the data generated, the decision was taken
not to proceed with any additional analyses or higher level interpretation of the
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results. Unfortunately, very little can be gleaned from this experiment as a result.
It has not been possible to identify genes or groups of genes with altered expression
in ASD cases, as compared to unaffected controls, nor differences in gene expres-
sion within ASD discordant twin pairs. Furthermore, we are not able to assess
the overall effectiveness of the methodology, in terms of the utility of microarray
expression profiling of peripheral blood samples in the investigation of ASD, and
whether the experiment is well powered enough to detect the very small differences
in expression expected between MZ twins.
While the analysis phase of this studywas being carried out, a pilot expression study
using RNA-seq, a newer, alternative profiling technology utilising next-generation
sequencing to directly measure transcript abundance, was underway. The prelim-
inary results showed promise, with all indications that the expression data was of a
better resolution and higher quality, and potentially able to identify much smaller
differences in expression. The experiment did go ahead and is described in the next
chapter.
101
References
[1] K. Kim, K. Lee, H. Bang, J. Y. Kim, and J. K. Choi, “Intersection of genetics
and epigenetics in monozygotic twin genomes,”Methods, 2015.
[2] J. T. Bell and T. D. Spector, “A twin approach to unraveling epigenetics,”
Trends in Genetics, vol. 27, no. 3, pp. 116–125, 2011.
[3] J. T. Bell and R. Saffery, “The value of twins in epigenetic epidemiology,” In-
ternational Journal of Epidemiology, p. dyr179, 2012.
[4] M. Ketelaar, R. Hofstra, and M. Hayden, “What monozygotic twins discor-
dant for phenotype illustrate about mechanisms influencing genetic forms of
neurodegeneration,” Clinical genetics, vol. 81, no. 4, pp. 325–333, 2012.
[5] J. Van Dongen, P. E. Slagboom, H. H. Draisma, N. G. Martin, and D. I.
Boomsma, “The continuing value of twin studies in the omics era,” Nature
Reviews Genetics, vol. 13, no. 9, pp. 640–653, 2012.
[6] E. L. Dempster, R. Pidsley, L. C. Schalkwyk, S. Owens, A. Georgiades,
F. Kane, S. Kalidindi, M. Picchioni, E. Kravariti, T. Toulopoulou, et al.,
“Disease-associated epigenetic changes in monozygotic twins discordant
for schizophrenia and bipolar disorder,” Human molecular genetics, vol. 20,
no. 24, pp. 4786–4796, 2011.
[7] N. Matigian, L. Windus, H. Smith, C. Filippich, C. Pantelis, J. McGrath,
B. Mowry, and N. Hayward, “Expression profiling in monozygotic twins dis-
cordant for bipolar disorder reveals dysregulation of the wnt signalling path-
way,”Molecular psychiatry, vol. 12, no. 9, pp. 815–825, 2007.
102
References
[8] F. Borovecki, L. Lovrecic, J. Zhou, H. Jeong, F. Then, H. Rosas, S. Hersch,
P. Hogarth, B. Bouzou, R. Jensen, et al., “Genome-wide expression profiling
of human blood reveals biomarkers for huntington’s disease,” Proceedings of
the National Academy of Sciences of the United States of America, vol. 102,
no. 31, pp. 11023–11028, 2005.
[9] V. W. Hu, B. C. Frank, S. Heine, N. H. Lee, and J. Quackenbush, “Gene ex-
pression profiling of lymphoblastoid cell lines from monozygotic twins dis-
cordant in severity of autism reveals differential regulation of neurologically
relevant genes,” BMC genomics, vol. 7, no. 1, p. 118, 2006.
[10] C. Wong, E. L. Meaburn, A. Ronald, T. Price, A. Jeffries, L. Schalkwyk,
R. Plomin, and J. Mill, “Methylomic analysis of monozygotic twins discor-
dant for autism spectrum disorder and related behavioural traits,”Molecular
psychiatry, 2013.
[11] A. Trouton, F. M. Spinath, and R. Plomin, “Twins early development study
(teds): a multivariate, longitudinal genetic investigation of language, cog-
nition and behavior problems in childhood,” Twin Research, vol. 5, no. 5,
pp. 444–448, 2002.
[12] B. R. Oliver and R. Plomin, “Twins’ early development study (teds): a mul-
tivariate, longitudinal genetic investigation of language, cognition and be-
havior problems from childhood through adolescence,” Twin Research and
Human Genetics, vol. 10, no. 01, pp. 96–105, 2007.
[13] C. Haworth, O. S. Davis, and R. Plomin, “Twins early development study
(teds): a genetically sensitive investigation of cognitive and behavioral de-
velopment from childhood to young adulthood,” Twin Research and Human
Genetics, vol. 1, no. 1, pp. 1–9, 2012.
[14] A. P. Association and A. P. A. T. F. on DSM-IV., Diagnostic and statistical
manual of mental disorders: DSM-IV. Amer Psychiatric Pub Inc, 1994.
[15] F. J. Scott, S. Baron-Cohen, P. Bolton, and C. Brayne, “The cast (childhood
asperger syndrome test) preliminary development of a uk screen for main-
103
References
stream primary-school-age children,” Autism, vol. 6, no. 1, pp. 9–31, 2002.
[16] J. Williams, F. Scott, C. Stott, C. Allison, P. Bolton, S. Baron-Cohen, and
C. Brayne, “The cast (childhood asperger syndrome test) test accuracy,”
Autism, vol. 9, no. 1, pp. 45–68, 2005.
[17] C. Lord, M. Rutter, and A. Le Couteur, “Autism diagnostic interview-revised:
a revised version of a diagnostic interview for caregivers of individuals with
possible pervasive developmental disorders,” Journal of autism and develop-
mental disorders, vol. 24, no. 5, pp. 659–685, 1994.
[18] C. Lord, S. Risi, L. Lambrecht, E. H. Cook Jr, B. L. Leventhal, P. C. DiLavore,
A. Pickles, and M. Rutter, “The autism diagnostic observation schedule—
generic: A standardmeasure of social and communication deficits associated
with the spectrum of autism,” Journal of autism and developmental disorders,
vol. 30, no. 3, pp. 205–223, 2000.
[19] R. C. Team, “R: A language and environment for statistical computing. vi-
enna, austria; 2014,” URL http://www. R-project. org, 2015.
[20] B. S. Carvalho and R. A. Irizarry, “A framework for oligonucleotide microar-
ray preprocessing,” Bioinformatics, vol. 26, no. 19, pp. 2363–2367, 2010.
[21] R. C. Gentleman, V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit,
B. Ellis, L. Gautier, Y. Ge, J. Gentry, et al., “Bioconductor: open software de-
velopment for computational biology and bioinformatics,” Genome biology,
vol. 5, no. 10, p. R80, 2004.
[22] B. Carvalho, pd.hugene.1.0.st.v1 - PlatformDesign Info for Affymetrix HuGene
1.0 st v1. R package version 3.14.1.
[23] R. A. Irizarry, B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis,
U. Scherf, T. P. Speed, et al., “Exploration, normalization, and summaries of
high density oligonucleotide array probe level data,” Biostatistics, vol. 4, no. 2,
pp. 249–264, 2003.
104
References
[24] affymetrix, “Dabg on gene level for exon and gene arrays -
https://stat.ethz.ch/pipermail/bioconductor/2010-september/035475.html,”
January 2015.
[25] T. Benaglia, D. Chauveau, D. Hunter, and D. Young, “mixtools: An r package
for analyzing finite mixture models,” Journal of Statistical Software, vol. 32,
no. 6, pp. 1–29, 2009.
[26] D. Smedley, S. Haider, B. Ballester, R. Holland, D. London, G. Thorisson, and
A. Kasprzyk, “Biomart–biological queriesmade easy,” BMC genomics, vol. 10,
no. 1, p. 22, 2009.
[27] WEHI, “http://bioinf.wehi.edu.au/software/gendergenes/index.html,” Jan-
uary 2016.
[28] L. Carrel and H. F. Willard, “X-inactivation profile reveals extensive vari-
ability in x-linked gene expression in females,” Nature, vol. 434, no. 7031,
pp. 400–404, 2005.
[29] H. Skaletsky, T. Kuroda-Kawaguchi, P. J. Minx, H. S. Cordum, L. Hillier,
L. G. Brown, S. Repping, T. Pyntikova, J. Ali, T. Bieri, et al., “The male-
specific region of the human y chromosome is a mosaic of discrete sequence
classes,” Nature, vol. 423, no. 6942, pp. 825–837, 2003.
[30] G. K. Smyth, Y. H. Yang, and T. Speed, “Statistical issues in cdna microarray
data analysis,” in Functional Genomics, pp. 111–136, Springer, 2003.
[31] D. Witten and R. Tibshirani, “A comparison of fold-change and the t-statistic
for microarray data analysis,” Technical Report, Stanford University., 2007.
[32] H. Yang and G. Churchill, “Estimating p-values in small microarray experi-
ments,” Bioinformatics, vol. 23, no. 1, pp. 38–43, 2007.
[33] G. K. Smyth, “Limma: linear models for microarray data,” in Bioinformatics
and computational biology solutions using R and Bioconductor, pp. 397–420,
Springer, 2005.
105
References
[34] G. K. Smyth, “Linear models and empirical bayes methods for assessing dif-
ferential expression in microarray experiments,” Statistical Applications in
Genetics and Molecular Biology, vol. 3, no. 1, 2004.
[35] G. K. Smyth, J. Michaud, and H. S. Scott, “Use of within-array replicate spots
for assessing differential expression inmicroarray experiments,” Bioinformat-
ics, vol. 21, no. 9, pp. 2067–2075, 2005.
[36] E. B. Robinson, P. Lichtenstein, H. Anckarsäter, F. Happé, and A. Ronald,
“Examining and interpreting the female protective effect against autistic be-
havior,” Proceedings of the National Academy of Sciences, vol. 110, no. 13,
pp. 5258–5262, 2013.
[37] A. A. Fodor, T. L. Tickle, and C. Richardson, “Towards the uniform distribu-
tion of null p values on affymetrix microarrays,” Genome Biol, vol. 8, no. 5,
p. R69, 2007.
[38] S. J. Barton, S. R. Crozier, K. A. Lillycrop, K. M. Godfrey, and H. M. Inskip,
“Correction of unexpected distributions of p values from analysis of whole
genome arrays by rectifying violation of statistical assumptions,” BMC ge-
nomics, vol. 14, no. 1, p. 161, 2013.
[39] A. C. Eklund, L. R. Turner, P. Chen, R. V. Jensen, A. R. Kopf-Sill, Z. Szallasi,
et al., “Replacing crna targets with cdna reduces microarray cross-
hybridization,” Nature biotechnology, vol. 24, no. 9, pp. 1071–1073, 2006.
[40] L. Shi, L. H. Reid, W. D. Jones, R. Shippy, J. A. Warrington, S. C. Baker, P. J.
Collins, F. De Longueville, E. S. Kawasaki, K. Y. Lee, et al., “The microarray
quality control (maqc) project shows inter-and intraplatform reproducibil-
ity of gene expression measurements,” Nature biotechnology, vol. 24, no. 9,
pp. 1151–1161, 2006.
[41] A. Brazma and J. Vilo, “Gene expression data analysis,” FEBS letters, vol. 480,
no. 1, pp. 17–24, 2000.
[42] E. A. Houseman, W. P. Accomando, D. C. Koestler, B. C. Christensen, C. J.
Marsit, H. H. Nelson, J. K. Wiencke, and K. T. Kelsey, “Dna methylation ar-
106
References
rays as surrogate measures of cell mixture distribution,” BMC bioinformatics,
vol. 13, no. 1, p. 1, 2012.
[43] A. E. Teschendorff, J. Zhuang, and M. Widschwendter, “Independent surro-
gate variable analysis to deconvolve confounding factors in large-scale mi-
croarray profiling studies,” Bioinformatics, vol. 27, no. 11, pp. 1496–1505,
2011.
107
3 | Characterising the transcriptome
in autism spectrum disorder us-
ing RNA-seq
3.1 Introduction
RNA-seq is a recently developed method for assessing gene expression using next-
generation sequencing. The technology has the potential to revolutionise func-
tional studies of psychiatric traits, by enabling more accurate quantification of low
abundance transcripts, as well as alternatively spliced, and non-coding regulatory
transcripts. To date, RNA-seq has been used to characterise genome-wide patterns
of expression for a range of neurodevelopmental and psychiatric conditions includ-
ing: major depressive disorder (MDD) [1], schizophrenia [2], bipolar disorder [3],
and Alzheimer’s disease [4].
Whilst there have been RNA-seq studies that have investigated gene expression
during normal development in typically developing controls and attempted to re-
late these findings to developmental conditions [3, 5], we were unable to find any
that directly interrogated the global transcriptome in ASD. In what we believe rep-
resents the first study of its kind, we revisit the gene expression profiling study
described in Chapter 2, this time employing RNA-seq to profile global patterns
of gene expression in ASD. As before, the subjects comprise ASD concordant,
ASD discordant, and unaffected concordant control MZ twin pairs from the TEDS
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longitudinal birth cohort [6]. Genome-wide gene expression profiles are gener-
ated and two main analyses carried out. Firstly, by comparing ASD affected with
unaffected, age-matched controls across the sample (between-groups), we aim to
identify genes and pathways commonly disrupted in ASD - attributable to genetic
and/or environmental factors. Secondly, by performing within-group and within-
pairs analyses of the discordant ASD pairs, we also hope to identify those genes
and pathways disrupted through non-genetic means (potentially sensitive to the
environment), both in common across discordant pairs and family-specific respec-
tively. As well as addressing these primary biological questions, we also hope to
provide support for previous epigenetic findings (from the methylation study - see
Chapter 2), and also to generate a high-quality gene expression dataset for use in
a planned integrative analysis, which will attempt to uncover the functional rela-
tionship between altered patterns of expression, disrupted epigenetic regulation,
and ASD. Finally, in the course of this work, we also investigate a couple of rele-
vant secondary technical and methodological issues including the cross-platform
reproducibility of the expression profiles, and a comparison of a selection of RNA-
seq geneset testing methods.
3.2 Methods
3.2.1 Subjects
Subjects were taken from the same cohort of concordant ASD, discordant ASD and
age-matched control twin-pairs fromTEDS, as previously detailed inChapter 2. To
recap, these included:
• group 1: 6 ASD concordant pairs - both co-twins in pair with formal ASD
diagnosis)
• group 2: 6 ASD discordant pairs - one co-twin in pair with a formal ASD
diagnosis)
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• group 6: 11 unaffected, concordant control pairs - both co-twins in pair
scored less than or equal to the sample mean in total CAST score
3.2.2 Pilot study
In order to assess the performance of the proposed platform and fine tune the ex-
perimental protocol, prior to themain study, a pilot RNA-seq study using 4 control
samples from group 6 (low total CAST - unaffected pairs) was conducted using the
Illumina TruSeq Stranded Total RNA protocol and HiSeq 2000 sequencing plat-
form (Illumina, USA). Library preparation was carried out by Matt Arno’s lab at
the Genomics Centre, King’s College London, Waterloo Campus, with sequencing
of the libraries conducted by Alka Saxena’s lab at the BRC Genomics Core Facility,
King’s College London, Guy’s Hospital. After reviewing the QCmetrics and results
from the preliminary analysis, performing power calculations using the web appli-
cation SCOTTY [7], and consulting the relevant literature (e.g. [8]), the decision
was taken to run the full experiment with the same library kit and on the same
platform. Only minor adjustments were made to the library preparation protocol,
see the Library preparation section below for more details.
3.2.3 Subject selection
When designing RNA-seq experiments, typically researchers attempt to strike a
balance between the desired breadth of coverage - in terms of the number of sam-
ples sequenced, and depth of coverage - the number of reads per library. The pri-
mary motivating factor here is the high cost associated with sequencing, but there
is also the potential to generate an abundance of redundant data from excessive
coverage of highly expressed transcripts which it would seem sensible to avoid. So
while sequencing to higher read depths does lead to an increase in the accuracy of
transcript abundance estimation (thereby increasing power to estimate differen-
tially expressed genes)[9], a read count of 40 M reads per sample is sufficient for
detecting the abundance of > 99 % of expressed mRNA [10, 11]. Based on these
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prior estimates and the data from the pilot study, for the main experiment the de-
cision was taken to sequence 40 samples on one full flow cell of the HiSeq, yielding
an estimated 40 M reads per sample. Subjects were selected from groups 1, 2 and
6, representing ASD concordant, ASD discordant, and unaffected control pairs re-
spectively. After assessing the quality of the total RNA obtained from the blood
samples (see RNA isolation below), a total of 17 MZ twin pairs and 6 individuals
(40 individuals in total) were available for the study (shown in Figure 3.1).
N = 19
group 6
Total N = 39 Key
ASD  non-ASD
Male
Female
MZ twins
N = 9 N = 11
group 1 group 2
concordant 
ASD
discordant 
ASD
concordant 
low CAST
Figure 3.1. The study sample - with group, sex, pair and ASD affected status indicated.
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3.2.4 RNA isolation
RNA was isolated from peripheral blood samples, taken from biobanked samples
not previously used in the microarray profiling experiment. RNA isolation was
performed by Matt Arno’s lab. Total RNA was extracted from whole blood sam-
ples using the PAXgene blood kit (PreAnalytiX, QIAGEN, Germany). 5 g total
RNA was treated with the Ribo-Zero Globin kit (Ambion, USA) to remove ribo-
somal and globin RNAs and underwent quality control using the RNA 6000 Nano
LabChip and Agilent 2100 BioAnalyzer system (Agilent Technologies, USA). This
generates an RNA integrity number (RIN) for each sample, a metric measuring the
quality of the starting material [12]. RIN scores range from 1 to 10, with 1 being
completely degraded and 10 being intact, and a minimum score of 8 typically rec-
ommended to proceed with library preparation [13]. Around 90% of the samples
(36/40) were found to be of high quality, with RIN values between 7 and 9 (mean
= 8.2). For the remaining samples, RIN values were < 7 (mean = 4.8). The decision
was taken to proceed with all but one of one samples : TG36392, from group 1
(ASD concordant), which was found to be severely degraded (RIN = 2.6). Library
preparation and sequencing went ahead for the remaining 39 samples.
3.2.5 Library preparation
Libraries of transcripts for each sample were generated. This stage of the exper-
iment was carried out by Matt Arno’s lab. The Illumina TruSeq Stranded Total
RNA Library Prep Kit v3 (Illumina, USA) was used to prepare RNA libraries fol-
lowing the manufacturers protocol for a low-throughput experiment. First, the
purified RNA samples were subjected to thermal fragmentation at 94 degrees for
4 minutes. This was then followed by random hexamer priming. The fragmented,
primed RNA then underwent reverse transcription for first strand cDNA synthe-
sis, which was then followed by second strand synthesis, where the RNA template
was removed, and a second strand of cDNA synthesised, this time incorporating
the strand-marking nucleotide dUTP, to form double stranded cDNA. Following
this, end repair, 3’ adenylation, and adapter ligation (Illumina Standard and In-
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dexed TruSeq adapters) were performed, along with dUTP-marked second strand
degradation, to prepare the double stranded cDNA from each of the samples to be
multiplexed (pooled) together and run across lanes (to randomize subjects on each
lane). Size selection was then performed by electrophoresis, producing fragments
with a median length of approximately 326 bp (160 bp inserts). PCR was carried
out to enrich for adaptor-bound fragments. The Agilent BioAnalser system was
used to assess the distribution of fragment sizes, as a measure of library quality, by
inspecting the resulting electropherograms.
3.2.6 Sequencing
The prepared libraries were then sent to the manufacturer Illumina UK for se-
quencing. Libraries were hybridised to a single flow cell (8 lanes) and sequenced
using the HiSeq 2500 (Illumina, USA). This generated 100 bp paired-end reads,
yielding an estimated 250 M reads per lane, approximately 50 M reads per sample
(with 5 samples per lane). Libraries were arranged in as close to a balanced, ran-
domised design as the available samples would permit, with twin pairs split across
the lanes, and each lane containing subjects from each study group (see Appendix
- Chapter 3 - Table B1). In order to ensure each lane had the same number of
samples and read density, sample TG78042 from group 1 was re-run as a techni-
cal replicate, meaning that in total RNA libraries for 40 samples were sequenced
(for 39 individuals). The resulting reads were demultiplexed at the BRC Genomics
Core Facility, filtering according to the 6 bp index sequences contained within the
adaptors and unique to each sample. A total of 80 .fastq files were provided, two
files per sample: R1 containing the forward reads and R2 the reverse reads.
3.2.7 Analysis pipeline
Expression profiling by RNA-seq brings with it many novel analytical challenges.
While the overall analysis flow is now quite well established (see [14]), consen-
sus has yet to be reached on absolute best practices for each of the analysis stages
[8, 15, 16]. A standard RNA-seq differential expression analysis typically proceeds
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Figure 3.2. The analysis pipeline used to process the RNA-seq data, produce estimates
of transcript abundance, and finally test for differential expression between conditions.
The software packages used at each stage is indicated.
through the following stages : pre-processing, pre-mapping quality control, map-
ping, post-mapping quality control, read mapping, quantification and normaliza-
tion, and finally differential expression analysis. A range of different methods are
available for each of these stages, with choice of read mapping and quantifica-
tion methods arguably having the greatest bearing on the final results produced.
For this experiment, a read mapper was chosen based on four main criteria: the
underlying method had to have been published, splice-aware (able to map exon-
junction spanning reads), with the provided software benchmarked and shown to
be computationally fast (as well as supporting parallelisation), and finally, a track
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record of being used for large-scale transcriptomic studies. Based on these crite-
ria, the TopHat aligner was chosen [17] (see Mapping section below). For later
quantification, it was decided that a fast method with parallel support and using
minimal statistical modelling would be desirable, to simplify the data being taken
forward for later differential expression analysis and data integration. To this end,
featureCounts from the subread package [18] was selected, see Quantification be-
low.
An overview of this analysis pipeline is provided in Fig 3.2, with each step de-
scribed in the sections below. This scripts are given in Appendix - Chapter 3 -
Figure B1, and are also available for download fromhttps://github.com/asaffa/PhD,
with software versions, parameters, settings, and additional information also pro-
vided.
3.2.8 Quality control I - pre-mapping
The FastQC program [19] was used to produce general sequencing metrics for the
.fastq files, to determine the effectiveness of library generation and sequencing,
and identify any potential technical biases prior to analysis. The output from pre-
mapping QC is given in Appendix - Chapter 3 - Table B2.
3.2.8.1 Number of reads and sequence quality
The number of reads per library ranged between 38 and 78 M, with a mean of
approximately 54 M reads per sample. Read depth is a known technical factor
in RNA-seq experiments [15], and most analysis flows include some method for
normalizing total read count in order to control for this effect, so at this stage no
further action was taken. Plots for per-base sequence quality, per-sequence qual-
ity, and sequence length distribution were inspected, and were found to be within
normal ranges for all samples with no major observable differences between the
samples.
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3.2.8.2 GC content
GC content was found to range from 46 to 49 % with a median of 47 %, close
to the expected 46 % for the human genome [20], confirming that the libraries
processed were human RNA, and that contamination from genomic DNAwas un-
likely to have occurred. For themajority of samples, a twin-peaked distribution for
GC count per read was observed, with the higher, narrower peak hypothesised to
represent highly expressed transcripts sequenced to an excessive depth. It was rea-
soned that this might be a characteristic of total RNA libraries derived from whole
blood, as this was also observed in the pilot study (conducted at a different se-
quencing centre). The manufacturer was contacted regarding this issue, but could
not offer any explanation. At the time also, no public datasets for whole blood ex-
periments were available for comparison. After some further investigation, it was
therefore decided not to take any further action, as there was no evidence for a sys-
tematic effect across the lanes (containing randomised samples from each group),
with correlation between lane and GC content : r2 = 0.25, p = 0.12. It was reasoned
too that subsequent normalisation and variance shrinkage should act to reduce any
potential bias introduced by the oversampling of particular transcripts - assumed
to be the underlying root cause of the GC profile spike.
3.2.8.3 Library composition and sequence diversity
Sequence duplication levels can be used to gain an impression of the diversity of
the libraries, and whether over sequencing is likely to have occured. Duplication
can either arise from excess amplification of fragments during PCR, or as a result
of the same sequence being sequenced multiple times. In this case, the average
sequence duplication rate for each library was around 0.21, around the value ex-
pected in an RNA-seq experiment [21]. Because there is a degree of uncertainty
in determining whether duplication reflects true abundance or PCR artefacts, and
because no systematic difference in duplication rates was immediately obvious, it
was decided not to remove these.
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3.2.8.4 Read removal/trimming
Illumina adapter sequence reads can sometimes make up a small proportion of
the libraries due to read through of small fragments. These are flagged as over-
represented sequences in FastQC. The cutadapt tool [22] was used to remove any
reads mapping to known Illumina adaptor sequences. Successful removal of these
readswas confirmedby re-runningFastQC and examining the output once again.
Sequencing chemistry generally becomes less reliable with read length, resulting in
lower-quality base pair calls towards the ends of reads. FastQC generates a boxplot
of read quality vs position in order to visualise this. Quality is assessed using the
phred score metric Q : Q = −10 × log10P , where P is the probability of an erro-
neous base pair call. cutadapt was once again used, this time to trim low quality
base pair calls, defined as those with phred quality scores <= 20, indicating a 1 in
100 chance of an incorrect base pair call, or 99% calling accuracy.
3.2.8.5 Preliminary mapping and determination of insert sizes
For optimization of the later mapping process, median insert size - defined as frag-
ment lengthminus the read adaptors (i.e. the actual length of target sequence read)
was estimated by mapping subsamples of 1M reads from each sample to the EN-
SEMBL GRCh37 reference transcriptome using the BWA aligner [23]. The picard
tools program [24] was then used to generate the relevant metrics, and insert sizes
were found to range from 169 - 189, with a median of 175 - close to the expected
value of 160.
3.2.9 Mapping
The .fastq reads were then mapped to the ENSEMBL GRCh37 reference genome
using the Tophat [17] software. This is a splice-aware aligner based on the Bowtie
short readmapper [25], which is rapidly becoming the standard formapping RNA-
seq data, due to its computational efficiency and capability in handling reads span-
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ning exon junctions. Binary sequence alignment (.bam) files are generated for each
sample.
3.2.10 Quality control II - post mapping
In order to assess the effectiveness of read mapping and the quality of the align-
ments, RNA-SeQC [26] was used to produce summary statistics including total
proportion of mapped reads, proportion of reads mapping in pairs, the effective-
ness of the stranded protocol, fraction of reads mapping to exonic or intronic re-
gions, and coverage along the length of the transcripts. These metrics were com-
pared to guidelines laid out by GEUVADIS [21]. The overall indications were that
the sequencing data generated was of a high quality, with on average 78% of total
reads mapping in their forward and reverse read pairs, 47% of these reads origi-
nating from exonic regions, a mean coverage of 6 × for less abundant transcripts
(bottom 1000) and 732 × for transcripts present at higher levels (top 1000). The
output from post-mapping QC is given in Appendix - Chapter 3 - Table B3.
3.2.11 Quantification
A count overlap method was chosen in preference to an isoform abundance esti-
mation method (the method used in cufflinks from the TopHat suite), as the distri-
butional properties of the former are better understood, allowing greater flexibility
with later choice of statistical modelling approach. The featureCounts program
from the subread package [18] was used to summarise and quantify the mapped
reads. In order to quantify reads, a counting scheme is used, whereby the number
of paired end reads overlapping with annotated genes from the ENSEMBL hg19
transcriptome are totalled. A table of gene counts is output in .csv format, ready
for import into R for further analysis. The output from post-quantification QC is
given in Appendix - Chapter 3 - Table B4.
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3.2.12 Filtering
Filtering was performed to remove genes with low counts, as these are potentially
unreliable measurements and are unlikely to be of interest for differential expres-
sion analysis. Across all of the libraries, reads were found mapping to 46,802 tran-
scripts. A filter requiring abundance >= 1 in at least 3 samples was used, leaving
count data for 17,833 transcripts.
3.2.13 Exploratory analysis of inter-individual expression profiles
To assess the quality of the count data, some exploratory analyses were performed.
Firstly, concordance between expression profileswithin the twin pairswas assessed.
As gene expression is heritable, profiles of twins pairs would be expected to be
more highly correlated compared to unrelated subjects. For this purpose, counts
were normalized by total library size and transformed into logCPM (log counts
per million), later reverting back to raw counts for inferential analysis. Correlation
was calculated using Pearson’s r, using the built-in cor function in R. A heatmap
was produced to visual the results, and mean correlation values within pairs, and
between unrelated subjects were recorded.
Next, Euclidean distances between samples were calculated using the complete set
of counts, and hierarchical, unsupervised clustering was performed using the dist
and hclust functions in R. Two different dendrograms were produced to visualise
the results: one in which subject labels were coloured by sex, and the other where
subject labels were coloured according to groupmembership/co-twin status.
Finally, multi-dimensional scaling (MDS)was performed to qualitatively assess the
contribution of different biological and technical variables to the overall variance
between samples- in this case sex, group, case and lane. MDS is a method which,
similar to principal components analysis (PCA), attempts to find a lower dimen-
sional representation of the data, but does so while maintaining distances between
objects [27]. In this case, the biological coefficient of variation (BCV) was used as
the measure of distance between samples, defined as
√
g, where g is the disper-
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sion parameter of the negative binomial distribution (see Differential expression
analysis section below). The resulting scatter plots weremanually inspected to help
highlight any issues.
3.2.14 Differential expression analysis
Count data generated by RNA-seq has particular characteristics that have to be
considered before inferential testing can be performed. Firstly, counts are a dis-
crete measurement perhaps best approximated by a negative binomial distribu-
tion, in contrast to the continuous, normally distributed intensity measurements
frommicroarrays [16]. Secondly, library size and diversity will vary between sam-
ple; the source of the variation can be technical, biological, or stochastic. Thirdly,
the number of reads per transcript is proportional to the length of the transcript
- longer transcripts will generate more fragments, and hence a greater number of
reads.
Normalisation strategies were originally recommended as ameans for dealing with
some of these issues, for example, the FPKM (Fragments Per Kilobase of transcript
per Million mapped reads) measure used by Cufflinks in the Tophat suite adjusts
counts by total number of reads mapped and length of the transcript. However,
the current advice is that such normalisation strategies not be used, as they are not
robust to the presence of different library sizes and compositions typically found
in RNA-seq [28]. More recently developed approaches, such as those implemented
in the bioconductor packages DESeq [29] and edgeR use model-based normaliza-
tion instead of transforming the raw counts. These methods adjust by total library
size, using either a scaling factor (median of the ratio of read count over geomet-
ric mean across all samples for each gene) or trimmed mean of M-values (TMM -
which minimizes logFCs between samples for the majority of genes) respectively.
Both of these methods have been empirically shown to be more robust than earlier
normalization methods [28].
For differential expression analysis, theDESeq,edgeR and limmamethods were first
benchmarked using a straight-forward sex analysis comparing expression levels
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between males and females (see below) and a “gold standard” set of sex genes -
those experimentally confirmed to display sex-specific patterns of expression [30].
Each method’s performance was assessed by measuring the sensitivity and speci-
ficity for identifying the sex genes as differentially expressed (see Appendix - Chap-
ter 3 - Tables B5, B6, and Figure B2). edgeR was selected for the main analysis as it
achieved the highest sensitivity, and also because of its similarities with limma (pre-
viously used in the microarray analysis). edgeR also borrows information across
genes to improve variance estimates, and a similar linear model-based approach,
but one specifically tailored for RNA-seq count data. The method works by calcu-
lating a value for common dispersion across all genes, and then using an empiri-
cal Bayes approach to shrink the dispersion for each individual gene towards the
common trend. Once dispersions have been estimated, differential expression is
assessed using a generalized linear model (GLM) likelihood ratio test (LRT). The
method proceeds as follows: first negative binomial GLMs for each gene are fit-
ted,
Ygi ∼ NB(Migj; g) (3.1)
where Ygi is the number of counts for gene g in sample i, Mi is the library size,
g is the dispersion, and gj is the relative abundance of gene g in experimental
group j which sample i belongs to. Then, a LRT is used to compare the full model
(which includes the covariate of interest) to the null model (where the covariate is
excluded), to derive a p-value for evidence of differential expression.
As in the microarray experiment previously (see Chapter 2), two major types of
analysis were performed. Firstly, by comparing all cases and controls between-
groups (14 ASD affected, 25 unaffected), we intended to identify commonly per-
turbed genes and pathways associated with ASD that could be genetic or environ-
mental in origin. This analysis will be referred to as “case-control” from here on.
The following generalized linear model was used:
expression ∼ pair + case (3.2)
121
Chapter 3. Characterising the transcriptome...
where pair is categorical variable representing twin-pair membership, and case a
binary variable denoting case status. Here, we have modelled pair as a fixed effect
as edgeR, like most negative-binomial distribution-based methods for RNA-seq,
assumes statistical independence between all samples and hence does not allow for
the fitting of random effects. This same analysis was also repeated usingmales only,
to explicitly control for sex, which we will refer to as “case-control males”.
For the second major type of analysis, a within-group comparison of the ASD dis-
cordant twins (group 2 : 5 ASD affected, 6 unaffected) was performed, to identify
differences in gene expression attributable to the environment. This analysis will be
referred to as “group 2”. The samemodel as above was used. This was also repeated
using males only, to explicitly control for sex - “group 2 males”.
Additionally, for the discordant pairs in group 2, within-pairs (or family-specific)
analyses were performed, referred to as “group 2 consensus”. For each of the 5 pairs
the following model was used:
expression ∼ case (3.3)
Since there are no replicates for the pair unit, this produces only descriptive mea-
sures of logFC difference in expression for each gene between case and control.
This was used to identify genes with a consistent direction of logFC across all un-
related twin pairs, which could indicate that these genes, as well potentially having
their expressionmodified by environmental factors, could also have a dosage effect
giving rise to ASD.
A sex contrast was also performed for benchmarking and quality control purposes,
using the following model:
expression ∼ sex (3.4)
Toqualitatively assess the overall effectiveness of the statisticalmodelling approaches
used, a number of visualisations were produced: QQ plots to indicate the over-
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all distribution of p-values, MA plots to visualize the relationship between logFC
and mean count, and volcano plots showing relationship between significance and
logFC.
3.2.15 Quantitative trait model
Autistic traits have previously been shown to exist as continuous, normal distributed
trait in the general population [31, 32]. An analytical approach that had been
planned for the original microarray experiment but later abandoned once it be-
came clear that the data was not usable, was to use total CAST score as a quantita-
tive trait as opposed to the binary case-control outcome in the linear regressions.
The idea was revisited in this study.
Before performing differential expression analysis with ASD as a quantitative trait,
first descriptive measures for the CAST data were produced. This involved ex-
amining the distribution of the data, and exploring the relationship between the
scores and other variables such as age. After examining this output it was clear
that the CAST score data was not normally distributed and that a data transforma-
tion would be required. The Van Der Waerden transformation was used, whereby
the data is ranked and then converted to quantiles of the standard normal distri-
bution:
V DW = −1( Ri
n + 1) (3.5)
where −1 is the inverse cumulative distribution function for the normal distri-
bution, Ri is the rank of observation i, and n is the sample size. Further analysis
indicated that such a transformation would not be necessary, due to the bimodal
nature of the distribution, whichmeant that for the sample used in this experiment
at least, that binary level case-control status would be more appropriate. The ob-
served non-normal CAST score is likely explained by the exclusion of groups 3,4
and 5 from the RNA-seq experiment - these individuals, being above-threshold
for one of the triad of traits, are likely to make up the middle (missing) portion of
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the distribution. On this basis, it was therefore decided again not to proceed with
quantitative trait analysis.
3.2.16 Geneset testing / pathway analysis
Geneset testing was performed for two main purposes. Firstly, small genesets with
potential relevance to autism were tested for association, to gauge the success of
the experiment in terms of replicating previously identified ASD loci. Secondly,
to identify enriched pathways and cellular processes within the differentially ex-
pressed genes, to perhaps give some insight as to the underlying processess affected
by the dysregulation.
3.2.16.1 Genesets
ASD-associated: To begin with focused testing of ASD-associated genesets was
carried out. Thefirst of these sets comprisedASDgenes fromSFARI (Simons Foun-
dation Autism Research Initiative [33]) gene 2.0 [34], a manually curated reference
dataset of ASD genes frompublishedmolecular studies including: candidate genes,
known common and rare variants, and copy number variants linked to ASD. The
second set used was ASD genes from the GWAS catalogue [35] (NHGRI-EBI Cat-
alog of published genome-wide association studies [36]), the entire collection of
association findings from GWA studies. The third set consisted of syndromic ASD
genes from the Online Mendelian Inheritance in Man (OMIM) [37], a database
of genes associated with mendelian disorders. Lastly, the set of all mitochondrial
genes discovered across the entire sample was compiled, in order to test for po-
tential enrichment of mitochondrial genes. For benchmarking purposes, a set of
sex specific genes from the WEHI bioinformatics group [30] was used. Further
information on all of these genesets is given in Table 3.1.
Pathways: Next, geneset testingwas performed to test for the enrichment of path-
ways and cellular processes. These sets were taken from the Molecular Signatures
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Gene set N Description Link
SFARI 741 Genes implicated in ASD https://gene.sfari.org/
GWAS 221 Catalog of published GWAS findings https://www.ebi.ac.uk/gwas/
OMIM 388 Genes for mendelian disorders related to ASD http://www.omim.org/
(mim_morbid_description field)
MT 21 Mitochondrial genes (discovered by seq) N/A
XiEgenes 66 Gender specific X chromosome genes http://bioinf.wehi.edu.au/software/GenderGenes/
msYgenes 34 Gender specific Y chromosome genes http://bioinf.wehi.edu.au/software/GenderGenes/N/A
Search terms
N/A
"autism" (all fields)
"auti", "[^p]mental","neur" 
N/A
N/A
Table 3.1. ASD relevant genesets used for geneset association testing of the differential
expression results
Database (MSigDB) [38] which brings together biochemical pathways (from Ky-
oto Encyclopedia of Genes and Genomes - KEGG [39] and REACTOME [40]),
gene families (from Gene Ontology - GO [41]), and various other sources of an-
notation, and organises them into various gene set collections of potential bio-
logical relevance. Two collections were selected for testing: the C2 curated set -
containing 4726 canonical pathways representing metabolic and signalling path-
ways, and disease gene expression signatures (from microarray studies). The H1
hallmark set was also used - with 50 genesets representing well-defined, biological
states or processess, in which genes are known to display coordinated expression
patterns.
3.2.16.2 Geneset testing methods
Geneset testing methods can broadly be divided into self-contained (association/
focused) and competitive (enrichment/ battery) methods, depending on the hy-
pothesis being tested. The self-contained null hypothesis is that no genes in the
gene set of interest are differentially expressed, whereas the competitive null is that
the genes in the set of interest are no more likely to be differentially expressed than
its complement (of non- pathway genes outside of the gene set) [42]. Bothmethods
can be further categorised into those using sample randomization or gene random-
ization to generate the required null distributions for inferential testing, or instead
making parametric assumptions [43].
The choice of geneset testing method has been shown to strongly influence the
results produced and the conclusions drawn, with different methods potentially
producing distinct, non-overlapping sets [44]. However, there is still debate on
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which methods should be used to test particular hypotheses in different experi-
mental contexts, and the advice can often be contradictory, see [43] for an in-depth
discussion. The same paper demonstrated that both self-contained and competi-
tive methods using sample randomization can produce statistically sound, biolog-
ical meaningful results, although the use of parametric based methods was cau-
tioned against [43]. This last point is relevant to RNA-seq count data, which is non-
normally distributed. Addressing this, Ramatallah et al. used simulated and real
data to test geneset methods on RNA-seq data and on this basis recommended the
use of self-contained methods based on non-parametric multivariate tests which
are found to exert better control over theType I error rate and have increased power
over parametric univariate-based methods [45].
For this analysis, it was decided to employ different methods depending on the
the characteristics of genesets being tested. In the focused testing of the ASD-
associated sets containing candidate genes, since these do not necessarily take part
in the same pathways andmay ormay not be co-expressed, both self-contained and
competitive methods would be used, and the consensus taken. And for pathway
enrichment testing using the MSigDB pathway sets, which are functionally related
and potentially co-expressed sets of genes, only a competitive method would be
used - since the aim is to identify pathways with more evidence for enrichment
than remaining genes. The edgeR package includes a variety of geneset meth-
ods designed specifically for use with RNA-seq count data. Here we used the
self-containedmethod ROAST [46] and competitive methods geneSetTest [47] and
ROMER [48].
ROAST: The ROAST method was selected for self-contained testing of the ASD-
associated genesets (SFARI, GWAS, OMIM). ROAST uses rotations instead of per-
mutations to generate the null distribution. Rotations can be thought of as a mul-
tivariate regression-based analogue of permutations which allow multiple covari-
ates to be randomized, whilst also allowing for correlations [49]. This allows more
complex experimental designs with fewer replicates to be used in deriving the null,
while avoiding problems with p-value granularity [46]. In simulations and using
real data, the method has been found to perform favourably, producing fewer false
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positives than a range of other self-contained methods [45]. The following ap-
proach is taken: 1. gene level tests are used to obtain moderated t statistics (using
the limma method), 2. these are converted to z-scores, 3. gene test statistics are
then calculated based either on whether a unidirectional or bidirectional hypothe-
sis is being tested (and choice of a summarizationmethod), 4. the data is rotated, 5.
and an exact p-value calculated by dividing the number of rotations that produced
a statistic as extreme as the observed one by the total number of rotations. Three
different summarization methods can be used in combining the t-statistics within
the sets, for genes g with z-scores Zg and optional weights ag in geneset S, where
A = ∑g∈S ∣ag ∣ (sum of absolute gene weights of genes in set) the set statistics are
computed as:
• Tmean ∶ weighted mean of all the genewise statistics (assumes all genes will
be differentially expressed by the same amount)
Tmean =∑
g∈S ∣agzg ∣/A (3.6)
• Tmsq ∶mean of squared genewise statistic (assumes only a small number of
genes are differentially expressed)
Tmsq =∑
g∈S ∣ag ∣z2g/A (3.7)
• Tmean50 ∶weightedmean of the top 50% of the genes (S50)(half of the genes
are differentially expressed)
Tmean50 = ∑
g∈S50 ∣agzg ∣/A (3.8)
• Tfloormean ∶floormeanwhich computes floored z-statistics (similar tomean50,
but faster to compute)
Tfloormean =max(∣zg ∣;0:67) (3.9)
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Since there was no prior hypothesis about the number of differentially expressed
genes expected, nor the direction of the effect, a mixed (bidirectional) hypothe-
sis was used, for which the Tmean50 statistic is generally found to be suitable for.
We also decided to implement a further two test statistic summarization meth-
ods:
• Tmax ∶maximumof all the other tests - assumes all the scenarios are equally
likely
Tmax =max(Tmean; Tmsq; Tmean50; Tfloormean) (3.10)
• Tartp ∶ adaptive rank truncated product (ARTP) - see main text .
Tartp = artp(g ∈ S) (3.11)
The adaptive rank truncated product (ARTP) is a general p-value combination
method (see Chapter 5) developed by Dudbridge and Koeleman [50], and initially
employed inGWASmeta-analysis. ARTP combines the top kmost significant gene
statistics for a range of truncation points k, selecting theminimum p observed over
all points. Yu et al. [51] demonstrated its applicability to gene-based pathway anal-
ysis, where it was later shown to outperform a number of alternative methods for
both self-contained and competitive tests [52]. The ROAST method was modified
to include these two additional methods, with the ARTP implementation adapted
from the R package ARTP. The modified ROAST function (TOAST) can be down-
loaded from: https://github.com/asaffa/PhD.
geneSetTest: The geneSetTestmethodwas used for competitive testing of theASD
sets. The average ranks of the moderated t-statistics in the geneset are calculated,
and compared to those in permuted sets in order to obtain a mean overall rank of
the geneset. The final p-value is computed using the Wilcoxon test.
ROMER: The geneSetTestmethod assumes genes are independent - which might
hold for small sets of candidate genes, but is unlikely to be the case in pathway en-
128
3.3. Results
richment testing. For this reason, an alternative competitive approach was selected
for testing of the MSigDB pathway sets. ROMER is similar to the popular Gene Set
Enrichment Analysis (GSEA) [53] method, but using rotation testing instead of
permutations.
3.2.17 Comparison with microarray data
A comparison between the microarray and RNA-seq data was performed with 16
MZ twin pairs and 7 individuals (39 individuals in total) for whom both microar-
ray and RNA-sequencing data were available. Spearman’s correlation was used to
perform pair-wise comparisons of the samples across the 13,729 genes that were
measured on both platforms:
xy = rRxRy (3.12)
where r is Pearson’s correlation for the ranks R of the variables x and y. A mean
between-platforms sample correlation was calculated, with 95% confidence inter-
vals obtained from Fisher’s z transformed values:
z = arctanh(r) (3.13)
Following this, the levels of correlation and intersection between the differential
expression from the different platforms were assessed using the recorded log fold
change values for all genes and the significant genes at p < 0.05.
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Figure 3.3. a,b. Dendrograms showing sample clustering based on genome-wide ex-
pression values. a. labels are coloured by sex, b. labels coloured by group membership
and twin pair. Twins clustering together in pairs are concordant for color hue and discor-
dant for shade, and cases of unrelated individuals clustering together are discordant for
hue. In this case, all individuals correctly cluster by sex, and all but one pair of twins are
found to cluster together as expected. c. Heatmap showing correlations between individ-
uals. High levels of correlation, r values of 0.99 and above, are indicated by the dark blue
coloured squares along the diagonal. Twin pairs are found to have an average correlation
of 0.98, compared to 0.96 for unrelated subjects.
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Figure 3.4. MDS plots showing similarity of samples based on BCV distance. a. labels
coloured by sex, b. by group membership, c. case status, d. sequencing lane. The
majority of the variation between samples projected on to the first two dimensions appears
to be mainly accounted for by sex, group and case.
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3.3 Results
3.3.1 Exploratory analysis
To begin with, between sample correlation was examined. The median correlation
r within pairs was 0.98, compared to a median of 0.96 between unrelated individu-
als. This is shown in the heatmap in Figure 3.3 c. Next, unsupervised hierarchical
clustering was performed using Euclidean distance as the measure. The cluster-
ing showed male and female subjects segregating into two distinct clusters with no
outliers, and twins were found to cluster together in nodes for 94% (15/16) of the
completeMZ twin pairs in the sample. The resulting dendrograms are shown in the
top panel of Figures 3.3 a. and b. Finally, MDS was performed to qualitatively ex-
amine the contribution of different biological and technical variables to the overall
variance between samples. Plots for the first 6 dimensions were inspected, which
revealed that sex, case, and group were all contributing to the largest dimension of
variance. Lane was not seen to divide the data on any of the first 6 dimensions, and
so it was decided on this basis not to include it as a covariate in the linear model.
The MDS plots for the first 2 dimensions are given in Figure 3.4. The overall indi-
cations from the exploratory analysis were that the count data generated was likely
to be of a high quality.
3.3.2 Differential expression analysis
Two main types of analysis were carried out to investigate patterns of gene expres-
sion in ASD. Firstly, a between-groups analysis of all affected and unaffected sub-
jects from groups 1,2, and 6 (case-control), which was then repeated excluding all
female subjects (case-control males). Secondly, a within-group analysis of the ASD
discordant pairs (group 2), which was once again repeated for males only (group 2
males). A within-pairs analysis for each of the ASD discordant pairs was also per-
formed, keeping only genes showing consistent direction of logFC across all the
pairs (group 2 consensus).
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Figure 3.5. QQ plots showing observed vs theoretical distribution of p-values for each of
the fitted models
To begin with QQ plots were inspected (plots for case-control and group 2 are
shown in Figure 3.5). For all of themodels, approximate null distributionswere ob-
served, with inflation of p-values nearer the tail. The relative lack of over-inflation
of p-values for was taken as an indication that the statistical approach and models
used were appropriate, and that there was unlikely to be any large-scale confound-
ing from un-modelled batch effects. Next, MA and volcano plots were produced
(case-control and group 2 shown in Figures 3.6, 3.7) to help visualise the propor-
tion of significant differentially expressed genes (at FDR < 0.2). These plots ap-
peared as expected, with only a very small number of highly significant results for
each, a roughly equal split between up and down regulated genes, and with signal
coming from low as well as high abundance genes. This was taken to indicate that
the statistical approach and models used were suitable, and further that they had
not appeared to produce any bias towards a particular class of gene (e.g. highly
expressed and up-regulated) being identified as differentially expressed.
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Figure 3.6. MA plots showing the relationship between logFC and mean count for a.
case-control and b. group 2 analyses. Significant genes (FDR < 0.2) are indicated by the
magenta coloured points, triangles indicate points that lie outside of the plot area. For
both of these analyses, only a small number of genes are significant as expected, both up
regulated and down regulated, and representing lowly as well as more highly expressed
genes.
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Figure 3.7. Volcano plots showing relationship between significance and logFC for a.
case-control and b. group 2 analyses. Significant genes (FDR < 0.2) are indicated by the
orange coloured points, triangles indicate points that lie outside of the plot area. For both
of these analyses, only a small number of genes are significant, and there appears to be
a roughly equal split between up and down regulated genes.
Now turning to the results, the top 50 differentially expressed genes from the case-
control analysis are presented in Table 3.2. Overall, while fold changes are modest
and the FDR adjusted p-values do not indicate any highly significant findings, a
number of genes do pass the FDR < 0.2 threshold, these are: DEPDC1B (logFC = -
1.31,FDR = 0.18), IGHG4 (logFC = 2.01, FDR = 0.18), and ZNF501 (logFC = -0.87,
FDR = 0.18). Further down the list, a number of other genes of potential interest
(rationale given in Discussion) are found to be nominally significant (p < 0.05):
HSPA8P14 (logFC= 2.42, p= 0.0004),HSPA13 (logFC= -0.5,p= 0.0006), SLC15A2
(logFC = 0.4, p = 0.0008). Results from the case-control males analysis are shown
in Table 3.3. The log fold changes are higher than in the case-control comparison,
and once again a number of genes pass the FDR < 0.2 threshold for significance:
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HSPA8P14 (logFC=5.52, FDR=0.13),TSPO2 (logFC= -1.85, FDR=0.14), IGHG4
(logFC = 1.8, FDR = 0.15), IGHG3 (logFC = 1.68, FDR = 0.19), ZNF501 (logFC =
5.52, FDR = 0.13). A nominally significant gene is also highlighted here: MT-ND5
(logFC = 1.45, p = 0.0002).
Case-control
ensembl_gene_id hgnc_symbol chr logFC logCPM LR PValue FDR
ENSG00000035499 DEPDC1B 5 -1.31 0.4812 18.1 2.1E-05 0.18
ENSG00000211892 IGHG4 14 2.01 0.956 17.5 2.9E-05 0.18
ENSG00000186446 ZNF501 3 -0.87 2.1658 17.4 0.00003 0.18
ENSG00000232184 1 1.11 1.0045 16.6 4.7E-05 0.21
ENSG00000187534 PRR13P5 19 1.52 0.2855 16.1 0.00006 0.21
ENSG00000236029 1.39 0.3512 14.8 0.00012 0.3
ENSG00000224442 2 0.65 2.9969 14.8 0.00012 0.3
ENSG00000127415 IDUA 4 0.82 2.3612 14.6 0.00014 0.3
ENSG00000138395 CDK15 2 1.7 0.6607 13.1 0.00029 0.49
ENSG00000165914 TTC7B 14 0.77 2.8224 13 0.00031 0.49
ENSG00000143401 ANP32E 1 -0.44 4.796 12.7 0.00037 0.49
ENSG00000101104 PABPC1L 20 0.53 3.6236 12.6 0.00039 0.49
ENSG00000260872 0.92 1.5983 12.6 0.00039 0.49
ENSG00000144589 STK11IP 2 0.49 3.6988 12.5 0.00041 0.49
ENSG00000257539 HSPA8P14 12 2.42 -0.4828 12.4 0.00043 0.49
ENSG00000205930 C21orf62-AS1 21 0.57 2.2037 12.4 0.00044 0.49
ENSG00000214226 C17orf67 17 0.58 2.3178 11.9 0.00056 0.51
ENSG00000155304 HSPA13 21 -0.5 4.9262 11.9 0.00056 0.51
ENSG00000176945 MUC20 3 0.9 0.8937 11.8 0.00058 0.51
ENSG00000260093 8 -0.65 1.8065 11.7 0.00063 0.51
ENSG00000153485 TMEM251 14 -0.62 2.1318 11.6 0.00067 0.51
ENSG00000262652 17 1.42 0.2442 11.5 0.00068 0.51
ENSG00000264575 LINC00526 18 -0.96 0.5939 11.5 0.00069 0.51
ENSG00000257390 12 1.08 0.49 11.4 0.00072 0.51
ENSG00000205544 TMEM256 17 -0.93 1.1805 11.4 0.00074 0.51
ENSG00000234737 KRT18P15 3 0.85 1.1455 11.3 0.00077 0.51
ENSG00000163406 SLC15A2 3 0.4 4.934 11.3 0.00079 0.51
ENSG00000137802 MAPKBP1 15 0.36 4.5608 11.2 0.00083 0.51
ENSG00000179271 GADD45GIP1 19 -0.61 2.8082 11 0.00089 0.51
ENSG00000267436 19 2.01 -0.5395 10.9 0.00094 0.51
ENSG00000239697 TNFSF12 17 1.08 0.8882 10.9 0.00097 0.51
ENSG00000075239 ACAT1 11 -0.57 3.0629 10.9 0.00099 0.51
ENSG00000243179 2 0.75 1.3659 10.8 0.001 0.51
ENSG00000174945 AMZ1 7 0.85 0.7247 10.7 0.001 0.51
ENSG00000242931 RPL7P49 17 0.84 1.1475 10.7 0.001 0.51
ENSG00000260339 HEXA-AS1 15 -1 0.622 10.7 0.0011 0.51
ENSG00000265416 2 1.22 0.4022 10.7 0.0011 0.51
ENSG00000136122 BORA 13 -0.45 3.2173 10.7 0.0011 0.51
ENSG00000239382 ALKBH6 19 0.6 1.8584 10.6 0.0011 0.52
ENSG00000237489 LINC00959 10 0.62 1.641 10.3 0.0013 0.53
ENSG00000207137 SNORD116-13 15 -1.05 0.2263 10.3 0.0013 0.53
ENSG00000185829 ARL17A 17 0.54 4.9967 10.2 0.0014 0.53
ENSG00000005882 PDK2 17 0.57 3.0857 10.2 0.0014 0.53
ENSG00000103260 METRN 16 -0.71 1.0787 10.2 0.0014 0.53
ENSG00000240288 GHRLOS 3 0.4 3.8838 10.2 0.0014 0.53
ENSG00000235162 C12orf75 12 -0.51 3.53 10.1 0.0014 0.53
ENSG00000267274 19 0.65 1.8282 10.1 0.0015 0.53
ENSG00000240695 3 0.86 1.6609 10 0.0015 0.53
ENSG00000137817 PARP6 15 0.34 4.8726 10 0.0016 0.53
ENSG00000273148 20 -0.64 1.7008 9.9 0.0016 0.53
Table 3.2. Differential expression results from the between-groups analysis (case-control)
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Case-control males
ensembl_gene_id hgnc_symbol chr logFC logCPM LR PValue FDR
ENSG00000257539 HSPA8P14 12 5.52 -0.4872 19.7 9.2E-06 0.13
ENSG00000265416 2 1.94 0.518 18.8 1.4E-05 0.13
ENSG00000112212 TSPO2 6 -1.85 0.2339 17.9 2.4E-05 0.14
ENSG00000211892 IGHG4 14 1.8 0.4683 17.3 3.3E-05 0.15
ENSG00000243679 7 1.68 0.6411 16.5 4.9E-05 0.17
ENSG00000211897 IGHG3 14 1.68 1.6038 15.9 6.6E-05 0.19
ENSG00000186446 ZNF501 3 -1.08 2.2266 15.6 7.8E-05 0.19
ENSG00000260872 1.21 1.7129 15.4 8.7E-05 0.19
ENSG00000172508 CARNS1 11 1.19 1.9664 15.1 0.0001 0.2
ENSG00000198786 MT-ND5 MT 1.45 4.4545 14.4 0.00015 0.24
ENSG00000267672 19 1.1 1.3494 14.3 0.00016 0.24
ENSG00000245466 14 1.81 0.4484 14.2 0.00016 0.24
ENSG00000230715 7 2.07 0.0641 14 0.00018 0.25
ENSG00000160392 C19orf47 19 1.05 1.7243 13.6 0.00022 0.28
ENSG00000246363 12 -1.46 1.2862 13.4 0.00026 0.29
ENSG00000149534 MS4A2 11 -1.59 0.9971 13.3 0.00026 0.29
ENSG00000211671 1.39 1.2094 13.3 0.00027 0.29
ENSG00000236029 2 0.1635 13.1 0.0003 0.29
ENSG00000267317 19 1.16 1.0758 12.5 0.0004 0.34
ENSG00000230724 LINC01001 11 1.5 2.6541 12.5 0.0004 0.34
ENSG00000140682 TGFB1I1 16 3.03 -0.6621 12.3 0.00046 0.34
ENSG00000070404 FSTL3 19 -1.01 1.3073 12.2 0.00047 0.34
ENSG00000207642 MIR571 4 1.62 0.4666 12.2 0.00048 0.34
ENSG00000221288 MIR663B 2 2.67 -0.2227 12.2 0.00049 0.34
ENSG00000271734 6 1.68 0.3657 12.1 0.0005 0.34
ENSG00000174547 MRPL11 11 -0.64 3.333 12.1 0.00051 0.34
ENSG00000170485 NPAS2 2 1.38 1.0971 12 0.00054 0.34
ENSG00000211692 TRGJP1 7 -1.82 -0.0611 12 0.00054 0.34
ENSG00000136122 BORA 13 -0.59 3.234 11.9 0.00055 0.34
ENSG00000269890 1 1.78 -0.1184 11.8 0.00058 0.35
ENSG00000204209 DAXX 6 0.72 3.6021 11.8 0.00061 0.35
ENSG00000265713 17 1.03 1.6509 11.7 0.00062 0.35
ENSG00000118113 MMP8 11 -1.21 1.1648 11.6 0.00065 0.35
ENSG00000224610 X 1.27 0.7317 11.4 0.00072 0.37
ENSG00000174945 AMZ1 7 1.1 0.8728 11.4 0.00072 0.37
ENSG00000254325 8 0.94 3.4187 11.4 0.00074 0.37
ENSG00000155755 TMEM237 2 -0.84 1.6707 11.1 0.00086 0.39
ENSG00000273165 2 0.93 1.9375 11.1 0.00087 0.39
ENSG00000130827 PLXNA3 X 0.91 3.3488 11 0.00089 0.39
ENSG00000185829 ARL17A 17 0.76 4.9539 10.9 0.00094 0.39
ENSG00000166171 DPCD 10 -0.78 1.8008 10.9 0.00094 0.39
ENSG00000224638 2 1.98 -0.304 10.9 0.00098 0.39
ENSG00000262652 17 1.57 0.4009 10.9 0.00099 0.39
ENSG00000110583 NAA40 11 0.68 3.4195 10.8 0.00099 0.39
ENSG00000162881 OXER1 2 1.07 2.1428 10.8 0.001 0.39
ENSG00000231047 GCNT1P3 3 0.99 1.4212 10.7 0.0011 0.39
ENSG00000100890 KIAA0391 14 -1.08 1.0129 10.7 0.0011 0.39
ENSG00000237489 LINC00959 10 0.82 1.6785 10.6 0.0011 0.39
ENSG00000260093 8 -0.8 1.7674 10.6 0.0011 0.39
ENSG00000267427 1.16 2.2799 10.5 0.0012 0.39
Table 3.3. Differential expression results from the between-groups, males subjects only
analysis (case-control males)
The top 50 differentially expressed genes from the group 2 analysis are given in
Table 3.4. The log fold changes once again appear to be modest, but here there
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is one significant finding at FDR < 0.2 : IGHG4 (logFC = 2.16, FDR = 0.0003).
A number of other genes also pass this threshold: EVI2A (logFC = -0.65, FDR
= 0.04), SNORD15B (logFC = -0.84, FDR = 0.04), RGS18 (logFC = -0.51, FDR =
0.15), LPAR6 (logFC = -0.6, FDR = 0.18), RPL9 (logFC = -0.65, FDR = 0.18). Some
nominally significant genes of potential relevance are also highlighted: DEPDC1B
(logFC= -1.3, p=0.0001),HSPA8P14 (logFC=2.42, p=0.0002),HIST1H3J (logFC
= -0.89, p = 0.0003). The differentially expressed gene list for the group 2 males
analysis is shown in Table 3.5. Here, the log fold changes are greater than the
group 2 analysis with genes that pass the FDR < 0.2 threshold for significance in-
cluding: HSPA8P14 (logFC = 5.75, FDR = 0.05), MT-ND5 (logFC = 1.46, FDR =
0.05), and IGHG3 (logFC = 1.68, FDR = 0.10). A number of nominally signifi-
cant genes of interest are also identified: HIST1H4C (logFC = -0.76, p = 0.0001),
HIST1H3J (logFC = -1.02, p = 0.0004), HIST1H2BL (logFC = -0.87, p = 0.0005).
Finally, Table 3.6 shows the group 2 consensus results. Potential genes of inter-
est with log fold change in a common direction across the discordant twin pairs
include: HSPA8P14 (mean logFC = 3.65), IGHV3-66 (mean logFC = 1.41), DE-
PDC1B (mean logFC = -1.25).
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Group 2
ensembl_gene_id hgnc_symbol chr logFC logCPM LR PValue FDR
ENSG00000211892 IGHG4 14 2.16 1.8994 32.1 1.5E-08 0.00027
ENSG00000126860 EVI2A 17 -0.65 5.0969 20.7 5.2E-06 0.03646
ENSG00000207445 SNORD15B 11 -0.84 3.0441 20.4 6.1E-06 0.03646
ENSG00000150681 RGS18 1 -0.51 6.9662 17.2 3.4E-05 0.15122
ENSG00000139679 LPAR6 13 -0.6 4.7714 16.4 5.1E-05 0.18161
ENSG00000163682 RPL9 4 -0.65 6.815 16.1 6.2E-05 0.18321
ENSG00000187534 PRR13P5 19 1.52 0.4577 15.1 0.0001 0.24671
ENSG00000163736 PPBP 4 -0.47 7.4058 14.5 0.00014 0.24671
ENSG00000035499 DEPDC1B 5 -1.3 0.5283 14.5 0.00014 0.24671
ENSG00000145425 RPS3A 4 -0.73 6.8576 14.2 0.00016 0.24671
ENSG00000198339 -0.66 3.727 14.1 0.00017 0.24671
ENSG00000138180 CEP55 10 -1.43 0.2215 13.9 0.00019 0.24671
ENSG00000184825 -0.73 3.5947 13.9 0.00019 0.24671
ENSG00000229117 RPL41 12 -0.55 6.9015 13.8 0.0002 0.24671
ENSG00000257539 HSPA8P14 12 2.42 -0.732 13.7 0.00022 0.24671
ENSG00000156482 RPL30 8 -0.49 8.3408 13.4 0.00025 0.24671
ENSG00000166710 B2M 15 -0.55 11.2918 13.4 0.00026 0.24671
ENSG00000165914 TTC7B 14 0.77 2.61 13.3 0.00027 0.24671
ENSG00000122862 SRGN 10 -0.57 9.362 13.2 0.00029 0.24671
ENSG00000127415 IDUA 4 0.81 2.3314 13.1 0.00029 0.24671
ENSG00000267436 19 2.03 -0.7294 13.1 0.0003 0.24671
ENSG00000197153 HIST1H3J 6 -0.89 3.1683 13 0.0003 0.24671
ENSG00000105708 ZNF14 19 -0.51 4.2661 12.9 0.00033 0.25421
ENSG00000232184 1 1.09 0.678 12.6 0.00039 0.28689
ENSG00000205413 SAMD9 7 -0.53 7.2945 12.3 0.00045 0.32267
ENSG00000186446 ZNF501 3 -0.85 2.1971 12.1 0.00049 0.33037
ENSG00000122026 RPL21 13 -0.49 7.1038 12 0.00053 0.33037
ENSG00000200312 RN7SKP255 14 -1.05 3.3458 12 0.00054 0.33037
ENSG00000100890 KIAA0391 14 -0.99 0.7893 11.9 0.00056 0.33037
ENSG00000163221 S100A12 1 -0.58 5.3353 11.9 0.00057 0.33037
ENSG00000236029 1.41 0.4708 11.8 0.00058 0.33037
ENSG00000156508 EEF1A1 6 -0.47 11.5375 11.8 0.00059 0.33037
ENSG00000224442 2 0.65 2.8985 11.7 0.00064 0.34354
ENSG00000155304 HSPA13 21 -0.5 5.0898 11.4 0.00074 0.36643
ENSG00000002726 AOC1 7 1.72 0.1013 11.4 0.00075 0.36643
ENSG00000185829 ARL17A 17 0.54 5.1594 11.3 0.00076 0.36643
ENSG00000177888 ZBTB41 1 -0.51 5.298 11.3 0.00076 0.36643
ENSG00000262202 17 -1.32 0.0213 11.2 0.00083 0.37324
ENSG00000263934 SNORD3A 17 -1.08 10.6755 11.1 0.00085 0.37324
ENSG00000257390 12 1.08 0.4513 11.1 0.00087 0.37324
ENSG00000262652 17 1.42 0.1638 11.1 0.00088 0.37324
ENSG00000143401 ANP32E 1 -0.44 4.988 11 0.0009 0.37324
ENSG00000138395 CDK15 2 1.69 -0.0285 11 0.0009 0.37324
ENSG00000168242 -0.59 4.4376 11 0.00092 0.37384
ENSG00000075239 ACAT1 11 -0.57 3.2791 10.9 0.00097 0.38459
ENSG00000127920 GNG11 7 -0.47 4.4967 10.7 0.0011 0.42065
ENSG00000134419 RPS15A 16 -0.43 6.1772 10.6 0.0011 0.42065
ENSG00000235316 DUSP8P5 10 1.17 0.2446 10.6 0.0011 0.42065
ENSG00000240695 3 0.86 1.4486 10.5 0.0012 0.42486
ENSG00000200959 SNORA74A 5 -0.97 1.9148 10.5 0.0012 0.42486
Table 3.4. Differential expression results from the within-group discordant ASD pairs anal-
ysis (group 2)
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Group 2 males
ensembl_gene_id hgnc_symbol chr logFC logCPM LR PValue FDR
ENSG00000257539 HSPA8P14 12 5.75 -0.7224 21.6 3.4E-06 0.049
ENSG00000198786 MT-ND5 MT 1.46 4.3655 20.6 5.5E-06 0.049
ENSG00000211897 IGHG3 14 1.68 2.5136 18.2 0.00002 0.096
ENSG00000198327 -0.9 4.5502 18.1 2.1E-05 0.096
ENSG00000256316 -1.01 4.1314 17.5 2.8E-05 0.1
ENSG00000265416 2 1.94 0.4929 16.3 5.4E-05 0.162
ENSG00000197061 HIST1H4C 6 -0.76 5.593 15 0.00011 0.26
ENSG00000211892 IGHG4 14 1.82 0.6321 14.8 0.00012 0.26
ENSG00000187534 PRR13P5 19 1.64 0.9873 14.5 0.00014 0.273
ENSG00000221288 MIR663B 2 2.75 0.0758 14.1 0.00017 0.31
ENSG00000172508 CARNS1 11 1.19 1.7947 13.5 0.00024 0.391
ENSG00000112212 TSPO2 6 -1.87 0.0914 13.1 0.00029 0.391
ENSG00000243679 7 1.66 0.7064 13 0.00031 0.391
ENSG00000230724 LINC01001 11 1.5 2.2247 12.9 0.00032 0.391
ENSG00000149534 MS4A2 11 -1.59 0.4446 12.8 0.00034 0.391
ENSG00000140682 TGFB1I1 16 3.06 -0.5897 12.6 0.00038 0.391
ENSG00000197153 HIST1H3J 6 -1.02 3.3004 12.6 0.00039 0.391
ENSG00000185829 ARL17A 17 0.76 5.0882 12.6 0.0004 0.391
ENSG00000259962 16 0.95 2.5704 12.4 0.00044 0.391
ENSG00000186446 ZNF501 3 -1.07 2.3449 12.3 0.00046 0.391
ENSG00000185130 HIST1H2BL 6 -0.87 3.2383 12.3 0.00046 0.391
ENSG00000120318 ARAP3 5 0.89 4.4212 11.7 0.00061 0.44
ENSG00000207642 MIR571 4 1.62 0.3808 11.7 0.00064 0.44
ENSG00000245466 14 1.83 0.0667 11.5 0.00069 0.44
ENSG00000182885 ADGRG3 16 0.68 5.1513 11.4 0.00073 0.44
ENSG00000008516 MMP25 16 0.68 6.3193 11.4 0.00073 0.44
ENSG00000184357 HIST1H1B 6 -0.72 5.4308 11.4 0.00075 0.44
ENSG00000011451 WIZ 19 0.97 2.8284 11.3 0.00078 0.44
ENSG00000162881 OXER1 2 1.07 1.5409 11.2 0.00081 0.44
ENSG00000207445 SNORD15B 11 -0.88 2.7396 11 0.0009 0.44
ENSG00000228434 7 0.87 3.4805 11 0.0009 0.44
ENSG00000177732 SOX12 20 1.62 0.9838 11 0.00092 0.44
ENSG00000198888 MT-ND1 MT 1.37 4.8715 10.9 0.00097 0.44
ENSG00000211692 TRGJP1 7 -1.84 0.0784 10.9 0.00098 0.44
ENSG00000196787 HIST1H2AG 6 -0.62 5.1652 10.9 0.00098 0.44
ENSG00000260872 1.2 1.5786 10.8 0.00099 0.44
ENSG00000270108 14 0.83 2.802 10.8 0.001 0.44
ENSG00000230715 7 2.04 0.092 10.8 0.001 0.44
ENSG00000168242 -0.73 4.5693 10.8 0.001 0.44
ENSG00000160392 C19orf47 19 1.07 1.6329 10.7 0.001 0.44
ENSG00000130827 PLXNA3 X 0.91 3.0318 10.7 0.0011 0.44
ENSG00000197459 -0.63 5.3538 10.7 0.0011 0.44
ENSG00000196532 -0.87 3.7928 10.7 0.0011 0.44
ENSG00000259379 15 1.13 1.6171 10.6 0.0011 0.44
ENSG00000236029 1.99 0.0621 10.5 0.0012 0.44
ENSG00000202354 RNY3 7 -1.05 2.1035 10.5 0.0012 0.44
ENSG00000189337 KAZN 1 0.94 2.0255 10.5 0.0012 0.44
ENSG00000246363 12 -1.52 0.4306 10.4 0.0012 0.44
ENSG00000271734 6 1.69 0.1293 10.4 0.0012 0.44
ENSG00000262292 17 1.18 1.4489 10.4 0.0012 0.44
Table 3.5. Differential expression results from the within-group discordant ASD pairs
males only analysis (group 2 males)
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Group 2 consensus
ensembl_gene_id hgnc_symbol chr mean_logFC
ENSG00000257539 HSPA8P14 12 3.65
ENSG00000092345 DAZL 3 -2.67
ENSG00000269877 19 2.55
ENSG00000002726 AOC1 7 2.44
ENSG00000267436 19 2.35
ENSG00000182586 LINC00334 21 2.07
ENSG00000141086 CTRL 16 2
ENSG00000256591 11 1.95
ENSG00000174697 LEP 7 -1.88
ENSG00000263642 MIR4802 4 1.81
ENSG00000218713 6 1.81
ENSG00000253305 PCDHGB6 5 -1.8
ENSG00000268947 19 1.73
ENSG00000173088 C10orf131 10 1.72
ENSG00000150556 LYPD6B 2 1.7
ENSG00000242114 MTFP1 22 -1.69
ENSG00000259357 1 1.67
ENSG00000226287 TMEM191A 22 -1.67
ENSG00000262202 17 -1.65
ENSG00000270030 11 -1.61
ENSG00000236029 1.6
ENSG00000177465 ACOT4 14 -1.57
ENSG00000207808 MIR27A 19 -1.56
ENSG00000105173 CCNE1 19 -1.56
ENSG00000166033 HTRA1 10 -1.56
ENSG00000241868 RN7SL434P 3 1.52
ENSG00000112742 TTK 6 -1.51
ENSG00000267479 1.51
ENSG00000268550 1.46
ENSG00000207820 MIR545 X 1.45
ENSG00000267342 17 1.45
ENSG00000246228 CASC8 8 1.42
ENSG00000211972 IGHV3-66 14 1.41
ENSG00000203867 RBM20 10 -1.4
ENSG00000214273 AGGF1P1 4 -1.39
ENSG00000237310 7 1.36
ENSG00000237773 7 -1.36
ENSG00000211710 TRBV4-1 7 -1.34
ENSG00000243607 RPL35AP26 11 1.33
ENSG00000255200 11 1.33
ENSG00000162522 KIAA1522 1 1.32
ENSG00000227684 CROCCP4 1 -1.3
ENSG00000226839 MTND6P11 2 1.28
ENSG00000213411 RBM22P2 13 1.25
ENSG00000035499 DEPDC1B 5 -1.25
ENSG00000163293 NIPAL1 4 1.23
ENSG00000214244 SETP21 5 1.22
ENSG00000232097 7 -1.22
ENSG00000147862 NFIB 9 -1.21
ENSG00000259196 HMBOX1-IT1 8 1.18
Table 3.6. P448 results group 2 consensus
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3.3.3 Geneset testing
3.3.3.1 ASD-associated
Focused testing of a number of ASD-associated genesets interest was performed,
in order to test for enrichment of previously identified risk genes. The results are
presented inTable 3.7. The case-control analysis shows no evidence for enrichment
of any of the sets across the different tests used, whereas the case-control males
analysis shows weak evidence for enrichment of the OMIM (p = 0.05) andMT sets
(p = 0.007), based on the results of the geneSet test. The group 2 analysis shows
no enrichment, while the group 2 males analysis shows enrichment for the MT set
(p = 0.002). Since none of the ROAST tests returned significant results, the overall
conclusion is that there is no evidence for enrichment of previously identified ASD
loci the lists of DE genes from the different contrasts.
3.3.3.2 Geneset statistics
In terms of the performance of the different statistical methods in ROAST, Tmax
is seen to perform almost identically to Tmean50, with TARTP appearing to be even
more conservative in its estimates. This is also confirmed by the sex analysis which
tested for enrichment of known sex specific genes. However, possibly due to lack
of adequate resolution because of the small sets being tested, significance values
produced are identical, making it difficult to draw any further conclusions.
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RNA-seq
Case-control
Competitive tests
Gene set geneSet test (LR) ROAST (Tmean50) ROAST (max) ROAST (ARTP)
SAFARI 1.72E-01 8.26E-02 8.51E-02 1.47E-01
GWAS 6.55E-01 1.54E-01 1.52E-01 2.81E-01
OMIM 4.33E-01 1.59E-01 1.55E-01 2.42E-01
MT 4.80E-01 4.20E-01 4.20E-01 6.10E-01
Case-control males
Competitive tests
Gene set geneSet test (LR) ROAST (Tmean50) ROAST (max) ROAST (ARTP)
SAFARI 6.22E-02 1.30E-01 1.29E-01 2.41E-01
GWAS 4.39E-01 1.35E-01 1.32E-01 2.48E-01
OMIM 4.92E-02 1.41E-01 1.36E-01 2.14E-01
MT 6.50E-03 9.95E-02 1.17E-01 1.60E-01
Group 2 
Competitive tests
Gene set geneSet test (LR) ROAST (Tmean50) ROAST (max) ROAST (ARTP)
SAFARI 2.52E-01 1.75E-01 1.78E-01 2.31E-01
GWAS 6.60E-01 2.13E-01 2.16E-01 2.53E-01
OMIM 5.77E-01 2.80E-01 2.81E-01 3.16E-01
MT 3.40E-01 5.80E-01 5.80E-01 6.40E-01
Group 2 males
Competitive tests
Gene set geneSet test (LR) ROAST (Tmean50) ROAST (max) ROAST (ARTP)
SAFARI 1.04E-01 3.22E-01 3.34E-01 2.74E-01
GWAS 4.04E-01 3.22E-01 3.19E-01 2.17E-01
OMIM 1.19E-01 3.36E-01 3.47E-01 3.34E-01
MT 1.50E-03 2.90E-01 3.10E-01 5.40E-01
Gender
Competitive tests
Gene set geneSet test (LR) ROAST (Tmean50) ROAST (max) ROAST (ARTP)
WEHI_XiE 2.20E-08 1.00E-04 1.00E-04 1.00E-04
WEHI_msY 1.45E-06 1.00E-04 1.00E-04 1.00E-04
Significance (mixed hypothesis)
Self-contained tests
Self-contained tests
Self-contained tests
Self-contained tests
Significance (mixed hypothesis)
Significance (mixed hypothesis)
Self-contained tests
Significance (mixed hypothesis)
Significance (mixed hypothesis)
Table 3.7. Results from focused testing of ASD-associated genesets. One competitive
test - geneSet test was run, alongside the self-contained method ROMER, for which three
different statistics were tested. This was performed for each of the experimental contrasts
of interest, as indicated by the headings in the table.143
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3.3.3.3 Pathways
Next, the MSigDB pathways were tested for enrichment. The results are presented
in Tables 3.8, 3.9, 3.10, 3.11. Firstly, for the case-control analysis, a number of po-
tentially relevant pathways are found to be significant (p < 0.05) including those
related to transcriptional control (HALLMARK_E2F_TARGETS), immune system
function (BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP, BIOCARTA_
HSP27_PATHWAY,KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN),PI3K/AKT
cellular signalling (BIOCARTA_AKT_PATHWAY,REACTOME_PI_3K_CASCADE).
The case-control males analysis also identifies PI3K/AKT cellular signalling as be-
ing enriched (REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING,REACTOME_
PI3K_EVENTS_IN_ERBB4_SIGNALING), as well as pathways involved in tran-
scriptional control (REACTOME_RNA_POL_I_TRANSCRIPTION).
For the group 2 analysis, immune related pathways are once again identified (BOHN_
PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP), as well as those involved in
transcriptional control (CROSBY_E2F4_TARGETS). And finally, for the group 2
males analysis, potentially interesting pathways with evidence of enrichment in-
clude those involved in: neuronal development(MODY_HIPPOCAMPUS_PRENATAL),
neurodegeneration(REACTOME_AMYLOIDS), immune system function (KEGG_
INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRO), transcriptional control (RE-
ACTOME_RNA_POL_I_TRANSCRIPTION,REACTOME_RNA_POL_I_PROMOTER_
OPENING)
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Case-control
MSigDB collection Pathway NGenes Up Down Mixed
Hallmark (H)
HALLMARK_E2F_TARGETS 196 0.993 0.0096 0.0492
HALLMARK_MITOTIC_SPINDLE 194 0.108 0.6247 0.063
HALLMARK_MYC_TARGETS_V1 199 0.997 0.0239 0.0934
HALLMARK_G2M_CHECKPOINT 191 0.978 0.0332 0.1247
HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 0.964 0.046 0.1539
HALLMARK_MYC_TARGETS_V2 58 0.704 0.0887 0.1692
HALLMARK_MTORC1_SIGNALING 196 0.962 0.021 0.1745
HALLMARK_NOTCH_SIGNALING 27 0.05 0.7497 0.1975
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 108 0.975 0.031 0.2212
HALLMARK_ANDROGEN_RESPONSE 86 0.953 0.0127 0.241
HALLMARK_UV_RESPONSE_DN 113 0.311 0.4048 0.2793
HALLMARK_WNT_BETA_CATENIN_SIGNALING 36 0.077 0.9746 0.2975
HALLMARK_PROTEIN_SECRETION 90 0.879 0.0669 0.3152
HALLMARK_TGF_BETA_SIGNALING 49 0.633 0.3169 0.3925
HALLMARK_APICAL_JUNCTION 139 0.127 0.8187 0.3973
HALLMARK_ADIPOGENESIS 177 0.821 0.1281 0.441
HALLMARK_DNA_REPAIR 145 0.924 0.0988 0.4512
HALLMARK_APICAL_SURFACE 30 0.218 0.7907 0.4564
HALLMARK_SPERMATOGENESIS 71 0.738 0.2528 0.5541
HALLMARK_PI3K_AKT_MTOR_SIGNALING 92 0.58 0.1669 0.5616
Curated (C2)
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER… 9 0.343 0.0198 2.00E-04
BIOCARTA_AKT_PATHWAY 19 0.249 0.1718 7.00E-04
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP 45 0.955 8.00E-04 0.001
NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON 14 0.002 0.9222 0.0019
GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_1… 9 0.001 0.9751 0.0022
WEBER_METHYLATED_HCP_IN_SPERM_UP 8 0.039 0.7233 0.003
BIOCARTA_HSP27_PATHWAY 12 0.287 0.2598 0.003
CHIARETTI_T_ALL_RELAPSE_PROGNOSIS 19 0.993 7.00E-04 0.0031
REACTOME_PI_3K_CASCADE 38 0.126 0.473 0.0034
REACTOME_TAK1_ACTIVATES_NFKB_... 21 0.194 0.5475 0.0039
LU_TUMOR_VASCULATURE_DN 4 0.925 0.0012 0.004
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_DN 106 0.786 8.00E-04 0.005
BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_UP 15 0.994 0.0023 0.005
CROSBY_E2F4_TARGETS 6 0.994 0.0023 0.005
MYLLYKANGAS_AMPLIFICATION_HOT_SPOT_8 10 0.007 0.6527 0.005
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_DN 17 0.144 0.0961 0.005
GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS… 11 0.479 0.1048 0.0053
SMID_BREAST_CANCER_LUMINAL_A_DN 16 0.694 0.0355 0.0055
REACTOME_MEIOTIC_SYNAPSIS 41 0.957 0.0029 0.0056
ASTON_MAJOR_DEPRESSIVE_DISORDER_UP 36 0.428 0.0966 0.0057
Table 3.8. Pathway enrichment for case-control. Results for the top 20 hallmark and top
20 curated sets are given. Here, we record only the result for the mixed hypothesis, which
tests for genes in the set being either up or down regulated.
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Case-control males
MSigDB collection Pathway NGenes Up Down Mixed
Hallmark (H)
HALLMARK_MTORC1_SIGNALING 196 0.834 0.043 0.0697
HALLMARK_DNA_REPAIR 145 0.888 0.0434 0.1126
HALLMARK_E2F_TARGETS 196 0.941 0.0313 0.1199
HALLMARK_MYC_TARGETS_V2 58 0.765 0.0634 0.1304
HALLMARK_G2M_CHECKPOINT 191 0.914 0.0855 0.1463
HALLMARK_MYC_TARGETS_V1 199 0.937 0.0464 0.1589
HALLMARK_NOTCH_SIGNALING 27 0.142 0.6496 0.1658
HALLMARK_P53_PATHWAY 174 0.352 0.2676 0.1677
HALLMARK_APICAL_SURFACE 30 0.044 0.8624 0.1864
HALLMARK_WNT_BETA_CATENIN_SIGNALING 36 0.086 0.9407 0.1994
HALLMARK_HEME_METABOLISM 190 0.793 0.1118 0.202
HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 0.97 0.0531 0.2195
HALLMARK_PI3K_AKT_MTOR_SIGNALING 92 0.471 0.3865 0.2327
HALLMARK_PROTEIN_SECRETION 90 0.894 0.0841 0.2395
HALLMARK_APICAL_JUNCTION 139 0.143 0.7707 0.2442
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 108 0.931 0.051 0.2836
HALLMARK_ALLOGRAFT_REJECTION 171 0.838 0.092 0.2873
HALLMARK_ADIPOGENESIS 177 0.867 0.061 0.2988
HALLMARK_MITOTIC_SPINDLE 194 0.389 0.6143 0.3002
HALLMARK_HYPOXIA 154 0.663 0.2923 0.3614
Curated (C2)
NAKAMURA_LUNG_CANCER 3 0.968 2.00E-04 4.00E-04
TRACEY_RESISTANCE_TO_IFNA2_DN 29 0.927 3.00E-04 0.001
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_QTL 16 0.396 0.0776 0.0019
PENG_GLUTAMINE_DEPRIVATION_UP 32 0.349 0.1691 0.0024
KIM_GLIS2_TARGETS_DN 6 0.881 9.00E-04 0.0029
PID_P73PATHWAY 67 0.431 0.1142 0.0029
MURAKAMI_UV_RESPONSE_1HR_UP 12 0.691 0.0129 0.0032
CHIBA_RESPONSE_TO_TSA_UP 35 0.066 0.2594 0.0032
BIOCARTA_DNAFRAGMENT_PATHWAY 10 0.951 0.0028 0.004
REACTOME_RNA_POL_I_TRANSCRIPTION 47 0.939 0.0055 0.0042
HASLINGER_B_CLL_WITH_6Q21_DELETION 14 0.811 0.0013 0.0051
ZIRN_TRETINOIN_RESPONSE_WT1_UP 19 0.511 0.2201 0.0061
KREPPEL_CD99_TARGETS_DN 8 0.018 0.0297 0.0063
SYED_ESTRADIOL_RESPONSE 19 0.019 0.6894 0.0063
REACTOME_PI3K_EVENTS_IN_ERBB4_SIGNALING 32 0.128 0.5176 0.007
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS… 36 0.897 0.0027 0.0071
FINETTI_BREAST_CANCER_KINOME_RED 14 0.967 0.0014 0.0073
XU_GH1_EXOGENOUS_TARGETS_UP 47 0.239 0.3667 0.0073
KYNG_RESPONSE_TO_H2O2_VIA_ERCC6_DN 43 0.591 0.0087 0.0093
REACTOME_PI3K_EVENTS_IN_ERBB2_SIGNALING 36 0.149 0.4985 0.0094
Table 3.9. Pathway enrichment for case-control males. Results for the top 20 hallmark
and top 20 curated sets are given. Here, we record only the result for the mixed hypoth-
esis, which tests for genes in the set being either up or down regulated
146
3.3. Results
Group 2
MSigDB collection Pathway NGenes Up Down Mixed
Hallmark (H)
HALLMARK_E2F_TARGETS 196 0.964 0.0399 0.0715
HALLMARK_G2M_CHECKPOINT 191 0.921 0.0809 0.1286
HALLMARK_MITOTIC_SPINDLE 194 0.193 0.6833 0.1336
HALLMARK_MTORC1_SIGNALING 196 0.936 0.0346 0.1503
HALLMARK_MYC_TARGETS_V1 199 0.984 0.0579 0.1901
HALLMARK_SPERMATOGENESIS 71 0.652 0.1957 0.2505
HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 0.904 0.1151 0.2722
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 108 0.981 0.0569 0.2989
HALLMARK_NOTCH_SIGNALING 27 0.145 0.7009 0.3338
HALLMARK_PROTEIN_SECRETION 90 0.832 0.1149 0.4019
HALLMARK_MYC_TARGETS_V2 58 0.777 0.1377 0.4113
HALLMARK_ANDROGEN_RESPONSE 86 0.885 0.115 0.4127
HALLMARK_KRAS_SIGNALING_UP 143 0.96 0.0172 0.4138
HALLMARK_PANCREAS_BETA_CELLS 13 0.842 0.1031 0.4249
HALLMARK_APOPTOSIS 141 0.93 0.0375 0.4337
HALLMARK_UV_RESPONSE_DN 113 0.393 0.5016 0.4492
HALLMARK_ADIPOGENESIS 177 0.886 0.1469 0.4511
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 49 0.77 0.2645 0.4611
HALLMARK_MYOGENESIS 122 0.245 0.7155 0.4771
HALLMARK_DNA_REPAIR 145 0.932 0.1652 0.4909
Curated (C2)
REACTOME_SIGNALING_BY_CONSTITUTIVELY_ACTIVE_EGFR 16 0.943 0.0027 3.00E-04
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_UP 45 0.978 0.004 3.00E-04
NAKAMURA_LUNG_CANCER 3 0.998 0.0017 0.001
RHODES_UNDIFFERENTIATED_CANCER 65 0.978 0.0031 0.0011
CROSBY_E2F4_TARGETS 6 0.988 0.0014 0.0012
REACTOME_N_GLYCAN_ANTENNAE_ELONGATION 11 0.084 0.1034 0.0012
BARRIER_CANCER_RELAPSE_TUMOR_SAMPLE_UP 15 0.986 0.0014 0.0021
NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON 14 0.004 0.8622 0.0021
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX3 4 0.608 0.0304 0.0023
LU_TUMOR_VASCULATURE_DN 4 0.963 0.0038 0.003
OHASHI_AURKA_TARGETS 5 0.579 0.1737 0.0035
NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON 19 0.131 0.1541 0.0038
REACTOME_NEF_MEDIATED_DOWNREGULATION_OF_MHC_CLASS_I_COMPLEX_CELL_SURFACE_EXPRESSION10 0.05 0.4585 0.004
HUTTMANN_B_CLL_POOR_SURVIVAL_DN 58 0.161 0.3485 0.004
REACTOME_ROLE_OF_DCC_IN_REGULATING_APOPTOSIS 7 0.001 0.7037 0.0042
SASAKI_ADULT_T_CELL_LEUKEMIA 160 0.992 0.0052 0.0042
LEE_LIVER_CANCER_SURVIVAL_DN 162 0.95 0.0075 0.0051
SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER… 9 0.51 0.0052 0.0052
FOURNIER_ACINAR_DEVELOPMENT_LATE_DN 19 0.841 0.0026 0.0055
GUTIERREZ_WALDENSTROEMS_MACROGLOBULINEMIA_1… 9 0.003 0.9877 0.0055
Table 3.10. Pathway enrichment for group 2. Results for the top 20 hallmark and top 20
curated sets are given. Here, we record only the result for the mixed hypothesis, which
tests for genes in the set being either up or down regulated
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Group 2 males
MSigDB collection Pathway NGenes Up Down Mixed
Hallmark (H)
HALLMARK_MTORC1_SIGNALING 196 0.743 0.1155 0.1507
HALLMARK_HYPOXIA 154 0.839 0.011 0.23
HALLMARK_E2F_TARGETS 196 0.835 0.0958 0.2371
HALLMARK_DNA_REPAIR 145 0.882 0.0995 0.268
HALLMARK_ALLOGRAFT_REJECTION 171 0.875 0.1067 0.2814
HALLMARK_MYC_TARGETS_V1 199 0.884 0.0947 0.2869
HALLMARK_MYC_TARGETS_V2 58 0.9 0.0966 0.2903
HALLMARK_HEME_METABOLISM 190 0.773 0.1566 0.2915
HALLMARK_G2M_CHECKPOINT 191 0.786 0.2033 0.3079
HALLMARK_APICAL_SURFACE 30 0.068 0.8845 0.329
HALLMARK_P53_PATHWAY 174 0.416 0.1373 0.3438
HALLMARK_OXIDATIVE_PHOSPHORYLATION 200 0.921 0.1235 0.381
HALLMARK_PI3K_AKT_MTOR_SIGNALING 92 0.553 0.4937 0.4227
HALLMARK_NOTCH_SIGNALING 27 0.274 0.5993 0.43
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 108 0.922 0.0956 0.4367
HALLMARK_COMPLEMENT 163 0.76 0.0626 0.44
HALLMARK_ADIPOGENESIS 177 0.925 0.0718 0.442
HALLMARK_APICAL_JUNCTION 139 0.265 0.6755 0.456
HALLMARK_IL6_JAK_STAT3_SIGNALING 72 0.238 0.6492 0.4592
HALLMARK_APOPTOSIS 141 0.925 0.1084 0.4621
Curated (C2)
SASAKI_ADULT_T_CELL_LEUKEMIA 160 0.858 0.0279 2.00E-04
ZIRN_TRETINOIN_RESPONSE_WT1_UP 19 0.584 0.2119 0.0011
SERVITJA_LIVER_HNF1A_TARGETS_DN 74 0.382 0.2709 0.0014
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON 71 0.048 0.9539 0.0016
MODY_HIPPOCAMPUS_PRENATAL 39 0.905 0.0018 0.0018
BIOCARTA_P27_PATHWAY 13 0.923 0.0047 0.0018
CHIBA_RESPONSE_TO_TSA_UP 35 0.039 0.3015 0.0019
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PROD… 34 0.813 0.0994 0.0019
GAVIN_PDE3B_TARGETS 20 0.584 0.001 0.0022
BIOCARTA_FAS_PATHWAY 30 0.438 0.4007 0.003
LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_SMALL_VS… 36 0.924 0.0061 0.0035
BIOCARTA_HER2_PATHWAY 18 0.035 0.8545 0.0039
WARTERS_IR_RESPONSE_5GY 38 0.011 0.6769 0.0041
RIZ_ERYTHROID_DIFFERENTIATION_HBZ 22 0.591 0.0754 0.0041
REACTOME_DEPOSITION_OF_NEW_CENPA_CONTAINING… 37 0.829 0.0063 0.0043
REACTOME_AMYLOIDS 33 0.95 0.0105 0.0047
REACTOME_RNA_POL_I_TRANSCRIPTION 47 0.866 0.0046 0.0048
REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBL… 21 0.335 0.2508 0.0048
REACTOME_MEIOTIC_RECOMBINATION 41 0.878 3.00E-04 0.006
REACTOME_RNA_POL_I_PROMOTER_OPENING 24 0.981 0.0113 0.0061
Table 3.11. Pathway enrichment for group 2 males. Results for the top 20 hallmark and
top 20 curated sets are given. Here, we record only the result for the mixed hypothesis,
which tests for genes in the set being either up or down regulated
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3.3.4 Comparison with microarray data
Comparison Correlation (r) Intersection Correlation (r) Intersection
case control 0.10 0.63 0.36 0.02
case control males 0.22 0.63 0.24 0.03
group 2 0.10 0.63 0.31 0.02
group 2 males 0.22 0.63 0.27 0.02
gender 0.45 0.63 0.84 0.28
Measure of correlation
logFC all genes logFC DE genes (P < 0.05)
Table 3.12. Correlation between the DE gene lists generated by the RNA-seq and mi-
croarray experiments. Overall, for each of the analyses, low values of correlation (∼ 0.1
- 0.2) are observed when comparing the logFCs for all 13,729 genes measured on both,
with the exception of the sex benchmark (0.45). When comparing logFCs for nominally
significant (p < 0.05) DE genes, there is little overlap between the gene lists (∼ 0.02 -
0.03),but for the genes that do overlap the correlation is slightly better (∼ 0.2 to 0.3), once
again with the exception of the sex comparison, which shows overlap of almost a third
(0.28), and highly correlated logFCs (0.84).
To assess the concordance between RNA-seq and microarray expression profiles,
gene abundances were compared for the 39 samples profiled on both technologies,
across 13,729 genes measured on both. The mean pair-wise correlation  is 0.63,
95% CI[0.4,0.8] ; much lower than the values for cross-platform correlation com-
monly reported in the literature, typically in the range of 0.8 to 0.9 [54, 55]. Next,
differential expression results were compared - see Table 3.12. The correlation be-
tween logFC for the different experimental contrasts is low, with values ranging
from 0.1 to 0.22. The sex contrast is included for comparative purposes as there
are known to be large differences in gene expression between males and females,
and here there does appear to be greater correlation between the datasets at 0.45.
For the genes identified as being differentially expressed (p < 0.05) )the array data
and RNA-seq data show little overlap, with overlapping genes ranging from 0.02
to 0.03. Where there is overlap, the level of correlation between reported logFC is
higher than it is for all genes, ranging from 0.24 to 0.36 across the different compar-
isons. Once again, the sex contrast is included, showing much higher correlation
at 0.84, and intersection at 0.28.
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3.4 Discussion
3.4.1 Differential expression
The results of differential expression analysis did not reveal any large scale dif-
ferences in gene expression in ASD compared to non-ASD individuals between-
groups (case-control), norwithin discordantMZ twins (group 2). While numerous
genes were found to be differentially expressed, the evidence was not particularly
strong, with only a small number of genes passing the already liberal FDR < 0.2
threshold used. There was overlap between the different experimental contrasts,
and the expression of a number of genes and pathways was found to be consistently
disrupted, which is what we will focus on here.
DEPDC1B was the most highly significant result in the case-control analysis, with
a logFC of -1.31 and a nominal p of 2:1× 10−5, and notably in the group 2 consen-
sus analysis was also found to be consistently down-regulated within discordant
twin pairs, with a mean family-specific logFC of -1.25. This gene is a member of
the DEP domain coding family, which is involved in regulating cell growth. While
it has not previously been associated with ASD, another family member DEPDC5
has been robustly associated with epilepsy. Given the frequent co-occurence of
epilepsy with ASD [56], DEPDC1B could also be relevant to ASD, potentially rep-
resenting a novel ASD risk gene. However, this finding would need to first be val-
idated using PCR, and ideally replicated in another sample, before this could be
stated with confidence.
A number of immune related genes were identified in the lists of differentially
expressed gene lists, which were found to be consistently up regulated in ASD
cases compared to controls. These included the immunoglobins IGHG4, IGHG3,
IGHV3-66 - antibodies involved in immune system response, and the heatshock
protein genes HSPA8P14, HSPA13 - involved in the cellular response to stress.
While none of these are believed to have been previously identified as ASD suscep-
tibility genes, the majority of other global gene expression studies into ASD have
also implicated immune system related genes (> 70% of the studies summarised in
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Chapter 1 - Table 1). Two results that are particularly relevant here are from a study
by Voineagu et al. in post mortem tissue samples which found genes related to im-
munity to be up regulated in cases compared to controls - consistent with what we
found here. Garbett et al. also identified heatshock proteins (HSPA6, HSPB8) as
being differentially regulated, this time in postmortem brain samples from ASD
patients [57].
In the wider context of ASD research, immune system disruption is one of themost
consistent findings, with epidemiological studies showing that families with ASD
affected individuals have a higher rate of autoimmune disorders [58, 59], serologi-
cal studies finding evidence of increased numbers of activated B and NK cells [60]
and elevated levels of pro-inflammatory cytokines [61] in peripheral blood sam-
ples, and postmortem studies finding evidence of microglial activation in the dor-
solateral prefrontal cortex [62]. In addition, there is also a potential causal link
between established environmental factors like pre-natal viral infection and pa-
ternal age with immune dysregulation and inflammation and increasing risk of
developmental disorder. In the case of viral infection, animal studies have linked
maternal influenza infection to altered brain development and behaviour inmouse
models of ASD and schizophrenia [63, 64]. As for paternal age, it has been sug-
gested that a link between increased paternal age and increased incidence of ASD,
schizophrenia, and bipolar disorder could be the result of immune dysregulation
[65], with increases in pro-inflammatory cytokines IL-1 and IL-6 observed in all
three disorders [66, 67]. We believe the accumulated evidence from these diverse
studies and the potential link to environmental factors makes a compelling case for
prioritising the immune related genes identified here for further study in our dis-
cordant pairs as well as potentially other twin cohorts, where we then might begin
to investigate links to environmental exposures.
3.4.2 Geneset testing
Focused geneset testing ofASDassociated genesets of interest indicated that overall
there was no evidence for enrichment of previously identified ASD loci. While
geneSet test did suggest enrichment of the OMIM andMT sets in the case-control
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males analysis, the results from ROAST were not in agreement. It may be the case
that geneSet test produced inflated estimates in this instance due to the assumption
about gene independence being broken, especially in the case of the MT genes,
which would be expected to display some level of co-expression.
Two alternative statistical measures were added to ROAST and tested here. Tmax
produced almost identical results toTmean50. This suggests that the existingTmean50
statistic is already adequate for testing the scenario where there is no strong prior
hypothesis about the number of genes expected to be DE in the set and the direc-
tion of those differences. TheTARTP produced evenmore conservative results than
the other methods, and given additional computational complexity of the method,
in this setting it does not appear to offer much advantage over the other statistics.
Further testing using a variety of real and simulated datasets would be required
before more general statements could be made about the utility of the different
measures. Furthermore, it would be desirable to implement the ARTP method for
ROMER, as it could perform differently in the competitive testing scenario. These
could be carried out as part of a benchmarking study for appraising the perfor-
mance of several different geneset methods for RNA-seq data.
Pathway enrichment testing was also performed using collections of genes from
MSigDB. In the case-control comparison, a number of potentially relevant path-
ways were identified. For instance, targets of the transcription factor E2F, although
not previously associated with ASD, does implicate transcriptional control, which
is known to be disrupted in monogenic forms of autism such as in Fragile X (see
Chapter 1). PI3K/AKT pathways were also identified. These pathways are impor-
tant for regulating neuronal growth, and in addition to previously being associated
with ASD [68], mutations in a constituent member of the pathway, PTEN, have
been observed inmonogenic cases of ASD [69]. Within-group 2 analysis identified
pathways involved in neurodevelopment and neurodegeneration pathways, which
would be worth investigating further, as these were not identified in the overall
case-control comparison. In both case-control and group 2 analyses immune sys-
tem function pathways were identified, which is a consistent finding frommicroar-
ray studies into ASD.The accumulated evidence would seem to hint at there being
a detectable ASD immune signature in blood. Future studies should be designed in
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order to establish themolecular drivers, look at the underlyingmechanisms, ascer-
tainwhether it is primary or secondary toASD, andwhether such immunemarkers
might have utility for prognosis, diagnosis, or endophenotype classification.
3.4.3 Comparison with microarray data
The concordance between the gene expression profiles produced on each platform
was found to be much lower than the estimates published previously. Further-
more, there was little agreement between the genes identified as differentially ex-
pressed for the different experimental contrasts, with the exception of sex. From
these findings we draw two conclusions. Firstly, since the indications were that the
RNA-seq measurements of transcript abundance were of a high quality, we believe
the non-concordance of the measurements with the microarray intensity readings
confirms the previous suspicions about that experiment having not produced accu-
rate measurements. Secondly, as the sex comparison showed a larger intersection
and greater correlation across the platforms (despite the likely issues with array
data quality), we conclude that these larger differences in expression are less likely
to be overwhelmed by noisy or inaccurate measurements. The opposite is also im-
plied - there would appear to be little margin for error when comparing expression
between ASD affected and unaffected individuals, as the fold change differences
are likely to be small to begin with.
3.4.4 Limitations
There are a number of drawbacks and limitations with the approach taken here.
Firstly, there is the assumption that MZ twins are genetically identical. In fact, MZ
twins have been found to display all manner of rare genetic differences, for exam-
ple point mutations, copy number variants, telomere length, uniparental disomy,
mosaicism, chromosomal aneuploidies, andmutations inmitochondrial DNA (see
[70] for a discussion of these issues). Unfortunately, without the necessary genetic
data on the individuals, it is impossible to rule out the possibility that the observed
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phenotypic discordances arise from rare genetic events. There is reasons to be op-
timistic however, as whole-genome sequencing studies have failed to find many
replicable differences between MZ twins [71], and there have been few reports of
MZ twins having a point mutation causative for a disease [70]. Copy number vari-
ants and chromosomal abnormalities are more common, and since such lesions
have been repeatedly implicated in the etiology of ASD, we would ideally screen
for these. This is outside of the scope of this project, but could make up part of a
future study using the same cohort.
Secondly, there is the use of whole blood samples. Whole blood is a highly het-
erogenous tissue, which raises the possibility of confounding by cell type compo-
sition. This has been discussed at length in the context of epigenetic studies where
various methods for adjustment have been suggested (see [72]). The potential im-
pact of heterogeneity on expression studies is not as widely discussed, but it is not
inconceivable that it could also have an impact. To address this, blood cell counts
could be generated for each sample, and a posthoc analysis conducted to test for
the association of DE genes with the different cell proportions. A complete dataset
was not available in this case, but could perhaps be generated in the course of con-
ducting a follow-up study.
Thirdly, there is also the question of concordance between gene expression in brain
and blood and the reliability of individual differences (as discussed in Chapter
1).The results from the different analyses conducted here contain few previously
identified ASD risk genes known to be important in the context of neurodevelop-
ment, which is perhaps a little surprising. One further analysis which we could
perhaps conduct as a follow up would be to use the Genotype-Tissue Expression
(GTEx) database in order to identify which of our top hits are also highly expressed
in the brain, and if any are the targets of known eQTLs which might be linked to
ASD. There is also the larger issue of whether RNA-seq profiling of whole blood
represents an effective way of identifying genes that are likely to be informative
about the pathomechanisms of ASD.This is an issue whichwe did not address here,
but would be worth investigating further, as it may be the case that whole blood
is primarily useful for investigating changes in gene expression that are secondary
to the disorder (to be used for diagnostic or classification purposes), in which case
154
3.4. Discussion
microarrays might already be adequate.
Finally, it is worth noting that the samples were collected from adolescents with
ASD. Since ASD is a disorder of development, it is not clear whether the molec-
ular differences identified reflect those present in early development, or whether
they are primary or secondary to onset. Relating this to the previous point about
a potential blood-based immune signature for ASD, ideally a prospective birth co-
hort could used with biological samples collected before ASD diagnosis. The use of
such a study design could allow questions to be asked about whether immunolog-
ical (or other) differences are likely to be relevant to ASD pathology, and whether
they have any value as predictive or prognostic biomarkers.
3.4.5 Future directions
It is hoped that the gene expression data generated here can serve as a valuable re-
source for future work. Over the course of this PhD project, we plan to integrate
this data with the DNA methylation data obtained on the same TEDS subjects,
in order to provide further support for the findings from the individual studies,
identify novel associations, and help place identified genes within their functional
context. Longer term, but sadly outside of the scope of this project, we may also
wish to use this dataset to investigate other transcriptomic and regulatory phe-
nomena. As with most expression profiling studies, here we have taken what could
be considered quite a simplistic view of the relationship between gene expression
and phenotype, by aiming to identify differences in overall abundance (i.e. mean
expression levels) that are relevant to our trait. Another dimension which would
be relatively straight-forward to investigate is whether any differences in the dy-
namic range of gene expression (i.e. the variability) are apparent in ASD.This type
of analysis is becoming popular in EWAS, where it has been used to identify loci
displaying methylation variability in cancer [73, 74], type I diabetes [75], and de-
pression [76]. While it is not yet known the extent to which differential variability
in DNAmethylation plays a role in health and disease, part of the appeal of investi-
gating the phenomenon is its potential to account for somemeasure of phenotypic
plasticity - where the range of responses for a particular genotype is dependent
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on the environmental conditions (a type of GxE interaction), which could also be
reflected by variation at the epigenome. There is then perhaps an equally strong
rationale for investigating variability in gene expression, given the functional link
between epigenome and transcriptome. This could be particularly interesting in
the context of ASD, where as we have discussed, epigenetic and gene regulatory
mechanisms are increasingly believed to play an important role.
Alternative isoform expression represents another possible avenue for future in-
vestigations. The vastmajority of genes (92-94%) undergo alternative splicing [77],
which allows multiple transcripts to be generated from a single coding region and
thus contributes to transcriptome complexity. There is interest in studying alter-
native splicing in the context of disease, where it is thought that perhaps asmany as
50% of diseases could arise from mutations disrupting alternative splicing mecha-
nisms [78]. Alternative splicing is thought to play a particularly important role in
the brain, and indeed disruption to splicing regulation has been consistently im-
plicated in the pathology of neurodegenerative disease like Parkinson’s [79]. As
for neurodevelopment and ASD, at least two studies have found that mutations
in the neuroligins NLGN3 and NLGN4, which have been robustly associated with
ASD, result in the expression of alternative isoforms [80, 81], which it is hypoth-
esised leads failure of cell recognition during synapse formation [80]. Another
study by Vioneagu et al. identified dysregulated splicing of a number of targets of
A2BP1, which showed enrichment for proteins involved in cytoskeleton reorgani-
zation and synaptogenesis [82]. Somewhat related to isoform expression, finally,
we may also wish to look at allele-specific expression, where genes are silenced
in parent-of-origin specific manner resulting in the expression of only one of the
parental alleles. Such mechanisms have been shown to be relevant to ASD risk,
for example at the CNTNAP2 locus [83], and at the imprinted 15q11-q13 locus,
where loss of a paternal imprinting for the entire region, or maternal imprinting of
the UBE3A gene is causative for Prader-Willi or Angelman syndrome respectively
[84].
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3.4.6 Conclusion
To our knowledge, this study represents the largest of its kind to systematically
investigate gene expression differences in ASD MZ twins using RNA-seq meth-
ods. While the results did not reveal any large-scale differences in transcript abun-
dance associated with ASD, a number of potential genes of interest were identified
including: DEPDC1B, IGHG4, IGHG3, IGHV3-66,HSPA8P14, HSPA13,SLC15A2.
Pathway analysis revealed that the identified genes might be converging on com-
mon pathways including those involved in transcriptional control, immunity and
PI3K/AKT signalling. These pathways appeared to be disrupted in the case-control
analysis, which compared ASD affected with non-ASD affected individuals, as well
as withASDdiscordant pairs, indicating that they could be sensitive to both genetic
and non-genetic factors.
The integrative work proceeded as planned and is described in Chapter 5. In the
next Chapter, we take a brief diversion from gene expression in ASD to address a
methodological issue in methylation-wide association studies (MWAS) with im-
plications for data integration.
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4 | Estimation of a significance
threshold for Epigenome-Wide
Association Studies
4.1 Introduction
Epigenetic marks are mitotically heritable chemical modifications to DNA and hi-
stone proteins, which act in concert to regulate gene expression across develop-
mental stages and tissues [1]. The most widely studied of these marks is DNA
methylation, describing the addition of a methyl group to the 5 carbon of cytosine
bases to form 5-methylcytosine (5mC), occurring predominantly in the context
of CpG dinucleotides. DNA methylation plays a crucial role in cellular processes
such as embryonic development, parental imprinting andX-inactivation. Aberrant
methylation patterns have been associated with a number of diseases [2], and vari-
ation in methylation between individuals could potentially explain a proportion
of phenotypic variance [3]. These observations in particular have led to the popu-
larisation of the epigenome-wide association study (EWAS), a type of epigenome-
wide association study (EWAS) which profiles methylomic variation genome-wide
in the context of normal development and in disease [4].
The growth of EWAS can be at least partially attributed to the introduction of the Il-
lumina Infinium HumanMethylation450K BeadChip (450K array) (Illumina, San
Diego, CA, USA). The Illumina 450K array is a low-cost, high-throughput, plat-
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form that interrogates just over 485,500 individual CpG sites across the genome,
covering <2% of all known CpG sites, and 99% of RefSeq genes (see [5] for a de-
scription of the technology). The platform has been used in investigations into the
role of methylomic variation across a range of phenotypes and health conditions
including cancers [6, 7], autoimmune disorders [8, 9], psychiatric conditions[10,
11] ,[12], age-related phenotypic changes [13], and environmental exposures [14,
15].
For such studies, as was previously the case with GWAS, the development of stan-
dardised experimental design protocols and statistical methods is crucial for en-
suring that reported findings are robust, reproducible, and biologically relevant
[16, 17, 4]. Whilst there are signs that analytical frameworks are beginning to
crystallise for EWAS, there is one particular aspect that has not received much
attention, and that is the level of evidence required for a test of association for a
differentially methylated CpG site (a differentially methylated position - DMP) to
reach genome-wide significance.
Establishment of a significance level for EWAS is complicated by the fact thatmulti-
ple CpG sites are tested for association simultaneously, and that sites in close prox-
imity can have correlated methylation states (co-methylation) [18, 19, 20]. These
are the related problems of multiple testing and dependence, which have previ-
ously been addressed in genetic studies, but require careful consideration within
the EWAS paradigm due to the specific characteristics of methylation data gener-
ated by the 450K.
4.1.1 Characteristics of 450K methylation data
Methylation is itself an inherently variable signal, with states varying by tissue type,
cell type, and in certain contexts varying even by haplotype (a phenomenon known
as allele specific methylation [21]) . Additionally, there is also uncertainty in the
measurements made by methylation assays. Array-based platforms like the 450K
must necessarily measure CpG methylation over millions of cells. This means that
whilst methylation at the level of an individual cell is a binary measurement, with
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a CpG being either methylated or unmethylated, the measurement generated by
the array is a continuous, quantitative variable averaged over cells [4]. This means
that the experimental data generated in EWAS is subject to levels of error and un-
certainty not previously experienced in genetic association studies. On the 450K,
the final experimental data generated comes in the form of Beta values (Beta =
methylated signal(methylated signal+unmethylated signal+100) ) orM values (M = log2(methylated signal+ 1(unmethylated signal+1)).
Another intriguing property of methylation measurements is that the methylation
status of CpGs has been shown to be strongly correlated up to genomic distances
of between 1 and 2Kb [18, 19, 20]. This is analogous to linkage disequilibrium (LD
- blocks of correlated SNP genotypes) in the genome, with some notable differ-
ences. In the case of LD, shared ancestry is responsible for the correlation between
SNPs, whereas the precise mechanism generating co-methylation is unknown. It is
entirely possible that LD could itself be generating dependency between CpG sites
based on their physical proximity. Indeed, a previous study found that some sets of
correlated methylated CpG sites appeared to be associated with SNPs in LD blocks
[22]. The extent of co-methylation might also depend on functional context [23].
For example, sites located in CpG islands (regions of high CpG density, often found
in gene promoters), would be expected to display a high degree of co-methylation,
as combined they form a functional unit involved in gene silencing.
The presence of a correlation structure within methylation data has two major im-
plications for downstream analysis. Perhaps most crucially, dependence between
measures needs to be taken into account when estimating a significance thresh-
old, for reasons to be discussed. Secondly, and more conveniently, the correlation
structure can also be exploited to enable discrete regions to be defined (or discov-
ered, using predefined genomic features).
4.1.2 Levels of analysis
Theexistence of correlated blocks ofmethylatedCpGsprovides a convenientmeans
for grouping together multiple sites. The goal of the analysis then becomes to iden-
tify differentially methylated regions (DMRs), which might be preferred over an
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individual site-level analysis, aiming to identify differentially methylated positions
(DMPs), for a number of reasons. Firstly, regions are considered to be more ro-
bust measurement units, since they capture information about the smaller number
of independent methylation states that actually exist [4], reducing the impact of
measurement uncertainty at the level of individual sites as well as the number of
hypotheses being tested. Secondly, regions are potentially a more predictive fea-
ture [24], with many reported functionally relevant findings being associated with
regions as opposed to single sites [25].
It is likely for these reasons, methods designed to define or identify regions have
proven popular, particularly on alternative array platforms. The “bump hunting”
method of Jaffe et al [25], primarily intended for use with data from the Nimbel-
Gen CHARM 1M and 2M arrays [26], detects regions of interest, defined as those
where methylation levels of a set of spatially contiguous probes associate with the
outcome (assessed by linear modelling). There have also been methods developed
specifically for 450K data: Ong and Holbrook’s region detection method works
similarly to bump hunting, defining candidate regions related to the outcome, this
time starting with at least two consecutive probes, and then using a sliding win-
dows approach to expand regions by adding further probes to the region [19]. The
non-homogenous hidden markov model (NHMM) approach of Kuan and Chi-
ang incorporates dependence of adjacent probes into a multiple testing framework
[20].
Regional analysis has a couple of major limitations however which might explain
why many researchers prefer site level analysis, and why reported associations still
tend to be for individual CpGs. Regional methods require that the data possesses
certain characteristics; for example, often, assumptions are made about the level
of correlation between sites. As such, these methods are optimised for data from
a specific platform, taking into account the distance between probes and evenness
of coverage. For example, bump hunting when applied to 450K data only covers
around 20% of the CpGs profiled on the array [19]. Even when the method is de-
signed for the specific platform in question, there is no guarantee that all CpGs
will be placed in regions. This is because CpG sites are distributed non-uniformly
throughout the genome in regions of both high and low density, therefore, it is
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expected that certain sites will not be located in any correlated block. Ong and
Holbrook [19] found that their method, though designed for the 450K, does not
include 24% of the probes on the array, leading the authors to suggest that sin-
gle probe analysis should be performed along side region discovery to maximize
discovery of differentially methylated sites.
4.1.3 The multiple testing problem
Whether an analysis aims to identify DMPs, DMRs, or both, because of the large
number of simultaneous tests being performed, an over abundance of false posi-
tive results is expected at nominal thresholds. This problem is complicated by the
presence of a correlation structure in the data, creating dependence between tests,
and meaning that the actual number of independent tests carried is less than the
total number of tests. There are several well-established strategies for controlling
the Type I error rate in genetic association studies, which suffer from the very same
issues. These are now discussed in turn.
4.1.4 FWER solutions to multiple testing
Awell-established approach for dealing with multiple testing under independence
is to control the family wise error rate (FWER), the probability of obtaining one or
more significant results under the null of no association. Typically, this is achieved
by approximating a per-test significance level ′ corresponding to a FWER  for n
number of tests, using the Bonferonni correction (′ = n ), or the more exact Šidák
correction (′ = 1 − (1 − ) 1n ) [27].
In the GWAS setting, control of the FWER by suchmethods is rarely carried out in
practice, as the estimated per-test significance level can be overly conservative for
rejecting individual hypotheses, and can increase the Type II error rate, reducing
power [28]. One of the reasons that such methods fail to produce desirable results
in GWAS is because the assumption of independence between tests is violated, due
to the presence of LD across the genome. This very same issue requires careful con-
172
4.1. Introduction
sideration in EWAS. The methylome has multiplicity of roughly the same order of
magnitude as the genome with approximately 28 million CpG sites that could po-
tentially be interrogated (although current technologies like the 450K measure far
fewer). As discussed earlier, it has also been shown that there exists correlation
between CpGs in close proximity. The presence of correlation between sites has
led some to suggest that a significance threshold based on Bonferonni correction
would similarly be overly conservative for EWAS [4, 29], and that FDR or permu-
tation solutions might be more suitable [30].
4.1.5 FDR solutions to multiple testing
To overcome some of the problems associated with FWER correction, false dis-
covery rate (FDR) methods can be employed. The FDR method as first proposed
by Benjamini and Hochberg [31] (or see [32] and [33] for more recent extensions
of the method) aims to control the proportion of Type I errors amongst the sig-
nificant results (rejected null hypotheses). The method first sorts the p-values in
ascending order, and then determines the number of tests (k) with a p-value of less
than  (FDR = n/k), giving the per-test significance level required to obtain an
overall FDR of the level desired, for example 5%. FDR assumes independence be-
tween tests, but themethod has been extended to account for complex dependence
structures between tests [34].
Controlling the error rate using FDRmethods can increase power, enabling a higher
number of associations to be identified [35]. This increased power can be achieved
by adjusting the error rate depending on the nature of the study (i.e. exploratory
or confirmatory), the number of tests being performed, and expected number of
true associations [36]. The intuitive definition of a FDR and the increased power it
offers for detecting true associations, has made it popular for genetic studies. FDR
is also finding application in EWAS, with all of the previously mentioned regional
methods designed to identify DMRs [25, 20, 19] utilising FDR in their significance
estimations.
There are a number of caveats to using FDR correction. Firstly, because FDR and
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FWER are not equivalent, the p-value as a measure of significance is not appropri-
ate and instead an analogous measure the q-value [37] is often used (the minimum
FDR required for a test to reach significance). Secondly, the FDR can be higher
than traditional Type I error rates [35].Thirdly, controling FDR under dependence
can be overly conservative. Overall, these conspire to make FDR more difficult to
use and the results arguably harder to interpret, complicating meta-analysis and
cross study comparison [38]. This last point is particularly relevant in the con-
text of EWAS, given the variety of different platforms used, and the importance of
independent replication.
4.1.6 Resampling solutions to multiple testing
Resampling methods such as permutation testing are well suited to dealing with
multiplicity and dependence in GWAS [39], and also have the advantage of pro-
ducing exact p-values, potentially making such an approach attractive for EWAS.
Permutation procedures typically involve randomly shuffling phenotypic labels to
generate an empirical distribution of a test statistic under the null hypothesis of no
association between the trait andmarkers being tested. Adjusted p-values can then
be obtained by comparing observed test statistics with the distribution of maxi-
mum test statistics from each permutation [40]. Since the genotypes are fixed, the
correlation structure remains intact, and the FWER is then correct under depen-
dence [41].
Permutation approaches have a few disadvantages, which have limited their appli-
cation in GWAS to some extent, and these would equally apply to EWAS. Firstly,
full permutation testing can be inefficient and computationally intensive [42]. This
inefficiency is largely due to the null distribution only being valid for the dataset
it was generated for, so even analysing a subset of the data would require com-
plete re-computation [41]. Another limitation of permutation testing is that the
multiplicity of the entire genome is not accounted for [35]. It has previously been
argued that the responsible use of a p-value threshold in GWAS should include all
polymorphisms across the genome [35], not just those that were actually tested -
an argument which could equally apply to the testing of differentially methylated
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CpG sites in the case of EWAS.
4.1.7 Permutation correction
An attractive alternative to full permutation testing is to use the results from a
permutation test to estimate an effective number of tests, which can then be used
to calculate a FWER . This is the approach taken by Dudbridge and Gusnanto
[35] for the estimation of a genome-wide significance level. The approach uses a
permutation scheme to generate a distribution of minimum p-values from which
to calculate a threshold for the dataset (the 5% point). A subsampling method is
then used to extrapolate the results to an array with saturated density, in order to
derive a genome-wide threshold accounting for genome-wide multiplicity. This
method has the advantages of permutation testing, in terms of allowing for both
multiplicity and dependence, and also the advantages of FWER, in that it provides
a frequentist p-value threshold which can be applied to other studies.
4.1.8 Estimating a significance threshold for EWAS
At present, there is no consensus on what an appropriate significance threshold
for EWAS might be, although several authors have made recommendations. As
mentioned previously, Tsai et al. [30] have suggested that a Bonferroni-adjusted
threshold of  = 10−7 (accounting only for those CpGs tested on the 450K) would
be overly conservative, and recommend using FDR or permutation methods for
controlling the error rate until a consensus is established. Rakyan et al. [4] have
proposed a liberal threshold of  = 10−6, based on a hypothetical set of 500K
CpG probes with sufficient and uniform spacing between probes such that inde-
pendence of individual measurements is assumed. Although the authors also ac-
knowledge that due to correlation between neighbouring CpG sites, a specific cal-
culation will be required, and a stringent level is more likely to lie between 10−8
and 10−7.
The current research hopes to address the perceived need for an empirically derived
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Table 4.1. Details about the five 450k datasets used.
Dataset GEO accession Population Tissue Age Status N
Gambian GSE59592 African - Gambian Blood 2-8 months Healthy 120
CRC N/A Caucasian - European Colon/rectum 58-80 years Cancer 18
Caucasian GSE40279 Caucasian - European Blood 19-101 years Healthy 426
Afr-Am GSE41826 African - American Brain 13-48 years Healthy 12
Cau-Am GSE41826 Caucasian - American Brain 13-79 years Healthy 65
p-value threshold for tests of differential methylation status of individual CpGs
by applying the permutation testing based correction approach of Dudbridge and
Gusnanto [35] mentioned above and described in further detail in the Methods
section. This is applied to five distinct 450K datasets from a variety of study pop-
ulations in order to derive specific significance thresholds. Further, in order to
account for all CpG sites across the genome and not only those covered on the
450k, a subsampling procedure is used to extrapolate the results to a hypotheti-
cal array with infinite CpG site density and provide a more generally applicable
genome-wide significance threshold.
4.2 Methods
4.2.1 Methylation datasets
Themethylation data was derived from five independent studies utilizing the Illu-
mina InfiniumHumanMethylation450k platform, primarily chosen for their diver-
sity in the populations studied and conditions under consideration, see Table 4.1.
Two of these were recentmethylomic profiling studies by collaborating groups who
kindly allowed us to use the data in this study, and the remaining three were taken
frompublicly available datasets in theNCBIsGene ExpressionOmnibus repository
(http://www.ncbi. nlm.nih.gov/geo/), which were accessed and downloaded via
the marmal-aid methylation database (http://marmal-aid.org) [43]. These public
datasets were at the time of searching the largest three studies comprising healthy
controls from Caucasian and African populations - which for the purpose of repli-
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cation, were selected for their similarity to the populations studied in our own
datasets.
For all datasets, the data was used in bothBeta value andM value form. To assess
the correlation structure,Beta values were used, as this is the form that 450K data
is most commonly deposited into public databases. For permutation testing, M
values were used, as these have previously been shown to provide better perfor-
mance in terms of detection rate and true positive rate in differential methylation
analysis [44]. In order to convert between Beta andM values the following rela-
tionships were used (from [44]):
Betai = 2Mi
2Mi + 1 (4.1)
Mi = log2 ( Betai(1 −Betai)) (4.2)
4.2.1.1 Gambian
The first dataset, from here on referred to as the “Gambian” dataset, comes from
an investigation into the effect of in utero exposure to aflatoxin B1 on embryonic
development in a mother/child cohort from the Gambia [45], where peripheral
blood samples from 120 infants between 3-6 months of age were used for methy-
lation profiling. This data was provided in the form of a matrix of processed Beta
values, which had undergone QC and normalization. Full details on the experi-
mental protocol and analysis method can be found in [45].
4.2.1.2 CRC
The second dataset, “CRC”, is taken from a study characterising methylation pat-
terns in 18 cases of colorectal carcinoma and 4 control samples of intestinal mu-
cosa from a European caucasian population (unpublished work). An Illumina
GenomeStudio report was provided which contained raw probe intensities, this
was first processed using themethylumi package inR [46] in order to perform color
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balance adjustment and quantile normalisation, and to generate a matrix of Beta
values. Control samples were removed due to the high level of discordance ex-
pected between cases and controls - a result of abberant CpG island methylation
[47] and other large scale methylomic alterations expected in the CRC cases [48].
The resulting dataset contained only the 18 cases.
4.2.1.3 Public datasets: Caucasian/Afr-Am/Cau-Am
A further three datasets were identified by searching the marmal-aid database for
healthy controls from Caucasian or African populations. This search identified
two datasets. The first, “Caucasian”, comes from a study into age related changes
to methylomic state as profiled in peripheral blood samples from 426 caucasian
individuals, spanning a wide age range [49] (GEO accession number: GSE40279).
The second, yielding subsets “Afr-Am” and “Cau-Am”, are from an unknown study
(missing annotation in marmal-aid) consisting of 12 African-American and 65
Caucasian-American controls. For all of these marmal-aid datasets, processed
Beta values were used which had undergone quantile normalization and impu-
tation of missing probes. This data was taken forward for analysis without any
further processing.
4.2.2 Correlation structure
Prior to carrying out permutation testing, the correlation structure within each
methylation dataset was assessed qualitatively. This was performed firstly to con-
firm previous findings demonstrating correlation between adjacent CpGs, and sec-
ondly, to investigate any potential differences in correlation structure between the
datasets, which could for example be attributable to the different tissues, ethnici-
ties, or diseases studied.
For each dataset, the following procedure was carried out to determine the level of
correlation between adjacent probes. Using the subset of 46K probes mapping to
chromosome 1, Pearson’s correlation between each of the probe Beta values was
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calculated. Next, pairwise inter-probe distanceswere calculated by taking the abso-
lute differences between the genomic positions of the CpGs (in bp) as given in the
450K annotation package in R [50]. This list of inter-pair distances was reduced by
retaining only those with distance less than or equal to 10,000 bp. These remaining
probe pairs were then binned into approximately 10,000 bins containing around
400 pairs each, and the median pairwise inter-probe distance of the bin recorded.
The mean pairwise correlation of Beta values per-bin was also recorded.
4.2.3 Permutation scheme
For each dataset, a permutation scheme was used to generate an empirical null
distribution of t-test values, from which a per-CpG significance level  could be
derived. Phenotypic labels were randomly assigned to samples, for sample size
n ∶ ⌊n/2⌋ were designated as cases and ⌈n/2⌉ as controls. The labels were then ran-
domly permuted 10,000 times, and for each of these permutations, independent
unrelated sample t-tests were performed for each CpG and the absolute t values
recorded. Details of the algorithm are provided in Figure 4.1. Both this and the
subsamplingmethods were implemented as command-line tools in pythonmaking
use ofmulti-processing (via the standardmultiprocessing library) and compressed,
memory-mapped files (using the HDF5 - high density file format) in order to re-
duce computation time andmemory requirements. The code is given in Appendix
C - Figure C1, and these are also available to download from https://github.com/
asaffa/PhD.
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1 #Input : x = m x n matrix of methylation M values, where m = probes, n = subjects.
2 #Output : y = p x m matrix of absolute t values, p = permutations, m = probes.
3
4 #1. Phenotypes (case v control) randomly shuffled 10,000 times
5
6 for n in subjects:
7 Extract case status from string, store as boolean in vector v
8 for permutation p in 0 to 10,000, p = p + 1:
9 u[p] <- shuffle(v)
10
11 #2. Perform independent t-test for all probes in each permutation,
12 #store in results matrix y
13
14 for permutation u 0 to 10,000, u = u + 1:
15 for probe m in 0 to length(m), m = m + 1:
16 tt <- two-sample_ttest(x[m,u["cases"] == True],x[m,u["controls"] == True])
17 y[p,m] <- absolute(tt)
Figure 4.1. Implementation details for permutation testing procedure
In order to estimate  corresponding to the significance threshold at the density
of CpGs present on the 450K array, the maximum t-test statistic scores for each
permutation were taken and corresponding p-values were calculated (under as-
sumption of equal variance), and  taken as the 5% point of the distribution of
minimum p-values.
4.2.4 Effective number of tests
The effective number of tests is the number of m independent tests required to
obtain the observed  using the Bonferroni correction:
m = 0:05/ (4.3)
this was calculated for each  derived from the permutation data. To test whether
the observed data was consistent with there being an effective number of indepen-
dent tests, for each set of permutation min p-values, a beta distribution was fitted.
If there is an effective number of tests then the minimum p-values from the per-
mutation replicates should follow a beta distribution with parameters:
(a = 1; b =m′) (4.4)
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corresponding to the Šidák correction:
1 − (1 − )m′ (4.5)
The parameters a and b of the  distribution can be estimated using the following
method of moments estimators:
a^ = x( x(1 − x
s2
) − 1) (4.6)
b^ = (1 − x)( x(1 − x)
s2
− 1) (4.7)
fixing the value of the first parameter a to be 1, a starting estimate for the second
parameter b can be obtained:
b^ = 1 − x
x
(4.8)
Maximum log-likelihood estimation (MLE) of (1; b^) was then performed using
the optim function in R to obtain a final estimate ofm′ and this was compared to
the value ofm obtained from the Bonferonni equation given above.
4.2.5 Subsampling method
For each set of permutation results, to extrapolate the findings to an array of infi-
nite density, a subsampling procedure was used. For each individual permutation
in the permutation matrix, the p-values were sampled over a uniform grid of 100
densities (i.e. different fractions of CpGs) from 0 to 1, in increments of 0.01, and
the minimum p-value at each density recorded. This procedure was repeated 100
times, and for each of these 100 replicates, the 5% point at each density across all
the permutations was recorded. The mean 5% point for each density across all 100
replicates was then used in subsequent analysis. Further details of the algorithm
are provided in Figure 4.2.
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1 #Input : y = p x m matrix of p-values, p = permutations, m = probes.
2 #Output: z = p x o matrix of mean 5% values at each density for each permutation
3
4 #1. for each permutation, obtain minimum p-values across probe sampling densities
5 #(0.01 to 1), then calculate the 5% point for each density across all the permutations.
6 #Repeat this procedure 100 times to obtain a mean 5% value for each density across all
7 #of the permutations.
8
9 Initialise matrix rp to store results
10 for replicates r in 0 to 100, r = r + 1:
11 Initialise matrix mp to store min p-values for each density across all permutations
12 for each permutation p in 0 to 10,000, i = i + 1:
13 Initialize vector vp to store min p-values for each density
14 for each density (d in 0.01 to 1.00, d = d + 0.01):
15 shuffle(p)
16 sb <- sample(from = p, sample size = (d*length(p)) ,
17 without replacement = True)
18 vp[d] <- min(of = sb)
19 mp[p] <- vp
20 rp[r] <- apply(to = columns of mp, function = percentile(of = mp[cols],
21 percentile point = 5), return = vector)
Figure 4.2. Implementation details for subsampling procedure
4.2.6 Estimation of a genome-wide threshold
At low densities, the CpGs are expected to be uncorrelated and hence independent.
Increasing the density will hence increase the observed level of correlation between
probes and according to the Bonferroni law, the 5% point should decrease in a
manner inversely proportional to the density. Therefore, at high densities where
the coverage is approaching saturation, the 5% point is expected to converge to an
asymptote, which represents  for the entire genome.
To obtain estimates for asymptote, the adjusted p-value was calculated:
 = 0:05/m (4.9)
and the Monod function fitted. TheMonod function was originally used to model
the growth of microorganisms, but finds application in many different settings
where growth is limited by resources (in this case, the growth in number of ef-
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fective tests is limited by site density). The equation takes the form:
f(x;u; k) = ux(k + x) (4.10)
where u is the limit as x→∞, and k is the value for x for which
f(x) = u/2 (4.11)
also known as the half saturation parameter. This function was fitted to the calcu-
lated values of m and the parameters estimated using least squares and genome-
wide  estimated as:
 = (0:05/u) (4.12)
4.2.7 Sample size estimation
In a recent paper, Tsai and Bell [29] estimated sample size requirements for case-
control and disease-discordantMZ twin design EWAS based on power simulations
across a range of different sample and effect sizes. The simulations were performed
using both t-test and Wilcoxon tests, for nominal (p = 0.05) and genome-wide
(p = 1 × 10−6) significance levels. Because a new estimate of genome-wise  is
derived here, we decided to re-calculate the sample sizes required for 80% power
provided inTable 2. of the paper. To this end, the non-central t-distributions giving
rise to the estimates were inferred, and then used to calculate sample sizes for the
thresholds calculated above. The following relationship was used:
1 −  = 1 − F(n−1;ncp)(t(1−/2)) + F(n−1;ncp)(−t(1−/2)) (4.13)
where 1 −  = 0.8, F(n−1;ncp) is the cumulative distribution function of the non-
central t distribution with n-1 degrees of freedom and non-centrality parameter
ncp, given by:
ncp =√n × 

(4.14)
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and t(1−/2) the critical value when  = 1 × 10−6. Treating as a minimum opti-
mization problem (using the optim function in R),and solving  across the range
of sample sizes n and mean methylation differences  yielded these estimates of .
These estimates were then used in another optimization, this time solving to obtain
sample sizes for each  using the empirically derived estimates of .
4.3 Results
4.3.1 Correlation structure
The correlation structure was assessed for each dataset, the line plots in Figure 4.3
show the overall pattern of correlation between methylation sites as a function of
the distance between their genomic positions. The relationship between these vari-
ables appears consistent across datasets. The curves show a characteristic shape
with pairs in close proximity having the highest average levels of correlation, which
tails off sharply as distances approach 1KB, and then decreases more slowly from
1KB to 2KB, afterwhich it appears to reach a limit just above zero, which is assumed
to be the mean background level of correlation across the genome. In terms of the
actual mean per-bin correlation values, these look comparable across the datasets,
with the exception of the CRC set, with the approximate maximum per-bin corre-
lations of 0.3, 0.55, 0.4, 0.35, 0.4 and approximate background levels of 0.07, 0.12,
0.04, 0.07, 0.07 for Gambian, CRC, Caucasian, Afr-Am, and Cau-Am sets respec-
tively. There are also differences in the variability and spread of correlation val-
ues between neighbouring bins, perhaps indicating differences in apparent level of
noise between sets.
4.3.2 Permutation and effective number of tests
The results from the permutation testing scheme are given in Table 4.2 . The 5%
points of the minimum p distributions vary between the different datasets: Gam-
bian  = 2:04 × 10−7, CRC  = 3:53 × 10−8, Caucasian  = 2:44 × 10−7, Afr-
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Figure 4.3. Correlation versus genomic distance for pairs of probes in chromosome 1. a.
Gambian, b. CRC, c. Caucasian, d. Afr-Am, e. Cau-Am
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Table 4.2. Permutation results showing the 5th percentile of the minimum p-values from
10,000 permutations of the datasets, m is the effective number of tests that this 5% point
represents according to the Bonferroni law, and b is the estimated b parameter after fitting
a beta distribution.
Dataset  m b
Gambian 2.04E-07 245563 170286
CRC 3.53E-08 1417410 161402
Caucasian 2.44E-07 204586 153670
Afr-Am 7.90E-08 633220 113038
Cau-Am 3.59E-07 139451 70782
Am  = 7:90 × 10−8, Cau-Am  = 3:59 × 10−7. The s obtained for Gambia,
Caucasian, and Cau-Am are larger than the Bonferonni adjusted 5% threshold of
 = 1:07 × 10−7, while the CRC and Afr-Am are smaller by almost a factor of
10. Investigating further, Figure 4.4 shows quantile-quantile plots of the observed
minimum p distributions against the expected quantiles according to this Bonfer-
onni threshold ((1;467264)). From these plots it can be observed for the Gam-
bia, Caucasian, and Cau-Am sets, that while Bonferonni produces uniformly dis-
tributed p-values, these are also deflated over the entire range. For the CRC and
Afr-Am sets, it appears that the observed data is not at all well modelled by the 
distribution, and there is not a clear pattern of over or under correction of p-values,
as they appear both deflated at low values and inflated at higher values.
Converting these 5% points to effective number of tests using Formula 1.9 gives:
Gambianm = 245,563, CRCm =1,417,410, Caucasianm = 204,586, Afr-Amm =
633,220, Cau-Amm = 139,451. Fitting the  distribution (Formulæ1.4 to 1.8) then
yields the following estimates for the b parameter: Gambian b = 170,286, CRC b =
161,402, Caucasian b = 153,670, Afr-Am b = 113,038, Cau-Am b = 70,782. These
different estimates of number of effective tests are not in close agreement, suggest-
ing that the  distribution with parameters (1;m) does not adequately model the
minimum p-value distribution for m tests. The results for CRC and Afr-Am in
particular do not seem to produce the expected distribution of min p-values, and
the estimated values for ,m and b show little resemblance to the values obtained
for the other datasets, perhaps indicating issues with these two particular sets, for
instance, both having small sample sizes.
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Table 4.3. Results from subsampling, showing the final values for the u and k param-
eters after fitting the Monod function, and the asymptote representing the genome-wide
significance threshold alpha.
Dataset u k Genome-wide 
Gambian 1.38E+06 4.71E+00 3.61E-08
CRC N/A N/A N/A
Caucasian 1.18E+06 4.79E+00 4.25E-08
Afr-Am N/A N/A N/A
Cau-Am 6.38E+05 3.54E+00 7.83E-08
Assuming the results from correlation analysis are reliable and have been correctly
interpreted, there are negligible differences between the overall patterns of co-
methylation in the data from the different populations. Therefore, the estimated
thresholds for the three groups producing permutation datamost closely fitting the
expected distribution, Gambian, Caucasian and Cau-Am, can be combined into a
single figure. Taking the weighted mean of these different estimates yields a 450K-
specific  = 2:5 × 10−7.
4.3.3 Subsampling and genome-wide threshold
For subsampling, Figure 4.5 shows the resulting plots of the mean 5% of the sam-
pled minimum p-values at each subsampling density. The asymptotes were esti-
mated by fitting the monod function to the effective number of tests, the closeness
of the fit can be seen in Figure 4.6. The resulting estimates for u, the limit as the
density approaches infinity, and k, the value for x at which half of genome-wide
multiplicity is accounted for, are given in Table 4.3. The asymptotes are shown
in Figure 4.5. It was not possible to fit the monod function to the CRC and Afr-
Am.
The estimates for u are: Gambian u= 1,380,000, Caucasian u= 1,180,000, andCau-
Am u = 638,000, which are used to calculate genome-wide corrected significance
thresholds, giving: Gambian  = 3:61×10−8, Caucasian  = 4:25×10−8, and Cau-
Am  = 7:83×10−8. Once again, assuming the results from correlation assessment
are correct and that there are minimal differences in the correlation structure be-
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Figure 4.4. QQ plots showing observed distribution of minimum p values verses the ex-
pected distribution under complete independence. a. Gambian, b. CRC, c. Caucasian,
d. Afr-Am, e. Cau-Am
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tween the different populations, these can be combined to give a weighted mean
of genome-wide  = 4:5 × 10−8.
4.3.4 Sample size estimation
Diff p < 0.05 p < 1 x 10-6 p < 2.5 x 10-7 p < 4.5 x 10-8 p < 0.05 p < 1 x 10-6 p < 2.5 x 10-7 p < 4.5 x 10-8
7 30 178 195 216 37 211 231 256
8 25 145 159 176 30 169 185 205
9 20 117 128 142 24 137 150 166
10 17 98 107 119 20 112 123 136
11 15 81 89 99 17 96 105 117
12 13 71 78 86 15 80 88 97
13 11 63 69 77 13 70 77 85
14 10 55 60 67 11 61 67 74
15 9 50 55 61 10 54 59 66
Twin Case-control
Table 4.4. Sample size estimates based on those presented in [29] using the estimates
for 450k and genome-wide significance derived in this study. Diff is the percentage mean
methylation difference between case and control, twin and case-control refer to the study
designs, and for each of the significance thresholds,the sample sizes required to achieve
a power of 0.8 are given.
Results for sample size calculations are given in  4.4 alongside the original results
from [29]. Using the 450K-specific  = 2:5 × 10−7, increases the sample size esti-
mates by ∼10% over those estimated from power simulations using the suggested
threshold of  = 1 × 10−6. With the estimated genome-wide  = 4:5 × 10−8, the
sample size estimates are increased by ∼20%.
4.4 Discussion
4.4.1 Correlation structure
In order to determine whether any differences in the overall correlation structure
between the different datasets exists, we investigated the relationship between co-
methylation and genomic distance between pairs. The results reveal a distinctive
relationship, whereby proximal sites, up to a distance of around 1K bases apart,
show amoderate level of correlation in the  0.25 to  0.4 range, falling to background
levels once inter-pair distances reach around 2KB.These results are consistent with
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Figure 4.5. Significance threshold as a function of CpG site density following the subsam-
pling procedure. Where possible, the monod function was fitted to estimate an asymptote
representing the threshold at fully saturated CpG density, this is indicated by a dashed
red line. a. Gambian, b. CRC, c. Caucasian, d. Afr-Am, e. Cau-Am.
190
4.4. Discussion
0
50,000
100,000
150,000
200,000
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Subsampling density
E
ff
e
c
ti
ve
 n
u
m
b
e
r 
o
f 
te
s
ts
0
200,000
400,000
600,000
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Subsampling density
E
ff
e
c
ti
ve
 n
u
m
b
e
r 
o
f 
te
s
ts
0
50,000
100,000
150,000
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Subsampling density
E
ff
e
c
ti
ve
 n
u
m
b
e
r 
o
f 
te
s
ts
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a.             b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   c.  
 
 
 
 
 
 
 
 
 
 
 
 
 
d.             e. 
0
50,000
100,000
150,000
200,000
250,000
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Subsampling density
E
ff
e
c
ti
ve
 n
u
m
b
e
r 
o
f 
te
s
ts
0
500,000
1,000,000
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
Subsampling density
E
ff
e
c
ti
ve
 n
u
m
b
e
r 
o
f
 t
e
s
ts
Figure 4.6. Estimated number of tests as a function of CpG site density. Where possible,
the monod function was fitted, this fit is shown by the blue line. a. Gambian, b. CRC, c.
Caucasian, d. Afr-Am, e. Cau-Am.
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previous findings, which have found moderate to strong correlations of between
0.26 [25] and 0.45 [19] extending over genomic distances of between 1 and 2 KB
[18, 25, 20, 19].
There do not appear to be any large-scale differences in overall patterns of co-
methylation between brain andbloodwhen comparing theCau-AmandCaucasian
datasets, or between Gambian and Caucasian populations when comparing the
Gambian and Caucasian datasets. Only the CRC dataset shows some slight differ-
ences. While it would be tempting to link this to the disease, this could equally
be due to data heterogeneity, especially given that all the datasets are taken from
separate studies, conducted by different labs, using different experimental proto-
cols. Differences in the variability between sets are also apparent, with the spread
of correlation values between adjacent bins of pairs showing a greater spread for
the datasets having smaller sample sizes. Once again, this is merely speculated, as
it is not possible to rule out the differences being purely the result of data hetereo-
geneity.
As far as we are aware, this is one of the first attempts to characterise the overall
patterns of co-methylation between CpGs in the context of different tissues, eth-
nicities and disease states. The initial indications here are there are unlikely to be
any large-scale differences in terms of the overall relationship between adjacent
probes across tissues and ethnicities considered. It is possible that there are dif-
ferences in the case of certain cancers such as CRC. Further experimental work
would be required before any more general conclusions could be made, preferably
involving the generation of new data under rigorously controlled conditions in or-
der to minimise confounders such as sample selection (especially controlling for
age and smoking), sample collection procedures, sample composition, and batch
effects, and to reduce variablilty in data processing.
4.4.2 450K threshold
We used a permutation scheme to obtain values for  for each dataset. Inspecting
the fit of the  distribution (1;467264) to the minimum p-values generated, the
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datasets CRC and Afr-Am deviate from the expected distribution quite substan-
tially, perhaps a sign that these datasets had not produced reliable results, possibly
due to their small sample sizes. For the Gambia, Caucasian, and Cau-Am, the 
function seems to produce inflated p-values consistently inflated over the range,
which suggests that reasonable fit might be acheived by adjusting the second pa-
rameter of the  distribution, in other words, choosing a different value for the
effective number of tests in the Bonferonni equation.
As for the actual 5% values, for the Gambia, Caucasian, and Cau-Am sets these are
all larger than the Bonferonni adjusted 5% threshold of  = 1:07 × 10−7. Assum-
ing that the results and conclusions from the assessment of correlation within the
different sets are correct, and that there are no major differences between differ-
ent populations, then the results from these three sets can be combined to give a
weighted mean of  = 2:5 × 10−7. From permutation testing results, we conclude
that a significance threshold of  = 2:5 × 10−7 would be appropriate for the 450K,
accounting for the subset of probes tested on the array but not the hypothetical set
of probes that could be tested with fully saturated genome-wide coverage.
4.4.3 Genome-wide threshold
To address the issue of genome-wide multiplicity, we used a subsampling method
to extrapolate the results of permutation testing to an array of infinite density. The
results of fitting the Monod function to the subsampling data revealed that the
limit for the number of tests as the coverage on the array becomes saturated is
somewhere in the region of 1 × 106, i.e. 1M probes, which is 4 times the current
density. The results from the three different sets were combined, giving genome-
wide  = 4:5 × 10−8. Interestingly, this figure is similar to that typically used for
GWAS :  = 5 × 10−8, although it is not clear why this would be the case consider-
ing they are different molecular modalities with their own particular characteris-
tics. Further investigation would be required to determine whether this is merely
coincidence.
Comparing this with previous recommendations, we see that the estimate for a
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genome-wide significance for EWAS obtained here is smaller than what would be
considered a liberal threshold of 10−6 [4], and would fall within the range con-
sidered stringent 10−8 to 10−7 [4]. This threshold is however much less stringent
than the genome-wide Bonferonni level, which assuming there are 28millionCpGs
across the genome, is  = 1:79 × 10−9. Bonferonni would then indeed be overly
conservative for methylation data, but perhaps not to the extent previously sug-
gested.
As for the limitations of this method, permutation correction attempts to identify
a limit for number of independent tests using a very small sample. The 450K offers
only ∼2% coverage of themethylome, fromwhichwe have attempted to extrapolate
amore general relationship between the 5%point of theminimum p-values and the
density of coverage. Further complicating matters is the design of the 450K array
itself, which has been described as offering relatively sparse and irregular coverage
[19], perhaps making it a less than ideal data type for such an approach.
Related to issues around extrapolation, is the question of whether any estimated
genome-wide threshold would be more generally applicable in EWAS, for DNA
methylation measurements generated from different tissues, different populations,
using different array platforms, or even different technologies such as MeDIP-
seq (methylated DNA immunoprecipitation sequencing), WGBS (whole genome
bisulfite-sequencing), or RRBS (reduced representation bisulfite sequencing). In
terms of cross-tissue applicability, given the now wide-spread availability of pub-
lic 450k datasets, further work could be done in comparing thresholds derived for
different tissues. In a similar vein, we could also repeat the study for different pop-
ulations, or perhaps even perform a huge meta-analysis using all healthy controls
from every available study (which it appears might be possible to do in the latest
version ofmarmalaid). As for cross-platform applicability, we would expect that a
genome-wide threshold could be used irrespective of the platform or level of cover-
age, with the caveat that any estimation should ideally be made based on data from
a platform with even, un-biased coverage of all features to increase confidence in
the extrapolation. Such a threshold could even find application in whole-genome
approaches such as WGBS where even though complete coverage of the methy-
lome can be achieved, because permutation testing is computationally expensive,
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time consuming, and study specific, an a-priori estimate (even though it will be
less accurate) could still be desirable.
4.4.4 Sample size estimation
A previous study by Tsai and Bell [29] used power simulations to estimate sample
sizes required to detect a range of mean methylation differences for both twin and
case control designs based on nominal significance of  = 0:05 and an estimated
genome-wide threshold of  = 1 × 10−6. By inferring the parameters of the t-
distributions giving rise to these estimates, we re-calculated sample sizes for our
empirically derived 450K and genome-wide thresholds. The results indicated that
using the 450K-specific  = 2:5 × 10−7 would require sample sizes ∼10% larger
than those previously estimated, and using the genome-wide  = 4:5×10−8 would
require samples ∼20% larger, in order to obtain the same power.
4.4.5 Conclusion
There are many reasons to prefer FDR or permutation methods over Bonferonni
type control of the FWER - especially if the identification of DMRs is the ana-
lytical goal, however, there is still value in obtaining a genome-wide significance
level for individual DMPs. Firstly, a significant global test can be taken as evi-
dence that there is a sufficiently strong signal present in the data to differentiate
true from false positive [35], which can inform downstream analytical decisions,
including whether to proceed with a site-specific or regional analysis. Secondly,
because EWAS are often conducted as exploratory studies, it is useful to have a
method for ranking associations to base decisions on which should be experimen-
tally replicated; the FWER adjusted significance provides a simple, statistically
sound method to do so. Thirdly, the use of a standard threshold also aids com-
parison across experiments, simplifying meta-analysis. Finally, having an a priori
threshold estimate enables power calculations to be made, which can aid in the
design of future experiments.
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The  = 2:5 × 10−7 threshold for significance for the 450K array that we have es-
timated here takes into account both dependency between test due to patterns of
co-methylation, and the multiplicity of the set of CpGs tested. As it is derived
from results averaged over European, African, and American populations, it could
therefore find general application for 450K methylation data, offering an empiri-
cally derived, more permissive alternative to FWER correction. One major lim-
itation of the 450K threshold is that it does not take into account genome-wide
multiplicity, although the impact of this on the accuracy of the estimate has not
been possible to determine. In addition, the non-random placement of probes and
the current limited coverage of the 450K makes extrapolation to saturated probe
coverage somewhat less reliable, reducing confidence in the derived genome-wide
 = 4:5 × 10−8.
With the recent release of Illumina’s 850K EPIC array, with almost double the cov-
erage of the 450k, the issue of significance in EWAS is as relevant as ever. Future
work may then seek to apply the methods outlined here to similarly derive signifi-
cance threshold estimates for the EPIC array, and compare with the findings of this
study. It is hoped doing so may go some way to addressing the question of whether
it will be possible to establish a universal, platform-agnostic EWAS threshold for
single site-level differential methylation analysis.
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5 | Integratingmulti-dimensional omics
datasets
5.1 Introduction
The rapidly falling cost of high-throughput sequencing technologies has led to a
deluge in high-resolution omics data. It is now possible to generate data on DNA
sequence variation, copy number variants, gene expression, non-coding RNA ex-
pression, DNA methylation levels and protein abundance, to name but a few. The
increased computational requirements for storing, processing and accessing this
data has been a major driving force behind the pace of innovation seen in bioin-
formatics. While some of the challenges associated with “big” data are likely to
remain with us for the foreseeable future, recently attention has started to shift
to another problem - how best to utilise this wealth of diverse molecular data to
ask new questions, make new insights and inform our biological understanding.
Integrative genomics approaches are being developed in order to tackle this prob-
lem.
Integrative genomics is primarily concerned with the development and application
of methodologies for combining data frommultiple omics datasets. Themain mo-
tivation for doing so is firstly to validate findings from individual studies, and sec-
ondly, to gain a more holistic, higher-resolution, systems-level view of the genome
and regulatory mechanisms involved in complex diseases. Integrative methods
have been successfully applied to a multitude of problems, from survival analysis
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in ovarian cancer [1], tumour subtype classification in glioblastoma [2], identifi-
cation of key molecular drivers in chronic obstructive pulmonary disease [3], and
discovery of disease susceptibility networks in type II diabetes [4].
5.1.1 An overview of integrative genomics
Perhaps due to the complex and interdisciplinary nature of the problem, the prob-
lem of data integration is not well defined and the literature is currently a little
disparate [5]. Nonetheless, a number of reviews have attempted to provide a gen-
eral overview of the area. In one of the earliest reviews, Hamid et al. [5] pro-
posed a conceptual framework for data integration, which considers integration
of both homogenous and heterogeneous data. The main biological questions that
integrative approaches might be used to address were identified as: 1) differential
expression, 2) copy number variation, 3) feature extraction, 4) disease classifica-
tion, 5) gene mapping. Integration approaches were classified as being either 1)
early, 2) intermediate, or 3) late referring to the level at which data is integrated,
whether raw experimental data, transformed data, or summary-level data respec-
tively. Some relevant statistical methods were discussed in detail, namely those
relevant to horizontal integration (e.g. p-value combination).
Hawkins et al. [6] considered integration from the view of the “bench” scientist,
discussing in terms of the types of experimental data available and the biological
questions thatmight be addressed. The primary questions that can be addressed by
integrationwere identified as, 1) annotation of functional features of the genome, 2)
inferring function of genetic variants, and 3) gaining a mechanistic understanding
of gene regulation. A brief overview of statistical and computational methods was
given, being categorised as those concerned with data dimensionality reduction
and supervised and unsupervised approaches, for classification type problems and
inference intended to uncover relationships between datasets.
In a Nature Genetics review published in 2015, Ritchie et al. [7] examined data
integration in an epidemiological context, where the analytical aim is to combine
data in order to improve statistical models of complex traits. Twomain approaches
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are described: multi-staged analysis, which combines data two sets at a time in
a stepwise fashion, and meta-dimensional analysis, where the different datasets
are combined simultaneously and used build a multi-variate model that relates
the molecular traits to the phenotypic trait of interest. Multi-staged analysis is
further divided into genomic variation analysis, where genetic data is the start-
ing point and the other datasets are used to functionally annotate SNPs (e.g. as
eQTLs, mQTLs), and domain-knowledge guided analysis, where functional anno-
tation is obtained from public repositories. Meta-dimensional analysis is divided
into concatenation-based, transformation-based, and mode-based, depending on
whether raw data is combined in the model, or if it transformed first before being
modelled, or if datasets are modelled individually and then integrated. A table list-
ing available bioinformatics software was also provided for each of these different
approaches.
Kannan et al. [8] discussed data acquisition as opposed to utilization, describing
some of the currently available large public data resources such as ENCODE (The
Encyclopaedia of DNA Elements) [9] and FANTOM5 (Functional Annotation of
Mammalian Genomes 5) [10]. There is a brief discussion of integration methods
where three main categories are identified: 1. exploratory data analysis to iden-
tify intra and inter dataset patterns, 2. network analysis, to refine interaction net-
works by using molecular data, 3. supervised meta-analysis, where findings from
one assay are refined by including further omics data. For each category, relevant
bioinformatics tools were listed.
Finally, the textbook “Integrating omics data” by Tseng et al. [11] covers a wide
range of topics in data integration in great detail, especially in relation to cancer
studies. The distinction is made between two main classes of integrative prob-
lem, horizontal integration, which is the ’classic’ meta-analysis of one molecular
data type across multiple studies, and vertical integration, where multiple hetero-
geneous datasets on the same sample are combined, and. There are chapters out-
lining methods for discovering functional relevant modules, penalized regression
methods for conducting joint analysis, Bayesian graphical models for integration,
among others.
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Taken together, these publications provide a comprehensive summary of the the-
oretical background, statistical methods or algorithms for particular classes of ap-
proaches, and available bioinformatics software to-date. However, wewere not able
to find any single review that adequately covered all three aspects from the perspec-
tive of neuropsychiatric or neurodevelopmental genetics, where there is consider-
able interest in combining heterogeneous datasets to help uncover the molecular
etiology and pathomechanisms underlying conditions such as ASD.
5.1.2 Vertical integration
Our group are interested in vertical integrative strategies as means to dissect the
molecular aetiology of cognitive and behavioural traits and neurodevelopmental
disorders, using multi-assay measurements on the same individuals. There is a
certain degree of overlap between the methods used in both horizontal and ver-
tical integration, and a real world problem might include both strategies (“diago-
nal” integration), nonetheless, in this chapter we focus on vertical type integration.
The rationale behind combining heterogeneous data is to leverage the available
evidence in the most effective way, increasing precision, accuracy and power for
identifying true signals [5]. Utilising data from distinct yet often complementary
molecular modalities can potentially reveal novel associations that would other-
wise not emerge from a piece-meal analysis of the individual datasets, and allow
regulatory and disease mechanisms to be explored. For example, the functional
consequences of susceptibility loci are often not well understood, but by combin-
ing SNP data with expression data, the causal relationships between the molecular
and phenotypic traits of interest can begin to be explored [12]. Similarly, the role
of CpGmethylation in gene regulation can be better understood by including gene
expression data [13]. There is great demand for statistically rigorous and compu-
tationally efficient methods to achieve such aims, and although many tools already
exist, information is sparse and difficult to find, and wide-spread adoption of such
methods has been limited.
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5.1.3 Classifying vertical integrative methods
Joint/meta 
analysis
Conf irmation
Feature 
selection
Disease mechanism
characterization
Disease subtype 
classification
Regulatory module 
discovery
Functional 
annotation
Multi -omics 
datasets
Meta-
dimensional 
associations
Novel  disease
associations
Regulatory 
mechanism
characterization
Qual i ty control
2. Meta-dimensional association1. Classification and prediction 3. Causal analysis
Diagnostic 
prediction
Figure 5.1. An overview of vertical integration
Here, we identify the three main classes of vertical integrative problem : 1. Clas-
sification and prediction - for disease subtype classification, regulatory module
discovery, and diagnostic prediction, 2. Meta-dimensional association - for func-
tional annotation and identification of novel disease associations, 3. Causal analy-
sis - for the characterization of molecular mechanisms involved in disease or gene
regulation (Figure 5.1). In the context of this thesis, we are specifically interested
inmeta-dimensional association, as ameans to utilise the available gene expression
and methylation datasets available for our sample of MZ ASD twins. We propose
a analysis flow with the following stages: 1) quality control, 2) confirmation, 3)
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feature selection, 4) joint/meta analysis. Strategies for the other two classes of in-
tegrative problem will not be discussed as firstly we do not intend to address these
particular biological questions in our study, and secondly, as they already achieve
a great deal of attention in the statistics and bioinformatics literature. For classifi-
cation and prediction, we direct the reader to a recent review covering mathemat-
ical aspects of predominantly classification type problems in an integrative con-
text [14], and two more reviews discussing the particular challenges involved and
methods used for integrative classification in the context of cancer genomics [15]
[16]. For causal analysis, we direct the reader to a paper by Schadt et al. describ-
ing a multi-step filtering approach followed by Bayesian network reconstruction
and model selection to identify the most likely causal model describing the data
[17], and a paper by Relton et al. describing the technique of Mendelian randomi-
sation applied to epigenetic epidemiology, using genetic data to infer the direc-
tion of causality between epigenetic differences and the trait under consideration
[18].
5.1.4 Analytical challenges and considerations
Integrating diverse, complex omics data presents a variety of analytical challenges,
as discussed in [7, 13]. The issue of high data dimensionality is particularly rele-
vant, as due to the typical sample sizes used in omics studies, there are likely to be
much fewer subjects than parameters (n « p problem). High dimensionality can
severely limit statistical power, making the threshold for significance of any asso-
ciations difficult to overcome. In addition, having many dimensions can also be
a computational burden, especially for an activity such as model selection, where
for example, to calculate all possible models for three variables would require the
testing of approximately 2 ×109 different models [7]. As a result, many integrative
methods necessarily include dimensionality reduction as a step.
Another challenge associated with data integration is heterogeneity between the
datasets. Data fromdifferent sources aremeasured on different scales and are likely
to have different distributional properties. For example, measurements of gene ex-
pression from an RNA-seq experiment can have integer values ranging from 0 to
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1000s, with approximate negative binomial distribution, whereas methylation as
profiled by microarray is usually provided in the form of Beta-values, which can
have a value from 0 to 1 with a bimodal distribution. There is also the issue of dif-
ferent omics sets taking measurements over different genomic scales or units, for
example single base, exon, gene or haplotype block. A simple approach would be
to aggregatemeasurements to bring them on to a common scale, but this is perhaps
of questionable biological plausibility and also then limits the analysis to investi-
gating cis effects. Another option could be to identify multiple features of interest
to test across the sets, but this then increases the multiple testing burden. Finally,
there are also dataset specific considerations such as the presence of confounding
and batch effects, which need to be adjusted for. These various issues can com-
plicate statistical modelling, preventing datasets from being incorporated into the
same regression model for example, or making the search-space unfeasibly large
for model selection.
Multicollinearity between datasets can also be an issue, with features likely to be
correlated between sets. This can create difficulties further downstream, for exam-
ple in regression-based approaches, where a high level of correlationmight prevent
matrix inversion, required for accurate coefficient estimation [19].
Finally, there is the question of how to interpret potentially complex findings. The
identification of susceptibility loci, even with the added level of information that
other datasets can add, is still difficult to relate to the outcomemechanistically. This
is perhaps where a systems-level view placing the identified perturbations within
the context of interaction networks, might prove more fruitful [12].
5.1.5 Integrating multi-dimensional omics datasets
This chapter is divided into two sections. In the first section, for each of the stages of
the proposed meta-dimensional association analysis flow, some theoretical back-
ground is covered and existing bioinformatics tools highlighted. In the second
section, a number of selected approaches are applied to biological basis of autism
spectrum disorder (ASD). In this case study we attempt to integrate expression and
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methylation datasets from the same sample of MZ twins concordant and discor-
dant for ASD, in order to maximise power to identify functionally relevant signals
across the datasets and help form a more coherent picture of the genes and mech-
anisms likely to be involved in the aetiology of the disorder.
5.2 Meta-dimensional analysis
5.2.1 Quality control
Prior to combining evidence, assurances will often be sought that the individual
datasets are of a high quality. Each profiling technology generates data with its own
characteristics and has its own recommendations with regards to quality assurance
and quality control, and adhering to these standards should help to reduce the risk
of encountering issues further downstream [7].
5.2.2 Confirmation
The aim of confirmation is to establish the extent to which the measurements from
the diverse modalities are related. If the study aims to explore global molecular
differences between subjects, comparing correlation across all features measured
in common across the datasets can be useful for gaining an impression of the over-
all agreement between the datasets. Alternatively, individual gene-wise correla-
tions are informative about functional relationships between different molecular
measurements at individual loci. For example, by testing the correlation between
the abundance of a gene and the methylation status of a cis CpG site allows for
the identification of methylation-expression quantitative trait loci (methyl-QTL) -
genes whose expression is under the control of a cis CpG.
In terms of the statistical methods, classic approaches such as Pearson’s and Spear-
man’s correlation are often appropriate. Anumber of studies have integratedmethy-
lation and gene expression data using such approaches. For example Rhee et al.
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[20] used correlation as part of a multi-staged integrative analysis in breast cancer,
first identifying differentially expressed genes for cancer subtype, and then exam-
ining the correlation between methylation and expression at each locus, verifying
the functional impact of DNA methylation in gene expression in relevant genes.
In another study, Zhao et al. integrated mRNA expression with both methylation
and miRNA to identify differentially regulated genes in CD4+T cels from systemic
lupus erythematosus patients [21].
Only limited inferences can be made using such methods, firstly due to the fact
that only two datasets can be correlated at a time, and secondly, because it is not
typically possible to determine the direction of the effect. As a result, this type
of analysis is often performed as a purely exploratory step, or to filter data before
performing another type of integration. For example, correlating SNP and expres-
sion data to identify likely eQTLs could be used to filter features for subsequent
modelling along with the trait.
5.2.3 Feature selection
One of the challenges of data integration is high dimensionality, as discussed pre-
viously. Reducing the number of variables being tested for association is an impor-
tant part of an integrative analysis - in fact some of the individual methods for joint
analysis include an inherent feature selection or dimension reduction step (e.g. pe-
nalized regression - see next section). Feature selection or dimension reduction is
important in the context of classification and prediction, where it can be used as an
inferential method in its own right, but for meta-dimensional association, it could
perhaps be considered more of an exploratory step used to filter the data before
performing inference - especially when the inferential method does not include an
inherent dimension reduction step (e.g. standard regression).
As for existing methods, machine learning methods such as principal components
analysis (PCA) or canonical correlation analysis (CCA) are often used. CCAworks
similarly to PCA describing associations between datasets by finding linear combi-
nations that maximise the correlations between the sets, but whereas PCA is pre-
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dominantly used to describe variance in a single set, CCA can be used for two
datasets [22]. The PMA package in R (https://cran.r-project.org/web/packages/
PMA/index.html) can be used to perform both sparse CCA and PCA [23]. Al-
ternatively, the mixOmics R package (https://cran.r-project.org/web/packages/
mixOmics/index.html) provides regularised CCA designed to deal with a large
number of variables as well as a sparse partial least squares method (PLS) [24]
.
5.2.4 Joint analysis
5.2.4.1 Regression
Linear regression and similar methods are popular for performing statistical tests
with single omics data. Intuitively, such methods could also be used in an inte-
grative setting where the goal is to identify meta-dimensional associations. These
potentially offer several advantages over alternativemeta-analytic approaches (dis-
cussed in the next section). When the genomic datasets are particularly rich in in-
formation for example, the effect of extraneous or confounding variables can per-
haps be more accurately estimated by combining the datasets. In cases too where
a causal hypothesis is to be tested, regression models are more amenable to testing
for directionality of an effect - this however would typically require the application
of another method such as model selection and/or network reconstruction.
Once data has been appropriately transformed, scaled to be approximately nor-
mally distributed, and genetic features brought on to the same scale, in the sim-
plest case where two datasets are to be combined, a multivariate or multivariable
model can be fit. For example, using SNP and methylation data, methylation is
treated as an intermediate trait and regressed on genotype groups. Bell et al. used
such an approach, summarising methylation by haplotype block and using sliding
windows to investigate the relationship between genotype and methylation for the
FTO diabetes susceptibility locus [25].
There are a number of R and bioconductor packages which use regression as the
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coremethod for integrating twodatasets. MethylMix (https://www.bioconductor.org/
packages/ release/bioc/html/MethylMix.html) is intended for integrating methy-
lation and expression data to determine significantly hypo and hypermethylated
transcriptionally predictive genes in cancer [26]. The MEAL package (http:// bio-
conductor.org/ packages/MEAL/) can also integrate methylation and expression
data using a linear regression-based approach, as well as containing several meth-
ods for differential methylation analysis and probe/region summarization.
Regression with dimension reduction: When the number of molecular datasets
to be integrated is > 2, and the number of variables is much greater than observa-
tions, traditional multivariate approaches (such as those described above) are no
longer appropriate [27]. In such instances, feature selection or dimension reduc-
tion methods can instead be used. Methods such as partial least squares (PLS),
Least Absolute Shrinkage and Selection Operator (LASSO) [28], and Elastic Net
(ENET) [29], combine dimension reduction with regression, removing uninfor-
mative parameters and hence mitigating issues with dimensionality. Addition-
aly, these methods can deal with multicollinearity [30], which standard regression
methods are less able to deal with.
TheplsgenomicsRpackage (https://cran.r-project.org/web/ packages/plsgenomics/
index.html) implements PLS spefically for integrative omics applications, its util-
ity demonstrated for combining expression and ChiP data to predict transcription
factor activities in the accompanying publication [31].
5.2.5 Meta-analysis
5.2.5.1 Combining evidence
As an alternative to regression based approaches, data can instead be combined at
the level of summary statistics such as odds ratios, test statistics or p-value. This ap-
proach has a long history in meta-analysis [32], and more recently p-value combi-
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nation methods have found application in GWAS [33], multiple testing correction
[34], and geneset testingmethods [35]. Suchmethods could also find application in
vertical data integration. Themain advantages are that the raw experimental data is
not always required, making it suitable for including extraneous data sources (e.g.
annotation, or publicly available GWAS summary data), and also circumventing
potential issues with data heterogeneity. The real value in such an approach is that
it is possible to gain statistical power, even the case where evidence from the indi-
vidual studies is weak [36]. Yet, despite the potential advantages, the idea of using
horizontal integration techniques for vertical integration has not been explored
much in the literature.
In choosing an evidence combining approach, several important factors relating to
the characteristics of the datasets and also the type of combined hypothesis being
tested should be carefully considered. Related to this, whether the measurements
are derived from the same individuals or unrelated individuals, and if the datasets
are fully independent or if, on the other hand, themeasurements across the datasets
are correlated. As for the nature of combined test, the majority of methods test the
global null, sometimes known as the conjunction test, which tests for at least one of
null hypotheses being false, but different combined hypotheses can also be tested
(see below). Lastly, it is important to consider whether the strength of evidence
from each study should be weighted equally - study weights are more easily incor-
porated into some approaches than others.
5.2.5.2 Methods for combining independent p-values
Quantile combination - Fisher’s and Stouffer-Liptak: Methods for combining p-
values can broadly be categorised into those based on either quantile combination
or order statistics. Quantile combinationmethods first select a parametric cumula-
tive distribution and then transform p-values into distributional quantiles through
a combining function	 = ∑ki=1 f(pi), where f is the transforming function and pi
the ith p-value from k tests, and use this to calculate a combined test p-value from
the sampling distribution of 	 [37]. Probably the best known quantile-based ap-
proach is Fisher’s combined p-value, which models combined p-values as a 2 dis-
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tribution using the following transformation: 	F = −2∑ logpi. One limitation of
Fisher’s method is that it cannot incorporate weights, an issue particularly inmeta-
analysis where it may be desirable to weigh statistics according to the reliability of
the study, or perhaps by how informative it is judged to be [38]. The Stouffer-Liptak
method (equivalent methods developed independently) is an extension to Fisher’s
which allows for weights to be incorporated by instead combining Z scores with:
	SL ∼ ∑ki=1 Zi√k . Or in terms of p: 	SL = ∑−1(1 − pi) where −1 is the inverse
cumulative distribution function of the normal distribution.
Order statistics - Tippet’s and rank truncated product: Order statistic methods
use a combining function: 	 = pr for a preselected r;1 <= r <= k, with the
sampling distribution a member of the beta distribution family. Tippet’s method
simply takes the minimum p-value and uses this as the combined value: 	T =
min(pi). There are also more recently developed methods such as rank truncated
product and adaptive rank truncated product which could perhaps be considered
hybrid approaches, making use of both order statistics and non-parametric cumu-
lative distributionmodelling. In the case of adaptive rank truncated product mini-
mum p-values are found to be accurately modelled by beta distribution, which can
be used to assess significance (see Chapter 4).
The distinctions between the different combination approaches will not be dis-
cussed any further here (see [37] for a review). Much more relevant are their sim-
ilarities in terms of the underlying assumptions made. Firstly, these combination
methods rely on the fact that for test statistics having continuous null distributions,
the p-values will be uniformly distributed across the interval 0 to 1 [37]. Secondly,
the conjunction, global, or combined null hypothesis is tested, where the alterna-
tive is that at least one of the null hypotheses is false. Finally, individual p-values are
assumed to be fully independent, that is to say, the measurements are uncorrelated
within and between assays.
P-value combination in multi-omics analysis: One of the difficulties with apply-
ing the above classic combination strategies to multi-omics data, is that some of
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the assumptions of the methods are violated. The issue of dependence in particu-
lar is problematic, given for example, well described phenomena in genetics such
as linkage disequilibrium (LD), whereby markers show correlation as a result of
being inherited non-randomly in haplotype blocks. As well as individual datasets
possessing their own complex correlation structures, when using different molec-
ular datasets derived from the same sample, there can also be correlation between
datasets. Applying Fisher’s method with correlated data has been shown in sim-
ulations to produce unexpectedly small p-values, thus over estimating the signifi-
cance of the combined hypothesis and increasing the Type I error rate of the test
[39].
5.2.5.3 Combining dependent p-values
Brown’s, empirical Brown’s and Kost’s: Brown was one of the first to suggest a
method for combining dependent p-values. Brown’s method is an extension of
Fisher’s, in which p-values are assumed to come from a multivariate normal dis-
tribution with specified covariance matrix [39]. A scaled 2 distribution is used:
	B ∼ c22f , where the constants f and c represent the re-scaled degrees of freedom
and a scale factor which is the ratio between the degrees of freedom in Fisher’s and
Brown’s [40]. These are calculated as follows:
f = E[	]2var[	]
c = var[	]2E[	] = kf
E[	] = 2k
var[	] = 4k + 2∑i<j cov(−2logPi − 2logPj)
	B = 1 − 2f(	F /c)
where 2f is the CDF of 22f and 	F is the distribution for Fisher’s method (as
previously defined).
Because the expectation and variance of 	B are calculated directly via multidi-
mensional numeric integration, the method is impractical for large datasets [40].
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This is a clearly an important issue in genomics, and has consequently motivated
the development of methods based on Brown’s, which use approximations of the
covariance term to reduce the computational burden. The first of these is a method
described by Kost et al. [39], in which exact co-variances for Fisher’s distribution
were computed across a grid of different correlation () values and differing de-
grees of freedom (v), and different polynomial regression models fitted. Approxi-
mations for covariance as a function of  and 1/v were then obtained, in both cases
where variance is known and unknown, these can then used by substituting into
Brown’s (formulae not given here for the sake of brevity). The secondmethod is the
empirical Brown’s approach of Poole et al. [40], which similarly uses approxima-
tion, but achieves this through alternative means by deriving an empirical calcula-
tion for the covariance term in Brown’s from the experimental data itself:
w⃗i = −2logF (x⃗i)
var[	] = 4k + 2∑i<j cov(w⃗i; w⃗j)
where w⃗i is a transformed vector based on x⃗i , samples from the raw data, and the
empirical CDF calculated from the sample x⃗i. The covariance is then calculated us-
ing w⃗i. Both Kost’s and empirical Brown’s methods are implemented in the EBM
bioconductor package
https://www.bioconductor.org/packages/ devel/bioc/html/EmpiricalBrownsMethod.html
Stouffer-Liptak-Kechris: As mentioned above, another issue with particular rel-
evance to omics data is that of correlation. This has implications for combining
not only genetic data, but also methylomic data too, with the methylation status
of CpGs showing patterns of correlation for distances up to several thousand base
pairs (see Chapter 4). The Stouffer-Liptak-Kechris (SLK)method, uses slidingwin-
dow correction where neighbouring p-values are weighted according to the ob-
served auto-correlation, before undergoing combination by Stouffer-Liptak [41].
The SLK method has been implemented in the Comb-p tool in python (https://
github.com/brentp/combined-pvalues), which uses p-combination to identify “peaks”,
or genomic regions of statistical significance within an individual dataset, which
can be applied to methylomic, or in theory any molecular dataset with inherent
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spatial correlation [42] . Although it is not explicitly mentioned in the paper,
SLK could also potentially be used in multi-omics integration, as a method to first
account for correlation within-dataset, as a precursor to then integrating across
datasets. This proposed framework for meta-dimensional association involving
multiple steps of p-value combination is explored further in the second section of
this paper.
5.2.5.4 Testing the partial conjunction
Touching briefly on one last aspect of p-combination which warrants considera-
tion, is the question of which hypothesis to test. All of themethodsmentioned pre-
viously test the conjunction hypothesis. Withmultiple omics datasets, conceivably,
testing that just one of the alternative hypotheses is true might not be biologically
meaningful, or adequately reflect the underlying molecular mechanisms. Using an
example to illustrate this point, in an investigation including SNP, methylation,
and CHIP-seq datasets, for any individual susceptibility locus, ideally we would
like evidence for association across all the datasets, not just one. The disjunction
hypothesis, which tests that all of the alternative hypotheses are significant, would
be overly restrictive, particularly since the relationship between methylation status
of individual CpGs or regions and chromatin status is not well understood - poten-
tially operating in either direction, distally, or indeed having no effect at all.
One solution to this scenario would then be to use the partial-conjunction, which
tests that a pre-specified n number of alternative hypotheses at a location are true
[36]. To use another example, when combining SNP, DNA methylation and gene
expression data, we might specify n ≥ 2, and perhaps further require that one of
the significant p-values is a genetic association, to increase the likelihood that any
identified signal will be a functionally relevant eQTL or mQTL. By relaxing the
constraint for the other two functional datasets by only requiring one show an as-
sociation, we are then able to screen for cis mQTLs, eQTLs, methQTLs, and not
just methQTLs (as we would be doing with the disjunction). Benjamini and Heller
[36] describe appropriate test statistics for a partial conjunction, theMatlab code is
available from the author’swebsite (http://www.math.tau.ac.il/ ruheller/Software.html).
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5.2.5.5 Utility of p-value combination in vertical integration
Within an integrative analysis framework p-value combination methods can be
used to achieve a couple of different analytical aims. Firstly, p-value combination
can be used for data filtering prior to performing amodelling-based integrative ap-
proach. The results from p-value combination can also be used stand-alone, where
significant meta-dimensional association indicate a dependence relationship be-
tween the molecular traits and phenotypic trait of interest, although determining
the direction of the relationship may require the application of additional meth-
ods.
5.3 Applicationof selected integrativemethods toASD
This section describes the application of some of the above methods to integrate
27K microarray methylation data and RNA-seq gene expression for our ASD MZ
twin cohort, in order to identifymeta-dimensional associations andhighlight func-
tionally relevant signals. Further information on the sample is given in Chapters
2 and 3. The 27K methylation data was generated as part of a previous study [43],
and the data provided for this in the form of pre-processed and normalized Beta
values, see the original paper for details on the methods used and data processing
steps. The RNA-seq data was generated as previously described in Chapter 3, and
the final processed data in the formof normalized gene counts permillion (NCPM)
used here along with the differential expression results.
5.3.1 Methods
5.3.1.1 Quality control
To beginwith, the expression andmethylation datasets were compared, and any in-
dividual not profiled on both assays removed. Following this step, the methylation
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Beta values were converted to M values (see Chapter 4) and differential methy-
lation analysis performed. The ComBat function from the SVA package [44] was
used to identify potential confounders and other unmeasured sources of variation,
which in this case failed to identify any significant surrogate variables. PCA plots
were also generated (seeAppendixDFigureD1) and inspected, with no evidence of
batch effects or confounding observed. Next, edgeR was used to fit a linear model
for a case-control comparison and a within group 2 comparison, using the same
model that was used for the expression data (see Chapters 3 and 4):
Case-control:
y ∼ pair + case (5.1)
Group 2 pairs:
y ∼ pair (5.2)
The results from differential methylation analysis were compared with those pub-
lished in the original research, the results compared, and top results showing good
overlap.
5.3.1.2 Confirmation
For confirmatory integration, firstly, Pearson’s correlation between samples across
the assays was assessed using Beta values for the methylation data and NCPM for
the expression data. Probes were binned according to genomic location - all, CpG
island, non-CpG island. Mean values for all the samples andCpG types were calcu-
lated, and 95% confidence intervals calculated using Fisher’s z transformed values.
Following this, the correlation and intersection between the differential methyla-
tion and differential expression results were measured using the reported log fold
change values for all genes and the significant genes at p < 0.05. Finally, Pearson’s
correlation between genes was assessed, by aggregating CpG probes and taking the
median Beta value for the gene.
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5.3.1.3 Joint analysis - p-value combination
To combine evidence across the sets, two rounds of p-value combinationwere used.
In the first, within-set combination step, in order to account for correlation within
the 27K dataset, the SLK method from comb-p was used setting the distance pa-
rameter to 2000 and region filter to 0.05. This produced SLK adjusted p-values
for each CpG site. Following this, sites mapping to the same gene in the 27K data
were aggregated by taking the minimum p-value as the gene-wise significance es-
timate. The gene expression data was assumed not to have any spatial correlation,
and so was not subject to any initial round of combination. In the second step,
to combine the SLK-adjusted methylation p-values and gene expression p-values,
empirical Brown’s was used to obtain the final combined p-value for genes mea-
sured in both assays, using the original raw data in the form of NCPM values for
the expression and M values for the methylation. In cases where a gene was un-
measured in either assay a p-value of 1 was assigned to that missing gene, and since
the covariance calculation would in that case not be possible, Fisher’s method was
instead used - thus ensuring that a significant result from a single dataset that un-
measured in the other assay would still remain significant, in order to produce a
complete combined set of results.
5.3.1.4 Joint analysis - regression modelling
Next, a regression-based model selection approach was used to combine the data
within the same model. The data was filtered to retain only loci which were mea-
sured in both expression and methylation assays that achieved nominal signifi-
cance in the previous p-value combination approach. Next, the expression NCPM
were transformed to Z scores in order to bring them onto a smaller scale closer
to that of the methylationM values, and the following three mixed effects models
fitted:
Model 1:
logit(case) ∼ 1∣pair +methylation (5.3)
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Model 2:
logit(case) ∼ 1∣pair + expression (5.4)
Model 3:
logit(case) ∼ 1∣pair +methylation + expression +methylation ∶ expression
(5.5)
With 1 | pair the random effect of pair, and alternatively fixed effects for methyla-
tion, expression, and the interaction between methylation and expression in mod-
els 1,2, and 3 respectively. For each gene tested, the Akaike information criterion
(AIC)was calculated for each of themodels using theAIC function inR.TheAIC is
calculated as : AIC = −2×(L)+2k, where theL is themaximum log-likelihood for
the model and k is the number of parameters. This favours models with a good fit
but penalizes those with more parameters (to prevent overfitting). In cases where
model 3 provided the lowest AIC score, this indicated that the inclusion of methy-
lation and expression and their interaction improved prediction of case status even
at the expense of increasing model complexity. This was used to identify function-
ally relevant signals, defined as those genes that in addition to showing significant
association with ASD in either the expression ormethylation datasets, also showed
evidence of association between methylation status and expression level.
5.3.2 Results
5.3.2.1 Confirmation
The per-sample interset correlation was assessed by comparing per-gene Beta val-
ues to gene expression NCPM.The results are given in Table 5.1. Samples showed
a modest level of correlation across the datasets, with a mean value of -0.15, 95%
CI[-0.49,0.18]. This was slightly lower when only taking into account CpGs lo-
cated in islands -0.13, 95% CI[-0.46,0.21], and higher for non-island CpGs -0.21,
95%CI[-0.55,0.12]. These results were taken as indicative of a relationship between
the datasets, even though the correlations would perhaps be expected to be slightly
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higher.
The agreement of the results from differential methylation and differential expres-
sion analyses was assessed by correlation and intersection between the mean log
fold change (logFC) values for all genes, and nominally significant genes. The re-
sults are shown in Table 5.2. For the case-control comparison, the correlation be-
tween the logFC values for all genes was -0.05, and -0.20 for significant genes. For
the group 2 comparison, the correlation between the logFC values for all genes was
-0.05, and 0.02 for significant genes. Based on these values, it was decided that fur-
ther integrative analysis should utilise only the case-control results, as these would
be more likely to reveal novel meta-dimensional associations - given the higher
correlation between significant genes across the platforms.
Overall correlation between genemeasurements across the different assayswas also
examined. Table 5.3 gives the top 50 genes in terms of absolute correlation of per-
gene mean CpG methylation Beta values and expression NCPM.
Comparison Sample correlation (p) 95% CI lower 95% CI upper
Betas (All CpGs) with CPM -0.15 -0.49 0.18
Betas (Island CpGs) with CPM -0.13 -0.46 0.21
Betas (Non-island CpGs) with CPM -0.21 -0.55 0.12
Table 5.1. The per-sample interset correlation between mean CpG methylation (Beta)
and transcript abundance (normalised counts per million) across all genes, with CpGs
classified by location (all, island, non-island)
Comparison Correlation (r) Intersection Correlation Intersection
case control -0.05 0.55 -0.20 0.06
group 2 -0.05 0.55 0.02 0.04
gender 0.00 0.55 -0.13 0.11
logFC DE genes (P < 0.05)logFC all genes
Table 5.2. Agreement of the results from differential methylation and differential expres-
sion analyses, as assessed by correlation and intersection between the mean log fold
change (logFC) values for all genes, and nominally significant genes.
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Gene symbol Correlation (r)
LDHC -0.851865076
IL1R2 -0.806544669
PNMA3 0.797076607
IL5RA -0.758055223
BTN3A2 -0.735685641
FADS2 -0.731084493
IRF6 -0.720178734
TREM1 -0.706696357
UBE4A 0.682398902
LRG1 -0.678783238
C8orf31 -0.668632019
FUT7 -0.666878672
HLA-C -0.662617802
RAB11FIP2 0.655762494
CSF3R -0.65400064
USP10 -0.652070938
ZNF691 0.645900146
GNLY -0.644868421
TRPM6 -0.643086325
CD3G -0.63391781
ATG10 0.629443839
GZMM -0.609802
NFE2 -0.607621139
HIPK3 -0.602083315
ENTPD1 -0.600549279
AQP9 -0.600356036
HAL -0.59864147
CXADR -0.598117028
SCNN1D 0.591966877
DDX43 -0.590682908
ATP13A4 0.588722496
CD19 -0.588227811
TREML2 -0.583088408
FBXL13 -0.581662955
EBPL -0.57808595
IL1B -0.577854054
KRT1 -0.569225662
CEACAM3 -0.564862165
MKRN3 -0.564686395
ZNF205 -0.564236741
CHI3L1 -0.563905026
PRSS21 -0.562284555
WDR45 0.557622035
SIGLEC11 -0.556642295
ARMC1 -0.554141787
ZFX -0.553541715
ITGAX -0.55309672
RNF17 -0.552319755
LY9 -0.550353001
RYBP -0.542635604
Table 5.3. The top 50 genes in terms of absolute correlation of per-gene mean CpG
methylation (Beta) and transcript abundance (normalised counts per million)
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5.3.2.2 Joint/meta analysis - p-value combination
Turning now to the p-value combination method, Table 5.4 gives the top 50 results
of p-combination for the case-control comparison. Here it is apparent that a num-
ber of the genes previously identified as being differentially expressed in the RNA-
seq experiment continue to be highly significant after combination, making up the
majority of the top 10. One example is DEPDC1B, which is not significantly dif-
ferentially methylated, but has enough evidence for differential expression so that
it remains significant. Table 5.5 gives the top 50 results of p-combination for the
group 2 comparison. Once again, the signal from the differentially expressed genes
seems to overwhelm that of the differentially methylated genes. Potential reasons
for this are numerous and could arise from inherent differences in the molecular
measurements, for example the different scales of the units being measured and
the need to combine CpG measurements in order to obtain gene-level estimates
(which may not reflect the underlying regulatory mechanisms), or perhaps in the
expected effect sizes and power to detect these.
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Case-control
Gene symbol 27K DM (SLK adjusted p) RNA-seq DE (p) Fisher's/E-brown's combined (p)
ZNF501 5.56E-01 2.96E-05 2.15E-04
IGHG4 1.00E+00 2.86E-05 3.28E-04
DEPDC1B 9.67E-01 2.05E-05 3.37E-04
ALKBH6 4.88E-02 1.14E-03 6.01E-04
PHKA2 2.16E-03 2.58E-02 6.36E-04
PRR13P5 1.00E+00 6.00E-05 6.43E-04
IDUA 5.67E-01 1.36E-04 8.09E-04
KBTBD8 1.59E-02 2.10E-03 9.81E-04
PARP6 6.31E-02 1.60E-03 1.05E-03
ARHGEF1 3.43E-03 4.40E-02 1.48E-03
MOCS3 2.96E-02 6.16E-03 1.75E-03
HOXA9 1.88E-04 1.00E+00 1.80E-03
C11orf49 2.13E-02 8.89E-03 1.81E-03
TINF2 8.77E-04 2.16E-01 1.82E-03
RNF43 1.04E-02 1.79E-02 1.82E-03
TAS2R60 4.24E-03 2.67E-02 1.83E-03
IMPA2 4.95E-04 3.90E-01 1.84E-03
ZNF499 1.96E-04 1.00E+00 1.87E-03
HCFC1R1 1.73E-02 7.49E-03 1.87E-03
AMPD3 8.29E-03 1.65E-02 1.87E-03
ASPM 1.18E-02 1.35E-02 2.05E-03
DNAJA1 8.43E-03 2.60E-02 2.07E-03
SNRPE 7.78E-02 3.06E-03 2.22E-03
ANXA1 8.44E-04 1.54E-01 2.24E-03
ANP32E 3.00E-01 3.68E-04 2.26E-03
PFKP 2.54E-04 9.80E-01 2.32E-03
MCM4 3.95E-03 4.51E-02 2.32E-03
RECQL5 1.76E-03 1.46E-01 2.37E-03
GADD45GIP1 3.01E-01 8.94E-04 2.48E-03
CKB 2.04E-02 9.23E-03 2.60E-03
BRIP1 1.85E-02 1.56E-02 2.64E-03
CDK15 1.00E+00 2.89E-04 2.64E-03
PPP1CC 9.11E-03 2.82E-02 2.65E-03
TTC7B 1.00E+00 3.10E-04 2.81E-03
MAP4 7.40E-03 4.29E-02 2.88E-03
RHOBTB1 6.45E-02 1.80E-03 2.89E-03
SSNA1 4.91E-02 6.88E-03 3.04E-03
GABBR1 3.18E-02 8.68E-03 3.21E-03
SPATA6 1.59E-01 2.30E-03 3.25E-03
PLAGL1 4.99E-02 5.95E-03 3.33E-03
MAPK8IP3 2.59E-02 9.04E-03 3.38E-03
PABPC1L 1.00E+00 3.86E-04 3.42E-03
CDC40 1.33E-02 3.04E-02 3.57E-03
STK11IP 1.00E+00 4.12E-04 3.62E-03
APOA1BP 1.93E-03 2.20E-01 3.73E-03
HSPA8P14 1.00E+00 4.33E-04 3.79E-03
C21orf62-AS1 1.00E+00 4.38E-04 3.82E-03
ASF1A 2.72E-02 1.62E-02 3.84E-03
SERBP1 3.42E-03 1.30E-01 3.87E-03
MPL 7.33E-02 4.10E-03 3.94E-03
Table 5.4. Top 50 genes for the case-control comparison following p-value combina-
tion using SLK to summarise the methylation data, and then either Fisher’s or empirical
Brown’s method to combine with expression data, depending on whether the gene was
measured in both assays.
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Group 2
Gene symbol 27K DM (SLK adjusted p) RNA-seq DE (p) Fisher's/E-brown's combined (p)
IGHG4 1.00E+00 1.50E-08 2.86E-07
SNORD15B 1.00E+00 6.13E-06 7.97E-05
EVI2A 4.28E-01 5.25E-06 9.59E-05
ASPM 6.35E-03 2.19E-03 2.54E-04
DNAJA1 8.61E-03 2.52E-03 2.55E-04
CEP55 1.13E-01 1.93E-04 2.69E-04
RGS18 1.00E+00 3.39E-05 3.83E-04
RPS3A 2.56E-01 1.60E-04 4.55E-04
LPAR6 1.00E+00 5.09E-05 5.54E-04
RPL9 5.83E-01 6.16E-05 6.05E-04
HOXA9 7.73E-05 1.00E+00 8.09E-04
AMPD3 2.12E-03 3.04E-02 9.91E-04
PRR13P5 1.00E+00 1.00E-04 1.02E-03
RNF43 4.07E-03 2.64E-02 1.12E-03
RPL21 2.21E-01 5.25E-04 1.17E-03
PPBP 1.00E+00 1.37E-04 1.35E-03
ANXA1 3.66E-04 1.91E-01 1.36E-03
S100A12 2.42E-01 5.71E-04 1.37E-03
RECQL5 6.11E-04 2.38E-01 1.43E-03
DAPP1 1.69E-03 9.05E-02 1.50E-03
TAS2R60 3.95E-03 2.27E-02 1.51E-03
KBTBD8 2.38E-02 2.51E-03 1.53E-03
TPT1 1.71E-02 6.57E-03 1.56E-03
B2M 6.51E-01 2.58E-04 1.63E-03
IDUA 6.04E-01 2.90E-04 1.69E-03
DEPDC1B 9.65E-01 1.37E-04 1.71E-03
TINF2 5.50E-04 3.31E-01 1.75E-03
EEF1A1 2.58E-01 5.93E-04 1.89E-03
RPL41 1.00E+00 2.04E-04 1.94E-03
HSPA8P14 1.00E+00 2.20E-04 2.07E-03
HCFC1R1 2.92E-02 5.42E-03 2.20E-03
CDC40 4.92E-03 4.87E-02 2.24E-03
ALKBH6 4.25E-02 5.85E-03 2.31E-03
MKRN3 6.67E-04 3.76E-01 2.33E-03
RPL30 1.00E+00 2.53E-04 2.35E-03
MMP8 2.65E-02 9.79E-03 2.40E-03
TTC7B 1.00E+00 2.70E-04 2.49E-03
COPS4 3.38E-02 8.10E-03 2.52E-03
SRGN 1.00E+00 2.86E-04 2.62E-03
HIST1H2AG 1.47E-01 2.00E-03 2.68E-03
ZNF501 5.68E-01 4.93E-04 2.71E-03
MOCS3 1.68E-02 1.79E-02 2.73E-03
C11orf49 1.08E-02 2.88E-02 2.82E-03
RPL39 2.45E-01 1.33E-03 2.94E-03
HIST1H3J 5.89E-01 3.04E-04 2.95E-03
PHKA2 6.46E-03 4.90E-02 2.98E-03
PPP1CC 4.11E-03 7.66E-02 3.16E-03
RPL23 2.35E-02 1.01E-02 3.22E-03
GADD45GIP1 2.12E-01 1.74E-03 3.28E-03
RPS15A 3.34E-01 1.11E-03 3.30E-03
Table 5.5. Top 50 genes for the within group 2 comparison following p-value combina-
tion using SLK to summarise the methylation data, and then either Fisher’s or empirical
Brown’s method to combine with expression data, depending on whether the gene was
measured in both assays.
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5.3.2.3 Joint/meta analysis - regression
Finally, the significant results from p-value combination were used to select genes
for model fitting. Those genes where the interaction model provided the best fit to
the data were retained and then annotated with correlation values and combined p
values from the previous steps. A final list of functionally relevant genes was gener-
ated, defined as those with a significant combined p-value (p < 0.05) and significant
correlation (-0.2 < r > 0.2). This produced a list of 45 potentially functionally rel-
evant genes. The results are shown in Table 5.6 and discussed below.
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gene corr pval slk.P.adj expr.P fishers.browns.P
TINF2 -0.25 2.00E-16 8.77E-04 2.16E-01 1.82E-03
SNRPE -0.26 2.00E-16 7.78E-02 3.06E-03 2.22E-03
RHOBTB1 0.28 3.98E-01 6.45E-02 1.80E-03 2.89E-03
ASF1A -0.45 2.00E-16 2.72E-02 1.62E-02 3.84E-03
SLC7A6 -0.50 8.93E-01 3.77E-02 1.66E-02 5.23E-03
SF3B2 0.33 4.10E-12 3.33E-02 1.22E-02 5.77E-03
MAGED1 -0.21 1.30E-01 7.61E-03 1.03E-01 6.38E-03
TTF2 0.30 1.77E-02 2.65E-03 1.46E-01 6.90E-03
RAP2A -0.28 1.91E-27 1.55E-01 5.97E-03 7.38E-03
PDK2 -0.27 2.00E-16 9.15E-01 1.41E-03 9.88E-03
PRKCA 0.20 7.33E-01 5.19E-02 1.98E-02 1.01E-02
RHOF -0.21 2.78E-01 2.02E-02 6.62E-02 1.02E-02
KCNE1 -0.35 5.40E-01 2.92E-01 4.77E-03 1.05E-02
HMBOX1 -0.26 2.00E-16 9.10E-02 1.58E-02 1.08E-02
CAMK2G -0.23 1.01E-01 6.95E-03 2.15E-01 1.12E-02
MC1R 0.24 5.48E-01 1.08E-02 1.32E-01 1.13E-02
PCSK7 0.31 3.14E-02 7.66E-03 2.04E-01 1.17E-02
BRD3 0.48 2.00E-16 4.24E-02 2.65E-02 1.41E-02
ZDHHC24 -0.26 2.07E-01 6.89E-03 3.00E-01 1.49E-02
FER -0.24 8.33E-01 7.49E-03 3.07E-01 1.63E-02
TSPAN15 -0.22 1.77E-12 4.01E-02 5.93E-02 1.67E-02
B4GALNT3 -0.21 1.73E-01 3.92E-01 5.51E-03 1.68E-02
CRIM1 -0.28 2.47E-01 4.11E-01 6.11E-03 1.76E-02
S100A9 -0.35 6.33E-02 6.48E-02 4.00E-02 1.80E-02
STIM1 0.23 2.00E-16 4.09E-02 4.28E-02 2.08E-02
XYLT1 -0.21 2.00E-16 9.26E-01 3.85E-03 2.36E-02
SEMA3B 0.23 9.29E-01 9.23E-03 3.36E-01 2.41E-02
PLSCR4 -0.21 1.63E-04 3.55E-01 1.16E-02 2.68E-02
SLC35B3 0.32 4.12E-04 1.62E-01 1.32E-02 2.87E-02
ZNF300 -0.36 6.10E-02 8.21E-01 5.61E-03 2.94E-02
MTHFD2 -0.21 2.00E-16 1.46E-01 3.38E-02 3.11E-02
UBE3A -0.26 3.74E-01 4.79E-02 1.10E-01 3.28E-02
DYNLT3 -0.26 3.97E-01 4.36E-01 1.25E-02 3.39E-02
RPS15A -0.26 2.98E-01 3.07E-01 1.83E-02 3.47E-02
FGFR2 -0.29 2.70E-01 5.95E-02 1.03E-01 3.73E-02
MBTPS2 0.28 2.90E-01 3.11E-02 1.35E-01 3.74E-02
TREM1 -0.71 7.22E-01 3.13E-02 2.03E-01 3.84E-02
GRIP1 0.39 1.57E-01 5.61E-01 6.04E-03 3.94E-02
TNFRSF13C -0.21 3.29E-02 4.46E-02 1.53E-01 4.09E-02
SUMO2 0.26 1.55E-01 9.44E-02 5.73E-02 4.32E-02
TCP11L1 -0.39 7.93E-04 3.55E-01 2.13E-02 4.45E-02
TAF6L -0.36 2.02E-01 2.66E-01 2.86E-02 4.48E-02
PFKL 0.23 9.08E-02 8.19E-03 9.54E-01 4.57E-02
NLGN2 0.27 2.20E-01 3.78E-01 1.65E-02 4.86E-02
OXTR 0.35 2.00E-16 1.19E-01 5.02E-02 4.91E-02
Table 5.6. Final list of 43 functionally relevant genes defined as those where the methyla-
tion and expression signals were significantly correlated (-0.2 < r > 0.2) and the interaction
model best explained the relationship between ASD and methylation and gene expres-
sion. The results show the regression p-value, the SLK adjusted p-value for differential
methylation, the p-value for differential expression, and finally the combined p-value after
applying empirical Brown’s method.
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5.4 Discussion
In the first section of this chapter, we attempted to bring together the collective
knowledge dispersed throughout the integrative genomics literature in order to un-
derstand the challenges involved andmethods available for heterogenous data inte-
gration in the context of complex disease epidemiology. Threemain classes of inte-
grative problem were identified : classification and prediction, meta-dimensional
association, and causal analysis. For meta-dimensional association, a suggested
analysis flow was proposed featuring quality control, feature selection, confirma-
tion, and joint analysis/meta-analysis. For each of these, some of the theoretical
background was covered, and available bioinformatics tools highlighted. Partic-
ular attention was paid to meta-analysis, which has so far not received much at-
tention in this particular setting. Such an approach might find more widespread
application use as it possesses a number of advantages over joint analytic tech-
niques. Firstly, evidence combination is firmly rooted in tried and tested statisti-
cal methods and often making use of parametric distributions, which should give
some measure of confidence in the significance estimates produced. Secondly, sig-
nificant interaction effects between multiple datasets can potentially be revealed,
which integrative approaches which use multiple regression steps or SNP filter-
ing could miss, due to being limited to examining two datasets at a time. Thirdly,
these methods could help reduce the impact of data heterogeneity, since first com-
bining results within datasets can be used to bring different assay measurements
onto a common genomic scale - here we used the SLK combination method to
derive per-gene differential methylation estimates to then combine with gene ex-
pression measurements. Also related to data heterogeneity, when performing in-
terset combination there is no need to remodel experiment-specific confounders,
as these have been accounted for in the statistical tests that produced the sets of
p-values. Finally, the size of the combined dataset is reduced, potentially reducing
the high-dimensionality problem for subsequent integration methods, and related
to this, evidence combination is also computationally relatively simple. In sum,
such methods could find application in integrative settings which seek to identify
functionally relevant signals for prioritisation, where the direction of causality is
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perhaps not of immediate importance.
5.4.1 Application of selected integrative methods to ASD
Next, we carried out an integrative analysis of our gene expression and methyla-
tion ASD dataset following the suggested analysis flow and a selection of joint anal-
ysis methods. Confirmatory analysis was first performed which revealed modest
correlation between the measurements on both platforms, and between loci iden-
tified as showing significant differences between ASD cases and controls across
the entire sample. Following this, two different inferential methods were applied
with the aim of uncovering meta-dimensional associations. The first of these was a
meta-analytic approach that involved two subsequent p-value combination steps,
where evidencewas combined firstly at the level of the individual datasets, using the
SLK method to account for intraset correlation in the methylation data, and then
across datasets, using empirical Brown’s method to account for interset correlation
(where raw experimental measurements were available from both assays). This
produced a combined results list from the separate expression and methylation
studies. For the second approach, the nominally significant trait-associated genes
from the combined results list were taken forward and a regression-basedmodel se-
lection procedure used to identify functionally relevant signals in the form of likely
cismethQTLs. The results of model selection where then combined with measures
of correlation (previously generated in the confirmatory stage of the analysis), in
order to provide a final set of meta-dimensional associations showing evidence for
significant association from both the regression based and p-combination based
methods, and high levels of correlation between the methylation and expression
values.
The final list of nominally significant integrative results revealed a number of inter-
esting and promising candidates. To begin with,NLGN2was identified, coding for
a neuroligin involved in synaptic cell adhesion. We believe that this could represent
a novel ASD risk gene, based on prior evidence of the association of other neuroli-
gin family genes with ASD, such as NLGN1 [45], NLGN3 and NLGN4 [46]. Fur-
ther, the NLGN2 gene has also been associated with schizophrenia [47], which has
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previously been shown to have a strong genetic overlap with ASD [48, 49, 50]. An-
other gene of interest, the ubiquitin coding gene UBE3A, is a well established ASD
susceptibility locus, having been identified as causative for Angelman syndrome, as
well as lying in an chromosomal region subject to duplication events frequently as-
sociated with idiopathic ASD [51, 52]. This gene is expressed exclusively from the
maternal allele, with the paternal allele silenced via epigenetic mechanisms, with
disruption to these parent-of-origin specific patterns being causative for Angelman
[53]. As there is evidence for both methylation and overall expression of this gene
being relevant to ASD, it is therefore extremely encouraging that integrative analy-
sis identified this as a functionally relevant signal, even if this does not constitute a
novel finding. Finally, OXTR was identified which codes for the oxytocin receptor
OXTR and is a well established ASD risk gene [54]. Previous studies have also in-
dicated that epigenetic and gene regulatory effects at this locus are associated with
ASD [55]. One previous study using cortex tissue samples from 8 ASD cases and
8 matched controls found statistically significant hypermethylation of the OXTR
gene along with an associated decrease in mRNA levels in samples from a sub-
set of these individuals [55]. Once again, while this does not constitute a novel
finding, the fact that the gene emerged here offers further support for that the in-
tegrative approach being used here is able to identify genuine meta-dimensional
signals.
It is perhaps worth noting that these 3 genes did not appear in the top 50-100 lists
from the individual differential expression and differential methylation analyses,
and achieved nominal significance in one or other (but not both) of the datasets.
The integrative approachusedhere identified these as significantmeta-dimensional
associations, with further evidence for functional relevance (in terms of likely gene
regulatory effects), which is corroborated by the evidence from other studies. We
believe this demonstrates the potential power of such methods, particularly when
dealing with genomics data generated by small family-based studies which are
likely to be individually underpowered to reveal robust signals.
In terms of potential limitations, our analysis focused on proximal, cis regulatory
effects. While this simplified the analysis, it means that we are potentially miss-
ing important trans regulatory effects, as for example, it is known that imprinting
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control centers can regulate the expression of genes several megabases away [56].
Investigation of distal relationships between CpG sites and gene expression would
require a much larger number of tests to be performed, which must then be ac-
counted for in significance calculation using both regression and p-value combi-
nation based methods. This is less of an issue when limiting analysis to cis sites,
as then only a relatively small number of tests are performed. Any future study
intending to examine distal regulation would have to address the issue of multiple
testing, perhaps using permutation-based strategy.
Another limitation of this study is the lack of integration with genetic data. There
are two main ways in which we might choose to include genetic data to enrich
the analysis. Firstly, by utilising genetic data on the same sample of twins, we in-
clude another dimension in which to identify associations. We could also then
potentially ask further questions about the direction of the effects by using meth-
ods such as Mendelian Randomization to tease apart the relationship between dis-
rupted methlyation, gene expression, and ASD. Secondly, we could use public data
in order to better place the findings within their functional context in relation to
ASD. For example, by examining the intersection between our findings and those
from ASD GWAS we could identify putative disorder-associated eQTLs - that is,
genes shown by our integrative analysis to have a regulatory signal that also har-
bour known ASD risk variants.
5.4.2 Future directions
For integrative genomics in general, because such a wide range of different statis-
tical methods and analytical frameworks are available, there needs to be an em-
pirical assessment of the effectiveness of the different approaches for addressing
particular classes of problem and types of data. To this end, a sensitivity study for a
selection of integrative approaches using a model gene regulatory system involved
in disease, with well characterised relationships between genetic variation, gene
expression, and epigenetic mechanisms, would be of great value to the wider re-
search community. As for data integration in the context of the ASD MZ twins
cohort, for future studies we may look to incorporate further sources of data and
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attempt to perform further integrative analyses. For example, exome chip data has
recently been generated, which could be used to perform causal inference, using
the genetic data to establish the directionality of the expression, methylation and
trait interactions.
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6 | Discussion
6.1 Gene expression signatures in ASD
In what we believe represents the largest study of its kind performed to date, we
generated gene expression profiles from whole-blood samples taken from a co-
hort of ASD concordant and discordant MZ twins using high resolution RNA-seq.
By comparing expression profiles between ASD affected and unaffected individ-
uals across the entire sample we were able to identify differences that could be
genetically or non-genetically mediated, and by comparing expression within dis-
cordant pairs, we were able to identify changes in gene expression likely to reflect
non shared environmental factors. Overall, we established convergent evidence for
a number of genes with potential relevance to ASD: DEPDC1B, IGHG4, IGHG3,
IGHV3-66, HSPA8P14, HSPA13, SLC15A2. Pathway analysis showed enrichment
for genes involved in transcriptional control, immunity and PI3K/AKT signalling.
The immune-related genes were of particular interest, due to the fact that they
were also present in the discordant MZ analysis, and showed a consistent direc-
tion of differential expression, being up-regulated in cases compared to unaffected
twins. Although there are many limitations to this study (as covered in the rele-
vant Discussions in Chapters 2 and 3) there are reasons to be confident that these
may include genuine associations. To begin with, the overwhelming majority of
previous gene expression studies into ASD have also implicated immune system
and inflammatory pathways (see Chapter 1 - Table 1). In addition, there is also
wealth of evidence for altered immune response in ASD that comes from a num-
ber of epidemiological, serological, imaging, and postmortem studies (see [1, 2]
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for reviews).
6.1.1 Future directions
While we hope that this work goes some way towards demonstrating the exciting
potential of functional genomics investigations utilizing theMZ twins paradigm in
order to tease apart genes from environment and identify molecular biomarkers in
ASD, we acknowledge that further work needs to be undertaken to really establish
the veracity and translational relevance of the findings.
Wehave previously discussed the various limitations and shortcomings of the study,
but just to re-iterate, one major issue is the use of whole-blood as a proxy for brain
which remains controversial. As was suggested in the Discussion section of Chap-
ter 4, one way in which we might address this is by comparing our results to those
from the GTEx project, to determine which of the identified signals is also highly
expressed in the brain, and hence likely to be disorder-relevant. However, this
would primarily serve as a way of annotating the results for follow up but would
not directly test whether differences in expression are also present in the brain and
are also associated with ASD, which is really the key question. In order to address
this, ideally we would attempt to replicate our findings in postmortem brain tissue
resource, but a major limitation is that samples are unlikely to be derived fromMZ
concordant and discordant twins, and so we lose an important aspect of our de-
sign here, which is the genetic matching of MZ twins to allow for investigation of
expression differences mediated by non-shared environment. Such a study would
then be primarily useful for replicating those differences which are likely to be ge-
netically driven. Alternatively, we could look at the possibility of profiling other
tissues in our cohort, in an attempt to get closer to the primary affected tissue. For
example, scalp hair follicles are non-invasive to collect and are derived from the
ectoderm, the same germ layer as brain tissue. We would perhaps be more confi-
dent of detecting gene expression (and indeed epigenetic) changes that have arisen
early in development and are hence more likely to be ASD relevant. Indeed, study
byMaekawa et al. investigated the utility of scalp hair follicles in schizophrenia and
ASD and identified a putative novel biomarker in schizophrenia, as well as finding
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that in ASD that CNTNAP2, a strong ASD candidate gene, was significantly down-
regulated in follicles [3].
Another related issue which was also discussed was the fact that the blood samples
were collected fromadolescent subjects, andhencewe are unable to saywhether the
identified expression signatures in blood are causal for ASD. Since the pathogene-
sis of ASD occurs during early development, identified signals could be a response
to the initial perturbation - this would seem particularly plausible in the case of the
immune signal identified. In which case, it is important to keep in mind that with
a sample such as this, we are in some ways looking at the shadows cast by an ear-
lier developmental disruption, making it difficult to draw inferences about causal
pathways. Perhaps the primary goal of any gene expression profiling using periph-
eral tissue should be the identification of biomarkers, with our cohort this would
be for diagnostic purposes and to help distinguish environmentally sensitivemark-
ers, but with a study cohort where samples were collected at an earlier stage this
could also potentially yield predictive and prognostic markers. Indeed, the accu-
mulated evidence from other gene expression profiling studies, which consistently
identify immune and transcriptional control pathways, suggests the existence of a
blood-based expression signature of ASD.While we are hopeful that refinement of
the methods used here can lead to the identification of a robust signature for use
in a clinical setting, from the outset this would seem to be a less than ideal way
of investigating molecular mechanisms, for the reasons stated. Studies aiming to
contribute to our mechanistic understanding of ASD could then perhaps look to
tissues other than blood (as discussed above) and ideally from prospective birth
cohorts. There could also be utility in utilizing iPSCs (induced pluripotent stem
cells), again to try and recreate developmental conditions as closely as possible us-
ing any available, non-invasive peripheral samples such as hair follicle.
Finally, on the issue of teasing apart genetic from environmentally mediated gene
expression alterations in ASD, it has previously been suggested that the repeated
identification of immune and transcriptional control related pathways suggests
that these might be sensitive to environmental influence [4, 5]. Our findings here
would seem to offer further support this hypothesis. Since extensive phenotypic
measures are available for our cohort, and genetic data will become available in
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the near future, an interesting follow up study would be perform causal analy-
sis in an attempt to link disrupted expression and methylation within discordant
pairs to any early-life environmental exposures. It might then be possible to link
for example, early viral infection with up-regulation of immune genes, and a pro-
inflammatory state interfering with development at a critical period and leading to
the development of ASD.
6.2 Significance thresholds and sample sizes required
for EWAS
We also addressed a methodological issue relevant to epigenome-wide association
studies by deriving an estimate for significance for a single site to be declared as
differentially methylated using the 450K array:  = 2:5 × 10−7, which was then
extrapolated to obtain a genome-wide estimate:  = 4:5 × 10−8. It was initially
anticipated that this estimate would be useful in our study for ensuring the robust-
ness of the results from themethylation dataset being taken forward for integration
with the gene expression dataset. However, when it was later realized that this sig-
nificance estimate is likely to be platform specific and the results of extrapolation
perhaps not reliable, this threshold was not applied. The work does however re-
main relevant to the ASD study, as we then also used the estimated thresholds to
calculate the sample sizes required for a methylomic profiling experiment. Here, it
was found that to detect differences of 10% inmethylation levels with 80% power at
the genome-wide significance level, a twin-based design would require ∼ 60 pairs
of twins. Given the functional link betweenmethylation and expression, this could
perhaps suggest that larger sample sizes might also be required for gene expression
studies, especially given that the log fold changes within twin pairs that we ob-
served tended to be of a similar magnitude. It might also suggest that our gene
expression study with 5 discordant pairs, was in hindsight underpowered to de-
tect robust, highly significant differences in gene expression - although we later
demonstrated that it might be possible to compensate for this by using integrative
methods.
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6.3 Integration of gene expression and methylation
data
The gene expression profiles generated here were then integrated with methyla-
tion profiles on the same MZ twin cohort. Key findings from integration were the
identification of NLGN2, UBE3A, OXTR as showing combined evidence for dys-
regulation in ASD.These failed to reach significance in the individual datasets, yet
by applying integrative methods they achieved nominal, combined significance.
That UBE3A and OXTR were identified is particularly encouraging, as previous
methylomic and expression studies have identified these genes as being differen-
tially methylated or differentially expressed in ASD [6, 7]. So while these might
not represent novel findings, they do at least suggest that the integrative approach
developed here has had some degree of succes in identifying ASD-associated genes
that are likely to display epigenetic and gene expression differences. This increases
confidence in the findings, and suggests that other potentially relevant genesmight
also have been identified. Future studies could prioritise some of these other genes
for follow up in order to identify novel candidates. Here, we suggested thatNLGN2
in particular would be a good candidate, asmutations in genes coding for a number
of other neuroligins have previously been associated with ASD [8, 9].
6.3.1 Future directions
We have generated a rich, multi-dimensional ASD dataset which could be used for
a number of interesting future research projects. One of the biggest challenges in
ASD research is in translating findings in order to improve the accuracy of diag-
nosis, and make better predictions about response to behavioural and potentially
pharmacological interventions. Here, we found evidence for an immune signature
in whole blood, which could have potential as a diagnostic biomarker. Since such
an immunologically focused, blood-based, gene expression test has in fact already
been developed [10], in order to introduce a novel aspect, we might wish to lever-
age our additional data sources to search for a multidimensional methylation and
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expression signature and see whether this improves diagnostic power.
Another issue that studies into ASD must contend with is phenotypic heterogene-
ity, which is believed to be related to the underlying genetic heterogeneity [11]. It
has been suggested this could be one of the main reasons behind the lack of ro-
bust association findings from ASD GWAS. A number of studies have suggested
using phenotypic or biological endophenotypes to reduce heterogeneity and im-
prove power, for example using trait severity [12], or subgroups based on iden-
tified genetic risks [11]. Future studies may wish to explore the idea of using a
multidimensional classifier in order to identify ASD endophenotypes across the
different molecular layers. This could potentially allow cases to be stratified ac-
cording to the primary pathway perturbation - for example: synaptic organisation,
synaptic function, immune response, transcriptional control. Finally, integrative
approaches might also be used to better dissect etiology, by using the available data
to obtainmultidimensional risk scores based on the burden of previously identified
risks across genetic, epigenetic, and gene expression datasets.
6.4 Conclusions
Molecular genetics aims to progress our understanding of ASD from the bottom-
up, by identifying the genes and pathways likely to be involved and then using this
to build up a mechanistic understanding. Two key challenges for molecular ASD
research are i) to develop a coherent model for population risk, ii) devise a unified
molecular model for pathology that explains the disparate genomics findings to
date and incorporates commonly observed findings and popular pathological ex-
planations such as synaptic dysfunction, alteredneural circuitry, inhibitory/excitatory
imbalance, transcriptional dysregulation, and inflammation. In this thesis, we con-
tributed to the second of these challenges, in attempting to find pathways upon
which risk factors converge that are genetically or potentially environmentally sen-
sitive, by identifying disorder-associated signals in gene expression andDNAmethy-
lation datasets from MZ twins both concordant and discordant for ASD. There
is increasing evidence that establishment and maintenance of methylation marks
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during development and coordination of gene expression is important in the con-
text of normal brain development. This, taken together with the accumulated ev-
idence from genetic and functional studies showing the involvement of genes and
pathways involved in transcriptional regulation in ASD, and that early environ-
mental exposures during development can leave an imprint on the epigenome,
suggests a possible multi-etiological risk pathway for ASD involving genes, epi-
genetic regulation of gene expression, and early environmental insults. Our re-
sults lend support to the hypothesis that disruption of activity dependent tran-
scriptional/translational could be a key component of themolecular chain of events
leading toASD, given the importance of gene expression flexibility during develop-
ment for forming and pruning synaptic connections [13]. Altered gene expression
dynamics could potentially lead to disruption of connectivity in higher centers of
the brain important for mediating social behaviours (e.g. frontal-parietal, frontal
temporal, frontal-striatal circuits) [14]. The possibility that regulatory disruption
could serve as an integrator of early genetic and environmental risk factors jus-
tifies further investigation into disrupted epigenetic and gene expression in ASD.
In order to explore such hypotheses more fully, we should look to integrative ge-
nomics approaches in order to consider the different molecular layers in combina-
tion, helping us to gain a more systems-level perspective on autism.
249
References
[1] D. L. Vargas, C. Nascimbene, C. Krishnan, A. W. Zimmerman, and C. A.
Pardo, “Neuroglial activation and neuroinflammation in the brain of patients
with autism,” Annals of neurology, vol. 57, no. 1, pp. 67–81, 2005.
[2] P. Ashwood, S. Wills, and J. Van de Water, “The immune response in autism:
a new frontier for autism research,” Journal of leukocyte biology, vol. 80, no. 1,
pp. 1–15, 2006.
[3] M. Maekawa, K. Yamada, M. Toyoshima, T. Ohnishi, Y. Iwayama,
C. Shimamoto, T. Toyota, Y. Nozaki, S. Balan, H. Matsuzaki, et al., “Utility
of scalp hair follicles as a novel source of biomarker genes for psychiatric
illnesses,” Biological psychiatry, vol. 78, no. 2, pp. 116–125, 2015.
[4] I. Voineagu, X. Wang, P. Johnston, J. K. Lowe, Y. Tian, S. Horvath, J. Mill,
R. M. Cantor, B. J. Blencowe, and D. H. Geschwind, “Transcriptomic analy-
sis of autistic brain reveals convergent molecular pathology,”Nature, vol. 474,
no. 7351, pp. 380–384, 2011.
[5] V. W. Hu, “From genes to environment: Using integrative genomics to build
a “systems-level” understanding of autism spectrum disorders,” Child devel-
opment, vol. 84, no. 1, pp. 89–103, 2013.
[6] Y.-h. Jiang, T. Sahoo, R. C.Michaelis, D. Bercovich, J. Bressler, C. D. Kashork,
Q. Liu, L. G. Shaffer, R. J. Schroer, D. W. Stockton, et al., “A mixed epige-
netic/genetic model for oligogenic inheritance of autism with a limited role
250
References
for ube3a,”American Journal ofMedical Genetics Part A, vol. 131, no. 1, pp. 1–
10, 2004.
[7] S. G. Gregory, J. J. Connelly, A. J. Towers, J. Johnson, D. Biscocho, C. A.
Markunas, C. Lintas, R. K. Abramson, H. H.Wright, P. Ellis, et al., “Genomic
and epigenetic evidence for oxytocin receptor deficiency in autism,” BMC
medicine, vol. 7, no. 1, p. 1, 2009.
[8] S. Jamain, H. Quach, C. Betancur, M. Råstam, C. Colineaux, I. C. Gillberg,
H. Soderstrom, B. Giros, M. Leboyer, C. Gillberg, et al., “Mutations of the
x-linked genes encoding neuroligins nlgn3 and nlgn4 are associated with
autism,” Nature genetics, vol. 34, no. 1, pp. 27–29, 2003.
[9] J. T. Glessner, K. Wang, G. Cai, O. Korvatska, C. E. Kim, S. Wood, H. Zhang,
A. Estes, C. W. Brune, J. P. Bradfield, et al., “Autism genome-wide copy
number variation reveals ubiquitin and neuronal genes,” Nature, vol. 459,
no. 7246, pp. 569–573, 2009.
[10] S. J. Glatt, M. T. Tsuang, M. Winn, S. D. Chandler, M. Collins, L. Lopez,
M. Weinfeld, C. Carter, N. Schork, K. Pierce, et al., “Blood-based gene ex-
pression signatures of infants and toddlers with autism,” Journal of the Amer-
ican Academy of Child & Adolescent Psychiatry, vol. 51, no. 9, pp. 934–944,
2012.
[11] S. S. Jeste and D. H. Geschwind, “Disentangling the heterogeneity of autism
spectrum disorder through genetic findings,” Nature Reviews Neurology,
vol. 10, no. 2, pp. 74–81, 2014.
[12] O. Veatch, J. Veenstra-VanderWeele, M. Potter, M. A. Pericak-Vance, and
J. Haines, “Geneticallymeaningful phenotypic subgroups in autism spectrum
disorders,” Genes, Brain and Behavior, vol. 13, no. 3, pp. 276–285, 2014.
[13] E. Yeh and L. A. Weiss, “If genetic variation could talk: What genomic data
may teach us about the importance of gene expression regulation in the ge-
netics of autism,” Molecular and Cellular Probes, vol. 30, no. 6, pp. 346–356,
2016.
251
References
[14] B. S. Abrahams and D. H. Geschwind, “Connecting genes to brain in the
autism spectrum disorders,”Archives of neurology, vol. 67, no. 4, pp. 395–399,
2010.
252
References
253
Appendix .
Appendix
A Chapter 2
1 twoCM <- function(x,c){
2
3 # R function for fitting a two component mixture model to array intensity data
4 # for filtering out probes measuring background noise (representing smaller
component)↪
5 # x is an oligo expression set object,
6 # c is the confidence level - probes that can be assigned to smaller
7 # noise distribution with this level of confidence
8
9 require('mixtools')
10
11 #collapse expression data into a single vector
12 exprs <- vector()
13 for (i in 1:ncol(exprs(x))) {
14 exprs <- c(exprs,exprs(x)[,i])
15 }
16
17 #run normalmix EM procedure
18 exprs_mix <- normalmixEM(exprs, k=2,epsilon = 1e-08, maxit = 1000, verb=TRUE,
19 fast=T, arbmean= T,arbvar = T)
20
21 #get posteriors
22 post_prob <- as.matrix(exprs_mix$posterior)
23
24 #keep only posteriors for smaller component (defined as one with smaller mean)
25 #and reconstitute into matrix
26 m <- dim(exprs(x))[1]
27 n <- dim(exprs(x))[2]
28 mix_matrix <- matrix(nrow=m, ncol=n)
29 for (i in (1:n)) {
30 mix_matrix[,i] <- post_prob[(((i*m)-m)+1):((i*m)),which.min(exprs_mix$mu)]
31 }
32
33 #calculate mean posteriors for each gene
34 post_means <- apply(mix_matrix, 1, function(x) mean(x))
35 post_means <- as.matrix(post_means)
36
37 #omit genes that can be assigned to smaller distribution with confidence > n%
38 omit_probes <- which(post_means > c)
39 return(x[-omit_probes,])
40 }
Figure A1. R function to fit a two component mixture model to microarray data
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B Chapter 3
Experimental Design - Lane assignments
P448
Key
LANE 1 LANE 2 LANE 3 LANE 4 LANE 5 LANE 6 LANE 7 LANE 8
TG98582 TG78042 TG74382 TG78041 TG36391 TG74381 TG36392 TG29291
TG104611 TG236001 TG200022 TG123521 TG139622 TG48482 TG200021 TG104612
TG17181 TG66562 TG66561 TG129672 TG126552 TG15321 TG15081 TG20481
TG46142 TG126551 TG19901 TG139621 TG17571 TG98581 TG49452 TG49451
TG129671 TG20482 TG15082 TG236002 TG113631 TG15322 TG48481 TG113632
Group 2
Group 1
Group 6
Table B1. Flow cell lane assignments for the RNA-seq experiment
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Appendix.Pre-alignment QC
Sample Gender Group Lane Library size(bp) RIN Read length (bp) Total Reads GC % Post-trimmed Reads Properly Paired Median insert size (bp) Insert size SD Duplication rate Mate inner distance
TG98582 M 1 1 NA 8.2 101 49,878,602 46 54,313,294 27,249,112 175 94 0.19 -27
TG104611 M 2 1 NA 4.13 101 66,983,208 49 67,591,455 35,603,340 169 86 0.21 -33
TG17181 F 6 1 NA 7.7 101 46,538,044 47 52,910,477 27,110,594 181 100 0.23 -21
TG46142 M 1 1 NA 8.4 101 46,247,316 47 51,715,190 26,373,198 173 88 0.23 -29
TG129671 M 6 1 NA NA 101 51,502,760 47 36,282,748 18,842,922 175 95 0.24 -27
TG78042-REP-L002 M 1 2 NA 8.4 101 52,929,574 46 55,935,851 28,958,120 172 90 0.16 -30
TG236001 F 2 2 NA 6.9 101 75,193,360 47 82,530,717 42,309,884 170 86 0.19 -32
TG66562 F 6 2 NA 8.1 101 59,129,470 47 69,599,533 35,466,788 175 88 0.24 -27
TG126551 F 6 2 NA NA 101 54,719,570 46 64,715,175 33,037,216 183 103 0.25 -19
TG20482 M 6 2 NA 7.8 101 58,716,442 46 38,444,405 18,462,628 181 95 0.14 -21
TG74382 M 1 3 NA 8.7 101 61,614,838 47 25,204,814 12,171,012 183 97 0.17 -19
TG200022 F 2 3 NA 7.6 101 66,007,688 46 70,018,926 33,890,386 181 96 0.20 -21
TG66561 F 6 3 NA 8.1 101 66,007,688 46 85,789,089 44,845,578 169 84 0.26 -33
TG19901 F 6 3 NA 8.6 101 64,217,692 48 46,730,873 23,813,958 177 96 0.26 -25
TG15082 F 6 3 NA 8.8 101 70,792,894 47 80,178,916 40,783,982 175 94 0.26 -27
TG78041 M 1 4 NA 8 101 43,675,538 47 48,002,965 24,012,374 175 91 0.21 -27
TG123521 F 2 4 NA 7.6 101 55,392,432 46 60,269,977 29,184,726 185 100 0.18 -17
TG129672 M 6 4 NA NA 101 55,094,368 48 48,243,438 25,197,434 174 96 0.26 -28
TG139621 M 2 4 NA 8.8 101 45,365,368 47 30,505,529 15,101,578 179 96 0.14 -23
TG236002 F 2 4 NA 8.2 101 47,034,014 48 28,318,691 14,353,394 177 92 0.22 -25
TG36391 M 1 5 NA 6.8 101 54,023,076 47 57,574,785 28,058,412 173 86 0.14 -29
TG139622 M 2 5 NA 9 101 49,249,946 46 52,166,754 24,331,170 189 106 0.21 -13
TG126552 F 6 5 NA NA 101 55,489,936 47 62,526,415 32,623,702 174 92 0.26 -28
TG17571 M 6 5 NA 8.8 101 56,069,690 47 35,507,100 17,634,376 176 92 0.16 -26
TG113631 F 6 5 NA 8.6 101 62,739,468 47 73,074,029 35,170,354 182 96 0.26 -20
TG74381 M 1 6 NA 8.6 101 61,241,626 47 22,335,499 11,464,580 176 91 0.19 -26
TG48482 M 2 6 NA 7.9 101 64,396,234 48 61,939,552 30,564,012 178 95 0.24 -24
TG15321 M 6 6 NA 8.4 101 59,004,344 48 48,352,495 25,011,632 172 93 0.21 -30
TG98581 M 1 6 NA 8.3 101 54,051,952 46 59,165,002 29,118,480 182 99 0.21 -20
TG15322 M 6 6 NA 8.5 101 78,700,222 46 38,649,453 18,882,186 176 98 0.17 -26
TG78042-REP-L007 M 1 7 NA 8.4 101 38,884,070 46 40,979,058 21,274,970 172 91 0.15 -30
TG200021 F 2 7 NA 8.3 101 47,613,398 47 53,937,420 27,940,906 174 91 0.25 -28
TG15081 F 6 7 NA 8.2 101 40,482,952 49 27,358,454 14,080,918 174 94 0.22 -28
TG49452 F 6 7 NA 7.9 101 39,669,620 47 45,114,982 22,744,352 178 94 0.22 -24
TG48481 M 2 7 NA 7.9 101 43,282,416 48 50,351,655 25,110,528 187 108 0.27 -15
TG29291 M 1 8 NA 7.2 101 41,892,950 47 34,947,388 18,052,380 170 87 0.18 -32
TG104612 M 2 8 NA 8.7 101 45,089,612 47 49,490,056 26,081,388 174 94 0.24 -28
TG20481 M 6 8 NA 8.5 101 49,114,472 47 27,464,415 14,004,048 174 95 0.17 -28
TG49451 F 6 8 NA 8.2 101 38,306,698 49 34,533,973 18,140,114 177 92 0.27 -25
TG113632 F 6 8 NA 8.8 101 40,364,354 48 46,891,155 24,402,376 173 94 0.25 -29
P448
FastQC (pre-trim)BioAnalyzer  Picard toolsSAM tools
Tissue type:  Whole-blood,  Library kit: TruSeq Total RNA,  Sequencing Platform:  Illumina Hi-Seq 2000 paired end
Table B2. Pre-alignment QC metrics for the RNA-seq experiment
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Post-alignment QC
Sample Mapping rate Mapped reads Uniquely mapped rate rRNA rate Mapped pairs Exonic rate Intronic rate Intergenic rate Transcripts detected Genes detected End 1 Sense rate End 2 Sense rate Bottom 1000 trans Middle 1000 trans Top 1000 trans
TG98582 0.81 45,111,859 0.83 NA 21,945,422 0.43 0.51 0.06 129,169 24,871 0.04 0.96 6.66 19.56 664.24
TG104611 0.81 56,089,720 0.81 NA 27,244,722 0.45 0.50 0.05 132,871 25,593 0.03 0.97 8.65 25.50 932.57
TG17181 0.77 41,955,146 0.79 NA 20,399,968 0.49 0.45 0.06 126,175 23,697 0.04 0.96 6.93 20.13 899.12
TG46142 0.80 42,358,182 0.79 NA 20,655,130 0.45 0.50 0.05 126,109 23,730 0.03 0.97 6.12 17.70 681.71
TG129671 0.75 27,729,901 0.78 NA 13,523,807 0.50 0.46 0.05 120,002 21,749 0.03 0.97 4.42 12.69 559.56
TG78042 0.82 47,205,721 0.86 NA 22,952,125 0.43 0.51 0.06 129,539 24,746 0.04 0.96 7.49 22.98 831.98
TG236001 0.79 66,751,817 0.83 NA 32,435,507 0.42 0.51 0.07 134,540 27,121 0.05 0.95 9.76 27.85 1050.95
TG66562 0.76 54,437,633 0.78 NA 26,555,210 0.46 0.49 0.05 127,054 24,172 0.03 0.97 7.74 21.60 789.71
TG126551 0.76 50,309,706 0.77 NA 24,568,037 0.52 0.43 0.05 128,231 24,189 0.03 0.97 8.58 24.66 1013.09
TG20482 0.82 32,239,667 0.88 NA 15,723,282 0.43 0.53 0.05 120,869 22,073 0.03 0.97 4.95 14.83 583.03
TG74382 0.80 20,744,894 0.85 NA 10,097,335 0.45 0.50 0.05 115,095 20,453 0.03 0.97 3.22 9.64 376.07
TG200022 0.78 56,012,753 0.83 NA 27,227,507 0.44 0.51 0.05 129,577 24,790 0.03 0.97 8.31 24.30 945.17
TG66561 0.76 66,589,171 0.75 NA 32,438,036 0.48 0.48 0.05 130,346 25,093 0.03 0.97 9.65 26.91 969.87
TG19901 0.75 35,934,807 0.76 NA 17,513,795 0.51 0.45 0.04 123,612 22,721 0.03 0.97 5.76 16.44 636.76
TG15082 0.77 63,715,361 0.76 NA 31,009,689 0.49 0.47 0.05 129,363 24,873 0.04 0.96 9.72 26.64 1046.22
TG78041 0.80 39,357,468 0.81 NA 19,147,327 0.47 0.48 0.05 126,406 23,544 0.03 0.97 6.17 17.93 679.69
TG123521 0.81 50,290,725 0.84 NA 24,486,366 0.49 0.46 0.05 127,571 23,774 0.03 0.97 8.89 26.33 1036.50
TG129672 0.74 36,617,326 0.76 NA 17,875,914 0.53 0.43 0.05 123,540 22,787 0.03 0.97 6.08 16.89 755.91
TG139621 0.83 26,172,091 0.88 NA 12,725,463 0.46 0.49 0.05 120,886 21,757 0.03 0.97 4.56 14.27 576.83
TG236002 0.76 21,958,673 0.80 NA 10,714,290 0.47 0.48 0.05 115,397 20,559 0.03 0.97 3.36 9.39 388.58
TG36391 0.82 48,686,185 0.89 NA 23,663,079 0.37 0.57 0.05 130,005 24,955 0.03 0.97 6.38 18.85 595.41
TG139622 0.82 44,131,033 0.82 NA 21,474,115 0.47 0.48 0.05 127,203 23,863 0.04 0.96 7.17 21.72 797.54
TG126552 0.77 49,063,556 0.76 NA 23,948,540 0.50 0.45 0.05 128,811 24,380 0.03 0.97 7.95 22.98 925.20
TG17571 0.81 29,416,998 0.86 NA 14,345,323 0.42 0.53 0.05 123,058 22,613 0.03 0.97 4.25 12.57 443.26
TG113631 0.76 57,294,128 0.76 NA 27,925,833 0.48 0.47 0.05 129,423 24,676 0.03 0.97 8.69 24.41 913.41
TG74381 0.78 17,763,438 0.83 NA 8,653,772 0.48 0.47 0.05 112,167 19,661 0.03 0.97 2.88 8.36 350.65
TG48482 0.78 50,034,010 0.79 NA 24,021,264 0.46 0.47 0.07 127,279 23,880 0.05 0.95 7.82 22.77 955.80
TG15321 0.75 37,394,083 0.81 NA 18,219,296 0.50 0.46 0.04 126,142 23,376 0.03 0.97 6.29 17.68 679.98
TG98581 0.80 48,420,208 0.81 NA 23,577,863 0.50 0.45 0.05 128,620 24,244 0.03 0.97 8.30 25.18 973.50
TG15322 0.80 31,708,674 0.86 NA 15,441,240 0.46 0.50 0.05 123,261 22,625 0.03 0.97 5.12 15.28 583.24
TG78042-REP-L007 0.83 34,741,525 0.87 NA 16,914,326 0.43 0.51 0.06 125,586 23,282 0.04 0.96 5.59 17.14 657.05
TG200021 0.78 43,059,799 0.77 NA 21,004,072 0.50 0.45 0.05 125,670 23,476 0.04 0.96 6.80 19.32 778.91
TG15081 0.77 21,733,410 0.80 NA 10,558,615 0.49 0.46 0.06 116,325 20,604 0.04 0.96 3.65 10.28 526.62
TG49452 0.79 36,254,767 0.80 NA 17,715,144 0.48 0.48 0.05 123,674 22,823 0.03 0.97 5.54 15.52 651.67
TG48481 0.75 38,789,025 0.75 NA 18,928,949 0.55 0.40 0.04 123,779 22,603 0.03 0.97 6.96 19.88 852.43
TG29291 0.80 28,563,057 0.84 NA 13,936,309 0.43 0.52 0.05 122,045 22,300 0.03 0.97 4.25 12.28 498.50
TG104612 0.79 39,993,761 0.78 NA 19,485,725 0.54 0.41 0.05 127,071 23,469 0.03 0.97 7.66 22.83 1028.47
TG20481 0.79 22,310,813 0.85 NA 10,905,182 0.46 0.50 0.05 115,962 20,650 0.04 0.97 3.49 10.36 415.69
TG49451 0.74 26,181,761 0.75 NA 12,788,294 0.52 0.44 0.04 118,333 21,132 0.03 0.97 4.21 11.17 516.25
TG113632 0.76 36,554,530 0.76 NA 17,833,505 0.51 0.44 0.05 122,916 22,634 0.04 0.96 5.98 16.88 708.86
634,562
782,891
480,932
797,486
852,757
534,570
393,087
18,938,144
12,792,062
17,844,635
Strand specificity
990,208
20,455,305 953,256
20,660,140
700,831
1,382,179
940,060
961,973
964,360
823,121
1,163,737
827,539
616,356
1,394,006
405,950
1,172,714
718,400
1,079,363
717,170
Transcript- associated reads Detection rate
Aligned pairs
Tophat
1,170,289
673,991
554,918
542,476
18,240,204
1,062,753
600,967
1,264,876
820,312
531,903
1,127,163
1,642,945
828,937
1,049,177
23,963,315
31,017,290
21,008,837
26,560,779
22,963,577
16,919,179
21,952,196
1,345,115
1,008,272
23,586,084
15,448,460
10,561,615
17,719,234
10,719,330
23,668,951
21,479,863
27,948,074
8,658,985
27,245,890
32,449,078
17,520,012
19,154,673
24,493,115
17,883,910
12,729,291
Chimeric pairs
27,256,332
19,491,305
24,577,762
970,512
Mean per base coverageGeneral mapping metrics
RNASeQC
14,348,758
10,907,673
13,939,608
24,032,595
13,535,778
32,452,198
15,727,038
10,100,033
Tissue type:  Whole-blood,  Library kit: TruSeq Total RNA,  Sequencing Platform:  Illumina Hi-Seq 2000 paired endP448
Table B3. Post-alignment QC metrics for the RNA-seq experiment
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P448
Quantification metrics
Sample Gender Group Lane Total read pairs % Assigned Assigned Unassigned_Ambiguity Unassigned_MultiMapping Unassigned_NoFeatures Un_Unmapped Un_MappingQuality Un_FragmentLength Un_Chimera Un_Secondary Un_Nonjunction Un_Duplicate
TG98582 M 1 1 27,885,131      30.42 8483627 263900 5188667 12275050 0 0 0 1673887 0 0 0
TG104611 M 2 1 34,726,440      31.49 10936655 258053 6908990 14839809 0 0 0 1782933 0 0 0
TG17181 F 6 1 27,087,504      31.39 8502642 174640 6534529 10086755 0 0 0 1788938 0 0 0
TG46142 M 1 1 26,487,759      29.49 7812333 178601 5488708 11119687 0 0 0 1888430 0 0 0
TG129671 M 6 1 18,555,933      29.73 5516109 130571 5208871 6570580 0 0 0 1129802 0 0 0
TG78042-REP-L002 M 1 2 28,716,605      31.64 9085146 216593 4959553 12897096 0 0 0 1558217 0 0 0
TG236001 F 2 2 42,365,827      28.09 11901919 279783 9285755 18521980 0 0 0 2376390 0 0 0
TG66562 F 6 2 35,626,619      27.76 9890272 244793 9056743 13958244 0 0 0 2476567 0 0 0
TG126551 F 6 2 33,079,412      32.21 10655516 286766 8745843 11336909 0 0 0 2054378 0 0 0
TG20482 M 6 2 19,687,806      30.63 6029807 128095 3476910 8775271 0 0 0 1277723 0 0 0
TG74382 M 1 3 12,933,524      30.79 3982687 87155 2550755 5400178 0 0 0 912749 0 0 0
TG200022 F 2 3 35,918,375      28.80 10346251 233055 7995368 15105441 0 0 0 2238260 0 0 0
TG66561 F 6 3 43,977,425      28.39 12486471 298912 11693515 16513016 0 0 0 2985511 0 0 0
TG19901 F 6 3 23,939,732      29.64 7095952 143745 6655845 8391337 0 0 0 1652853 0 0 0
TG15082 F 6 3 41,128,005      30.66 12610416 252111 10060808 15572842 0 0 0 2631828 0 0 0
TG78041 M 1 4 24,635,925      31.31 7714509 181215 5049522 9919884 0 0 0 1770795 0 0 0
TG123521 F 2 4 30,898,665      35.27 10898004 239395 5700054 12122461 0 0 0 1938751 0 0 0
TG129672 M 6 4 24,663,640      30.87 7613898 167982 7282623 8170087 0 0 0 1429050 0 0 0
TG139621 M 2 4 15,659,443      34.45 5394501 118971 2451250 6812115 0 0 0 882606 0 0 0
TG236002 F 2 4 14,485,972      28.08 4067010 81970 3855341 5482933 0 0 0 998718 0 0 0
TG36391 M 1 5 29,577,690      26.72 7903371 178488 4842827 14659909 0 0 0 1993095 0 0 0
TG139622 M 2 5 26,766,868      34.55 9247696 191219 4474314 11241208 0 0 0 1612431 0 0 0
TG126552 F 6 5 31,965,976      32.20 10291765 246839 8129431 11525726 0 0 0 1772215 0 0 0
TG17571 M 6 5 18,184,989      28.90 5255336 120125 3508756 8195230 0 0 0 1105542 0 0 0
TG113631 F 6 5 37,401,457      30.31 11337856 264082 9236701 13962682 0 0 0 2600136 0 0 0
TG74381 M 1 6 11,445,557      30.62 3504379 82971 2747279 4375774 0 0 0 735154 0 0 0
TG48482 M 2 6 32,096,674      29.66 9520833 193845 6994254 13416755 0 0 0 1970987 0 0 0
TG15321 M 6 6 24,747,651      30.82 7627412 192827 6605054 8889592 0 0 0 1432766 0 0 0
TG98581 M 1 6 30,331,007      34.14 10356458 227732 6209643 11546047 0 0 0 1991127 0 0 0
TG15322 M 6 6 19,813,594      31.79 6299534 141152 4034740 8145458 0 0 0 1192710 0 0 0
TG78042-REP-L007 M 1 7 21,015,761      31.91 6705590 159170 3571993 9440885 0 0 0 1138123 0 0 0
TG200021 F 2 7 27,606,108      31.27 8633522 197096 6548658 10229714 0 0 0 1997118 0 0 0
TG15081 F 6 7 14,040,673      30.36 4262068 90706 3477579 5357849 0 0 0 852471 0 0 0
TG49452 F 6 7 23,060,658      30.90 7126214 151488 5298223 8995135 0 0 0 1489598 0 0 0
TG48481 M 2 7 25,741,520      33.41 8599981 168999 7122870 8142306 0 0 0 1707364 0 0 0
TG29291 M 1 8 17,882,945      28.78 5146543 125823 3794995 7807635 0 0 0 1007949 0 0 0
TG104612 M 2 8 25,355,530      36.10 9152575 224402 5759987 8636698 0 0 0 1581868 0 0 0
TG20481 M 6 8 14,028,781      30.61 4293535 102843 3083137 5785075 0 0 0 764191 0 0 0
TG49451 F 6 8 17,654,003      29.01 5120946 112125 5235561 5953729 0 0 0 1231642 0 0 0
TG113632 F 6 8 23,986,032      31.74 7613077 190212 6373054 8364232 0 0 0 1445457 0 0 0
Grouping variable Av read pairs Av % assigned
Lane 1 26,948,553      30.51  
Lane 2 31,895,254      30.07  
Lane 3 31,579,412      29.66  
Lane 4 22,068,729      32.00  
Lane 5 28,779,396      30.54  
Lane 6 23,686,897      31.41  
Lane 7 22,292,944      31.57  
Table B4. Post-quantification QC metrics for the RNA-seq experiment
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1 #!/bin/sh
2 #################################################################################
3 #script to run a fastqc batch job on a set of fastqc.gz files
4 #
5 #fastq files either need to be in input, or you need to create symbolic links
6 #in the input directory that point to where they are stored
7 #################################################################################
8 #input : ../input/*fastq.gz
9 #output : fastqc.zip containing fastqc output
10 #################################################################################
11
12 FILES=`find -L ../input/ -name "*.fastq.gz"`
13 echo $FILES
14
15 #make sure files exist before running the rest of commands
16 if [ "${FILES}" -eq 0 ]; then echo "no fastq.gz files found!"; exit 0; fi
17
18 mkdir ../output/FastQC
19
20 #don't unzip files, use 4 cores to process simultaneously
21 fastqc -o ../output/FastQC --noextract --threads=4 $FILES
22 #################################################################################
Figure B1. Bash scripts for RNA-seq analysis pipeline
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1 #!/bin/sh
2 ##################################################################################
3 #this script will remove illumina truseq adaptors from paired end reads
4 #and trim low quality reads (phred <20) from the ends of reads
5 #
6 #files should be named following this convention:
7 #name_tag_lanenumber_R1_replication.fastq.gz
8 #
9 #for more than one sample, run qsub with -t 1-n,
10 #where n is number of samples sequenced, to submit as an array job
11 ##################################################################################
12 #input: ../input/*.fastq.gz
13 #output: ../input/*_trimmed.fastq.gz
14 ##################################################################################
15 #find the files, set up input and output names
16 find -L ../input/ -name "*_R1_*.fastq.gz"| sort -d -o ../input/cutadapt_file_list.txt
17 #make sure files exist before running the rest of commands
18 FILES=`cat ../input/cutadapt_file_list.txt | wc -l`
19 if [ "${FILES}" -eq 0 ]; then echo "no fastq.gz files found!"; exit 0; fi
20 echo "multiple tasks submitted"
21 TASKS=`cat ../input/cutadapt_file_list.txt | wc -l`
22 TASKS=$((${TASKS} + 1))
23 for (( NUM=1; NUM<${TASKS}; NUM++ ))
24 do
25 sedcommand="${NUM}p"
26 R1FN=`cat ../input/cutadapt_file_list.txt | sed -n "$sedcommand"`
27 R1BN=`basename "${R1FN}"`
28 R2REGEX="`echo $R1BN | cut -d'_' -f1`""*""_R2_""`echo $R1BN | cut -d'_' -f5`"
29 R2FN=`find -L ../input/ -name $R2REGEX`
30 R2BN=`basename "${R2FN}"`
31 R1OUTPUT="../input/""`echo $R1BN | cut -d'.' -f1`""_trimmed"".fastq.gz"
32 R2OUTPUT="../input/""`echo $R2BN | cut -d'.' -f1`""_trimmed"".fastq.gz"
33 TMP1="${SGE_TASK_ID}""_""tmp1.fastq.gz"
34 TMP2="${SGE_TASK_ID}""_""tmp2.fastq.gz"
35
36 echo -e "task ID: ""${SGE_TASK_ID}\n""read 1 input: ""${R1FN}\n""read 2 input:
""${R2FN}\n"\↪
37 "read 1 temp: ""${TMP1}\n""read 2 temp: ""${TMP2}\n"\
38 "read 1 output: ""${R1OUTPUT}\n""read 2 output: ""${R2OUTPUT}\n"
39
40 ADPTFW="AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC"
41 ADPTREV="AGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTATCATT"
42
43 cutadapt -a "${ADPTFW}" --minimum-length 20 --quality-cutoff=20 \
44 --paired-output "${TMP2}" -o "${TMP1}" "${R1FN}" "${R2FN}"
45 cutadapt -a "${ADPTREV}" --minimum-length 20 --quality-cutoff=20 \
46 --paired-output "${R1OUTPUT}" -o "${R2OUTPUT}" "${TMP2}" "${TMP1}"
47
48 rm *tmp1.fastq.gz *tmp2.fastq.gz
49 done
50 #################################################################################
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1 #!/bin/sh
2 ########################################################################################
3 #script to run a fastqc batch job on a set of fastqc.gz files
4 #
5 #if fastq files are stored anywhere other than input, create symbolic links in the input
directory↪
6 ########################################################################################
7 #input : ../input/*trimmed_fastq.gz
8 #output : fastqc.zip containing fastqc output
9 #######################################################################################
10
11 FILES=`find -L ../input/ -name "*_trimmed.fastq.gz"`
12 echo $FILES
13
14 #make sure files exist before running the rest of commands
15 if [ "${FILES}" -eq 0 ]; then echo "no trimmed_fastq.gz files found!"; exit 0; fi
16
17 mkdir ../output/trimmed_FastQC
18
19 #don't unzip files, use 4 threads in parallel
20 fastqc -o ../output/trimmed_FastQC --noextract --threads=4 $FILES
21 #################################################################################
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1 #!/bin/sh
2 #$ -cwd
3 #$ -j y
4 #$ -N bwa_align
5 #$ -S /bin/sh
6 #$ -M asaffa01@mail.bbk.ac.uk
7 #$ -m bea
8 #$ -pe mpi 8
9 #####################################################################
10 #script to align subset of reads to transcriptome using bwa
11 #####################################################################
12 export PATH="$SGE_O_PATH"
13
14 FILES=`cat ../input/bwa_file_list.txt | wc -l`
15 if [ "${FILES}" -eq 0 ]; then echo "no fastq files found"; exit 0; fi
16
17 mkdir ../output/bwa
18
19 if [ "${SGE_TASK_ID}" != "undefined" ]; then
20 echo "multiple tasks submitted"
21 sedcommand="${SGE_TASK_ID}p"
22 R1FN=`cat ../input/bwa_file_list.txt | sed -n "$sedcommand"`
23 R1BN=`basename "${R1FN}"`
24 R2REGEX="`echo "${R1BN}" | \
25 cut -d'_' -f1,2,3`""_R2_""`echo "${R1BN}" | cut -d'_' -f5,6`"
26 R2FN=`find -L ../input/ -name "${R2REGEX}"`
27 OUTPUTFN="../output/""bwa/""`echo "${R1BN}" | \
28 cut -d'_' -f1,2,3,5`""_""${SGE_TASK_ID}""_hits.sam.gz"
29 TEMPFN1="/scratch/""${SGE_TASK_ID}""_tmp1.fastq"
30 TEMPFN2="/scratch/""${SGE_TASK_ID}""_tmp2.fastq"
31 > "${TEMPFN1}"
32 > "${TEMPFN2}"
33 zcat "${R1FN}" | head -n4000000 > "${TEMPFN1}"
34 zcat "${R2FN}" | head -n4000000 > "${TEMPFN2}"
35 else
36 echo "single task submitted"
37 R1FN=`head -n1 ../input/bwa_file_list.txt`
38 R1BN=`basename "${R1FN}"`
39 R2REGEX="`echo "${R1BN}" | \
40 cut -d'_' -f1,2,3`""_R2_""`echo "${R1BN}" | cut -d'_' -f5,6`"
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1 R2FN=`find -L ../input/ -name "${R2REGEX}"`
2 OUTPUTFN="../output/""bwa/""`echo "${R1BN}" | \
3 cut -d'_' -f1,2,3,5`""_hits.sam.gz"
4 TEMPFN1="/scratch/tmp1.fastq"
5 TEMPFN2="/scratch/tmp2.fastq"
6 > "${TEMPFN1}"
7 > "${TEMPFN2}"
8 zcat "${R1FN}" | head -n4000000 > "${TEMPFN1}"
9 zcat "${R2FN}" | head -n4000000 > "${TEMPFN2}"
10 fi
11
12 echo -e "task ID: ""${SGE_TASK_ID}\n""read 1 input: ""${R1FN}\n""read 2 input:
""${R2FN}\n"\↪
13 "output file: ""${OUTPUTFN}\n""temp 1: ""${TEMPFN1}\n""temp 2: ""${TEMPFN2}\n"
14
15 ~/apps/bwa-0.7.10/bwa mem -t 8 -M -v 3 ../genome/hg19_transcriptome/mrna.fa.gz \
16 "${TEMPFN1}" "${TEMPFN2}" | gzip -3 > "${OUTPUTFN}"
17 #################################################################################
1 #!/bin/bash
2 #####################################################################
3 #script to make tophat bowtie indexes
4 #####################################################################
5
6 echo "making tophat bowtie indexes:"
7 tophat -G ../genome/Homo_sapiens/UCSC/hg19/Annotation/Genes/genes.gtf \
8 --transcriptome-index=../genome/transcriptome_index \
9 ../genome/Homo_sapiens/UCSC/hg19/Sequence/Bowtie2Index/genome
10 #####################################################################
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1 #!/bin/sh
2 ##########################################################################################
3 #script to run a tophat array job on a set of fastqc.gz files
4 #
5 #fastqs should be in input folder, if data is stored elsewhere,
6 #need to have symbolic links in the input folder
7 ##########################################################################################
8 #input : ../input/*_trimmed.fastq.gz
9 #output : tophat/accepted_hits.bam among others
10 ##########################################################################################
11
12 #find the files, set up input and output names
13 find -L ../input/ -name "*R1_*_trimmed.fastq.gz" | sort -d -o ../input/tophat_file_list.txt
14 #make sure files exist before running the rest of commands
15 FILES=`cat ../input/tophat_file_list.txt | wc -l`
16 if [ "${FILES}" -eq 0 ]; then echo "no fastq files found"; exit 0; fi
17
18 echo "multiple tasks submitted"
19 TASKS=`cat ../input/tophat_file_list.txt | wc -l`
20 TASKS=$((${TASKS} + 1))
21 for (( NUM=1; NUM<${TASKS}; NUM++ ))
22 do
23 sedcommand="${NUM}p"
24 R1FN=`cat ../input/tophat_file_list.txt | sed -n "$sedcommand"`
25 R1BN=`basename $R1FN`
26 R2REGEX="`echo "${R1BN}" | cut -d'_' -f1,2,3`""_R2_""`echo "${R1BN}" | cut -d'_' -f5,6`"
27 R2FN=`find -L ../input/ -name $R2REGEX`
28 OUTPUTFN="../output/""tophat_""`echo "${R1BN}" | cut -d'_' -f1,2,3,5`""_""${NUM}"
29
30 echo -e "task ID: ""${TASKS}\n""read 1 input: ""${R1FN}\n""read 2 input:
""${R2FN}\n""output file: ""${OUTPUTFN}\n"↪
31
32 # tophat parameters
33 # p is number of threads to use - leave this as 8
34 # g is number of multihits allowed
35 # r is expected inner distance between mate pairs: r = library fragment size - (2 * read
length)↪
36 # segment length = 0.5 * read length
37 # library type is fr-unstranded for standard illumina platforms
38 # G is the reference genome annotation to use
39 # o is output file
40 # need to provide location of bowtie indexes
41 # need to provide input fastq file
42 tophat -p 4 -r -10 --mate-std-dev 50 --library-type fr-firststrand -o "${OUTPUTFN}" \
43 --transcriptome-index=../genome/transcriptome_index \
44 ../genome/Homo_sapiens/UCSC/hg19/Sequence/Bowtie2Index/genome "${R1FN}" "${R2FN}"
45 echo "${OUTPUTFN}" >> ../output/cufflinks_file_list.txt
46 sort ../output/cufflinks_file_list.txt -d -o ../output/cufflinks_file_list.txt
47 done
48 #####################################################################
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1 #!/bin/sh
2 #$ -cwd
3 #$ -j y
4 #$ -N picard_tools_insert_size.sh
5 #$ -S /bin/sh
6 #$ -M asaffa01@mail.bbk.ac.uk
7 #$ -m bea
8 #####################################################################
9 #script to get insert size metrics for bwa alignment
10 #####################################################################
11 export PATH="$SGE_O_PATH"
12
13 find -L ../output/bwa/ -name "*hits.sam.gz" | sort -d -o ../output/bwa/picard_file_list.txt
14 FILES=`cat ../output/bwa/picard_file_list.txt | wc -l`
15 if [ "${FILES}" -eq 0 ]; then echo "no sam files found"; exit 0; fi
16
17 if [ "${SGE_TASK_ID}" != "undefined" ]; then
18 echo "multiple tasks submitted"
19 sedcommand="${SGE_TASK_ID}p"
20 R1FN=`cat ../output/bwa/picard_file_list.txt | sed -n "$sedcommand"`
21 else
22 echo "single task submitted"
23 R1FN=`head -n1 ../output/bwa/picard_file_list.txt`
24 fi
25
26 R1BN=`basename "${R1FN}"`
27 OUTPUTFN="../output/""bwa/""`echo "${R1BN}" | cut -d'.' -f1`"".sorted.sam.gz"
28 METRICS="../output/""bwa/""`echo "${R1BN}" | cut -d'.'
-f1`""_collect_insert_size_metrics"".txt"↪
29 HISTO="../output/""bwa/""`echo "${R1BN}" | cut -d'.'
-f1`""_collect_insert_size_metrics"".hist"↪
30
31 echo -e "task ID: ""${SGE_TASK_ID}\n""sam input: ""${R1FN}\n""sam output: ""${OUTPUTFN}\n"
32
33 java -Xmx2g -jar /home/saffaria/apps/picard-tools-1.124/picard.jar SortSam INPUT="${R1FN}"
OUTPUT="${OUTPUTFN}" SORT_ORDER=coordinate↪
34 java -Xmx2g -jar /home/saffaria/apps/picard-tools-1.124/picard.jar
CollectInsertSizeMetrics INPUT="${OUTPUTFN}" OUTPUT="${METRICS}"
HISTOGRAM_FILE="${HISTO}"
↪↪
35 #####################################################################
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1 #!/bin/sh
2 #####################################################################
3 #script to run post-alignment QC
4 #####################################################################
5 find ../output/ -name "accepted_hits.bam" | sort -d -o ../output/tophat_alignments.txt
6 FILES=`cat ../output/tophat_alignments.txt | wc -l`
7 if [ "${FILES}" -eq 0 ]; then echo "no files found"; exit 0; fi
8
9 echo "multiple tasks submitted"
10 TASKS=`cat ../output/tophat_alignments.txt | wc -l`
11 TASKS=$((${TASKS} + 1))
12 for (( NUM=1; NUM<${TASKS}; NUM++ ))
13 do
14 sedcommand="${NUM}p"
15 R1FN=`cat ../output/tophat_alignments.txt | sed -n "$sedcommand"`
16
17 #set up filenames and directories
18 PICARDREOOUT="..""`echo "${R1FN}"| cut -d'.' -f3`""_reordered.bam"
19 PICARDRGOUT="..""`echo "${R1FN}"| cut -d'.' -f3`""_reordered_rg.bam"
20 PICARDDUPOUT="..""`echo "${R1FN}"| cut -d'.' -f3`""_reo_rg_mkdups.bam"
21 SORTSAMOUT="..""`echo "${R1FN}"| cut -d'.' -f3`""_reo_rg_mkdups.bam.bai"
22 OUTPUTDIR="`dirname "${R1FN}"`""/"
23 mkdir "${OUTPUTDIR}"samtools/
24 mkdir "${OUTPUTDIR}"picard/
25 mkdir "${OUTPUTDIR}"RNA-SeQC/
26
27 echo -e "task ID: ""${NUM}\n""bam input: ""${R1FN}\n" \
28 "reordered sam: ""${R1OUTFN}\n""outputdir: ""${OUTPUTDIR}\n" \
29 "picard mark dups: ""${PICARDDUPOUT}"
30
31 #add read groups to SAM for benefit of picardtools and RNA-SeQC
32 SAMPLE=`echo "${R1FN}" | cut -d '/' -f3 | cut -d '_' -f2`
33 LANE=`echo "${R1FN}" | cut -d '/' -f3 | cut -d '_' -f4`
34 BARCODE=`echo "${R1FN}" | cut -d '/' -f3 | cut -d '_' -f3`
35 RGID="P410-C5RWMACXX.""${LANE}"
36 RGLB="TRUSEQ_dUTP_P410"
37 RGPL="ILLUMINA"
38 RGPU="C5RWMACXX-""${BARCODE}.""${LANE}"
39
40 echo -e "${RGID} \n""${SAMPLE} \n""${RGLB} \n""${RGPL} \n""${RGPU} \n"
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1 java -jar ~/apps/picard-tools-1.124/picard.jar AddOrReplaceReadGroups INPUT="${R1FN}" \
2 OUTPUT="${PICARDRGOUT}" RGID="${RGID}" RGSM="${SAMPLE}" RGLB="${RGLB}" RGPL="${RGPL}"
RGPU="${RGPU}"↪
3
4 #reorder SAM for benefit of picardtools and RNA-SeQC
5 java -jar ~/apps/picard-tools-1.124/picard.jar ReorderSam INPUT="${PICARDRGOUT}" \
6 OUTPUT="${PICARDREOOUT}" VALIDATION_STRINGENCY=LENIENT \
7 REFERENCE=../genome/Homo_sapiens/UCSC/hg19/Sequence/WholeGenomeFasta/genome.fa
CREATE_INDEX=false↪
8
9 #mark duplicates - also required for RNA-SeQC to run
10 java -jar ~/apps/picard-tools-1.124/picard.jar MarkDuplicates INPUT="${PICARDREOOUT}" \
11 OUTPUT="${PICARDDUPOUT}" METRICS_FILE="${OUTPUTDIR}"picard/dup_metrics.txt \
12 REMOVE_DUPLICATES=false
13
14 #index SAM file - required for RNA-SeQC
15 samtools index "${PICARDDUPOUT}" "${PICARDDUPOUT}".bai
16
17 #remove intermediate BAM files
18 rm "$PICARDREOOUT" "$PICARDRGOUT"
19
20 #multiple metrics
21 java -jar ~/apps/picard-tools-1.124/picard.jar CollectMultipleMetrics
INPUT="${PICARDDUPOUT}" \↪
22 REFERENCE_SEQUENCE=../genome/Homo_sapiens/UCSC/hg19/Sequence/WholeGenomeFasta/genome.fa \
23 OUTPUT="${OUTPUTDIR}"picard/picard
24
25 #RNA-SeQC
26
27 #create sequence dictionary for genome fasta- required
28 java -jar ~/apps/picard-tools-1.124/picard.jar CreateSequenceDictionary \
29 REFERENCE=../genome/Homo_sapiens/UCSC/hg19/Sequence/WholeGenomeFasta/genome.fa \
30 OUTPUT=../genome/hg19_sequence_dictionary.bam
31
32 #index genome fasta
33 if [ "${NUM}" -eq 1 ];then samtools faidx
../genome/Homo_sapiens/UCSC/hg19/Sequence/WholeGenomeFasta/genome.fa;fi↪
34 java -Xmx2g -jar ~/apps/RNA-SeQC_v1.1.8.jar \
35 -n 1000 -o "${OUTPUTDIR}"RNA-SeQC/ -r
../genome/Homo_sapiens/UCSC/hg19/Sequence/WholeGenomeFasta/genome.fa \↪
36 -s ""${SGE_TASK_ID}"|"${PICARDDUPOUT}"|1" -t
../genome/Homo_sapiens/UCSC/hg19/Annotation/Genes/genes.gtf \↪
37 -BWArRNA ../genome/human_all_rRNA.fasta
38 done
39 #####################################################################
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1 #! bin/sh
2 #$ -cwd
3 #$ -j y
4 #$ -N htseq_make_count_table.sh
5 #$ -S /bin/sh
6 #$ -M asaffa01@mail.bbk.ac.uk
7 #$ -m bea
8 #####################################################################
9 #script to quantify seq counts
10 #####################################################################
11 export PATH="$SGE_O_PATH"
12
13 if [ "${SGE_TASK_ID}" != "undefined" ]; then
14 echo "multiple tasks submitted"
15 sedcommand="${SGE_TASK_ID}p"
16 R1FN=`cat ../output/sam_name_sort.txt | sed -n "$sedcommand"`
17 else
18 echo "single task submitted"
19 R1FN=`head -n1 ../output/sam_name_sort.txt`
20 fi
21
22 R1OUTFN="..""`echo "${R1FN}"| cut -d'.' -f3`""_nsort"
23 OUTPUTDIR="`dirname "${R1FN}"`""/"
24
25 echo -e "task ID: ""${SGE_TASK_ID}\n""bam input: ""${R1FN}\n""reordered sam:
""${R1OUTFN}\n""outputdir: "↪
26 "${OUTPUTDIR}"
27
28 #sort sam by read name for HTSeq
29 samtools sort -n -m 1000000000 "${R1FN}" "${R1OUTFN}"
30
31 #run HTSeq to generate gene count table
32 samtools view -h "${R1OUTFN}".bam | \
33 python -m HTSeq.scripts.count --stranded=reverse - ../genome/transcriptome_index.gff > \
34 "${R1OUTFN}"_rev.count
35 #####################################################################
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Comparison Model limma voom edgeR DESeq2
Case-control y ~ pair + case 1 0 55
Group 2 y ~ pair + case 0 3 28
Gender y ~ gender 156 280 287
Group 6 (mock) y ~ mock_case 1 5 0
Comparison Model limma voom edgeR DESeq2
Case-control y ~ pair + case 1 0 75
Group 2 y ~ pair + case 0 3 48
Gender y ~ gender 290 430 1028
Group 6 (mock) y ~ mock_case 2 5 0
Comparison Model limma voom edgeR DESeq2
Case-control y ~ pair + case 1 3 205
Group 2 y ~ pair + case 0 6 52
Gender y ~ gender 549 995 2176
Group 6 (mock) y ~ mock_case 2 6 0
Number of DE genes at FDR < 0.2
 Number of DE genes called
Number of DE genes at FDR < 0.05
Number of DE genes at FDR < 0.1
Table B5. Comparison of differential expression analysis methods for RNA-seq - for each
regression model and for each method, the number of genes called as DE for a range of
FDR thresholds is given
Proportion of expected DE genes
Comparison Model limma voom edgeR DESeq2 limma voom edgeR DESeq2
Case-control y ~ pair + case 0.83 0.88 0.82 3036 2226 3219
Group 2 y ~ pair + case 0.85 0.92 1 2520 1446 <1
Gender y ~ gender 0.89 0.84 0.84 1889 2803 2859
Group 6 (mock) y ~ mock_case 1 1 1 <1 <1 <1
Sensitivity and specifcity
 
Comparison Model limma voom edgeR DESeq2 limma voom edgeR DESeq2
Gender y ~ gender 0.1 0.58 0.53 0.99 0.99 0.99
Comparison Model limma voom edgeR DESeq2 limma voom edgeR DESeq2
Gender y ~ gender 1.04 2.14 2.05 2.33E-13 2.20E-16 2.20E-16
log(DOR) Fisher's exact p
Expected number of DE genes Proportion of expected true nulls (pi0)
Sensitivity  Specificity 
Table B6. Comparison of differential expression analysis methods for RNA-seq - sensitiv-
ity and specificity of the different methods for the male-female contrast, comparing genes
called as DE with those previously known to display gender differences.
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Figure B2. Comparison of differential expression analysis methods for RNA-seq - overlap
between the top 900 most significantly differentially expressed genes for the three different
methods for the case-control, group 2, and gender contrasts.
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Figure B3. Distribution of CAST scores across the entire sample, along with distributions
for Van Der Waerden transformed CAST scores and Z transformed CAST scores.
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C Chapter 4
1 print """
2 #/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/
3 # Permutation analysis of methylation data:
4 # 1. Permutation procedure
5 #^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
6 # author. Ayden Saffari <asaffa01@mail.bbk.ac.uk>
7 # affiliations. Birkbeck, University of London,
8 # London School of Hygiene and Tropical Medicine
9 #^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
10 # description: randomly permutes phenotypes of subjects, performs t-tests, and records max
11 # t stat value obtained for each probe over all the perms
12 #
13 # prerequisites: Python 2.7 + necessary libraries (see below)
14 #
15 # notes: colnames (subjects) in methylation data must follow this naming convention:
16 # [experimental_group]_[some other identifier]_[affected or unaffected
status]↪
17 # eg. 2_TP3_A and 2_TP3_U.
18 #
19 # input args: 1 = processor cores, 2 = permutations per thread (needs to be divisible
20 # by n cores), 3 = input methylation data (.csv)
21 # 4 = experimental groups to use in analysis (0 for all
subjects),↪
22 # 5 = related samples (not implemented, set to 0),
23 # 6 = equal variance (not implemented, set to 1),
24 # 7 = number of permutations to generate
25 # 8 = output file (.h5)
26 #
27 # output: hdf table of results, containing the p-values for each probe (rows) for each↪
28 # permutation (columns) and the minimum p.
29 #
30 #/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/
31 """
32 import sys
33 import os
34 import subprocess
35 import argparse
36 import gc
37 import gzip
38 import time
39 import math
40 import random
Figure C1. Python code for permutations generating procedure
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1 import re
2 import pdb
3 import itertools as itperm
4 import multiprocessing as multipro
5 import logging
6
7 import numpy as np
8 import pandas as pd
9 from scipy import stats as sp
10 import tables
11 import IPython
12
13 #########################
14 # load methylation data #
15 #########################
16
17 def load_data(s):
18 file_name = s
19
20 try:
21 in_data = open(file_name)
22 except IOError as e:
23 logger.error("I/O error({0}): {1}".format(e.errno, e.strerror))
24
25 pd.options.display.max_columns = 101
26 #load dataframe
27 meth_data = pd.DataFrame.from_csv(in_data, sep = ',', header = 0)
28 in_data.close()
29 logger.info("Dataframe dimensions: %i rows by %i columns" %(
30 len(meth_data.index),len(meth_data.columns)))
31
32 meth_data_redux = meth_data
33 #sort by column label to arrange subjects by pair and phenotype
34 meth_data_redux = meth_data_redux.sort_index(axis = 1)
35
36 return meth_data_redux
37
38 ##########################################
39 # select experimental group for analysis #
40 ##########################################
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1 #groups are numbered, all for case/control using all subjects
2
3 def sel_group(s, df):
4 inp = s
5 group = inp.split(",")
6
7 if (group[0] == "all"):
8 meth_data_redux_group = df
9 else:
10 #filter according to selected group(s)
11 regex = ""
12 for idx, item in enumerate(group):
13 regex += "\A%s_TP*" %(item)
14 if idx < len(group) - 1 :
15 regex += "|"
16 meth_data_redux_group = df.filter(regex = regex)
17
18 #store size of selected group
19 n = len(meth_data_redux_group.columns)
20 #if group wasn't found in table or has odd number of subjects
21 if (n == 0):
22 try:
23 raise ValueError
24 except ValueError:
25 print "Error: No subjects specified"
26 raise
27
28 #add row for phenotypic/case-control status
29 case_control = np.empty([(n)], dtype=int)
30 for idx, col in enumerate(meth_data_redux_group.columns):
31 if re.match('.*_A$', col):
32 case_control[idx] = 1
33 elif re.match('.*_U$', col):
34 case_control[idx] = 0
35 meth_data_redux_group.loc["case-control",:] = case_control
36 logger.info(meth_data_redux_group.loc["case-control",:])
37 logger.info("Dataframe dimensions: %i rows by %i columns" %(
38 len(meth_data_redux_group.index), len(meth_data_redux_group.columns)))
39 return (meth_data_redux_group)
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1 ###############################
2 # randomly permute phenotypes #
3 ###############################
4
5 #recursive function to unpack list of tuples into flat list
6 #(no longer required)
7 def unpack(a, b):
8 if type(a) is not tuple:
9 b.append(a)
10 else:
11 for i in range(0,len(a)):
12 unpack(a[i], b)
13
14 #function for randomly permuting case-control labels
15 def rand_perm(i, df, rel):
16 nperms = i
17
18 #data paired (related samples) -> shuffle labelling within pairs
19 if rel == True:
20 #labels = list(df.ix["case-control", 0:2])
21 labels = [1,0]
22 n_labels = len(list(df.loc["case-control", :]))
23 all_perms = []
24 for i in range(0,int(nperms)):
25 temp_perm = []
26 for i in range(0, n_labels / 2):
27 random.shuffle(labels)
28 temp_perm = temp_perm + labels
29 all_perms.append([bool(item) for item in temp_perm])
30
31 #unpaired -> randomly assign labels by individual
32 elif rel == False:
33 labels = list(df.loc["case-control", :])
34 all_perms = []
35 for i in range(0, int(nperms)):
36 random.shuffle(labels)
37 all_perms.append([bool(item) for item in labels])
38
39 #output
40 unique = [list(x) for x in
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1 set(tuple(x) for x in all_perms)]
2 logger.info("%i random permutations performed, of which %i are unique" %(
3 int(nperms), len(unique)))
4 return all_perms
5
6 #debug - the zeroth permutation is fixed to use the true phenotypes
7 def add_orig_pheno(df, pm):
8 real_pheno = df.loc["case-control", :]
9 temp = [bool(item) for item in real_pheno]
10 pm[0] = temp
11 df.loc["case-control", :] = pm[0]
12 return df
13
14 ####################################
15 # perform t-test for permuted data #
16 ####################################
17
18 #select type of t-test to be performed
19 def ttest_selector(rel, var):
20 if rel == True:
21 t = "sp.ttest_rel(cases,controls,0)"
22 else:
23 t = "sp.ttest_ind(cases,controls,0,{})".format(var)
24 return t
25
26 #perform for every probe in every permutation
27 def mp_ttest_probes_in_perm(t):
28 start = time.time()
29 len_df = len(mp_meth_matrix)
30 pval = list()
31
32 for perm in t:
33 tup_p = tuple(perm)
34 #ttest diff methylation for each probe, return vector of p-vals
35 for m in xrange(0,(len_df - 1)):
36 #get shuffled cases and controls from df
37 #controls are those that have a 0 in the case-control row
38 #select cases by taking remaining subjects
39 bool_sel = np.array(perm)
40 controls = mp_meth_matrix[m, bool_sel]
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1 cases = mp_meth_matrix[m, ~bool_sel]
2 #perform ttest
3 res = sp.ttest_ind(cases,controls,0)
4 #add to complete list of p-vals
5 pval.append(abs(res[0]))
6
7 logger.info('%s: finished' %(multipro.current_process().name))
8 #print time-taken
9 elapsed = time.time() - start
10 m,s = divmod(elapsed, 60)
11 h,m = divmod(m, 60)
12 logger.info("mp_ttest_probes_in_perm_unp: time taken: %d:%02d:%02d" %(h, m, s))
13 #return complete list of p-vals (for all perms and all probes for this worker)
14 logger.warn('Free memory after worker finished: {m} MB'.format(
15 m = free_memory()))
16 return pval
17
18 ######################################
19 # set up multiprocessing environment #
20 ######################################
21
22 # set up worker pool
23 def mp_worker_pool(d, n):
24 len_d = len(d)
25 quo_task_div, rem_task_div = divmod(len_d, n)
26 task_list = list()
27 start_it = 0
28
29 for i in xrange(0, n):
30 if i < rem_task_div:
31 inc_it = quo_task_div
32 else:
33 inc_it = (quo_task_div - 1)
34 task_list.append(d[start_it:(start_it + inc_it + 1)])
35 start_it += inc_it + 1
36
37 return task_list
38
39 def mp_main(ts, n):
40 start = time.time()
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1 #number of processors
2 num_proc = n
3 mp_pool = multipro.Pool(num_proc)
4
5 p_results = list()
6 pool_arr = mp_pool.map(mp_ttest_probes_in_perm, ts)
7 p_results.append(pool_arr)
8
9 mp_pool.close()
10 mp_pool.join()
11
12 #print time-taken
13 elapsed = time.time() - start
14 m,s = divmod(elapsed, 60)
15 h,m = divmod(m, 60)
16 logger.info("mp_main: time taken: %d:%02d:%02d \n" %(h, m, s))
17 return p_results
18
19 ##################
20 # write results #
21 #################
22
23 def write_file(s):
24 #global pvals_tab
25 global store
26 #open file for writing
27 file_name = s
28 file_out = open(file_name, 'a')
29 #write to file
30 store = pd.HDFStore(file_out.name)
31 file_out.close()
32
33 def mp_write_results(r, c, n):
34 #get individual results back from pooled results
35 start = time.time()
36
37 #num probes
38 len_r = len(r)
39 #init results table, get col names and add column for min p val
40 names = np.append([r[0:(len_r - 1)]],["max_t_val"])
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1 global pvals_tab
2 pvals_tab = pd.DataFrame(np.zeros((len_r, c),dtype='float32'))
3 pvals_tab.index = names
4
5 #counter for perms
6 count_p = -1
7 #for each set of results from each worker
8 for result in p_results:
9 #for each of the lists of results
10 #(multiple permutation tests all flattened together)
11 for j in xrange(0, len(result)):
12 pval_temp = pd.DataFrame(np.zeros((len_r, c / n),dtype='float32'))
13 pval_temp.index = names
14 #separate into individual perms and store as cols in results table
15 for i in xrange(0,len(result[j]),(len_r - 1)):
16 count_p += 1
17 #store row
18 temp_row = result[j][i:(i + len_r - 1)]
19 #get minimum for row
20 min_row = max(result[j][i:(i + len_r - 1)])
21 temp_row.append(min_row)
22 pval_temp.ix[:,count_p] = temp_row
23
24 #write to csv
25 start_col = j * (c/n)
26 end_col = j * (c/n) + (c/n)
27 pvals_tab.ix[:, start_col : end_col] = pval_temp
28
29 #print time-taken
30 elapsed = time.time() - start
31 m,s = divmod(elapsed,60)
32 h,m = divmod(m,60)
33 logger.info("WriteResults: time taken: %d:%02d:%02d \n" %(h,m,s))
34
35 def main():
36 #these variables global so that each subprocess can share same memory
37 global mp_meth_matrix, all_perms, ttest, cols, p_results, pvals_tab, store
38 global logger
39 logger = multipro.log_to_stderr(logging.INFO)
40 logger.warn('Initial free memory: {m} MB'.format(m = free_memory()))
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1
2 #parse arguments from the command line
3 parser = argparse.ArgumentParser()
4 parser.add_argument("numcores", type = int)
5 parser.add_argument("chunksz", type = int)
6 parser.add_argument("inputcsv")
7 parser.add_argument("groupsel")
8 parser.add_argument("relsamp", type = int)
9 parser.add_argument("equalvar", type = int)
10 parser.add_argument("numperms", type = int)
11 parser.add_argument("outputh5")
12 args = parser.parse_args()
13
14 start = time.time()
15
16 #load methylation data
17 meth_data_redux = load_data(args.inputcsv)
18 #show 1st row
19 logger.info("First row of data (sorted by column/sample name) : ")
20 logger.info(meth_data_redux.head(1))
21
22 #select group for analysis
23 meth_data_redux_group = sel_group(args.groupsel, meth_data_redux)
24 del meth_data_redux
25
26 #select type of t-test to use
27 args.relsamp = bool(args.relsamp)
28 args.equalvar = bool(args.equalvar)
29 ttest = ttest_selector(args.relsamp,args.equalvar)
30 logger.info("Type of t-test used: %s" %(ttest))
31
32 #generate permutations
33 all_perms = rand_perm(args.numperms,meth_data_redux_group,args.relsamp)
34 meth_data_redux_group = add_orig_pheno(meth_data_redux_group, all_perms)
35 mp_meth_matrix = meth_data_redux_group.as_matrix()
36 row_names = meth_data_redux_group.index.tolist()
37 len_df = len(meth_data_redux_group.index)
38 del meth_data_redux_group
39 logger.warn('Free memory after loading data: {m} MB'.format(m = free_memory()))
40 num_proc = args.numcores
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1 num_perms = len(all_perms)
2
3 #create hdf data store
4 write_file(args.outputh5)
5
6 #########
7 # split #
8 #########
9 #process in chunks
10 inc = args.chunksz
11 logger.info("chunksize: {c}".format(c = inc))
12 for n in xrange(0, num_perms, inc):
13 logger.info("chunk = {m}".format(m=int(
14 (n / float(num_perms)) * int(num_perms / float(inc)))))
15 #split between cores
16 task_list = mp_worker_pool(all_perms[n:(n + inc)], num_proc)
17 #########
18 # apply #
19 #########
20 p_results = mp_main(task_list, num_proc)
21 ###########
22 # combine #
23 ###########
24 logger.warn('Free memory after all workers done: {m} MB'.format(
25 m = free_memory()))
26 mp_write_results(row_names, inc, num_proc)
27 hdf_node = str(int((n / float(num_perms)) * (num_perms / float(inc))))
28 logger.warn('Free memory after combining results from workers: {m} MB'.format(
29 m = free_memory()))
30 store[hdf_node] = pvals_tab
31 logger.warn('Free memory after writing results to h5 file: {m} MB'.format(
32 m = free_memory()))
33 #cleanup
34 del pvals_tab
35 del p_results
36 del task_list
37 gc.collect()
38
39 #close hdf data store
40 store.close()
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1
2 #print time-taken
3 elapsed = time.time() - start
4 m,s = divmod(elapsed,60)
5 h,m = divmod(m,60)
6 logger.info("main: time taken: %d:%02d:%02d" %(h,m,s))
7
8 def free_memory():
9 total = 0
10 a = list()
11 p = subprocess.Popen('free -m', shell=True, stdout=subprocess.PIPE,
12 stderr=subprocess.STDOUT)
13 for line in p.stdout.readlines():
14 a.append(line)
15 total = int([x for x in a[1].split()][6])
16 return total
17
18 def free_memory_mac():
19 total = 0
20 a = list()
21 p = subprocess.Popen('/usr/bin/vm_stat', shell=True, stdout=subprocess.PIPE,
22 stderr=subprocess.STDOUT)
23 for line in p.stdout.readlines():
24 a.append(line)
25 tempint = int(a[1].strip(' \t\n\rPagesfree:.'))
26 total = ((tempint * 4096) / 1024) / 1024
27 return total
28
29 if __name__ == "__main__":
30 main()
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1 # coding: utf-8
2 # In[1]:
3
4 print """
5 #/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/
6 # Permutation analysis of methylation data:
7 # Subsampling procedure
8 #
9 # prerequisites: Python 2.7 + necessary libraries (see below)
10 # input args: 1 = processor cores , 2= input permutations file (.h5),
11 # 3 = number of sample cases, 4 = output file name (.csv)
12 # output: .csv file
13 #
14 # author. Ayden Saffari <asaffa01@mail.bbk.ac.uk>
15 # affiliations. Birkbeck, University of London,
16 # London School of Hygiene and Tropical Medicine
17 #/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/
18 """
19 import sys
20 import os.path
21 import gc
22 import argparse
23 import math
24 import itertools as itperm
25 import random
26 import re
27 import time
28 from timeit import Timer
29 import multiprocessing as multipro
30
31 import numpy as np
32 import pandas as pd
33 import tables
34 from scipy import stats as sp
35
36
37 # In[2]:
38
39 ########################
40 #load permutation data #
Figure C2. Python code for subsampling procedure
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1 ########################
2
3 def load_data(file_name):
4 global h5
5 try:
6 in_data = open(file_name)
7 except IOError as e:
8 print "I/O error({0}): {1}".format(e.errno, e.strerror)
9 h5 = pd.HDFStore(file_name)
10 return h5
11
12 def select_frame(n):
13 global perms
14 perms = h5.select(n)
15 return perms
16
17 # In[3]:
18
19 ########################
20 # get p values #
21 # for table of abs Ts #
22 ########################
23
24 def get_p(df,n):
25 df = df.applymap(lambda x: (sp.t.sf(x,(n - 2))) * 2)
26 return df
27
28
29 # In[165]:
30
31 def mp_sub_sample(t):
32 global perms
33 idx_start = t[0]
34 idx_fin = t[1]
35
36 all_res = list()
37
38 npop = len(perms)
39 nreps = 100
40 inc = int((1/float(100)) * npop)
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12 for p in range(idx_start, idx_fin):
3 print "p: %s" %(p)
4 pop = np.array(perms.ix[:,p])
5 p_res = np.zeros(101)
6 p_res[0] = 0
7
8 for reps in xrange(0,nreps):
9 np.random.shuffle(pop)
10 min_p = np.zeros(101) * np.nan
11 min_p[0] = 0
12 #for each density, get the min p of subsample starting from
13 #position 0 in the pop up to current density
14 for dens in xrange(1,101):
15 min_p[dens] = np.amin(pop[0:int((dens * inc) + 1)])
16 #add results for this rep to the cumulative results
17 p_res += min_p
18 #divide cumulative results by reps to get mean values for each probe density
19 p_res = p_res/(float(nreps))
20 #add to list of results for each worker
21 all_res.append(p_res.tolist())
22 del min_p
23 del p_res
24 del pop
25 return all_res
26
27
28 # In[71]:
29
30 def mp_worker_pool(d, n):
31
32 quo_task_div, rem_task_div = divmod(d, n)
33 task_list = list()
34 start_it = 0
35
36 for i in xrange(0, n):
37 if i < rem_task_div:
38 inc_it = quo_task_div
39 else:
40 inc_it = (quo_task_div - 1)
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1 task_list.append([start_it,(start_it + inc_it + 1)])
2 start_it += inc_it + 1
3 print 'task list: %s' %(task_list)
4 return task_list
5
6
7 # In[171]:
8
9 def mp_main(ts, n):
10 start = time.time()
11 num_proc = n
12 mp_pool = multipro.Pool(num_proc)
13
14 l_res = list()
15 pool_arr = mp_pool.map(mp_sub_sample, ts)
16 l_res.append(pool_arr)
17 mp_pool.close()
18 mp_pool.join()
19
20 #print time-taken
21 elapsed = time.time() - start
22 m,s = divmod(elapsed, 60)
23 h,m = divmod(m, 60)
24 print "mp_main: time taken: %d:%02d:%02d \n" %(h, m, s)
25
26 return l_res
27
28
29 # In[170]:
30
31 def to_table(lr, n):
32
33 ncol = 101
34 dtypes = np.repeat('f8',ncol)
35 names = ["{:01d}".format(x) for x in range(0,ncol)]
36 cols = zip(names,dtypes)
37 tab = pd.DataFrame(np.zeros(n,dtype=cols))
38 count = -1
39
40 #get results back from each worker
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1 for worker in lr:
2 for res in worker:
3 for perm in xrange(0,(len(res))):
4 count += 1
5 tab.iloc[count,:] = (res[perm])
6 return tab
7
8
9 # In[173]:
10
11 ####################################
12 # write subsampling results to csv #
13 ####################################
14
15 def write_file(file_name):
16 global res_tab
17
18 #open file for writing
19 #file_name = raw_input("Enter name of file to save results to : ")
20 #file_out = open(file_name, 'a')
21
22 #append to file (or create new if none exists)
23 if(os.path.exists(file_name)):
24 file_out = open(file_name, 'a')
25 pd.DataFrame.to_csv(res_tab,file_out.name,sep = ',',mode='a',header = False, index
= False)↪
26 else:
27 file_out = open(file_name, 'w')
28 pd.DataFrame.to_csv(res_tab,file_out.name,sep = ',',mode='w',header = True, index =
False)↪
29 file_out.close()
30
31
32 # In[174]:
33
34 def main():
35
36 global h5, perms, num_proc, res_tab
37 #pd.set_eng_float_format(accuracy = 8)
38
39 parser = argparse.ArgumentParser()
40 parser.add_argument("numcores", type = int)
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1 parser.add_argument("inputcsv")
2 parser.add_argument("ncase", type = int)
3 parser.add_argument("outputcsv")
4 args = parser.parse_args()
5
6 #start timer
7 start = time.time()
8
9 #hd5 file
10 h5 = load_data(args.inputcsv)
11
12 #for each dataframe in file
13 for df in xrange(0,len(h5)):
14 print "dataframe : %s" %(df)
15 #load dataframe
16 perms = select_frame(str(df))
17
18 perms.head()
19 print "Dataframe dimensions: %i rows by %i columns" %(
20 len(perms.index),len(perms.columns))
21
22 #remove last row (max t val)
23 perms = perms.ix[:-1]
24
25 print "Dataframe dimensions: %i rows by %i columns" %(
26 len(perms.index),len(perms.columns))
27 len_df = len(perms.columns)
28 perms = get_p(perms,args.ncase)
29 task_list = mp_worker_pool(len_df, args.numcores)
30 l_res = mp_main(task_list, args.numcores)
31 res_tab = to_table(l_res, len_df)
32 write_file(args.outputcsv)
33
34
35 # In[175]:
36
37 if __name__ == "__main__":
38 main()
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Figure D1. 27K methylation QC. a. - distribution of normalised beta values, b to e. - PCA
plots of first two principal components with b. gender indicated, c. case status, d. - sentrix
chip id, e. experimental group
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D Chapter 5
1 #/\/\/\/\/\/\/\/\/\/\/\/\/\//\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\\/\/\/\/\/\/\/\/
2 # Functions for combining p-values from gene expression and methylation
3 # data on the same sample using Fisher's and empirical Brown's methods
4 #/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\\/\
5 #
6 #^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
7 # author. Ayden Saffari <asaffa01@mail.bbk.ac.uk>
8 # affiliations. Birkbeck, University of London,
9 # London School of Hygiene and Tropical Medicine
10 #^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^#
11 # requires empirical Brown's method from EmpiricalBrownsMethod R package in bioconductor
12 #
13 #/\/\/\\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\/\//\/\/\/\/\/\/\/\/\/\/\/\/\/\/
14
15 install.packages('../R_scripts/EmpiricalBrownsMethod_0.99.1.tar.gz',
16 repos=NULL,type='source')
17 library('EmpiricalBrownsMethod')
18
19
20 fishers_pcomb <- function(x){
21 return(pchisq(-2 * sum(log(x)), 2 * length(x), lower.tail=FALSE))
22 }
23
24 fishers_browns <- function(meth,expr,pvals,dsets=2){
25
26 #input:
27 #meth - methylation dataset
28 #expr - expression dataset
29 #pvals - matrix/dataframe containing obtained p-values for differential tests
30 #for each gene for the different datasets. Should be m x d, where m is number
31 #of genes tested (matching the order in data_mat), and d is the number of datasets
32 #
33 #dsets allows the number of datasets to be specified, default is 2 (not implemented)
34 #
35 #output:
36 #vector of p-values combined using either empirical Brown's method, where a cross
set↪
37 #dependency exists, and Fisher's where this is not possible because gene has not
been↪
38 #measured in all the assays
Figure D2. R functions for combining p-values from gene expression and methylation
data on the same sample using either Fisher’s or empirical Brown’s methods
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1 samples <- colnames(meth)
2 n <- length(samples)
3 meth_genes <- rownames(meth)
4 expr_genes <- rownames(expr)
5 all_genes <- rownames(pvals)
6 ngenes <- length(all_genes)
7 res <- vector(mode='numeric',length=ngenes)
8 names(res) <- all_genes
9
10 combi_data <- as.data.frame(setNames(replicate(n,numeric(0),
11 simplify = F),samples))
12
13 for(i in all_genes){
14 print(i)
15 combi_data[1:2,] <- rep(1,n)
16
17 if (i %in% meth_genes){
18 combi_data[1,] <- meth[i,]
19 }
20
21 if (i %in% expr_genes){
22 combi_data[2,] <- expr[i,]
23 }
24
25 #if a gene has no variance (because it was unmeasured in one set) brown's
will↪
26 #fail because covariances can't be calculated, so run Fisher's instead
27 adjp <- ifelse(any(apply(combi_data,1,var) == 0),fishers_pcomb(pvals[i,]),
28 empiricalBrownsMethod(combi_data,pvals[i,],
29 extra_info=FALSE)[1])
30 names(adjp) <- i
31 res[i] <- adjp
32 }
33 return(res)
34 }
Dataset Sensitivity Specificity logDOR
27K 0.40 0.82 0.48 4.30E-09
RNA-seq 0.31 0.86 0.44 5.43E-06
Pval combination approach Sensitivity Specificity logDOR
Fisher's 0.57 0.84 0.85 2.20E-16
Stouffer-Liptak-Kechris + Empirical Brown's 0.57 0.86 0.92 2.20E-16
Fisher's exact p
Fisher's exact p
Figure D3. Sensitivity and specificity for detection of gender specific genes in the gene
expression and methylation datasets before and after p-value combination by Fisher’s
or using a combination of Stouffer-Liptak-Kechris (within methylation data) followed by
Empirical Brown’s (across both expression and methylation sets)
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